[{"text": "Binding of  hydroxyflutamide  to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of  PSA  expression, suggesting that  hydroxyflutamide  acted as an agonist of the m-AR", "triple_list": [["hydroxyflutamide", "ACTIVATOR", "PSA"]]}, {"text": "Down-regulation of  prostate-specific antigen  (PSA) expression, an AR-target gene, by  estramustine  and bicalutamide was accompanied by the blockade of the mutated androgen receptor", "triple_list": [["estramustine", "DOWNREGULATOR", "prostate-specific antigen"]]}, {"text": "Down-regulation of prostate-specific antigen ( PSA   expression, an AR-target gene, by  estramustine  and bicalutamide was accompanied by the blockade of the mutated androgen receptor", "triple_list": [["estramustine", "DOWNREGULATOR", "PSA"]]}, {"text": "Down-regulation of prostate-specific antigen (PSA) expression, an  AR  target gene, by  estramustine  and bicalutamide was accompanied by the blockade of the mutated androgen receptor", "triple_list": [["estramustine", "DOWNREGULATOR", "AR"]]}, {"text": "Down-regulation of  prostate-specific antigen  (PSA) expression, an AR-target gene, by estramustine and  bicalutamide  was accompanied by the blockade of the mutated androgen receptor", "triple_list": [["bicalutamide", "DOWNREGULATOR", "prostate-specific antigen"]]}, {"text": "Down-regulation of prostate-specific antigen ( PSA   expression, an AR-target gene, by estramustine and  bicalutamide  was accompanied by the blockade of the mutated androgen receptor", "triple_list": [["bicalutamide", "DOWNREGULATOR", "PSA"]]}, {"text": "Down-regulation of prostate-specific antigen (PSA) expression, an  AR  target gene, by estramustine and  bicalutamide  was accompanied by the blockade of the mutated androgen receptor", "triple_list": [["bicalutamide", "DOWNREGULATOR", "AR"]]}, {"text": "The levels of  PSA  mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of  estramustine   respectively (IC50 = 10.97 +/- 1.68 microM)", "triple_list": [["estramustine", "DOWNREGULATOR", "PSA"]]}, {"text": "Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by  estramustine  and bicalutamide was accompanied by the blockade of the mutated  androgen receptor   Exposure of LNCaP cells to  estramustine  for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner", "triple_list": [["estramustine", "DOWNREGULATOR", "androgen receptor"]]}, {"text": "Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and  bicalutamide  was accompanied by the blockade of the mutated  androgen receptor   Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner", "triple_list": [["bicalutamide", "DOWNREGULATOR", "androgen receptor"]]}, {"text": "Exposure of LNCaP cells to  estramustine  for 24 hr caused transcriptional inhibition of  PSA  in a concentration-dependent manner", "triple_list": [["estramustine", "DOWNREGULATOR", "PSA"]]}, {"text": "Binding of  hydroxyflutamide  to m- AR  in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that  hydroxyflutamide  acted as an agonist of the m- AR   Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of  AR , an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.", "triple_list": [["hydroxyflutamide", "AGONIST", "AR"]]}, {"text": "Our data indicate that  estramustine phosphate  metabolites perform as androgen antagonists of  AR   an additional mechanism involved in the therapeutic effect of  estramustine phosphate  in patients with prostate cancer.", "triple_list": [["estramustine phosphate", "ANTAGONIST", "AR"]]}, {"text": "Our data indicate that estramustine phosphate metabolites perform as  androgen  antagonists of  AR   an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.", "triple_list": [["androgen", "ANTAGONIST", "AR"]]}, {"text": " Androgen  antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated  androgen receptor   Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer", "triple_list": [["Androgen", "ANTAGONIST", "androgen receptor"]]}, {"text": "Androgen antagonistic effect of  estramustine phosphate  (EMP) metabolites on wild-type and mutated  androgen receptor   Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer", "triple_list": [["estramustine phosphate", "ANTAGONIST", "androgen receptor"]]}, {"text": "Androgen antagonistic effect of estramustine phosphate ( EMP   metabolites on wild-type and mutated  androgen receptor   Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer", "triple_list": [["EMP", "ANTAGONIST", "androgen receptor"]]}, {"text": "In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of  Torpedo californica AChE  soaked with the reversible inhibitor  edrophonium   using a total X-ray exposure time of 24 ms", "triple_list": [["edrophonium", "DOWNREGULATOR", "Torpedo californica AChE"]]}, {"text": "The current study evaluates the effects of a selective  COX-2  inhibitor ( SC-236   on renal function in cirrhotic rats with ascites", "triple_list": [["SC-236", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective  COX-1  COX-2 inhibitor,  ketorolac   resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism", "triple_list": [["ketorolac", "DOWNREGULATOR", "COX-1"]]}, {"text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/ COX-2  inhibitor,  ketorolac   resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism", "triple_list": [["ketorolac", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective inhibition of  cyclooxygenase 2  spares renal function and  prostaglandin  synthesis in cirrhotic rats with ascites", "triple_list": [["prostaglandin", "PRODUCT-OF", "cyclooxygenase 2"]]}, {"text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective  COX-1  COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of  prostaglandins   and glomerular filtration rate and in a significant impairment in renal water metabolism", "triple_list": [["prostaglandins", "PRODUCT-OF", "COX-1"]]}, {"text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/ COX-2  inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of  prostaglandins   and glomerular filtration rate and in a significant impairment in renal water metabolism", "triple_list": [["prostaglandins", "PRODUCT-OF", "COX-2"]]}, {"text": "Inhibition of LTC4 synthesis precedes the global cytotoxic effects of  FP  as indicated by the simultaneous upregulation of  annexin-1  expression", "triple_list": [["FP", "ACTIVATOR", "annexin-1"]]}, {"text": "FMLP/CB-stimulated translocation of  cPLA2  to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by  FP   By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M  FP , and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)", "triple_list": [["FP", "DOWNREGULATOR", "cPLA2"]]}, {"text": "Inhibition of  cPLA2  translocation and leukotriene C4 secretion by  fluticasone propionate  in exogenously activated human eosinophils", "triple_list": [["fluticasone propionate", "DOWNREGULATOR", "cPLA2"]]}, {"text": "We find that  FP  causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by  phospholipase A2  (PLA2)", "triple_list": [["FP", "DOWNREGULATOR", "phospholipase A2"]]}, {"text": "We find that FP causes a decrease in stimulated eosinophil secretion of  LTC4  that is regulated by  phospholipase A2  (PLA2)", "triple_list": [["LTC4", "PRODUCT-OF", "phospholipase A2"]]}, {"text": "We find that FP causes a decrease in stimulated eosinophil secretion of  LTC4  that is regulated by phospholipase A2 ( PLA2  ", "triple_list": [["LTC4", "PRODUCT-OF", "PLA2"]]}, {"text": "We conclude that decreased  NET  synthesis may contribute to the chronic, but not acute, effect of  desipramine  to downregulate the  NET  ", "triple_list": [["desipramine", "DOWNREGULATOR", "NET"]]}, {"text": "The antidepressant  desipramine  has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ( NET   in vivo and in vitro, on both an acute and a chronic basis", "triple_list": [["desipramine", "DOWNREGULATOR", "NET"]]}, {"text": "The antidepressant  desipramine  has been shown to decrease synaptic membrane concentrations of the  norepinephrine re-uptake transporter  (NET) in vivo and in vitro, on both an acute and a chronic basis", "triple_list": [["desipramine", "DOWNREGULATOR", "norepinephrine re-uptake transporter"]]}, {"text": " Desipramine  treatment decreases 3H-nisoxetine binding and  norepinephrine transporter  mRNA in SK-N-SHSY5Y cells", "triple_list": [["Desipramine", "DOWNREGULATOR", "norepinephrine transporter"]]}, {"text": "Inhibition of the  human ether-a-go-go-related gene (HERG) potassium channel  by  cisapride   affinity for open and inactivated states", "triple_list": [["cisapride", "DOWNREGULATOR", "human ether-a-go-go-related gene (HERG) potassium channel"]]}, {"text": "6 In conclusion,  HERG  channel inhibition by  cisapride  exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "2 In a chronic transfection model using CHO-K1 cells,  cisapride  inhibited  HERG  tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "These profiles suggest a mechanism of action for each agent,  5-HT1A  agonism for  ziprasidone  and alpha 1 antagonism for clozapine and olanzapine", "triple_list": [["ziprasidone", "AGONIST", "5-HT1A"]]}, {"text": "The  5-HT1A  agonist activity reported here clearly distinguishes  ziprasidone  from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.", "triple_list": [["ziprasidone", "AGONIST", "5-HT1A"]]}, {"text": "While it is an antagonist at these latter receptors,  ziprasidone  behaves as a  5-HT1A  agonist in vitro in adenylate cyclase measurements", "triple_list": [["ziprasidone", "AGONIST", "5-HT1A"]]}, {"text": "Pretreatment with the  5-HT1A  antagonist  WAY-100,635  (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of  WAY-100,635  had little effect on the inhibition produced by clozapine and olanzapine", "triple_list": [["WAY-100,635", "ANTAGONIST", "5-HT1A"]]}, {"text": "Pretreatment with the  5-HT1A  antagonist  WAY-100,635  (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of  WAY-100,635  had little effect on the inhibition produced by clozapine and olanzapine", "triple_list": [["WAY-100,635", "ANTAGONIST", "5-HT1A"]]}, {"text": "The nonselective and irreversible  MAO  inhibitors,  phenelzine  (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement", "triple_list": [["phenelzine", "DOWNREGULATOR", "MAO"]]}, {"text": "The nonselective and irreversible  MAO  inhibitors, phenelzine (3-10 mg/kg),  tranylcypromine  (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "MAO"]]}, {"text": "The nonselective and irreversible  MAO  inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and  nialamide  (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement", "triple_list": [["nialamide", "DOWNREGULATOR", "MAO"]]}, {"text": "The irreversible  MAO-B  inhibitors,  pargyline  (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice", "triple_list": [["pargyline", "DOWNREGULATOR", "MAO-B"]]}, {"text": "The reversible  MAO-A  inhibitor,  befloxatone  (0.3-3 mg/kg), and the irreversible  MAO-A  inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration", "triple_list": [["befloxatone", "DOWNREGULATOR", "MAO-A"]]}, {"text": "The reversible  MAO-A  inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible  MAO-A  inhibitor,  clorgyline  (10-30 mg/kg), also reduced ethanol self-administration", "triple_list": [["clorgyline", "DOWNREGULATOR", "MAO-A"]]}, {"text": "The irreversible  MAO-B  inhibitors, pargyline (30 mg/kg) and  l-deprenyl  (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice", "triple_list": [["l-deprenyl", "DOWNREGULATOR", "MAO-B"]]}, {"text": " Dicumarol   a potent inhibitor of  quinone oxidoreductase   at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin", "triple_list": [["Dicumarol", "DOWNREGULATOR", "quinone oxidoreductase"]]}, {"text": "Activity of the mutant  delta-aminolevulinate synthase  protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of  pyridoxal 5'-phosphate   consistent with the clinical response of the patient to pyridoxine treatment", "triple_list": [["pyridoxal 5'-phosphate", "ACTIVATOR", "delta-aminolevulinate synthase"]]}, {"text": "Preferential cerebrospinal fluid  acetylcholinesterase  inhibition by  rivastigmine  in humans", "triple_list": [["rivastigmine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "Inhibition of  AChE  in the CSF after  rivastigmine  administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours", "triple_list": [["rivastigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "Plasma  BuChE  activity was significantly lower after  rivastigmine  than after placebo, but this was not clinically relevant", "triple_list": [["rivastigmine", "DOWNREGULATOR", "BuChE"]]}, {"text": " BuChE  activity in CSF was significantly lower after  rivastigmine  than after placebo for up to 3.6 hours after dosing, but this difference was not sustained", "triple_list": [["rivastigmine", "DOWNREGULATOR", "BuChE"]]}, {"text": "This study confirms the feasibility of using continuous measurement of  AChE  activity in CSF over prolonged periods, that  rivastigmine  markedly inhibits CSF  AChE  after a single oral dose of 3 mg, and that the inhibition of central  AChE  is substantially greater than that of peripheral  AChE  or BuChE.", "triple_list": [["rivastigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "This study confirms the feasibility of using continuous measurement of  AChE  activity in CSF over prolonged periods, that  rivastigmine  markedly inhibits CSF  AChE  after a single oral dose of 3 mg, and that the inhibition of central  AChE  is substantially greater than that of peripheral  AChE  or BuChE.", "triple_list": [["rivastigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "This study confirms the feasibility of using continuous measurement of  AChE  activity in CSF over prolonged periods, that  rivastigmine  markedly inhibits CSF  AChE  after a single oral dose of 3 mg, and that the inhibition of central  AChE  is substantially greater than that of peripheral  AChE  or BuChE.", "triple_list": [["rivastigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that  rivastigmine  markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or  BuChE  ", "triple_list": [["rivastigmine", "DOWNREGULATOR", "BuChE"]]}, {"text": "However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the  5-HT(1A)  agonist actions of  yohimbine  suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.", "triple_list": [["yohimbine", "AGONIST", "5-HT(1A)"]]}, {"text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at  h5-HT(1A)  sites", "triple_list": [["yohimbine", "AGONIST", "h5-HT(1A)"]]}, {"text": "In vivo, agonist actions of  yohimbine  at  5-HT(1A)  sites are revealed by WAY100,635-reversible induction of hypothermia in the rat", "triple_list": [["yohimbine", "AGONIST", "5-HT(1A)"]]}, {"text": "In guinea pigs, antagonist actions of yohimbine at  5-HT(1B)  receptors are revealed by blockade of hypothermia evoked by the  5-HT(1B)  agonist,  GR46,611   In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs", "triple_list": [["GR46,611", "AGONIST", "5-HT(1B)"]]}, {"text": "In distinction to  yohimbine   fluparoxan shows only modest partial agonist actions at  h5-HT(1A)  sites versus marked antagonist actions at halpha(2)-ARs", "triple_list": [["yohimbine", "AGONIST", "h5-HT(1A)"]]}, {"text": "In distinction to yohimbine,  fluparoxan  shows only modest partial agonist actions at  h5-HT(1A)  sites versus marked antagonist actions at halpha(2)-ARs", "triple_list": [["fluparoxan", "AGONIST", "h5-HT(1A)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors  (AR)s   serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "AGONIST", "(AR)s"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin  (5-HT)(1A)   5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "AGONIST", "(5-HT)(1A)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  5-HT(1B)   5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "AGONIST", "5-HT(1B)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  5-HT(1D)  and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "AGONIST", "5-HT(1D)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "AGONIST", "alpha(2)-adrenergic receptors"]]}, {"text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at alpha(2)-adrenergic receptors  (AR)s   serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["fluparoxan", "AGONIST", "(AR)s"]]}, {"text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["fluparoxan", "AGONIST", "alpha(2)-adrenergic receptors"]]}, {"text": "In conclusion, the  alpha(2)-AR  antagonist properties of  yohimbine  increase DA and NAD levels both alone and in association with fluoxetine", "triple_list": [["yohimbine", "ANTAGONIST", "alpha(2)-AR"]]}, {"text": "However, in contrast to the selective  alpha(2)-AR  antagonist,  fluparoxan   the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.", "triple_list": [["fluparoxan", "ANTAGONIST", "alpha(2)-AR"]]}, {"text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at  halpha(2A)-AR   h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites", "triple_list": [["yohimbine", "ANTAGONIST", "halpha(2A)-AR"]]}, {"text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR,  h5-HT(1B)   h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites", "triple_list": [["yohimbine", "ANTAGONIST", "h5-HT(1B)"]]}, {"text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B),  h5-HT(1D)   and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites", "triple_list": [["yohimbine", "ANTAGONIST", "h5-HT(1D)"]]}, {"text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and  hD(2)  sites, yet partial agonist actions at h5-HT(1A) sites", "triple_list": [["yohimbine", "ANTAGONIST", "hD(2)"]]}, {"text": "Herein, we evaluate the interaction of the  alpha(2)-AR antagonist    yohimbine   as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats", "triple_list": [["yohimbine", "ANTAGONIST", "alpha(2)-AR antagonist"]]}, {"text": "In vivo, agonist actions of yohimbine at  5-HT(1A)  sites are revealed by  WAY100,635  reversible induction of hypothermia in the rat", "triple_list": [["WAY100,635", "ANTAGONIST", "5-HT(1A)"]]}, {"text": "In guinea pigs, antagonist actions of  yohimbine  at  5-HT(1B)  receptors are revealed by blockade of hypothermia evoked by the  5-HT(1B)  agonist, GR46,611", "triple_list": [["yohimbine", "ANTAGONIST", "5-HT(1B)"]]}, {"text": "Herein, we evaluate the interaction of the  alpha(2)-AR antagonist   yohimbine, as compared to  fluparoxan   at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats", "triple_list": [["fluparoxan", "ANTAGONIST", "alpha(2)-AR antagonist"]]}, {"text": "In distinction to  yohimbine   fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at  halpha(2)-ARs   While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover,  yohimbine  also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT", "triple_list": [["yohimbine", "ANTAGONIST", "halpha(2)-ARs"]]}, {"text": "In distinction to yohimbine,  fluparoxan  shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at  halpha(2)-ARs   While  fluparoxan  selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT", "triple_list": [["fluparoxan", "ANTAGONIST", "halpha(2)-ARs"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors  (AR)s   serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "ANTAGONIST", "(AR)s"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin  (5-HT)(1A)   5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "ANTAGONIST", "(5-HT)(1A)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  5-HT(1B)   5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "ANTAGONIST", "5-HT(1B)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  5-HT(1D)  and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "ANTAGONIST", "5-HT(1D)"]]}, {"text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["yohimbine", "ANTAGONIST", "alpha(2)-adrenergic receptors"]]}, {"text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at alpha(2)-adrenergic receptors  (AR)s   serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["fluparoxan", "ANTAGONIST", "(AR)s"]]}, {"text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors", "triple_list": [["fluparoxan", "ANTAGONIST", "alpha(2)-adrenergic receptors"]]}, {"text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and  kappa-opioid receptor  ( BRL 52974   produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively", "triple_list": [["BRL 52974", "AGONIST", "kappa-opioid receptor"]]}, {"text": "The nonselective  opioid receptor  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of  codeine  or SB 227122, indicating that the antitussive activity of both compounds is  opioid receptor -mediated", "triple_list": [["codeine", "AGONIST", "opioid receptor"]]}, {"text": "The nonselective  opioid receptor  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of  codeine  or SB 227122, indicating that the antitussive activity of both compounds is  opioid receptor  mediated", "triple_list": [["codeine", "AGONIST", "opioid receptor"]]}, {"text": "The nonselective  opioid receptor  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or  SB 227122   indicating that the antitussive activity of both compounds is  opioid receptor -mediated", "triple_list": [["SB 227122", "AGONIST", "opioid receptor"]]}, {"text": "The nonselective  opioid receptor  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or  SB 227122   indicating that the antitussive activity of both compounds is  opioid receptor  mediated", "triple_list": [["SB 227122", "AGONIST", "opioid receptor"]]}, {"text": "The  delta-receptor  antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of  SB 227122  (20 mg/kg, i.p.)", "triple_list": [["SB 227122", "AGONIST", "delta-receptor"]]}, {"text": "In this study, the activity of the  delta-opioid receptor  subtype-selective agonist,  SB 227122   was investigated in a guinea pig model of citric acid-induced cough", "triple_list": [["SB 227122", "AGONIST", "delta-opioid receptor"]]}, {"text": "The  sigma-receptor  antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of  dextromethorphan  (30 mg/kg, i.p.), a  sigma-receptor  agonist, but not that of SB 227122", "triple_list": [["dextromethorphan", "AGONIST", "sigma-receptor"]]}, {"text": "These studies provide compelling evidence that the antitussive effects of  SB 227122  in this guinea pig cough model are mediated by agonist activity at the  delta-opioid receptor  ", "triple_list": [["SB 227122", "AGONIST", "delta-opioid receptor"]]}, {"text": "Parenteral administration of selective agonists of the  delta-opioid receptor  ( SB 227122  , mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively", "triple_list": [["SB 227122", "AGONIST", "delta-opioid receptor"]]}, {"text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122),  mu-opioid receptor  ( codeine  and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively", "triple_list": [["codeine", "AGONIST", "mu-opioid receptor"]]}, {"text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122),  mu-opioid receptor  (codeine and  hydrocodone  , and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively", "triple_list": [["hydrocodone", "AGONIST", "mu-opioid receptor"]]}, {"text": "The nonselective  opioid receptor  antagonist,  naloxone  (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is  opioid receptor -mediated", "triple_list": [["naloxone", "ANTAGONIST", "opioid receptor"]]}, {"text": "The  delta-receptor  antagonist,  SB 244525  (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.)", "triple_list": [["SB 244525", "ANTAGONIST", "delta-receptor"]]}, {"text": "In contrast, combined pretreatment with  beta-funaltrexamine  ( mu-receptor  antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)", "triple_list": [["beta-funaltrexamine", "ANTAGONIST", "mu-receptor"]]}, {"text": "In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and  norbinaltorphimine  ( kappa-receptor  antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and  kappa-receptor  agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)", "triple_list": [["norbinaltorphimine", "ANTAGONIST", "kappa-receptor"]]}, {"text": "The  sigma-receptor  antagonist  rimcazole  (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a  sigma-receptor  agonist, but not that of SB 227122", "triple_list": [["rimcazole", "ANTAGONIST", "sigma-receptor"]]}, {"text": "New modes of therapy have recently been introduced, and data on the  cyclooxygenase-2  (COX-2)-specific inhibitors  celecoxib  and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.", "triple_list": [["celecoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 ( COX-2  -specific inhibitors  celecoxib  and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "New modes of therapy have recently been introduced, and data on the  cyclooxygenase-2  (COX-2)-specific inhibitors celecoxib and  rofecoxib  suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.", "triple_list": [["rofecoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 ( COX-2  -specific inhibitors celecoxib and  rofecoxib  suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": " Dichloroally]-lawsone  was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for  mammalian dihydroorotate dehydrogenases   Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W", "triple_list": [["Dichloroally]-lawsone", "DOWNREGULATOR", "mammalian dihydroorotate dehydrogenases"]]}, {"text": "Another inhibitor,  brequinar  was previously reported to be a slow-binding inhibitor of the  human dihydroorotate dehydrogenase  [W", "triple_list": [["brequinar", "DOWNREGULATOR", "human dihydroorotate dehydrogenase"]]}, {"text": "Loffler, Species-related inhibition of  human and rat dihyroorotate dehydrogenase  by immunosuppressive  isoxazol  and cinchoninic acid derivatives, Biochem", "triple_list": [["isoxazol", "DOWNREGULATOR", "human and rat dihyroorotate dehydrogenase"]]}, {"text": "Loffler, Species-related inhibition of  human and rat dihyroorotate dehydrogenase  by immunosuppressive isoxazol and  cinchoninic acid  derivatives, Biochem", "triple_list": [["cinchoninic acid", "DOWNREGULATOR", "human and rat dihyroorotate dehydrogenase"]]}, {"text": "With respect to the substrate  dihydroorotate   atovaquone was an uncompetitive inhibitor of human  dihydroorotate  dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM)", "triple_list": [["dihydroorotate", "DOWNREGULATOR", "human dihydroorotate dehydrogenase"]]}, {"text": "With respect to the substrate dihydroorotate,  atovaquone  was an uncompetitive inhibitor of  human dihydroorotate dehydrogenase  (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM)", "triple_list": [["atovaquone", "DOWNREGULATOR", "human dihydroorotate dehydrogenase"]]}, {"text": "Kinetics of inhibition of  human and rat dihydroorotate dehydrogenase  by atovaquone, lawsone derivatives,  brequinar sodium  and polyporic acid", "triple_list": [["brequinar sodium", "DOWNREGULATOR", "human and rat dihydroorotate dehydrogenase"]]}, {"text": "Kinetics of inhibition of  human and rat dihydroorotate dehydrogenase  by atovaquone, lawsone derivatives, brequinar sodium and  polyporic acid   Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate", "triple_list": [["polyporic acid", "DOWNREGULATOR", "human and rat dihydroorotate dehydrogenase"]]}, {"text": "Kinetics of inhibition of  human and rat dihydroorotate dehydrogenase  by  atovaquone   lawsone derivatives, brequinar sodium and polyporic acid", "triple_list": [["atovaquone", "DOWNREGULATOR", "human and rat dihydroorotate dehydrogenase"]]}, {"text": "Kinetics of inhibition of  human and rat dihydroorotate dehydrogenase  by atovaquone,  lawsone  derivatives, brequinar sodium and polyporic acid", "triple_list": [["lawsone", "DOWNREGULATOR", "human and rat dihydroorotate dehydrogenase"]]}, {"text": "With respect to the quinone co-substrate of the dihydroorotate dehydrogenase,  atovaquone  (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of  human dihydroorotate dehydrogenase   Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme", "triple_list": [["atovaquone", "DOWNREGULATOR", "human dihydroorotate dehydrogenase"]]}, {"text": "With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and  dichloroally-lawsone  (Kic = 9.8 nM) were shown to be competitive inhibitors of  human dihydroorotate dehydrogenase   Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme", "triple_list": [["dichloroally-lawsone", "DOWNREGULATOR", "human dihydroorotate dehydrogenase"]]}, {"text": "Mitochondrially-bound  dihydroorotate dehydrogenase  (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of  uridine monophosphate   The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects", "triple_list": [["uridine monophosphate", "PRODUCT-OF", "dihydroorotate dehydrogenase"]]}, {"text": "Mitochondrially-bound dihydroorotate dehydrogenase ( EC 1.3.99.11   catalyzes the fourth sequential step in the de novo synthesis of  uridine monophosphate   The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects", "triple_list": [["uridine monophosphate", "PRODUCT-OF", "EC 1.3.99.11"]]}, {"text": "With respect to the  quinone  co-substrate of the  dihydroorotate dehydrogenase   atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human  dihydroorotate dehydrogenase ", "triple_list": [["quinone", "PRODUCT-OF", "dihydroorotate dehydrogenase"]]}, {"text": " Mibefradil  blocked alpha1A and alpha1E with a Kd comparable to that reported for  T-type channels   but had a lower affinity (approximately 30-fold) for alpha1C", "triple_list": [["Mibefradil", "DOWNREGULATOR", "T-type channels"]]}, {"text": " Mibefradil  (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block  T-type Ca2+ channels   However, this molecule has also been shown to inhibit other Ca2+ channel subtypes", "triple_list": [["Mibefradil", "DOWNREGULATOR", "T-type Ca2+ channels"]]}, {"text": "Determinants of voltage-dependent inactivation affect  Mibefradil  block of  calcium channels   The voltage gated calcium channel family is a major target for a range of therapeutic drugs", "triple_list": [["Mibefradil", "DOWNREGULATOR", "calcium channels"]]}, {"text": "Mibefradil ( Ro 40-5967   belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block  T-type Ca2+ channels   However, this molecule has also been shown to inhibit other Ca2+ channel subtypes", "triple_list": [["Ro 40-5967", "DOWNREGULATOR", "T-type Ca2+ channels"]]}, {"text": "Postoperative concentrations of  plasminogen  were decreased significantly in the  tranexamic acid  group (P < 0.001)", "triple_list": [["tranexamic acid", "DOWNREGULATOR", "plasminogen"]]}, {"text": "Iontophoresis of  +/- propranolol   whose serotonergic actions include antagonism and partial agonism at  5-HT1  receptors, also increased serotonin and decreased firing (n=4)", "triple_list": [["+/- propranolol", "AGONIST", "5-HT1"]]}, {"text": " Methiothepin  (intravenous, 1 mg/kg), whose serotonergic actions include  5-HT1  and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)", "triple_list": [["Methiothepin", "ANTAGONIST", "5-HT1"]]}, {"text": " Methiothepin  (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and  5-HT2  antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)", "triple_list": [["Methiothepin", "ANTAGONIST", "5-HT2"]]}, {"text": "Iontophoresis of  +/- propranolol   whose serotonergic actions include antagonism and partial agonism at  5-HT1  receptors, also increased serotonin and decreased firing (n=4)", "triple_list": [["+/- propranolol", "ANTAGONIST", "5-HT1"]]}, {"text": "In this study, we demonstrate that  geldanamycin  treatment blocks  interleukin (IL)-2  secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes", "triple_list": [["geldanamycin", "DOWNREGULATOR", "interleukin (IL)-2"]]}, {"text": "In this study, we demonstrate that  geldanamycin  treatment blocks interleukin (IL)-2 secretion,  IL-2 receptor  expression, and proliferation of stimulated T-lymphocytes", "triple_list": [["geldanamycin", "DOWNREGULATOR", "IL-2 receptor"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of  Lck  and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "Lck"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of Lck and  Raf-1  kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "Raf-1"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of Lck and Raf-1  kinases  and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "kinases"]]}, {"text": "Through demonstrating the selective inhibition of  kinase  related T-lymphocyte responses by  geldanamycin   our results emphasize the substantial role of Hsp90- kinase  complexes in T-cell activation.", "triple_list": [["geldanamycin", "DOWNREGULATOR", "kinase"]]}, {"text": "Improper function of these proteins can be induced by selective disruption of their complexes with  Hsp90  using the  benzoquinonoid ansamycin  geldanamycin", "triple_list": [["benzoquinonoid ansamycin", "DOWNREGULATOR", "Hsp90"]]}, {"text": "Improper function of these proteins can be induced by selective disruption of their complexes with  Hsp90  using the benzoquinonoid ansamycin  geldanamycin   In this study, we demonstrate that  geldanamycin  treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes", "triple_list": [["geldanamycin", "DOWNREGULATOR", "Hsp90"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of  Lck  and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "Lck"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of Lck and  Raf-1  kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "Raf-1"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of Lck and Raf-1  kinases  and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "kinases"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the  extracellular signal regulated kinase (ERK)-2  kinase", "triple_list": [["geldanamycin", "DOWNREGULATOR", "extracellular signal regulated kinase (ERK)-2"]]}, {"text": "Moreover,  geldanamycin  decreases the amount and phosphorylation of Lck and Raf-1  kinase s and prevents activation of the extracellular signal regulated  kinase  (ERK)-2  kinase   Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT)", "triple_list": [["geldanamycin", "DOWNREGULATOR", "kinase"]]}, {"text": " Geldanamycin  also disrupts the  T-cell receptor  mediated activation of nuclear factor of activated T-cells (NF-AT)", "triple_list": [["Geldanamycin", "DOWNREGULATOR", "T-cell receptor"]]}, {"text": " Geldanamycin  also disrupts the T-cell receptor-mediated activation of  nuclear factor of activated T-cells  (NF-AT)", "triple_list": [["Geldanamycin", "DOWNREGULATOR", "nuclear factor of activated T-cells"]]}, {"text": " Geldanamycin  also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells ( NF-AT  ", "triple_list": [["Geldanamycin", "DOWNREGULATOR", "NF-AT"]]}, {"text": "The  Hsp90  specific inhibitor  geldanamycin  selectively disrupts kinase-mediated signaling events of T-lymphocyte activation", "triple_list": [["geldanamycin", "DOWNREGULATOR", "Hsp90"]]}, {"text": "The Hsp90-specific inhibitor  geldanamycin  selectively disrupts  kinase  mediated signaling events of T-lymphocyte activation", "triple_list": [["geldanamycin", "DOWNREGULATOR", "kinase"]]}, {"text": " gamma-Butyrobetaine hydroxylase  catalyse the last step in  carnitine  biosynthesis, the formation of L- carnitine  from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen", "triple_list": [["carnitine", "PRODUCT-OF", "gamma-Butyrobetaine hydroxylase"]]}, {"text": " gamma-Butyrobetaine hydroxylase  catalyse the last step in carnitine biosynthesis, the formation of  L-carnitine  from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen", "triple_list": [["L-carnitine", "PRODUCT-OF", "gamma-Butyrobetaine hydroxylase"]]}, {"text": " gamma-Butyrobetaine hydroxylase  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from  gamma-butyrobetaine   a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen", "triple_list": [["gamma-butyrobetaine", "PRODUCT-OF", "gamma-Butyrobetaine hydroxylase"]]}, {"text": "Inhibition of the actions of  ET-1  by  salicylates  is apparently competitive", "triple_list": [["salicylates", "DOWNREGULATOR", "ET-1"]]}, {"text": "Among the various enzymes,  dicoumarol  inhibitable cytosolic  NAD(P)H:quinone oxidoreductase1  (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity", "triple_list": [["dicoumarol", "DOWNREGULATOR", "NAD(P)H:quinone oxidoreductase1"]]}, {"text": "Among the various enzymes,  dicoumarol  inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ( NQO1   was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity", "triple_list": [["dicoumarol", "DOWNREGULATOR", "NQO1"]]}, {"text": "This activity, like  NQO1   was inhibited by  dicoumarol  and immunologically related to  NQO1 .", "triple_list": [["dicoumarol", "DOWNREGULATOR", "NQO1"]]}, {"text": "Among the various enzymes, dicoumarol inhibitable cytosolic  NAD(P)H:quinone oxidoreductase1  (NQO1) was shown to catalyse bioreductive activation of  MMC  leading to cross-linking of the DNA and cytotoxicity", "triple_list": [["MMC", "PRODUCT-OF", "NAD(P)H:quinone oxidoreductase1"]]}, {"text": "Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ( NQO1   was shown to catalyse bioreductive activation of  MMC  leading to cross-linking of the DNA and cytotoxicity", "triple_list": [["MMC", "PRODUCT-OF", "NQO1"]]}, {"text": "However, the role of  NQO1  in metabolic activation of  MMC  has been disputed", "triple_list": [["MMC", "PRODUCT-OF", "NQO1"]]}, {"text": "In this report, we present cellular and animal models to demonstrate that  NQO1  may play only a minor role in metabolic activation of  MMC   We further demonstrate that bioreductive activation of  MMC  is catalysed by a unique cytosolic activity which is related but distinct from  NQO1 ", "triple_list": [["MMC", "PRODUCT-OF", "NQO1"]]}, {"text": "A unique cytosolic activity related but distinct from  NQO1  catalyses metabolic activation of  mitomycin C   Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer", "triple_list": [["mitomycin C", "PRODUCT-OF", "NQO1"]]}, {"text": "In cultures from severely obese subjects,  troglitazone  induced a decrease of  PAI-1  antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05)", "triple_list": [["troglitazone", "DOWNREGULATOR", "PAI-1"]]}, {"text": "Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to  troglitazone  induced a similar reduction of  PAI-1  concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively)", "triple_list": [["troglitazone", "DOWNREGULATOR", "PAI-1"]]}, {"text": "CONCLUSION/INTERPRETATION: This study provides evidence that  troglitazone  reduces  PAI-1  production in human adipocytes, probably at the transcriptional level", "triple_list": [["troglitazone", "DOWNREGULATOR", "PAI-1"]]}, {"text": "RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml  troglitazone  for 72 h caused a reduction of both  PAI-1  secretion (by 29 +/- 5%; p < 0.01) and  PAI-1  mRNA expression (by 26 +/- 3%; p < 0.05)", "triple_list": [["troglitazone", "DOWNREGULATOR", "PAI-1"]]}, {"text": "RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml  troglitazone  for 72 h caused a reduction of both  PAI-1  secretion (by 29 +/- 5%; p < 0.01) and  PAI-1  mRNA expression (by 26 +/- 3%; p < 0.05)", "triple_list": [["troglitazone", "DOWNREGULATOR", "PAI-1"]]}, {"text": " Troglitazone  reduces  plasminogen activator inhibitor-1  expression and secretion in cultured human adipocytes", "triple_list": [["Troglitazone", "DOWNREGULATOR", "plasminogen activator inhibitor-1"]]}, {"text": "In these tissues,  JTH-601   prazosin (a non-selective  alpha(1)-adrenoceptor  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner", "triple_list": [["JTH-601", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "In these tissues, JTH-601,  prazosin  (a non-selective  alpha(1)-adrenoceptor  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner", "triple_list": [["prazosin", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and  tamsulosin  (an  alpha(1A)-adrenoceptor  antagonist) competitively antagonized contraction in a concentration-dependent manner", "triple_list": [["tamsulosin", "ANTAGONIST", "alpha(1A)-adrenoceptor"]]}, {"text": "We examined the effect of JTH-601 (3- inverted question mark N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom  ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs", "triple_list": [["N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom", "ANTAGONIST", "alpha(1L)-adrenoceptor"]]}, {"text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-m ethyl phenoxy) ethyl ]-N-m ethyl aminom  ethyl  inverted question mark-4-methoxy-2,5,6-trim ethyl phenol hemifumarate), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs", "triple_list": [["ethyl", "ANTAGONIST", "alpha(1L)-adrenoceptor"]]}, {"text": " JTH-601  is expected to be an effective  alpha(1)-adrenoceptor  antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.", "triple_list": [["JTH-601", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark- 4-methoxy-2,5,6-trimethylphenol hemifumarate  , a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs", "triple_list": [["4-methoxy-2,5,6-trimethylphenol hemifumarate", "ANTAGONIST", "alpha(1L)-adrenoceptor"]]}, {"text": "We examined the effect of  JTH-601  (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs", "triple_list": [["JTH-601", "ANTAGONIST", "alpha(1L)-adrenoceptor"]]}, {"text": "These data directly demonstrate that  NKCC1  is the major  Cl(-)  uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.", "triple_list": [["Cl(-)", "PRODUCT-OF", "NKCC1"]]}, {"text": "The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/2 Cl(-)  cotransporter mediated  Cl(-)  uptake", "triple_list": [["Cl(-)", "PRODUCT-OF", "Na(+)/K(+)/2Cl(-) cotransporter"]]}, {"text": "UNLABELLED: Apparent  muscarinic acetylcholine (mAch) receptor  occupancy in mouse cerebral cortex, hippocampus, and striatum by  scopolamine   an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)", "triple_list": [["scopolamine", "ANTAGONIST", "muscarinic acetylcholine (mAch) receptor"]]}, {"text": "UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and  biperiden   a relatively selective  M1  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)", "triple_list": [["biperiden", "ANTAGONIST", "M1"]]}, {"text": "Treatment of lactating mice with a single injection of  bezafibrate   an activator of the  peroxisome proliferator-activated receptor  (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice", "triple_list": [["bezafibrate", "ACTIVATOR", "peroxisome proliferator-activated receptor"]]}, {"text": "Treatment of lactating mice with a single injection of  bezafibrate   an activator of the peroxisome proliferator-activated receptor ( PPAR  , raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice", "triple_list": [["bezafibrate", "ACTIVATOR", "PPAR"]]}, {"text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  troglitazone   a specific activator of  PPAR-gamma   also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice", "triple_list": [["troglitazone", "ACTIVATOR", "PPAR-gamma"]]}, {"text": "It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free  fatty acids  by mechanisms involving activation of  PPARs   The impaired expression of the UCP-3 gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of  fatty acids  as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.", "triple_list": [["fatty acids", "ACTIVATOR", "PPARs"]]}, {"text": "Impaired expression of the  uncoupling protein-3  gene in skeletal muscle during lactation: fibrates and  troglitazone  reverse lactation-induced downregulation of the  uncoupling protein-3  gene", "triple_list": [["troglitazone", "ACTIVATOR", "uncoupling protein-3"]]}, {"text": "Treatment of lactating mice with a single injection of  bezafibrate   an activator of the peroxisome proliferator-activated receptor (PPAR), raises  UCP-3  mRNA in skeletal muscle to levels similar to those in virgin mice", "triple_list": [["bezafibrate", "ACTIVATOR", "UCP-3"]]}, {"text": " 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid  (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in  UCP-3  mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases  UCP-3  mRNA abundance in skeletal muscle of lactating mice", "triple_list": [["4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid", "ACTIVATOR", "UCP-3"]]}, {"text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( WY-14,643  , a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in  UCP-3  mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases  UCP-3  mRNA abundance in skeletal muscle of lactating mice", "triple_list": [["WY-14,643", "ACTIVATOR", "UCP-3"]]}, {"text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in  UCP-3  mRNA, whereas  troglitazone   a specific activator of PPAR-gamma, also significantly increases  UCP-3  mRNA abundance in skeletal muscle of lactating mice", "triple_list": [["troglitazone", "ACTIVATOR", "UCP-3"]]}, {"text": " Retigabine   a novel anti-convulsant, enhances activation of KCNQ2/Q3  potassium channels    Retigabine  [N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid; D-23129] is a novel anticonvulsant, unrelated to currently available antiepileptic agents, with activity in a broad range of seizure models", "triple_list": [["Retigabine", "ACTIVATOR", "potassium channels"]]}, {"text": "RESULTS:  NF-kappaB  Rel activity induced by tumor necrosis factor alpha,  12-O-tetradecanoylphorbol-13-acetate   or overexpression of  NF-kappaB -inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine", "triple_list": [["12-O-tetradecanoylphorbol-13-acetate", "ACTIVATOR", "NF-kappaB"]]}, {"text": "RESULTS: NF-kappaB/ Rel  activity induced by tumor necrosis factor alpha,  12-O-tetradecanoylphorbol-13-acetate   or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine", "triple_list": [["12-O-tetradecanoylphorbol-13-acetate", "ACTIVATOR", "Rel"]]}, {"text": "The suppression of  NF-kappaB  activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of  sulfasalazine  ", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "The suppression of NF-kappaB activation by inhibition of the  IKKs  contributes to the well-known anti-inflammatory and immunosuppressive effects of  sulfasalazine  ", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "IKKs"]]}, {"text": "The aim of this study was to define the molecular mechanism by which  sulfasalazine  inhibits  NF-kappaB  activation", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "RESULTS:  NF-kappaB  Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of  NF-kappaB -inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "RESULTS: NF-kappaB/ Rel  activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "Rel"]]}, {"text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of  NF-kappaB-inducing kinase   IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "NF-kappaB-inducing kinase"]]}, {"text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase,  IKK-alpha   IKK-beta, or constitutively active  IKK-alpha  and IKK-beta mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified  IKK-alpha  and IKK-beta in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "IKK-alpha"]]}, {"text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha,  IKK-beta   or constitutively active IKK-alpha and  IKK-beta  mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and  IKK-beta  in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "IKK-beta"]]}, {"text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase,  IKK-alpha , IKK-beta, or constitutively active  IKK-alpha  and IKK-beta mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified  IKK-alpha  and IKK-beta in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "IKK-alpha"]]}, {"text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha,  IKK-beta , or constitutively active IKK-alpha and  IKK-beta  mutants was inhibited dose dependently by  sulfasalazine   Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and  IKK-beta  in vitro", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "IKK-beta"]]}, {"text": " Sulfasalazine  inhibited  tumor necrosis factor alpha  induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "tumor necrosis factor alpha"]]}, {"text": " Sulfasalazine  inhibited tumor necrosis factor alpha-induced activation of endogenous  IKK  in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified  IKK -alpha and  IKK -beta in vitro", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "IKK"]]}, {"text": " Sulfasalazine  inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified  IKK-alpha  and IKK-beta in vitro", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "IKK-alpha"]]}, {"text": " Sulfasalazine  inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and  IKK-beta  in vitro", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "IKK-beta"]]}, {"text": "Suppression of  NF-kappaB  activity by  sulfasalazine  is mediated by direct inhibition of IkappaB kinases alpha and beta", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of  IKKs  and can be antagonized by excess  adenosine triphosphate   CONCLUSIONS: These data identify sulfasalazine as a direct inhibitor of IKK-alpha and -beta by antagonizing  adenosine triphosphate  binding", "triple_list": [["adenosine triphosphate", "DOWNREGULATOR", "IKKs"]]}, {"text": "This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of  Bcl-2   as has been demonstrated for some nonselective NSAIDs, for instance,  flurbiprofen   COX-2 mRNA and COX-2 protein is constitutively expressed in the kidney, brain, spinal cord, and ductus deferens, and in the uterus during implantation", "triple_list": [["flurbiprofen", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "In contrast, aspirin-like nonselective NSAIDs such as sulindac and  indomethacin  inhibit not only the enzymatic action of the highly inducible, proinflammatory  COX-2  but the constitutively expressed, cytoprotective COX-1 as well", "triple_list": [["indomethacin", "DOWNREGULATOR", "COX-2"]]}, {"text": "In contrast, aspirin-like nonselective NSAIDs such as sulindac and  indomethacin  inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective  COX-1  as well", "triple_list": [["indomethacin", "DOWNREGULATOR", "COX-1"]]}, {"text": "Selective  COX-2  inhibitors, such as  meloxicam   celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as  meloxicam   celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam,  celecoxib  (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam,  celecoxib  (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam, celecoxib ( SC-58635  , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["SC-58635", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam, celecoxib ( SC-58635  , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["SC-58635", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam, celecoxib (SC-58635), and  rofecoxib  (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam, celecoxib (SC-58635), and  rofecoxib  (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ( MK-0966  , are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["MK-0966", "DOWNREGULATOR", "COX-2"]]}, {"text": "Selective  COX-2  inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ( MK-0966  , are NSAIDs that have been modified chemically to preferentially inhibit  COX-2  but not COX-1", "triple_list": [["MK-0966", "DOWNREGULATOR", "COX-2"]]}, {"text": "For instance,  meloxicam  inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express  COX-2  but has no effect on HCT-116 tumor cells that do not express  COX-2 ", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "In contrast,  aspirin  like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory  COX-2  but the constitutively expressed, cytoprotective COX-1 as well", "triple_list": [["aspirin", "DOWNREGULATOR", "COX-2"]]}, {"text": "In contrast,  aspirin  like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective  COX-1  as well", "triple_list": [["aspirin", "DOWNREGULATOR", "COX-1"]]}, {"text": "In contrast, aspirin-like nonselective NSAIDs such as  sulindac  and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory  COX-2  but the constitutively expressed, cytoprotective COX-1 as well", "triple_list": [["sulindac", "DOWNREGULATOR", "COX-2"]]}, {"text": "In contrast, aspirin-like nonselective NSAIDs such as  sulindac  and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective  COX-1  as well", "triple_list": [["sulindac", "DOWNREGULATOR", "COX-1"]]}, {"text": " COX-2  produces  prostaglandins  that inhibit apoptosis and stimulate angiogenesis and invasiveness", "triple_list": [["prostaglandins", "PRODUCT-OF", "COX-2"]]}, {"text": "To assess the feasibility of targeting these high  AAAD  levels for chemotherapy,  AAAD  inhibitors  carbidopa  (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells", "triple_list": [["carbidopa", "DOWNREGULATOR", "AAAD"]]}, {"text": "To assess the feasibility of targeting these high  AAAD  levels for chemotherapy,  AAAD  inhibitors carbidopa ( alpha-methyl-dopahydrazine  , alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells", "triple_list": [["alpha-methyl-dopahydrazine", "DOWNREGULATOR", "AAAD"]]}, {"text": "To assess the feasibility of targeting these high  AAAD  levels for chemotherapy,  AAAD  inhibitors carbidopa (alpha-methyl-dopahydrazine),  alpha-monofluoromethyldopa  (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells", "triple_list": [["alpha-monofluoromethyldopa", "DOWNREGULATOR", "AAAD"]]}, {"text": "To assess the feasibility of targeting these high  AAAD  levels for chemotherapy,  AAAD  inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa ( MFMD  , and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells", "triple_list": [["MFMD", "DOWNREGULATOR", "AAAD"]]}, {"text": "To assess the feasibility of targeting these high  AAAD  levels for chemotherapy,  AAAD  inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and  3-hydroxybenzylhydrazine  (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells", "triple_list": [["3-hydroxybenzylhydrazine", "DOWNREGULATOR", "AAAD"]]}, {"text": "To assess the feasibility of targeting these high  AAAD  levels for chemotherapy,  AAAD  inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine ( NSD-1015   were incubated (72 h) with NCI-H727 human lung carcinoid cells", "triple_list": [["NSD-1015", "DOWNREGULATOR", "AAAD"]]}, {"text": " Hexahydrochromeno[4,3-b]pyrrole  derivatives as  acetylcholinesterase  inhibitors", "triple_list": [["Hexahydrochromeno[4,3-b]pyrrole", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "Since this compound retains good  AChE  inhibitory activity and its  hexahydrochromeno[4,3-b]pyrrole  moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human  AChE  and BChE", "triple_list": [["hexahydrochromeno[4,3-b]pyrrole", "DOWNREGULATOR", "AChE"]]}, {"text": "Since this compound retains good  AChE  inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the  hexahydropyrrolo[2,3-b]indole of physostigmine  (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human  AChE  and BChE", "triple_list": [["hexahydropyrrolo[2,3-b]indole of physostigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "When the anti-corticosterone drug  aminoglutethimide  ( CYP11A1  inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and  CYP11A1  mRNA expression were decreased at 14 days after tumor inoculation", "triple_list": [["aminoglutethimide", "DOWNREGULATOR", "CYP11A1"]]}, {"text": "When the anti-corticosterone drug  aminoglutethimide  ( CYP11A1  inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and  CYP11A1  mRNA expression were decreased at 14 days after tumor inoculation", "triple_list": [["aminoglutethimide", "DOWNREGULATOR", "CYP11A1"]]}, {"text": "Furthermore, h[ Gly2  -GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited  poly(ADP-ribose) polymerase  cleavage in heterologous cells transfected with the GLP-2 receptor", "triple_list": [["Gly2", "DOWNREGULATOR", "poly(ADP-ribose) polymerase"]]}, {"text": "We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of  topoisomerase I  inhibitor  irinotecan hydrochloride  or the antimetabolite 5-fluorouracil", "triple_list": [["irinotecan hydrochloride", "DOWNREGULATOR", "topoisomerase I"]]}, {"text": "OBJECTIVES: The hypothesis of the present study was that differences among  dopamine transporter  ( DA T) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as  DA  uptake inhibitors", "triple_list": [["DA", "PRODUCT-OF", "dopamine transporter"]]}, {"text": "OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter ( DA T  ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as  DA  uptake inhibitors", "triple_list": [["DA", "PRODUCT-OF", "DAT"]]}, {"text": "Accordingly, self-administration of a group of local anesthetics that are  DA T ligands was compared to their effects as  DA  uptake blockers in vitro in brain tissue", "triple_list": [["DA", "PRODUCT-OF", "DAT"]]}, {"text": "Bumetanide-sensitive  Cl-  secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of  NKCC1  mediated  Cl-  transport", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "Contribution of the Na+-K+-2 Cl-  cotransporter NKCC1 to  Cl-  secretion in rat OMCD", "triple_list": [["Cl-", "PRODUCT-OF", "Na+-K+-2Cl- cotransporter"]]}, {"text": "Contribution of the Na+-K+-2 Cl-  cotransporter  NKCC1  to  Cl-  secretion in rat OMCD", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete  Cl-  into the luminal fluid through  NKCC1  mediated  Cl-  uptake across the basolateral membrane in series with  Cl-  efflux across the apical membrane", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete  Cl-  into the luminal fluid through  NKCC1  mediated  Cl-  uptake across the basolateral membrane in series with  Cl-  efflux across the apical membrane", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete  Cl-  into the luminal fluid through  NKCC1  mediated  Cl-  uptake across the basolateral membrane in series with  Cl-  efflux across the apical membrane", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "The physiological role of  NKCC1  mediated  Cl-  uptake remains to be determined", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes  Cl-  and whether transepithelial  Cl-  transport occurs, in part, through  Cl-  uptake across the basolateral membrane mediated by  NKCC1  in series with  Cl-  efflux across the apical membrane", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes  Cl-  and whether transepithelial  Cl-  transport occurs, in part, through  Cl-  uptake across the basolateral membrane mediated by  NKCC1  in series with  Cl-  efflux across the apical membrane", "triple_list": [["Cl-", "PRODUCT-OF", "NKCC1"]]}, {"text": "In mice,  AS-8112  (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  dopamine D3 receptor  agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)", "triple_list": [["AS-8112", "DOWNREGULATOR", "dopamine D3 receptor"]]}, {"text": "In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of  2-methyl-5HT   a  5-HT3 receptor  agonist (pA2 value of 7.04)", "triple_list": [["2-methyl-5HT", "AGONIST", "5-HT3 receptor"]]}, {"text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  dopamine D3 receptor  agonist;  R(+)-7-OH-DPAT  (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)", "triple_list": [["R(+)-7-OH-DPAT", "AGONIST", "dopamine D3 receptor"]]}, {"text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  dopamine D3 receptor  agonist; R(+)-7-OH-DPAT ( R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline   (0.3 mg kg(-1) s.c.)", "triple_list": [["R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline", "AGONIST", "dopamine D3 receptor"]]}, {"text": "In guinea-pig isolated colon,  AS-8112  produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a  5-HT3 receptor  agonist (pA2 value of 7.04)", "triple_list": [["AS-8112", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order:  granisetron   ondansetron=AS-8112>>metoclopramide", "triple_list": [["granisetron", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order: granisetron>  ondansetron  AS-8112>>metoclopramide", "triple_list": [["ondansetron", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron= AS-8112  >metoclopramide", "triple_list": [["AS-8112", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>> metoclopramide   In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)", "triple_list": [["metoclopramide", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": "The broad-spectrum anti-emetic activity of  AS-8112   a novel dopamine D2, D3 and  5-HT3 receptors  antagonist", "triple_list": [["AS-8112", "ANTAGONIST", "5-HT3 receptors"]]}, {"text": "In conclusion,  AS-8112  is a potent dopamine D2, D3 and  5-HT3 receptors  antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity", "triple_list": [["AS-8112", "ANTAGONIST", "5-HT3 receptors"]]}, {"text": " Rofecoxib  is a selective  cyclo-oxygenase (COX)-2  inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day", "triple_list": [["Rofecoxib", "DOWNREGULATOR", "cyclo-oxygenase (COX)-2"]]}, {"text": " Rofecoxib  has greater selectivity for  COX-2  than celecoxib, meloxicam, diclofenac and indomethacin", "triple_list": [["Rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": " Fenofibrate  and GW2331 induced expression of  acyl-coenzyme A (CoA) oxidase  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs", "triple_list": [["Fenofibrate", "ACTIVATOR", "acyl-coenzyme A (CoA) oxidase"]]}, {"text": " Fenofibrate  and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and  enoyl-CoA hydratase  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs", "triple_list": [["Fenofibrate", "ACTIVATOR", "enoyl-CoA hydratase"]]}, {"text": "Fenofibrate and  GW2331  induced expression of  acyl-coenzyme A (CoA) oxidase  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs", "triple_list": [["GW2331", "ACTIVATOR", "acyl-coenzyme A (CoA) oxidase"]]}, {"text": "Fenofibrate and  GW2331  induced expression of acyl-coenzyme A (CoA) oxidase and  enoyl-CoA hydratase  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs", "triple_list": [["GW2331", "ACTIVATOR", "enoyl-CoA hydratase"]]}, {"text": " Rosiglitazone  modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of  glucose transporter 4  and phosphoenolpyruvate carboxykinase in adipose tissue", "triple_list": [["Rosiglitazone", "ACTIVATOR", "glucose transporter 4"]]}, {"text": " Rosiglitazone  modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and  phosphoenolpyruvate carboxykinase  in adipose tissue", "triple_list": [["Rosiglitazone", "ACTIVATOR", "phosphoenolpyruvate carboxykinase"]]}, {"text": " Rosiglitazone  modestly increased  apolipoprotein C-III  mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue", "triple_list": [["Rosiglitazone", "ACTIVATOR", "apolipoprotein C-III"]]}, {"text": " Fenofibrate  and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced  apolipoprotein C-III  and phosphoenolpyruvate carboxykinase mRNAs", "triple_list": [["Fenofibrate", "DOWNREGULATOR", "apolipoprotein C-III"]]}, {"text": " Fenofibrate  and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  phosphoenolpyruvate carboxykinase  mRNAs", "triple_list": [["Fenofibrate", "DOWNREGULATOR", "phosphoenolpyruvate carboxykinase"]]}, {"text": "Fenofibrate and  GW2331  induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced  apolipoprotein C-III  and phosphoenolpyruvate carboxykinase mRNAs", "triple_list": [["GW2331", "DOWNREGULATOR", "apolipoprotein C-III"]]}, {"text": "Fenofibrate and  GW2331  induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  phosphoenolpyruvate carboxykinase  mRNAs", "triple_list": [["GW2331", "DOWNREGULATOR", "phosphoenolpyruvate carboxykinase"]]}, {"text": " Long-chain alkanols  are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral  nicotinic acetylcholine receptor  (AChR) by binding to one or more specific sites on the AChR", "triple_list": [["Long-chain alkanols", "DOWNREGULATOR", "nicotinic acetylcholine receptor"]]}, {"text": " Cembranoids  are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal  AChRs   which have no demonstrable general anesthetic activity in vivo", "triple_list": [["Cembranoids", "DOWNREGULATOR", "AChRs"]]}, {"text": " Sulfasalazine  was fortuitously found to be a novel, potent inhibitor of the  x(c)- transporter   It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "x(c)- transporter"]]}, {"text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  x(c)  -mediated cystine uptake, in contrast to its colonic metabolites,  sulfapyridine  and 5-aminosalicylic acid", "triple_list": [["sulfapyridine", "DOWNREGULATOR", "x(c)"]]}, {"text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  x(c)  -mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and  5-aminosalicylic acid   Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures", "triple_list": [["5-aminosalicylic acid", "DOWNREGULATOR", "x(c)"]]}, {"text": " Sulfasalazine   a potent suppressor of lymphoma growth by inhibition of the  x(c)- cystine transporter   a new action for an old drug", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "x(c)- cystine transporter"]]}, {"text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  x(c)  -mediated  cystine  uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid", "triple_list": [["cystine", "PRODUCT-OF", "x(c)"]]}, {"text": "The  x(c)- cystine transporter  represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular  cyst(e)ine  ", "triple_list": [["cyst(e)ine", "PRODUCT-OF", "x(c)- cystine transporter"]]}, {"text": "Like conventional ACE inhibitors,  omapatrilat  causes extracellular volume reduction and vasodilatation; moreover, it increases levels of  atrial and brain natriuretic peptides  and bradykinin", "triple_list": [["omapatrilat", "ACTIVATOR", "atrial and brain natriuretic peptides"]]}, {"text": "Like conventional ACE inhibitors,  omapatrilat  causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and  bradykinin   Effective blood pressure control, especially in the high-risk patient, usually necessitates combination therapy", "triple_list": [["omapatrilat", "ACTIVATOR", "bradykinin"]]}, {"text": "Like conventional  ACE  inhibitors,  omapatrilat  causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin", "triple_list": [["omapatrilat", "DOWNREGULATOR", "ACE"]]}, {"text": "Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with  omapatrilat   a  vasopeptidase  inhibitor", "triple_list": [["omapatrilat", "DOWNREGULATOR", "vasopeptidase"]]}, {"text": " Omapatrilat   the prototypical  vasopeptidase  inhibitor, inhibits not only ACE but also neutral endopeptidase", "triple_list": [["Omapatrilat", "DOWNREGULATOR", "vasopeptidase"]]}, {"text": " Omapatrilat   the prototypical vasopeptidase inhibitor, inhibits not only  ACE  but also neutral endopeptidase", "triple_list": [["Omapatrilat", "DOWNREGULATOR", "ACE"]]}, {"text": " Omapatrilat   the prototypical vasopeptidase inhibitor, inhibits not only ACE but also  neutral endopeptidase   Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin", "triple_list": [["Omapatrilat", "DOWNREGULATOR", "neutral endopeptidase"]]}, {"text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to  Na+  H+ exchange ( NHE1  isoform)", "triple_list": [["Na+", "PRODUCT-OF", "NHE1"]]}, {"text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+- H+  exchange ( NHE1  isoform)", "triple_list": [["H+", "PRODUCT-OF", "NHE1"]]}, {"text": " Salicylates  inhibited  ATPase  activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression", "triple_list": [["Salicylates", "DOWNREGULATOR", "ATPase"]]}, {"text": " Aspirin  and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its  ATPase  activity in human fibroblasts", "triple_list": [["Aspirin", "DOWNREGULATOR", "ATPase"]]}, {"text": "Aspirin and  salicylate  bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its  ATPase  activity in human fibroblasts", "triple_list": [["salicylate", "DOWNREGULATOR", "ATPase"]]}, {"text": "The specific activity of only  ornithine aminotransferase  (OAT), the rate-limiting enzyme in the conversion of ornithine to  proline   increased in 2 weeks of hypertrophy", "triple_list": [["proline", "PRODUCT-OF", "ornithine aminotransferase"]]}, {"text": "The specific activity of only ornithine aminotransferase ( OAT  , the rate-limiting enzyme in the conversion of ornithine to  proline   increased in 2 weeks of hypertrophy", "triple_list": [["proline", "PRODUCT-OF", "OAT"]]}, {"text": "The specific activity of only  ornithine  aminotransferase (OAT), the rate-limiting enzyme in the conversion of  ornithine  to proline, increased in 2 weeks of hypertrophy", "triple_list": [["ornithine", "PRODUCT-OF", "ornithine aminotransferase"]]}, {"text": "The specific activity of only  ornithine  aminotransferase ( OAT  , the rate-limiting enzyme in the conversion of  ornithine  to proline, increased in 2 weeks of hypertrophy", "triple_list": [["ornithine", "PRODUCT-OF", "OAT"]]}, {"text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective  cyclooxygenase (COX)-2  inhibitor ( celecoxib   in comparison to a dual COX-1/COX-2 inhibitor (ketorolac)", "triple_list": [["celecoxib", "DOWNREGULATOR", "cyclooxygenase (COX)-2"]]}, {"text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual  COX-1  COX-2 inhibitor ( ketorolac  ", "triple_list": [["ketorolac", "DOWNREGULATOR", "COX-1"]]}, {"text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/ COX-2  inhibitor ( ketorolac  ", "triple_list": [["ketorolac", "DOWNREGULATOR", "COX-2"]]}, {"text": " Celecoxib  selectively suppressed PGE2 but not TxB2 at time points consistent with  COX-2  activity, while producing analgesia", "triple_list": [["Celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of  prostaglandin E2  (PGE2; a product of both  COX-1  and COX-2) and thromboxane B2 (as a biomarker for  COX-1  activity) with parallel assessments of pain", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "COX-1"]]}, {"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of  prostaglandin E2  (PGE2; a product of both COX-1 and  COX-2   and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "COX-2"]]}, {"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ( PGE2   a product of both  COX-1  and COX-2) and thromboxane B2 (as a biomarker for  COX-1  activity) with parallel assessments of pain", "triple_list": [["PGE2", "PRODUCT-OF", "COX-1"]]}, {"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ( PGE2   a product of both COX-1 and  COX-2   and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain", "triple_list": [["PGE2", "PRODUCT-OF", "COX-2"]]}, {"text": "The time course of  PGE2  production was consistent with early release due to  COX-1  activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression", "triple_list": [["PGE2", "PRODUCT-OF", "COX-1"]]}, {"text": "The time course of  PGE2  production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with  COX-2  expression", "triple_list": [["PGE2", "PRODUCT-OF", "COX-2"]]}, {"text": "Celecoxib selectively suppressed  PGE2  but not TxB2 at time points consistent with  COX-2  activity, while producing analgesia", "triple_list": [["PGE2", "PRODUCT-OF", "COX-2"]]}, {"text": "These studies demonstrate the ability to assess the time course and selective effects of  COX-2  inhibitors in vivo and suggest that suppression of  COX-2  mediated  PGE2  is temporally related to NSAID analgesia.", "triple_list": [["PGE2", "PRODUCT-OF", "COX-2"]]}, {"text": "Acute and chronic  PLZ  administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme,  GABA transaminase  (GABA-T)", "triple_list": [["PLZ", "DOWNREGULATOR", "GABA transaminase"]]}, {"text": "Acute and chronic  PLZ  administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase ( GABA-T  ", "triple_list": [["PLZ", "DOWNREGULATOR", "GABA-T"]]}, {"text": "The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of  PLZ  on  alanine transaminase  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced", "triple_list": [["PLZ", "DOWNREGULATOR", "alanine transaminase"]]}, {"text": "The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of  PLZ  on alanine transaminase ( ALA-T  , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced", "triple_list": [["PLZ", "DOWNREGULATOR", "ALA-T"]]}, {"text": "In addition, we also showed that the elevation in alanine levels and the inhibition of  alanine transaminase  in the brain are retained after 14 days of  PLZ  treatment, and that  PLZ  produces a marked increase in extracellular levels of alanine", "triple_list": [["PLZ", "DOWNREGULATOR", "alanine transaminase"]]}, {"text": "As with GABA, the metabolism of  alanine  involves a  pyridoxal phosphate-dependent transaminase   3", "triple_list": [["alanine", "PRODUCT-OF", "pyridoxal phosphate-dependent transaminase"]]}, {"text": "In the study reported here, the effects of acute PLZ treatment on the levels of various  amino acids   some of which are also metabolized by  pyridoxal phosphate-dependent transaminases  were compared in rat whole brain", "triple_list": [["amino acids", "PRODUCT-OF", "pyridoxal phosphate-dependent transaminases"]]}, {"text": "In addition, we also showed that the elevation in  alanine  levels and the inhibition of  alanine  transaminase in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of  alanine ", "triple_list": [["alanine", "PRODUCT-OF", "alanine transaminase"]]}, {"text": "The elevation in brain  alanine  levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on  alanine  transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced", "triple_list": [["alanine", "PRODUCT-OF", "alanine transaminase"]]}, {"text": "The elevation in brain  alanine  levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on  alanine  transaminase ( ALA-T  , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced", "triple_list": [["alanine", "PRODUCT-OF", "ALA-T"]]}, {"text": "Acute and chronic PLZ administration increase brain  GABA  levels, an effect due, at least in part, to an inhibition of the activity of the  GABA  metabolizing enzyme,  GABA  transaminase ( GABA -T)", "triple_list": [["GABA", "PRODUCT-OF", "GABA transaminase"]]}, {"text": "Acute and chronic PLZ administration increase brain  GABA  levels, an effect due, at least in part, to an inhibition of the activity of the  GABA  metabolizing enzyme,  GABA  transaminase ( GABA -T ", "triple_list": [["GABA", "PRODUCT-OF", "GABA-T"]]}, {"text": " Cyclooxygenase-1  (COX-1) inhibitors ( flurbiprofen   ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction", "triple_list": [["flurbiprofen", "DOWNREGULATOR", "Cyclooxygenase-1"]]}, {"text": "Cyclooxygenase-1 ( COX-1   inhibitors ( flurbiprofen   ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction", "triple_list": [["flurbiprofen", "DOWNREGULATOR", "COX-1"]]}, {"text": " Cyclooxygenase-1  (COX-1) inhibitors (flurbiprofen,  ketoprofen  and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction", "triple_list": [["ketoprofen", "DOWNREGULATOR", "Cyclooxygenase-1"]]}, {"text": "Cyclooxygenase-1 ( COX-1   inhibitors (flurbiprofen,  ketoprofen  and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction", "triple_list": [["ketoprofen", "DOWNREGULATOR", "COX-1"]]}, {"text": " Cyclooxygenase-1  (COX-1) inhibitors (flurbiprofen, ketoprofen and  ketrolack   attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction", "triple_list": [["ketrolack", "DOWNREGULATOR", "Cyclooxygenase-1"]]}, {"text": "Cyclooxygenase-1 ( COX-1   inhibitors (flurbiprofen, ketoprofen and  ketrolack   attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction", "triple_list": [["ketrolack", "DOWNREGULATOR", "COX-1"]]}, {"text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and  cyclooxygenase-2  (COX-2) inhibitors at high concentrations ( nimesulide  and NS-389) slightly attenuated the contraction", "triple_list": [["nimesulide", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 ( COX-2   inhibitors at high concentrations ( nimesulide  and NS-389) slightly attenuated the contraction", "triple_list": [["nimesulide", "DOWNREGULATOR", "COX-2"]]}, {"text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and  cyclooxygenase-2  (COX-2) inhibitors at high concentrations (nimesulide and  NS-389   slightly attenuated the contraction", "triple_list": [["NS-389", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 ( COX-2   inhibitors at high concentrations (nimesulide and  NS-389   slightly attenuated the contraction", "triple_list": [["NS-389", "DOWNREGULATOR", "COX-2"]]}, {"text": "A  TXA2 synthetase  inhibitor ( OKY-046   attenuated the contraction to a small extent only at high concentrations", "triple_list": [["OKY-046", "DOWNREGULATOR", "TXA2 synthetase"]]}, {"text": "A  TXA2 receptor  antagonist ( S-1452   attenuated the contraction in a concentration-dependent manner", "triple_list": [["S-1452", "ANTAGONIST", "TXA2 receptor"]]}, {"text": "A  nicotinic receptor  antagonist ( hexamethonium   attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction", "triple_list": [["hexamethonium", "ANTAGONIST", "nicotinic receptor"]]}, {"text": "A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an  alpha-adrenoceptor  antagonist ( prazosin   nearly abolished the contraction", "triple_list": [["prazosin", "ANTAGONIST", "alpha-adrenoceptor"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen,  zomepirac   indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["zomepirac", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac,  indomethacin   diclofenac and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["indomethacin", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin,  diclofenac  and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["diclofenac", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and  meclofenamic acid  were undertaken using the AMBER program", "triple_list": [["meclofenamic acid", "DOWNREGULATOR", "COX"]]}, {"text": "Non- steroidal  anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  cyclooxygenase  (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid", "triple_list": [["steroidal", "DOWNREGULATOR", "cyclooxygenase"]]}, {"text": "Non- steroidal  anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( COX  , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid", "triple_list": [["steroidal", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands:  rofecoxib   ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib,  ketoprofen   suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["ketoprofen", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen,  suprofen   carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["suprofen", "DOWNREGULATOR", "COX"]]}, {"text": "Accordingly, docking of different  COX  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen,  carprofen   zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program", "triple_list": [["carprofen", "DOWNREGULATOR", "COX"]]}, {"text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  cyclooxygenase  (COX), the enzyme that mediates biosynthesis of  prostaglandins  and thromboxanes from arachidonic acid", "triple_list": [["prostaglandins", "PRODUCT-OF", "cyclooxygenase"]]}, {"text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( COX  , the enzyme that mediates biosynthesis of  prostaglandins  and thromboxanes from arachidonic acid", "triple_list": [["prostaglandins", "PRODUCT-OF", "COX"]]}, {"text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  cyclooxygenase  (COX), the enzyme that mediates biosynthesis of prostaglandins and  thromboxanes  from arachidonic acid", "triple_list": [["thromboxanes", "PRODUCT-OF", "cyclooxygenase"]]}, {"text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( COX  , the enzyme that mediates biosynthesis of prostaglandins and  thromboxanes  from arachidonic acid", "triple_list": [["thromboxanes", "PRODUCT-OF", "COX"]]}, {"text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  cyclooxygenase  (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from  arachidonic acid   There are at least two different isoforms of the enzyme known as COX-1 and -2", "triple_list": [["arachidonic acid", "PRODUCT-OF", "cyclooxygenase"]]}, {"text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( COX  , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from  arachidonic acid   There are at least two different isoforms of the enzyme known as  COX -1 and -2", "triple_list": [["arachidonic acid", "PRODUCT-OF", "COX"]]}, {"text": "Olopatadine hydrochloride ( olopatadine   11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ histamine H1-receptor  antagonistic drug that was synthesized and evaluated in our laboratories", "triple_list": [["olopatadine", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": "Olopatadine hydrochloride (olopatadine,  11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride   is a novel antiallergic/ histamine H1-receptor  antagonistic drug that was synthesized and evaluated in our laboratories", "triple_list": [["11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": " Olopatadine  is a selective  histamine H1-receptor  antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils", "triple_list": [["Olopatadine", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": " Olopatadine hydrochloride  (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ histamine H1-receptor  antagonistic drug that was synthesized and evaluated in our laboratories", "triple_list": [["Olopatadine hydrochloride", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": "A molecular mechanism of action of  theophylline   Induction of  histone deacetylase  activity to decrease inflammatory gene expression", "triple_list": [["theophylline", "ACTIVATOR", "histone deacetylase"]]}, {"text": "Thus we have shown that low-dose  theophylline  exerts an anti-asthma effect through increasing activation of  HDAC  which is subsequently recruited by corticosteroids to suppress inflammatory genes.", "triple_list": [["theophylline", "ACTIVATOR", "HDAC"]]}, {"text": "We show both in vitro and in vivo that low-dose  theophylline  enhances  HDAC  activity in epithelial cells and macrophages", "triple_list": [["theophylline", "ACTIVATOR", "HDAC"]]}, {"text": "Inhibition of  human liver OATPs  can explain the previously observed effects of  rifamycin SV  and rifampicin on hepatic organic anion elimination.", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "human liver OATPs"]]}, {"text": "Inhibition of  human liver OATPs  can explain the previously observed effects of rifamycin SV and  rifampicin  on hepatic organic anion elimination.", "triple_list": [["rifampicin", "DOWNREGULATOR", "human liver OATPs"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited  human organic anion transporting polypeptide C  (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "human organic anion transporting polypeptide C"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C ( SLC21A6   (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "SLC21A6"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) ( OATP-C  , human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "OATP-C"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C),  human organic anion transporting polypeptide 8  (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "human organic anion transporting polypeptide 8"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 ( SLC21A8   (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "SLC21A8"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) ( OATP8  , human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "OATP8"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8),  human organic anion transporting polypeptide B  (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "human organic anion transporting polypeptide B"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B ( SLC21A9   (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "SLC21A9"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) ( OATP-B  , and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "OATP-B"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and  human organic anion transporting polypeptide A  (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "human organic anion transporting polypeptide A"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A ( SLC21A3   (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "SLC21A3"]]}, {"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  rifamycin SV  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) ( OATP-A   mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "OATP-A"]]}, {"text": " Rifampicin  (10 micromol/L) inhibited  OATP8  mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%", "triple_list": [["Rifampicin", "DOWNREGULATOR", "OATP8"]]}, {"text": " Rifampicin  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of  OATP-C  , OATP-B-, and OATP-A-mediated BSP transport was below 15%", "triple_list": [["Rifampicin", "DOWNREGULATOR", "OATP-C"]]}, {"text": " Rifampicin  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-,  OATP-B  , and OATP-A-mediated BSP transport was below 15%", "triple_list": [["Rifampicin", "DOWNREGULATOR", "OATP-B"]]}, {"text": " Rifampicin  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and  OATP-A  mediated BSP transport was below 15%", "triple_list": [["Rifampicin", "DOWNREGULATOR", "OATP-A"]]}, {"text": "In rats,  rifamycin SV  and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the  organic anion transporting polypeptides  Oatp1 and Oatp2", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "organic anion transporting polypeptides"]]}, {"text": "In rats,  rifamycin SV  and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides  Oatp1  and Oatp2", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "Oatp1"]]}, {"text": "In rats,  rifamycin SV  and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and  Oatp2   Therefore, we investigated the effects of  rifamycin SV  and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers", "triple_list": [["rifamycin SV", "DOWNREGULATOR", "Oatp2"]]}, {"text": "100 micromol/L  rifampicin  inhibited  OATP-C   and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["rifampicin", "DOWNREGULATOR", "OATP-C"]]}, {"text": "100 micromol/L  rifampicin  inhibited OATP-C- and  OATP8  , OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["rifampicin", "DOWNREGULATOR", "OATP8"]]}, {"text": "100 micromol/L  rifampicin  inhibited OATP-C- and OATP8-,  OATP-B   and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["rifampicin", "DOWNREGULATOR", "OATP-B"]]}, {"text": "100 micromol/L  rifampicin  inhibited OATP-C- and OATP8-, OATP-B- and  OATP-A  mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["rifampicin", "DOWNREGULATOR", "OATP-A"]]}, {"text": "In rats, rifamycin SV and  rifampicin  were shown to interfere with hepatic organic anion uptake by inhibition of the  organic anion transporting polypeptides  Oatp1 and Oatp2", "triple_list": [["rifampicin", "DOWNREGULATOR", "organic anion transporting polypeptides"]]}, {"text": "In rats, rifamycin SV and  rifampicin  were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides  Oatp1  and Oatp2", "triple_list": [["rifampicin", "DOWNREGULATOR", "Oatp1"]]}, {"text": "In rats, rifamycin SV and  rifampicin  were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and  Oatp2   Therefore, we investigated the effects of rifamycin SV and  rifampicin  on the OATPs of human liver and determined whether  rifampicin  is a substrate of 1 or several of these carriers", "triple_list": [["rifampicin", "DOWNREGULATOR", "Oatp2"]]}, {"text": "Rifampicin (10 micromol/L) inhibited  OATP8  mediated  BSP  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated  BSP  transport was below 15%", "triple_list": [["BSP", "PRODUCT-OF", "OATP8"]]}, {"text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated  BSP  uptake by 50%, whereas inhibition of  OATP-C  , OATP-B-, and OATP-A-mediated  BSP  transport was below 15%", "triple_list": [["BSP", "PRODUCT-OF", "OATP-C"]]}, {"text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated  BSP  uptake by 50%, whereas inhibition of OATP-C-,  OATP-B  , and OATP-A-mediated  BSP  transport was below 15%", "triple_list": [["BSP", "PRODUCT-OF", "OATP-B"]]}, {"text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated  BSP  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and  OATP-A  mediated  BSP  transport was below 15%", "triple_list": [["BSP", "PRODUCT-OF", "OATP-A"]]}, {"text": "100 micromol/L rifampicin inhibited  OATP-C   and OATP8-, OATP-B- and OATP-A-mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["BSP", "PRODUCT-OF", "OATP-C"]]}, {"text": "100 micromol/L rifampicin inhibited OATP-C- and  OATP8  , OATP-B- and OATP-A-mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["BSP", "PRODUCT-OF", "OATP8"]]}, {"text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-,  OATP-B   and OATP-A-mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["BSP", "PRODUCT-OF", "OATP-B"]]}, {"text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and  OATP-A  mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively", "triple_list": [["BSP", "PRODUCT-OF", "OATP-A"]]}, {"text": "Direct transport of  rifampicin  could be shown for  OATP-C  (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L)", "triple_list": [["rifampicin", "PRODUCT-OF", "OATP-C"]]}, {"text": "Direct transport of  rifampicin  could be shown for OATP-C (apparent K(m) value 13 micromol/L) and  OATP8  (2.3 micromol/L)", "triple_list": [["rifampicin", "PRODUCT-OF", "OATP8"]]}, {"text": "We recently reported that  AMPK  is activated by  metformin  in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "In the present study, we evaluated whether therapeutic doses of  metformin  increase  AMPK  activity in vivo in subjects with type 2 diabetes", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": " Metformin  treatment for 10 weeks significantly increased  AMPK alpha2  activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity", "triple_list": [["Metformin", "ACTIVATOR", "AMPK alpha2"]]}, {"text": " Metformin  treatment for 10 weeks significantly increased  AMPK  alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of  AMPK  on Thr172 and decreased acetyl-CoA carboxylase-2 activity", "triple_list": [["Metformin", "ACTIVATOR", "AMPK"]]}, {"text": " Metformin  increases  AMP-activated protein kinase  activity in skeletal muscle of subjects with type 2 diabetes", "triple_list": [["Metformin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "The increase in  AMPK alpha2  activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after  metformin  treatment", "triple_list": [["metformin", "ACTIVATOR", "AMPK alpha2"]]}, {"text": " Metformin  induced increases in  AMPK  activity were associated with higher rates of glucose disposal and muscle glycogen concentrations", "triple_list": [["Metformin", "ACTIVATOR", "AMPK"]]}, {"text": " Metformin  treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased  acetyl-CoA carboxylase-2  activity", "triple_list": [["Metformin", "DOWNREGULATOR", "acetyl-CoA carboxylase-2"]]}, {"text": " AMP-activated protein kinase  (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of  glucose  uptake into skeletal muscle and the inhibition of liver gluconeogenesis", "triple_list": [["glucose", "PRODUCT-OF", "AMP-activated protein kinase"]]}, {"text": "AMP-activated protein kinase ( AMPK   activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of  glucose  uptake into skeletal muscle and the inhibition of liver gluconeogenesis", "triple_list": [["glucose", "PRODUCT-OF", "AMPK"]]}, {"text": "CONCLUSIONS: These results collectively indicate that  thalidomide  prevents alcoholic liver injury through suppression of  TNF-alpha  production and abolishment of KC sensitization.", "triple_list": [["thalidomide", "DOWNREGULATOR", "TNF-alpha"]]}, {"text": " Thalidomide  has been shown to suppress  TNF-alpha  production from macrophages", "triple_list": [["Thalidomide", "DOWNREGULATOR", "TNF-alpha"]]}, {"text": " Thalidomide  prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and  TNF-alpha  production", "triple_list": [["Thalidomide", "DOWNREGULATOR", "TNF-alpha"]]}, {"text": "Furthermore,  thalidomide  abolished the LPS-induced increase in  CD14  expression and [Ca2+]i elevation in KCs", "triple_list": [["thalidomide", "DOWNREGULATOR", "CD14"]]}, {"text": "Moreover,  thalidomide  reduced the LPS-induced  TNF-alpha  production by KCs by decreasing  TNF-alpha  messenger RNA", "triple_list": [["thalidomide", "DOWNREGULATOR", "TNF-alpha"]]}, {"text": "Moreover,  thalidomide  reduced the LPS-induced  TNF-alpha  production by KCs by decreasing  TNF-alpha  messenger RNA", "triple_list": [["thalidomide", "DOWNREGULATOR", "TNF-alpha"]]}, {"text": "The  PAO  inhibitor,  MDL-72,527   only partially blocked oxidation of spermine while a previously reported  PAO  substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction", "triple_list": [["MDL-72,527", "DOWNREGULATOR", "PAO"]]}, {"text": "During polyamine catabolism, spermine and  spermidine  are first acetylated by  spermidine /spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  polyamine oxidase  (PAO) to produce  spermidine  and putrescine, respectively", "triple_list": [["spermidine", "PRODUCT-OF", "polyamine oxidase"]]}, {"text": "During polyamine catabolism, spermine and  spermidine  are first acetylated by  spermidine /spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( PAO   to produce  spermidine  and putrescine, respectively", "triple_list": [["spermidine", "PRODUCT-OF", "PAO"]]}, {"text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  polyamine oxidase  (PAO) to produce spermidine and  putrescine   respectively", "triple_list": [["putrescine", "PRODUCT-OF", "polyamine oxidase"]]}, {"text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( PAO   to produce spermidine and  putrescine   respectively", "triple_list": [["putrescine", "PRODUCT-OF", "PAO"]]}, {"text": "During polyamine catabolism,  spermine  and spermidine are first acetylated by spermidine/ spermine  N(1)-acetyltransferase ( SSAT   and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively", "triple_list": [["spermine", "PRODUCT-OF", "SSAT"]]}, {"text": "During polyamine catabolism,  spermine  and spermidine are first acetylated by spermidine/ spermine  N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively", "triple_list": [["spermine", "PRODUCT-OF", "spermidine/spermine N(1)-acetyltransferase"]]}, {"text": "In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves  spermine  in the absence of prior acetylation by  SSAT   A BLAST search using maize PAO sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 amino acids", "triple_list": [["spermine", "PRODUCT-OF", "SSAT"]]}, {"text": "During polyamine catabolism, spermine and  spermidine  are first acetylated by  spermidine /spermine N(1)-acetyltransferase ( SSAT   and subsequently oxidized by polyamine oxidase (PAO) to produce  spermidine  and putrescine, respectively", "triple_list": [["spermidine", "PRODUCT-OF", "SSAT"]]}, {"text": "During polyamine catabolism, spermine and  spermidine  are first acetylated by  spermidine /spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce  spermidine  and putrescine, respectively", "triple_list": [["spermidine", "PRODUCT-OF", "spermidine/spermine N(1)-acetyltransferase"]]}, {"text": "During  polyamine  catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ( SSAT   and subsequently oxidized by  polyamine  oxidase (PAO) to produce spermidine and putrescine, respectively", "triple_list": [["polyamine", "PRODUCT-OF", "SSAT"]]}, {"text": "During  polyamine  catabolism, spermine and spermidine are first acetylated by  spermidine/spermine N(1)-acetyltransferase  (SSAT) and subsequently oxidized by  polyamine  oxidase (PAO) to produce spermidine and putrescine, respectively", "triple_list": [["polyamine", "PRODUCT-OF", "spermidine/spermine N(1)-acetyltransferase"]]}, {"text": "Substrate specificity using lysates of  oxidase -transfected HEK-293 cells revealed that the newly identified  oxidase  strongly favoured  spermine  over N (1)-acetyl spermine  and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetyl spermine ", "triple_list": [["spermine", "PRODUCT-OF", "oxidase"]]}, {"text": "Substrate specificity using lysates of  oxidase -transfected HEK-293 cells revealed that the newly identified  oxidase  strongly favoured spermine over  N (1)-acetylspermine  and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine", "triple_list": [["N (1)-acetylspermine", "PRODUCT-OF", "oxidase"]]}, {"text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred  PAO  substrate,  N (1), N (12)-diacetylspermine   The  PAO  inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported  PAO  substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction", "triple_list": [["N (1), N (12)-diacetylspermine", "PRODUCT-OF", "PAO"]]}, {"text": "The  PAO  inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported  PAO  substrate,  N (1)-( n -octanesulphonyl)spermine   potently inhibited the reaction", "triple_list": [["N (1)-( n -octanesulphonyl)spermine", "PRODUCT-OF", "PAO"]]}, {"text": "In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or  ADP  stimulated  CD62P  expression", "triple_list": [["ADP", "ACTIVATOR", "CD62P"]]}, {"text": "Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or  ADP  induced  CD62P  expression", "triple_list": [["ADP", "ACTIVATOR", "CD62P"]]}, {"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  beta-lyases  to  pyruvate   ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["pyruvate", "PRODUCT-OF", "beta-lyases"]]}, {"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate,  ammonia   and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["ammonia", "PRODUCT-OF", "beta-lyases"]]}, {"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate, ammonia, and an  alpha-chloroenethiolate  (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["alpha-chloroenethiolate", "PRODUCT-OF", "beta-lyases"]]}, {"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate, ammonia, and an alpha-chloroenethiolate (with  DCVC   or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["DCVC", "PRODUCT-OF", "beta-lyases"]]}, {"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an  alpha-difluoroalkylthiolate  (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["alpha-difluoroalkylthiolate", "PRODUCT-OF", "beta-lyases"]]}, {"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with  TFEC   that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["TFEC", "PRODUCT-OF", "beta-lyases"]]}, {"text": "Most halogenated  cysteine S-conjugates  are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins", "triple_list": [["cysteine S-conjugates", "PRODUCT-OF", "beta-lyases"]]}, {"text": "The juvenile visceral steatosis (jvs) mouse, having a mutation in the  carnitine  transporter gene  Octn2   is a model of primary systemic  carnitine  deficiency in humans (SCD, OMIM 212140)", "triple_list": [["carnitine", "PRODUCT-OF", "Octn2"]]}, {"text": "The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the  OCT3  inhibitors cyanine 863,  oestradiol  and corticosterone", "triple_list": [["oestradiol", "DOWNREGULATOR", "OCT3"]]}, {"text": "The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the  OCT3  inhibitors cyanine 863, oestradiol and  corticosterone   In contrast, cyanine 863 enhanced the radioactive outflow from cultures preloaded with [3H]-NA", "triple_list": [["corticosterone", "DOWNREGULATOR", "OCT3"]]}, {"text": "However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of  MPP+   indicating the  NAT  and not an OCT as their primary site of action", "triple_list": [["MPP+", "PRODUCT-OF", "NAT"]]}, {"text": "Our observations indicate an  OCT  mediated transmembrane transport of  [3H]-MPP+   Amongst the three  OCT s expressed in the SCG,  OCT 3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  [3H]-MPP+  release.", "triple_list": [["[3H]-MPP+", "PRODUCT-OF", "OCT"]]}, {"text": "Amongst the three  OCTs  expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  [3H]-MPP+  release.", "triple_list": [["[3H]-MPP+", "PRODUCT-OF", "OCTs"]]}, {"text": "Amongst the three OCTs expressed in the SCG,  OCT3  best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  [3H]-MPP+  release.", "triple_list": [["[3H]-MPP+", "PRODUCT-OF", "OCT3"]]}, {"text": "Reuptake of extracellular  noradrenaline  (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the  noradrenaline  transporter (NAT, uptake 1)", "triple_list": [["noradrenaline", "PRODUCT-OF", "noradrenaline transporter"]]}, {"text": "Reuptake of extracellular  noradrenaline  (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the  noradrenaline  transporter ( NAT   uptake 1)", "triple_list": [["noradrenaline", "PRODUCT-OF", "NAT"]]}, {"text": "The outflow of  [3H]-MPP+  was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for  OCT  related transmembrane transporters", "triple_list": [["[3H]-MPP+", "PRODUCT-OF", "OCT"]]}, {"text": "The outflow of  [3H]-MPP+  was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related  transmembrane transporters   However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action", "triple_list": [["[3H]-MPP+", "PRODUCT-OF", "transmembrane transporters"]]}, {"text": "The outflow of [3H]- MPP+  was significantly enhanced by  MPP+   guanidine, choline and amantadine as potential substrates for  OCT  related transmembrane transporters", "triple_list": [["MPP+", "PRODUCT-OF", "OCT"]]}, {"text": "The outflow of [3H]- MPP+  was significantly enhanced by  MPP+   guanidine, choline and amantadine as potential substrates for OCT-related  transmembrane transporters   However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of  MPP+ , indicating the NAT and not an OCT as their primary site of action", "triple_list": [["MPP+", "PRODUCT-OF", "transmembrane transporters"]]}, {"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+,  guanidine   choline and amantadine as potential substrates for  OCT  related transmembrane transporters", "triple_list": [["guanidine", "PRODUCT-OF", "OCT"]]}, {"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+,  guanidine   choline and amantadine as potential substrates for OCT-related  transmembrane transporters   However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action", "triple_list": [["guanidine", "PRODUCT-OF", "transmembrane transporters"]]}, {"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine,  choline  and amantadine as potential substrates for  OCT  related transmembrane transporters", "triple_list": [["choline", "PRODUCT-OF", "OCT"]]}, {"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine,  choline  and amantadine as potential substrates for OCT-related  transmembrane transporters   However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action", "triple_list": [["choline", "PRODUCT-OF", "transmembrane transporters"]]}, {"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and  amantadine  as potential substrates for  OCT  related transmembrane transporters", "triple_list": [["amantadine", "PRODUCT-OF", "OCT"]]}, {"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and  amantadine  as potential substrates for OCT-related  transmembrane transporters   However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action", "triple_list": [["amantadine", "PRODUCT-OF", "transmembrane transporters"]]}, {"text": "Long-term administration of  propargylamines  to rats increased the activities of antioxidative enzymes  superoxide dismutase  (SOD) and catalase in the brain regions containing dopamine neurons", "triple_list": [["propargylamines", "ACTIVATOR", "superoxide dismutase"]]}, {"text": "Long-term administration of  propargylamines  to rats increased the activities of antioxidative enzymes superoxide dismutase ( SOD   and catalase in the brain regions containing dopamine neurons", "triple_list": [["propargylamines", "ACTIVATOR", "SOD"]]}, {"text": "Long-term administration of  propargylamines  to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and  catalase  in the brain regions containing dopamine neurons", "triple_list": [["propargylamines", "ACTIVATOR", "catalase"]]}, {"text": " Rasagiline  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic  Bcl-2  and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)", "triple_list": [["Rasagiline", "ACTIVATOR", "Bcl-2"]]}, {"text": " Rasagiline  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a  neurotrophic factor   glial cell line-derived  neurotrophic factor  (GDNF)", "triple_list": [["Rasagiline", "ACTIVATOR", "neurotrophic factor"]]}, {"text": " Rasagiline  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor,  glial cell line-derived neurotrophic factor  (GDNF)", "triple_list": [["Rasagiline", "ACTIVATOR", "glial cell line-derived neurotrophic factor"]]}, {"text": " Rasagiline  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor ( GDNF  ", "triple_list": [["Rasagiline", "ACTIVATOR", "GDNF"]]}, {"text": "An inhibitor of  type B monoamine oxidase  (MAO-B),  (-)deprenyl  (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it", "triple_list": [["(-)deprenyl", "DOWNREGULATOR", "type B monoamine oxidase"]]}, {"text": "An inhibitor of type B monoamine oxidase ( MAO-B  ,  (-)deprenyl  (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it", "triple_list": [["(-)deprenyl", "DOWNREGULATOR", "MAO-B"]]}, {"text": "An inhibitor of  type B monoamine oxidase  (MAO-B), (-)deprenyl ( selegiline  , was reported to have neuroprotective activity, but clinical trials failed to confirm it", "triple_list": [["selegiline", "DOWNREGULATOR", "type B monoamine oxidase"]]}, {"text": "An inhibitor of type B monoamine oxidase ( MAO-B  , (-)deprenyl ( selegiline  , was reported to have neuroprotective activity, but clinical trials failed to confirm it", "triple_list": [["selegiline", "DOWNREGULATOR", "MAO-B"]]}, {"text": "A streamlined and high-yielding synthesis of  aprepitant  (1), a potent  substance P (SP) receptor  antagonist, is described", "triple_list": [["aprepitant", "ANTAGONIST", "substance P (SP) receptor"]]}, {"text": "Practical asymmetric synthesis of  aprepitant   a potent human  NK-1 receptor  antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction", "triple_list": [["aprepitant", "ANTAGONIST", "NK-1 receptor"]]}, {"text": "Pentosan polysulfate  sodium  (PPS) has been shown to exert antitumor activity by antagonizing the binding of  bFGF  to cell surface receptors", "triple_list": [["sodium", "ANTAGONIST", "bFGF"]]}, {"text": "These findings suggest that  RhBG  and RhCG may play important and cell-specific roles in  ammonium  transport and signaling in these regions of the kidney.", "triple_list": [["ammonium", "PRODUCT-OF", "RhBG"]]}, {"text": "These findings suggest that RhBG and  RhCG  may play important and cell-specific roles in  ammonium  transport and signaling in these regions of the kidney.", "triple_list": [["ammonium", "PRODUCT-OF", "RhCG"]]}, {"text": "This approach is validated by the clinical efficacy and safety of  sildenafil   the pioneering drug for selective  PDE5  inhibitor therapy for ED", "triple_list": [["sildenafil", "DOWNREGULATOR", "PDE5"]]}, {"text": " Sildenafil  exhibits inhibitory potency against  PDE 5 and a 10-fold lower dose-related inhibitory potency against rod outer segment  PDE 6, the predominant  PDE  in the phototransduction cascade in rods", "triple_list": [["Sildenafil", "DOWNREGULATOR", "PDE"]]}, {"text": " Sildenafil  exhibits inhibitory potency against  PDE5  and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods", "triple_list": [["Sildenafil", "DOWNREGULATOR", "PDE5"]]}, {"text": " Sildenafil  exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment  PDE6   the predominant PDE in the phototransduction cascade in rods", "triple_list": [["Sildenafil", "DOWNREGULATOR", "PDE6"]]}, {"text": "As free  sildenafil  plasma concentrations approach concentrations sufficient to inhibit retinal  PDE6   usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently", "triple_list": [["sildenafil", "DOWNREGULATOR", "PDE6"]]}, {"text": "Selective inhibition of  PDE5  is a rational therapeutic approach in ED, as proved by the clinical success of  sildenafil  ", "triple_list": [["sildenafil", "DOWNREGULATOR", "PDE5"]]}, {"text": "Therefore, in men with ED, elevation of  cGMP  in corpus cavernosal tissue via selective inhibition of  cGMP  specific  PDE5  is a means of improving erectile function at minimal risk of adverse events", "triple_list": [["cGMP", "DOWNREGULATOR", "PDE5"]]}, {"text": " PDE5  is the predominant PDE in the corpus cavernosum, and  cGMP  is its primary substrate", "triple_list": [["cGMP", "PRODUCT-OF", "PDE5"]]}, {"text": " PDE 5 is the predominant  PDE  in the corpus cavernosum, and  cGMP  is its primary substrate", "triple_list": [["cGMP", "PRODUCT-OF", "PDE"]]}, {"text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the  GAB-1  HG1A receptor, but attenuated the GABA response of the  GAB-1 /HG1E receptor", "triple_list": [["ivermectin", "ACTIVATOR", "GAB-1"]]}, {"text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the GAB-1/ HG1A  receptor, but attenuated the GABA response of the GAB-1/HG1E receptor", "triple_list": [["ivermectin", "ACTIVATOR", "HG1A"]]}, {"text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the  GAB-1 /HG1A receptor, but attenuated the GABA response of the  GAB-1  HG1E receptor", "triple_list": [["ivermectin", "DOWNREGULATOR", "GAB-1"]]}, {"text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/ HG1E  receptor", "triple_list": [["ivermectin", "DOWNREGULATOR", "HG1E"]]}, {"text": " Yohimbine  is a potent and selective  alpha2- versus alpha1-adrenoceptor  antagonist", "triple_list": [["Yohimbine", "ANTAGONIST", "alpha2- versus alpha1-adrenoceptor"]]}, {"text": "These results demonstrate that  imidazoquinoline  molecules directly induce pDC maturation as determined by  cytokine  induction, CCR7 and co-stimulatory marker expression and prolonging viability.", "triple_list": [["imidazoquinoline", "ACTIVATOR", "cytokine"]]}, {"text": "The immune response modifiers,  imiquimod  and resiquimod, are TLR7 agonists that induce  type I interferon  in numerous species, including humans", "triple_list": [["imiquimod", "ACTIVATOR", "type I interferon"]]}, {"text": "Results indicate that  imiquimod  and resiquimod induce  IFN-alpha  and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood", "triple_list": [["imiquimod", "ACTIVATOR", "IFN-alpha"]]}, {"text": "Results indicate that  imiquimod  and resiquimod induce IFN-alpha and  IFN-omega  from purified pDC, and pDC are the principle IFN-producing cells in the blood", "triple_list": [["imiquimod", "ACTIVATOR", "IFN-omega"]]}, {"text": "The immune response modifiers, imiquimod and  resiquimod   are TLR7 agonists that induce  type I interferon  in numerous species, including humans", "triple_list": [["resiquimod", "ACTIVATOR", "type I interferon"]]}, {"text": " Resiquimod  stimulated pDC also produce a number of other  cytokines  including TNF-alpha and IP-10", "triple_list": [["Resiquimod", "ACTIVATOR", "cytokines"]]}, {"text": " Resiquimod  stimulated pDC also produce a number of other cytokines including  TNF-alpha  and IP-10", "triple_list": [["Resiquimod", "ACTIVATOR", "TNF-alpha"]]}, {"text": " Resiquimod  stimulated pDC also produce a number of other cytokines including TNF-alpha and  IP-10    Resiquimod  enhances co-stimulatory marker expression, CCR7 expression, and pDC viability", "triple_list": [["Resiquimod", "ACTIVATOR", "IP-10"]]}, {"text": " Resiquimod  enhances co-stimulatory marker expression,  CCR7  expression, and pDC viability", "triple_list": [["Resiquimod", "ACTIVATOR", "CCR7"]]}, {"text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the  TLR7  agonists, imiquimod and  resiquimod   The immune response modifiers, imiquimod and  resiquimod , are  TLR7  agonists that induce type I interferon in numerous species, including humans", "triple_list": [["resiquimod", "AGONIST", "TLR7"]]}, {"text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the  TLR7  agonists,  imiquimod  and resiquimod", "triple_list": [["imiquimod", "AGONIST", "TLR7"]]}, {"text": "The immune response modifiers,  imiquimod  and resiquimod, are  TLR7  agonists that induce type I interferon in numerous species, including humans", "triple_list": [["imiquimod", "AGONIST", "TLR7"]]}, {"text": "Here, we characterize the activation of human pDC with the  TLR7  agonists  imiquimod  and resiquimod", "triple_list": [["imiquimod", "AGONIST", "TLR7"]]}, {"text": "Here, we characterize the activation of human pDC with the  TLR7  agonists imiquimod and  resiquimod   Results indicate that imiquimod and  resiquimod  induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood", "triple_list": [["resiquimod", "AGONIST", "TLR7"]]}, {"text": "The immune response modifiers, imiquimod and  resiquimod   are  TLR7  agonists that induce type I interferon in numerous species, including humans", "triple_list": [["resiquimod", "AGONIST", "TLR7"]]}, {"text": "Pre-treatment with arsenite increased  protein kinase B  (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after  H2O2   However, while Akt phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by CHX", "triple_list": [["H2O2", "ACTIVATOR", "protein kinase B"]]}, {"text": "Pre-treatment with arsenite increased protein kinase B ( Akt   and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after  H2O2   However, while  Akt  phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by CHX", "triple_list": [["H2O2", "ACTIVATOR", "Akt"]]}, {"text": "The results show that transient  arsenite  pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of  Akt  following H2O2", "triple_list": [["arsenite", "ACTIVATOR", "Akt"]]}, {"text": "The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces  H2O2 -induced astrocyte death; and it causes selective activation of  Akt  following  H2O2   It is suggested that HSP expression at the time of  H2O2  exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival  Akt .", "triple_list": [["H2O2", "ACTIVATOR", "Akt"]]}, {"text": "Induction of  heat shock proteins  (HSPs) by  sodium arsenite  in cultured astrocytes and reduction of hydrogen peroxide-induced cell death", "triple_list": [["sodium arsenite", "ACTIVATOR", "heat shock proteins"]]}, {"text": "Induction of heat shock proteins ( HSPs   by  sodium arsenite  in cultured astrocytes and reduction of hydrogen peroxide-induced cell death", "triple_list": [["sodium arsenite", "ACTIVATOR", "HSPs"]]}, {"text": "The results show that transient  arsenite  pre-treatment induces  Hsp72   HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2", "triple_list": [["arsenite", "ACTIVATOR", "Hsp72"]]}, {"text": "The results show that transient  arsenite  pre-treatment induces Hsp72,  HO-1  and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2", "triple_list": [["arsenite", "ACTIVATOR", "HO-1"]]}, {"text": "The results show that transient  arsenite  pre-treatment induces Hsp72, HO-1 and, to a lesser extent,  Hsp27   it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2", "triple_list": [["arsenite", "ACTIVATOR", "Hsp27"]]}, {"text": " Arsenite  triggered strong induction of  HSPs   which was prevented by 1 micro g/mL cycloheximide (CXH)", "triple_list": [["Arsenite", "ACTIVATOR", "HSPs"]]}, {"text": "Arsenite triggered strong induction of  HSPs   which was prevented by 1 micro g/mL  cycloheximide  (CXH)", "triple_list": [["cycloheximide", "DOWNREGULATOR", "HSPs"]]}, {"text": "Arsenite triggered strong induction of  HSPs   which was prevented by 1 micro g/mL cycloheximide ( CXH  ", "triple_list": [["CXH", "DOWNREGULATOR", "HSPs"]]}, {"text": "However, while  Akt  phosphorylation was prevented by  CHX , Erk1/2 phosphorylation was further enhanced by  CHX   The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of  Akt  following H2O2", "triple_list": [["CHX", "DOWNREGULATOR", "Akt"]]}, {"text": " GW660511X  and omapatrilat increased the production of both  BrBK1-8  and Br-Phe5 but not that of BrBK4-8 and BrBK2-8", "triple_list": [["GW660511X", "ACTIVATOR", "BrBK1-8"]]}, {"text": " GW660511X  and omapatrilat increased the production of both BrBK1-8 and  Br-Phe5  but not that of BrBK4-8 and BrBK2-8", "triple_list": [["GW660511X", "ACTIVATOR", "Br-Phe5"]]}, {"text": "GW660511X and  omapatrilat  increased the production of both  BrBK1-8  and Br-Phe5 but not that of BrBK4-8 and BrBK2-8", "triple_list": [["omapatrilat", "ACTIVATOR", "BrBK1-8"]]}, {"text": "GW660511X and  omapatrilat  increased the production of both BrBK1-8 and  Br-Phe5  but not that of BrBK4-8 and BrBK2-8", "triple_list": [["omapatrilat", "ACTIVATOR", "Br-Phe5"]]}, {"text": "In addition the production of  BrBK1-8  was enhanced in the presence of these inhibitors with a greater accumulation being observed with  omapatrilat   The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with  omapatrilat  after 4 h of incubation", "triple_list": [["omapatrilat", "ACTIVATOR", "BrBK1-8"]]}, {"text": " GW660511X  and omapatrilat reduced the production of  BrBK1-5  and BrBK1-7 with more effect being observed with omapatrilat", "triple_list": [["GW660511X", "DOWNREGULATOR", "BrBK1-5"]]}, {"text": " GW660511X  and omapatrilat reduced the production of BrBK1-5 and  BrBK1-7  with more effect being observed with omapatrilat", "triple_list": [["GW660511X", "DOWNREGULATOR", "BrBK1-7"]]}, {"text": "GW660511X and  omapatrilat  reduced the production of  BrBK1-5  and BrBK1-7 with more effect being observed with  omapatrilat ", "triple_list": [["omapatrilat", "DOWNREGULATOR", "BrBK1-5"]]}, {"text": "GW660511X and  omapatrilat  reduced the production of BrBK1-5 and  BrBK1-7  with more effect being observed with  omapatrilat ", "triple_list": [["omapatrilat", "DOWNREGULATOR", "BrBK1-7"]]}, {"text": "GW660511X and  omapatrilat  reduced the production of  BrBK1-5  and BrBK1-7 with more effect being observed with  omapatrilat   GW660511X and  omapatrilat  increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8", "triple_list": [["omapatrilat", "DOWNREGULATOR", "BrBK1-5"]]}, {"text": "GW660511X and  omapatrilat  reduced the production of BrBK1-5 and  BrBK1-7  with more effect being observed with  omapatrilat   GW660511X and  omapatrilat  increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8", "triple_list": [["omapatrilat", "DOWNREGULATOR", "BrBK1-7"]]}, {"text": "Unlike GW660511X,  omapatrilat  abolished the production of  BrBK1-5  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found", "triple_list": [["omapatrilat", "DOWNREGULATOR", "BrBK1-5"]]}, {"text": "Unlike GW660511X,  omapatrilat  abolished the production of BrBK1-5 and  BrBK1-7   suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found", "triple_list": [["omapatrilat", "DOWNREGULATOR", "BrBK1-7"]]}, {"text": "The production of  Br-Phe5  was reduced with  GW660511X  while no significant change was observed with omapatrilat after 4 h of incubation", "triple_list": [["GW660511X", "DOWNREGULATOR", "Br-Phe5"]]}, {"text": "This study shows that the potency of  GW660511X  in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of  ACE  NEP inhibition in relation to effects in humans.", "triple_list": [["GW660511X", "DOWNREGULATOR", "ACE"]]}, {"text": "This study shows that the potency of  GW660511X  in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/ NEP  inhibition in relation to effects in humans.", "triple_list": [["GW660511X", "DOWNREGULATOR", "NEP"]]}, {"text": "This study shows that the potency of GW660511X in comparison with  omapatrilat  is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/ NEP  inhibition in relation to effects in humans.", "triple_list": [["omapatrilat", "DOWNREGULATOR", "NEP"]]}, {"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual  ACE  NEP inhibitors ( GW660511X  and omapatrilat) currently under clinical trial", "triple_list": [["GW660511X", "DOWNREGULATOR", "ACE"]]}, {"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/ NEP  inhibitors ( GW660511X  and omapatrilat) currently under clinical trial", "triple_list": [["GW660511X", "DOWNREGULATOR", "NEP"]]}, {"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual  ACE  NEP inhibitors (GW660511X and  omapatrilat   currently under clinical trial", "triple_list": [["omapatrilat", "DOWNREGULATOR", "ACE"]]}, {"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/ NEP  inhibitors (GW660511X and  omapatrilat   currently under clinical trial", "triple_list": [["omapatrilat", "DOWNREGULATOR", "NEP"]]}, {"text": "Unlike GW660511X,  omapatrilat  abolished the production of BrBK1-5 and BrBK1-7, suggesting a better  ACE  inhibition effect over GW660511X as no NEP activity was found", "triple_list": [["omapatrilat", "DOWNREGULATOR", "ACE"]]}, {"text": "Unlike  GW660511X , omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better  ACE  inhibition effect over  GW660511X  as no NEP activity was found", "triple_list": [["GW660511X", "DOWNREGULATOR", "ACE"]]}, {"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual  ACE  NEP inhibitors  GW660511X  and omapatrilat", "triple_list": [["GW660511X", "DOWNREGULATOR", "ACE"]]}, {"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/ NEP  inhibitors  GW660511X  and omapatrilat", "triple_list": [["GW660511X", "DOWNREGULATOR", "NEP"]]}, {"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual  ACE  NEP inhibitors GW660511X and  omapatrilat   Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various  ACE i", "triple_list": [["omapatrilat", "DOWNREGULATOR", "ACE"]]}, {"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/ NEP  inhibitors GW660511X and  omapatrilat   Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi", "triple_list": [["omapatrilat", "DOWNREGULATOR", "NEP"]]}, {"text": "The development of specific  BuChE  inhibitors and further experience with the dual enzyme inhibitor  rivastigmine  will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.", "triple_list": [["rivastigmine", "DOWNREGULATOR", "BuChE"]]}, {"text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both  AChE  and BuChE,  rivastigmine   indicates potential therapeutic benefits of inhibiting both  AChE  and BuChE in AD and related dementias", "triple_list": [["rivastigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "Experimental evidence from the use of agents with enhanced selectivity for  BuChE  (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and  BuChE    rivastigmine   indicates potential therapeutic benefits of inhibiting both AChE and  BuChE  in AD and related dementias", "triple_list": [["rivastigmine", "DOWNREGULATOR", "BuChE"]]}, {"text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both  AChE  and BuChE,  rivastigmine   indicates potential therapeutic benefits of inhibiting both  AChE  and BuChE in AD and related dementias", "triple_list": [["rivastigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "Experimental evidence from the use of agents with enhanced selectivity for  BuChE  (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and  BuChE ,  rivastigmine   indicates potential therapeutic benefits of inhibiting both AChE and  BuChE  in AD and related dementias", "triple_list": [["rivastigmine", "DOWNREGULATOR", "BuChE"]]}, {"text": "Acetylcholinesterase ( AChE   predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels", "triple_list": [["acetylcholine", "PRODUCT-OF", "AChE"]]}, {"text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with  butyrylcholinesterase  (BuChE) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels", "triple_list": [["acetylcholine", "PRODUCT-OF", "butyrylcholinesterase"]]}, {"text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase ( BuChE   considered to play a minor role in regulating brain  acetylcholine  (ACh) levels", "triple_list": [["acetylcholine", "PRODUCT-OF", "BuChE"]]}, {"text": " Acetylcholinesterase  (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels", "triple_list": [["acetylcholine", "PRODUCT-OF", "Acetylcholinesterase"]]}, {"text": "Acetylcholinesterase ( ACh E  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ( ACh   levels", "triple_list": [["ACh", "PRODUCT-OF", "AChE"]]}, {"text": "Acetylcholinesterase ( ACh E) predominates in the healthy brain, with  butyrylcholinesterase  (BuChE) considered to play a minor role in regulating brain acetylcholine ( ACh   levels", "triple_list": [["ACh", "PRODUCT-OF", "butyrylcholinesterase"]]}, {"text": "Acetylcholinesterase ( ACh E) predominates in the healthy brain, with butyrylcholinesterase ( BuChE   considered to play a minor role in regulating brain acetylcholine ( ACh   levels", "triple_list": [["ACh", "PRODUCT-OF", "BuChE"]]}, {"text": " Acetylcholinesterase  ( ACh E) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ( ACh   levels", "triple_list": [["ACh", "PRODUCT-OF", "Acetylcholinesterase"]]}, {"text": "Agents which have recently been shown to block  cyclin D1  translation by regulating calcium levels are the  unsaturated essential fatty acid   eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole", "triple_list": [["unsaturated essential fatty acid", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "Agents which have recently been shown to block  cyclin D1  translation by regulating calcium levels are the unsaturated essential fatty acid,  eicosapentaenoic acid  (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole", "triple_list": [["eicosapentaenoic acid", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "Agents which have recently been shown to block  cyclin D1  translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid ( EPA  , the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole", "triple_list": [["EPA", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "Agents which have recently been shown to block  cyclin D1  translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic  thiazolidinediones   and the antifungal agent, clotrimazole", "triple_list": [["thiazolidinediones", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "Agents which have recently been shown to block  cyclin D1  translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent,  clotrimazole   Two types of agent which have been shown to inhibit angiogenesis are the teratogen, thalidomide, and the selective inhibitors of cyclo-oxygenase 2 (COX-2)", "triple_list": [["clotrimazole", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "We investigated the effect of  AT1 receptor  blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent  pancuronium bromide   The characteristic increase in heart rate, blood pressure and phrenic nerve activity evoked by electrical stimulation of HDA is decreased by the microinjection of the  AT1 receptor  antagonist losartan into the NTS and the cardiovascular response to carotid body chemical stimulation is also reduced", "triple_list": [["pancuronium bromide", "DOWNREGULATOR", "AT1 receptor"]]}, {"text": " Angiotensin AT1 receptor  antagonist  losartan  and the defence reaction in the anaesthetised rat", "triple_list": [["losartan", "ANTAGONIST", "Angiotensin AT1 receptor"]]}, {"text": "RESULTS: Rolipram unmasked the inhibitory effect of  beta(2)-adrenoceptor  stimulation with  salmeterol  and significantly attenuated the stimulated release of AA and subsequent LTC(4)", "triple_list": [["salmeterol", "ACTIVATOR", "beta(2)-adrenoceptor"]]}, {"text": "Inhibition corresponded to increased cAMP production caused by  rolipram  alone or  rolipram  plus salmeterol and blocked proportionately the phosphorylation and activation of  gIV-PLA(2)  in FMLP/B-activated eosinophils", "triple_list": [["rolipram", "DOWNREGULATOR", "gIV-PLA(2)"]]}, {"text": "Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus  salmeterol  and blocked proportionately the phosphorylation and activation of  gIV-PLA(2)  in FMLP/B-activated eosinophils", "triple_list": [["salmeterol", "DOWNREGULATOR", "gIV-PLA(2)"]]}, {"text": "CONCLUSIONS: Inhibition of  PDE4  by  rolipram  unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.", "triple_list": [["rolipram", "DOWNREGULATOR", "PDE4"]]}, {"text": "OBJECTIVE: To determine (a) whether  PDE4  inhibition alone with  rolipram  blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if  PDE4  inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP", "triple_list": [["rolipram", "DOWNREGULATOR", "PDE4"]]}, {"text": "Blockade of  LTC4  synthesis caused by additive inhibition of  gIV-PLA2  phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils", "triple_list": [["LTC4", "PRODUCT-OF", "gIV-PLA2"]]}, {"text": "Anabolic effects of  clenbuterol  on skeletal muscle are mediated by  beta 2-adrenoceptor  activation", "triple_list": [["clenbuterol", "ACTIVATOR", "beta 2-adrenoceptor"]]}, {"text": "These effects were not mimicked by oral administration of the  beta 2-adrenoceptor  agonist  salbutamol  even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet)", "triple_list": [["salbutamol", "AGONIST", "beta 2-adrenoceptor"]]}, {"text": "These effects were not mimicked by oral administration of the  beta 2-adrenoceptor  agonist salbutamol even at high dose (52 mg/kg diet), and the effects of  clenbuterol  were not inhibited by addition of DL-propranolol (200 mg/kg diet)", "triple_list": [["clenbuterol", "AGONIST", "beta 2-adrenoceptor"]]}, {"text": "The potent anabolic effects of the  beta 2-adrenoceptor  agonist  clenbuterol  on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors", "triple_list": [["clenbuterol", "AGONIST", "beta 2-adrenoceptor"]]}, {"text": "In the hot-plate test in mice, the antinociceptive action of the  alpha 2-adrenoceptor  agonist,  UK 14,304   was abolished by the  alpha 2-adrenoceptor  antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408", "triple_list": [["UK 14,304", "AGONIST", "alpha 2-adrenoceptor"]]}, {"text": "The preferential  alpha 2A-adrenoceptor  partial agonist,  guanfacine   partially inhibited UK 14,304-induced antinociception", "triple_list": [["guanfacine", "AGONIST", "alpha 2A-adrenoceptor"]]}, {"text": "The preferential  alpha 2A-adrenoceptor  partial agonist, guanfacine, partially inhibited  UK 14,304  induced antinociception", "triple_list": [["UK 14,304", "AGONIST", "alpha 2A-adrenoceptor"]]}, {"text": "In the hot-plate test in mice, the antinociceptive action of the  alpha 2-adrenoceptor  agonist, UK 14,304, was abolished by the  alpha 2-adrenoceptor  antagonist,  idazoxan   the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408", "triple_list": [["idazoxan", "ANTAGONIST", "alpha 2-adrenoceptor"]]}, {"text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent  alpha 2A-adrenoceptor  antagonist,  RX 821002  and the preferential  alpha 2A-adrenoceptor  antagonist, BRL 44408", "triple_list": [["RX 821002", "ANTAGONIST", "alpha 2A-adrenoceptor"]]}, {"text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent  alpha 2A-adrenoceptor  antagonist, RX 821002 and the preferential  alpha 2A-adrenoceptor  antagonist,  BRL 44408   In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive", "triple_list": [["BRL 44408", "ANTAGONIST", "alpha 2A-adrenoceptor"]]}, {"text": "Formation of  pyruvate  by  SDH  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce  pyruvate ", "triple_list": [["pyruvate", "PRODUCT-OF", "SDH"]]}, {"text": "Formation of  pyruvate  by  SDH  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce  pyruvate   The crystal structure of rat liver apo- SDH  was determined by single isomorphous replacement at 2.8 A resolution", "triple_list": [["pyruvate", "PRODUCT-OF", "SDH"]]}, {"text": " SDH  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield  pyruvate  and ammonia", "triple_list": [["pyruvate", "PRODUCT-OF", "SDH"]]}, {"text": "SDH (L-serine dehydratase,  EC 4.3.1.17   catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield  pyruvate  and ammonia", "triple_list": [["pyruvate", "PRODUCT-OF", "EC 4.3.1.17"]]}, {"text": "SDH  (L-serine dehydratase   EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield  pyruvate  and ammonia", "triple_list": [["pyruvate", "PRODUCT-OF", "(L-serine dehydratase"]]}, {"text": " SDH  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and  ammonia   Liver  SDH  plays an important role in gluconeogenesis", "triple_list": [["ammonia", "PRODUCT-OF", "SDH"]]}, {"text": "SDH (L-serine dehydratase,  EC 4.3.1.17   catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and  ammonia   Liver SDH plays an important role in gluconeogenesis", "triple_list": [["ammonia", "PRODUCT-OF", "EC 4.3.1.17"]]}, {"text": "SDH  (L-serine dehydratase   EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and  ammonia   Liver SDH plays an important role in gluconeogenesis", "triple_list": [["ammonia", "PRODUCT-OF", "(L-serine dehydratase"]]}, {"text": " SDH  ( L-serine  dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  L-serine  to yield pyruvate and ammonia", "triple_list": [["L-serine", "PRODUCT-OF", "SDH"]]}, {"text": "SDH ( L-serine  dehydratase,  EC 4.3.1.17   catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  L-serine  to yield pyruvate and ammonia", "triple_list": [["L-serine", "PRODUCT-OF", "EC 4.3.1.17"]]}, {"text": "SDH ( L-serine  dehydratase  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  L-serine  to yield pyruvate and ammonia", "triple_list": [["L-serine", "PRODUCT-OF", "(L-serine dehydratase"]]}, {"text": "Formation of pyruvate by  SDH  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce  aminoacrylate   and then the  aminoacrylate  is deaminated by nonenzymatic hydrolysis to produce pyruvate", "triple_list": [["aminoacrylate", "PRODUCT-OF", "SDH"]]}, {"text": "Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI)  GW572016  decreased the postradiation survival of irradiated  Ras  transformed cells and normal cells but had no effect on the survival of unirradiated cells", "triple_list": [["GW572016", "DOWNREGULATOR", "Ras"]]}, {"text": "Blocking  EGFR  signaling with the  EGFR /HER-2 kinase inhibitor (KI)  GW572016  decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "Thus,  Ras  utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI  GW572016  acts as a radiosensitizer", "triple_list": [["GW572016", "DOWNREGULATOR", "Ras"]]}, {"text": "The observation that  Ras  transformed cells can be sensitized to killing by ionizing radiation with  GW572016  demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on  Ras -driven autocrine signaling through EGFR.", "triple_list": [["GW572016", "DOWNREGULATOR", "Ras"]]}, {"text": "Blocking  EGFR  signaling with the  EGFR  HER-2 kinase inhibitor (KI)  GW572016  decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "Blocking EGFR signaling with the EGFR/ HER-2  kinase inhibitor (KI)  GW572016  decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells", "triple_list": [["GW572016", "DOWNREGULATOR", "HER-2"]]}, {"text": "Ras-CM and TGF-alpha also increase  PI3-K  activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by  GW572016   Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI  GW572016  acts as a radiosensitizer", "triple_list": [["GW572016", "DOWNREGULATOR", "PI3-K"]]}, {"text": "Ras-CM and TGF-alpha also increase PI3-K activity downstream of the  EGFR  and increase postradiation survival, both of which are abrogated by  GW572016   Thus, Ras utilizes autocrine signaling through  EGFR  to increase radioresistance, and the  EGFR  KI  GW572016  acts as a radiosensitizer", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "Thus, Ras utilizes autocrine signaling through  EGFR  to increase radioresistance, and the  EGFR  KI  GW572016  acts as a radiosensitizer", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with  GW572016  demonstrates that  EGFR  KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through  EGFR .", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "(-)-Isoprenaline and a nonconventional  beta(3)-adrenoceptor  agonist,  (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride  ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations", "triple_list": [["(+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride", "AGONIST", "beta(3)-adrenoceptor"]]}, {"text": "(-)-Isoprenaline and a nonconventional  beta(3)-adrenoceptor  agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ( (+/-)-CGP12177A  , induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations", "triple_list": [["(+/-)-CGP12177A", "AGONIST", "beta(3)-adrenoceptor"]]}, {"text": "Pretreatment with a combination of  (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate  (CGP20712A, a selective  beta(1)-adrenoceptor  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors", "triple_list": [["(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate", "ANTAGONIST", "beta(1)-adrenoceptor"]]}, {"text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate ( CGP20712A   a selective  beta(1)-adrenoceptor  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors", "triple_list": [["CGP20712A", "ANTAGONIST", "beta(1)-adrenoceptor"]]}, {"text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and  (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride  (ICI-118,5511, a selective  beta(2)-adrenoceptor  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and  beta(2)-adrenoceptor s", "triple_list": [["(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride", "ANTAGONIST", "beta(2)-adrenoceptor"]]}, {"text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride ( ICI-118,5511   a selective  beta(2)-adrenoceptor  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and  beta(2)-adrenoceptor s", "triple_list": [["ICI-118,5511", "ANTAGONIST", "beta(2)-adrenoceptor"]]}, {"text": "The specificity of tracer uptake was determined by adding the  NET  inhibitor  imipramine   Rat PC12 cells served as positive controls", "triple_list": [["imipramine", "DOWNREGULATOR", "NET"]]}, {"text": " [(131)I]MIBG  uptake in PC12 cells, which express the  NET  endogenously, was 20- to 28-fold lower than in transduced cells", "triple_list": [["[(131)I]MIBG", "PRODUCT-OF", "NET"]]}, {"text": "In vivo, A431 NET  tumors demonstrated a 33-fold higher  [(123)I]MIBG  uptake than parental tumors", "triple_list": [["[(123)I]MIBG", "PRODUCT-OF", "NET"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin,  formoterol   broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["formoterol", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol,  broxaterol   and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["broxaterol", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( epinephrine   nor epinephrine , isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["epinephrine", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine,  norepinephrine   isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["norepinephrine", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine,  isoproterenol   fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["isoproterenol", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol,  fenoterol   salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["fenoterol", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol,  salbutamol   salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["salbutamol", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol,  salmeterol   terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["salmeterol", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol,  terbutalin   formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["terbutalin", "AGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists ( propranolol   alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["propranolol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol,  alprenolol   atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["alprenolol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol,  atenolol   metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["atenolol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol,  metoprolol   bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["metoprolol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol,  bisoprolol   carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["bisoprolol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol,  carvedilol   pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["carvedilol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol,  pindolol   BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["pindolol", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol,  BRL 37344   CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["BRL 37344", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344,  CGP 20712   SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["CGP 20712", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712,  SR 59230A   CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["SR 59230A", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A,  CGP 12177   ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["CGP 12177", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177,  ICI 118551   at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background", "triple_list": [["ICI 118551", "ANTAGONIST", "human beta-adrenergic receptors"]]}, {"text": "Manipulation of kinetic profiles in  2-aryl propionic acid   cyclooxygenase  inhibitors", "triple_list": [["2-aryl propionic acid", "DOWNREGULATOR", "cyclooxygenase"]]}, {"text": "Effects of the  EGFR  HER2 kinase inhibitor  GW572016  on  EGFR - and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "Effects of the EGFR/ HER2  kinase inhibitor  GW572016  on EGFR- and  HER2 -overexpressing breast cancer cell line proliferation, radiosensitization, and resistance", "triple_list": [["GW572016", "DOWNREGULATOR", "HER2"]]}, {"text": "Effects of the EGFR/HER2  kinase  inhibitor  GW572016  on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance", "triple_list": [["GW572016", "DOWNREGULATOR", "kinase"]]}, {"text": "Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of  GW572016  to inhibit downstream ERK and Akt activation, despite inhibition of  HER2  phosphorylation", "triple_list": [["GW572016", "DOWNREGULATOR", "HER2"]]}, {"text": "CONCLUSION:  GW572016  potently inhibits receptor phosphorylation in either  EGFR   or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "CONCLUSION:  GW572016  potently inhibits receptor phosphorylation in either EGFR- or  HER2  overexpressing cell lines and has both antiproliferative and radiosensitizing effects", "triple_list": [["GW572016", "DOWNREGULATOR", "HER2"]]}, {"text": "To gauge the potential clinical utility of targeting both  EGFR  and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual  EGFR  HER2 inhibitor,  GW572016   on the proliferation and radiation response of either  EGFR - or HER2-overexpressing human breast cancer cell lines", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "To gauge the potential clinical utility of targeting both EGFR and  HER2  to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/ HER2  inhibitor,  GW572016   on the proliferation and radiation response of either EGFR- or  HER2 -overexpressing human breast cancer cell lines", "triple_list": [["GW572016", "DOWNREGULATOR", "HER2"]]}, {"text": "RESULTS:  GW572016  inhibited constitutive and/or ligand-induced  EGFR  or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line", "triple_list": [["GW572016", "DOWNREGULATOR", "EGFR"]]}, {"text": "RESULTS:  GW572016  inhibited constitutive and/or ligand-induced EGFR or  HER2  tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line", "triple_list": [["GW572016", "DOWNREGULATOR", "HER2"]]}, {"text": "Incubation with  metformin  (0.2-1 mM) activated  AMPK  in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": " Metformin   a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of  AMP-activated protein kinase  (AMPK)", "triple_list": [["Metformin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": " Metformin   a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase ( AMPK  ", "triple_list": [["Metformin", "ACTIVATOR", "AMPK"]]}, {"text": "Whether  metformin  or the satiety factor leptin, which also stimulates  AMPK  in muscle, regulates this enzyme in pancreatic islets is unknown", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on  glucose  stimulated  insulin  secretion", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "Incubation with  metformin  (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of  insulin  secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells", "triple_list": [["metformin", "DOWNREGULATOR", "insulin"]]}, {"text": "The inhibitory effects of  metformin  on  insulin  secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.", "triple_list": [["metformin", "DOWNREGULATOR", "insulin"]]}, {"text": "Increases in  glucose  concentration from 0 to 3 and from 3 to 17 mM inhibited  AMPK  activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells", "triple_list": [["glucose", "DOWNREGULATOR", "AMPK"]]}, {"text": "A 5'-flanking region capable of supporting  RA  induced  blr1  activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by  RA ", "triple_list": [["RA", "ACTIVATOR", "blr1"]]}, {"text": " RA  is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels  RA -induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of  blr1  expression by  RA   The  RA -treated HL-60 cells used here expressed all  RA  receptor ( RA R) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma", "triple_list": [["RA", "ACTIVATOR", "blr1"]]}, {"text": "A novel  retinoic acid -responsive element regulates  retinoic acid  induced  BLR1  expression", "triple_list": [["retinoic acid", "ACTIVATOR", "BLR1"]]}, {"text": " RA  is known to induce expression of the  Burkitt's lymphoma receptor 1  (BLR1) gene which propels  RA -induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by  RA ", "triple_list": [["RA", "ACTIVATOR", "Burkitt's lymphoma receptor 1"]]}, {"text": " RA  is known to induce expression of the Burkitt's lymphoma receptor 1 ( BLR1   gene which propels  RA -induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by  RA ", "triple_list": [["RA", "ACTIVATOR", "BLR1"]]}, {"text": "In sum the results of the present study indicate that  RA  induced expression of  blr1  expression depends on a novel  RA  response element", "triple_list": [["RA", "ACTIVATOR", "blr1"]]}, {"text": "The ability of this cis-acting  RA R-RXR binding element to activate transcription in response to  RA  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a  nuclear factor of activated T cells  (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary", "triple_list": [["RA", "DOWNREGULATOR", "nuclear factor of activated T cells"]]}, {"text": "The persistent membrane retention of  desipramine  causes lasting inhibition of  norepinephrine transporter  function", "triple_list": [["desipramine", "DOWNREGULATOR", "norepinephrine transporter"]]}, {"text": "[3H]DMI trapped in membranes was displaceable by the structurally unrelated  NET  inhibitor,  nisoxetine   in a concentration-dependent manner, implying interaction of retained [3H]DMI with the  NET ", "triple_list": [["nisoxetine", "DOWNREGULATOR", "NET"]]}, {"text": " Irbesartan  may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of  angiotensin II    Irbesartan  given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.", "triple_list": [["Irbesartan", "DOWNREGULATOR", "angiotensin II"]]}, {"text": " Irbesartan  may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this  AT1  blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II", "triple_list": [["Irbesartan", "DOWNREGULATOR", "AT1"]]}, {"text": "AT1-receptor antagonism in hypertension: what has been learned with irbesartan?  Irbesartan  is a long-acting  angiotensin II  antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)", "triple_list": [["Irbesartan", "ANTAGONIST", "angiotensin II"]]}, {"text": "To verify the hypothesis that the non-conventional partial agonist  (-)-CGP12177  binds at two beta(1)-adrenoceptor sites,  human beta(1)-adrenoceptors   expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177", "triple_list": [["(-)-CGP12177", "AGONIST", "human beta(1)-adrenoceptors"]]}, {"text": "To verify the hypothesis that the non-conventional partial agonist  (-)-CGP12177  binds at two  beta(1)-adrenoceptor  sites, human  beta(1)-adrenoceptor s, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177", "triple_list": [["(-)-CGP12177", "AGONIST", "beta(1)-adrenoceptor"]]}, {"text": " Imiquimod  (IMQ), an activator of  Toll-like receptor-7  (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo", "triple_list": [["Imiquimod", "ACTIVATOR", "Toll-like receptor-7"]]}, {"text": " Imiquimod  (IMQ), an activator of Toll-like receptor-7 ( TLR-7  , induces by several routes a profound anti-viral and anti-tumor effect in vivo", "triple_list": [["Imiquimod", "ACTIVATOR", "TLR-7"]]}, {"text": "Imiquimod ( IMQ  , an activator of  Toll-like receptor-7  (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo", "triple_list": [["IMQ", "ACTIVATOR", "Toll-like receptor-7"]]}, {"text": "Imiquimod ( IMQ  , an activator of Toll-like receptor-7 ( TLR-7  , induces by several routes a profound anti-viral and anti-tumor effect in vivo", "triple_list": [["IMQ", "ACTIVATOR", "TLR-7"]]}, {"text": "Thus, the biological activity of  IMQ  appears to exceed its previously known functions, inasmuch as it boosts up significantly the  perforin  granule system.", "triple_list": [["IMQ", "ACTIVATOR", "perforin"]]}, {"text": "In peripheral lymphocytes of healthy and diseased subjects,  IMQ  induced a significant increase of  perforin  +) CTLs within 12h in all experiments performed", "triple_list": [["IMQ", "ACTIVATOR", "perforin"]]}, {"text": "This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal  perforin  expression: as compared to  perforin (+) CTLs detected at time point zero (100%), up to 270% of  perforin  +) CTLs were induced by 2.5 microg/ml [corrected]  IMQ   Perforin release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by  IMQ ", "triple_list": [["IMQ", "ACTIVATOR", "perforin"]]}, {"text": " Imiquimod   a Toll-like receptor-7 agonist, induces  perforin  in cytotoxic T lymphocytes in vitro", "triple_list": [["Imiquimod", "ACTIVATOR", "perforin"]]}, {"text": " Imiquimod   a  Toll-like receptor-7  agonist, induces perforin in cytotoxic T lymphocytes in vitro", "triple_list": [["Imiquimod", "AGONIST", "Toll-like receptor-7"]]}, {"text": " Ang II  level in plasma and mesenteric arteries in imidapril group was significantly lower than that in  irbesartan  group (P<0.05)", "triple_list": [["irbesartan", "ACTIVATOR", "Ang II"]]}, {"text": "The  c-Jun  absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY,  imidapril   and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in  imidapril  group than in irbesartan group (P<0.05)", "triple_list": [["imidapril", "ACTIVATOR", "c-Jun"]]}, {"text": "The c-Jun absorbed light value/ GAPDH  absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY,  imidapril   and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in  imidapril  group than in irbesartan group (P<0.05)", "triple_list": [["imidapril", "ACTIVATOR", "GAPDH"]]}, {"text": "The  c-Jun  absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and  irbesartan  groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in  irbesartan  group (P<0.05)", "triple_list": [["irbesartan", "ACTIVATOR", "c-Jun"]]}, {"text": "The c-Jun absorbed light value/ GAPDH  absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and  irbesartan  groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in  irbesartan  group (P<0.05)", "triple_list": [["irbesartan", "ACTIVATOR", "GAPDH"]]}, {"text": " Ang II  level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in  irbesartan  group and lower in imidapril group", "triple_list": [["irbesartan", "ACTIVATOR", "Ang II"]]}, {"text": "The ratio of  TGF-beta1  absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group,  imidapril  group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)", "triple_list": [["imidapril", "ACTIVATOR", "TGF-beta1"]]}, {"text": "The ratio of TGF-beta1 absorbed light value to  GAPDH  absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group,  imidapril  group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)", "triple_list": [["imidapril", "ACTIVATOR", "GAPDH"]]}, {"text": "The ratio of  TGF-beta1  absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and  irbesartan  group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)", "triple_list": [["irbesartan", "ACTIVATOR", "TGF-beta1"]]}, {"text": "The ratio of TGF-beta1 absorbed light value to  GAPDH  absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and  irbesartan  group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)", "triple_list": [["irbesartan", "ACTIVATOR", "GAPDH"]]}, {"text": " Ang II  level in plasma and mesenteric arteries in  imidapril  group was significantly lower than that in irbesartan group (P<0.05)", "triple_list": [["imidapril", "DOWNREGULATOR", "Ang II"]]}, {"text": "CONCLUSION:  Imidapril  and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of  TGF-beta1   c-Jun in SHR", "triple_list": [["Imidapril", "DOWNREGULATOR", "TGF-beta1"]]}, {"text": "CONCLUSION:  Imidapril  and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1,  c-Jun  in SHR", "triple_list": [["Imidapril", "DOWNREGULATOR", "c-Jun"]]}, {"text": "CONCLUSION: Imidapril and  irbesartan  can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of  TGF-beta1   c-Jun in SHR", "triple_list": [["irbesartan", "DOWNREGULATOR", "TGF-beta1"]]}, {"text": "CONCLUSION: Imidapril and  irbesartan  can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1,  c-Jun  in SHR", "triple_list": [["irbesartan", "DOWNREGULATOR", "c-Jun"]]}, {"text": " Ang II  level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in  imidapril  group", "triple_list": [["imidapril", "DOWNREGULATOR", "Ang II"]]}, {"text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter ( NET ) function, we chronically antagonized  NET  by a range of doses of  duloxetine  [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process", "triple_list": [["duloxetine", "ANTAGONIST", "NET"]]}, {"text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter ( NET ) function, we chronically antagonized  NET  by a range of doses of duloxetine [ (+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine  , which blocks the NE reuptake process", "triple_list": [["(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine", "ANTAGONIST", "NET"]]}, {"text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine ( NE ) transporter ( NE T) function, we chronically antagonized  NE T by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the  NE  reuptake process", "triple_list": [["NE", "PRODUCT-OF", "NET"]]}, {"text": " Auranofin   an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and  glutathione peroxidase   These enzymes play an important role in protecting cardiac tissue from oxidative stress generated during ischaemia-reperfusion", "triple_list": [["Auranofin", "DOWNREGULATOR", "glutathione peroxidase"]]}, {"text": " Auranofin   an antirheumatic gold compound, is an inhibitor of  selenocysteine enzymes   such as thioredoxin reductase and glutathione peroxidase", "triple_list": [["Auranofin", "DOWNREGULATOR", "selenocysteine enzymes"]]}, {"text": " Auranofin   an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as  thioredoxin reductase  and glutathione peroxidase", "triple_list": [["Auranofin", "DOWNREGULATOR", "thioredoxin reductase"]]}, {"text": "There was significantly less  thioredoxin reductase  activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of  auranofin  used was able to selectively inhibit one of these enzyme systems", "triple_list": [["auranofin", "DOWNREGULATOR", "thioredoxin reductase"]]}, {"text": "Furthermore,  gallium  also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on  vacuolar-type H(+)-ATPases   Apart from the consequences of iron deprivation,  gallium  exerts cytotoxic effects by direct interaction with the iron-dependent enzyme ribonucleotide reductase, resulting in reduced dNTP pools and inhibition of DNA synthesis", "triple_list": [["gallium", "DOWNREGULATOR", "vacuolar-type H(+)-ATPases"]]}, {"text": "However, some experimental findings raise the question whether these effects resulting from the  iron  mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting  tubulin  polymerization", "triple_list": [["iron", "DOWNREGULATOR", "tubulin"]]}, {"text": "However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of  gallium  are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting  tubulin  polymerization", "triple_list": [["gallium", "DOWNREGULATOR", "tubulin"]]}, {"text": "GABA-evoked currents were completely and reversibly blocked by the competitive  GABAA receptor  antagonist  bicuculline  (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors", "triple_list": [["bicuculline", "ANTAGONIST", "GABAA receptor"]]}, {"text": " Histamine H1-receptor  (H1R) antagonists, or  antihistamines   often induce sedative side effects when used for the treatment of allergic disorders", "triple_list": [["antihistamines", "ANTAGONIST", "Histamine H1-receptor"]]}, {"text": "Histamine H1-receptor ( H1R   antagonists, or  antihistamines   often induce sedative side effects when used for the treatment of allergic disorders", "triple_list": [["antihistamines", "ANTAGONIST", "H1R"]]}, {"text": "A novel membrane sensor for  histamine H1-receptor  antagonist \" fexofenadine  ", "triple_list": [["fexofenadine", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates  ZD1694  (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent  TS  inhibitors", "triple_list": [["ZD1694", "DOWNREGULATOR", "TS"]]}, {"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 ( raltitrexed   Tomudex) and AG337 (Thymitag) are more specific and potent  TS  inhibitors", "triple_list": [["raltitrexed", "DOWNREGULATOR", "TS"]]}, {"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed,  Tomudex   and AG337 (Thymitag) are more specific and potent  TS  inhibitors", "triple_list": [["Tomudex", "DOWNREGULATOR", "TS"]]}, {"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and  AG337  (Thymitag) are more specific and potent  TS  inhibitors", "triple_list": [["AG337", "DOWNREGULATOR", "TS"]]}, {"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 ( Thymitag   are more specific and potent  TS  inhibitors", "triple_list": [["Thymitag", "DOWNREGULATOR", "TS"]]}, {"text": " Thymidylate synthase  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of  2-deoxythymidine-5-monophosphate   a precursor for DNA synthesis", "triple_list": [["2-deoxythymidine-5-monophosphate", "PRODUCT-OF", "Thymidylate synthase"]]}, {"text": "Thymidylate synthase ( TS   continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of  2-deoxythymidine-5-monophosphate   a precursor for DNA synthesis", "triple_list": [["2-deoxythymidine-5-monophosphate", "PRODUCT-OF", "TS"]]}, {"text": "The availability of the  5-FU  prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that  thymidine phosphorylase   the activating enzyme for  5-FU   is expressed at a higher level in tumor tissue compared with normal tissue counterparts", "triple_list": [["5-FU", "PRODUCT-OF", "thymidine phosphorylase"]]}, {"text": " Orlistat  is an inhibitor of  pancreatic lipase  which is able to block the absorption of 30% of ingested fat", "triple_list": [["Orlistat", "DOWNREGULATOR", "pancreatic lipase"]]}, {"text": " Troglitazone   bosentan and glibenclamide inhibit the  bile salt export pump  (Bsep) which transports taurocholate into bile", "triple_list": [["Troglitazone", "DOWNREGULATOR", "bile salt export pump"]]}, {"text": " Troglitazone   bosentan and glibenclamide inhibit the bile salt export pump ( Bsep   which transports taurocholate into bile", "triple_list": [["Troglitazone", "DOWNREGULATOR", "Bsep"]]}, {"text": "Troglitazone,  bosentan  and glibenclamide inhibit the  bile salt export pump  (Bsep) which transports taurocholate into bile", "triple_list": [["bosentan", "DOWNREGULATOR", "bile salt export pump"]]}, {"text": "Troglitazone,  bosentan  and glibenclamide inhibit the bile salt export pump ( Bsep   which transports taurocholate into bile", "triple_list": [["bosentan", "DOWNREGULATOR", "Bsep"]]}, {"text": "Troglitazone, bosentan and  glibenclamide  inhibit the  bile salt export pump  (Bsep) which transports taurocholate into bile", "triple_list": [["glibenclamide", "DOWNREGULATOR", "bile salt export pump"]]}, {"text": "Troglitazone, bosentan and  glibenclamide  inhibit the bile salt export pump ( Bsep   which transports taurocholate into bile", "triple_list": [["glibenclamide", "DOWNREGULATOR", "Bsep"]]}, {"text": "Troglitazone, bosentan and glibenclamide inhibit the  bile salt export pump  (Bsep) which transports  taurocholate  into bile", "triple_list": [["taurocholate", "PRODUCT-OF", "bile salt export pump"]]}, {"text": "Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump ( Bsep   which transports  taurocholate  into bile", "triple_list": [["taurocholate", "PRODUCT-OF", "Bsep"]]}, {"text": "Unique binding interactions of  valdecoxib  with  COX-2  translate into a fast rate of inactivation of  COX-2  (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)", "triple_list": [["valdecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "We report here the pharmacological properties of a third selective  COX-2  inhibitor,  valdecoxib   which is the most potent and in vitro selective of the marketed  COX-2  inhibitors that we have studied", "triple_list": [["valdecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "We report here the pharmacological properties of a third selective  COX-2  inhibitor,  valdecoxib   which is the most potent and in vitro selective of the marketed  COX-2  inhibitors that we have studied", "triple_list": [["valdecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": " Valdecoxib  potently inhibits recombinant  COX-2   with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib", "triple_list": [["Valdecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Valdecoxib potently inhibits recombinant  COX-2   with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for  celecoxib   0.5 microM for rofecoxib, and 5 microM for etoricoxib", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Valdecoxib potently inhibits recombinant  COX-2   with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for  rofecoxib   and 5 microM for etoricoxib", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Valdecoxib potently inhibits recombinant  COX-2   with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for  etoricoxib   Unique binding interactions of valdecoxib with  COX-2  translate into a fast rate of inactivation of  COX-2  (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for  etoricoxib )", "triple_list": [["etoricoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": " Valdecoxib  inhibits  COX-1  in a competitive fashion only at very high concentrations (IC(50) = 150 microM)", "triple_list": [["Valdecoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": " Valdecoxib  showed similar activity in the  human whole-blood COX  assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)", "triple_list": [["Valdecoxib", "DOWNREGULATOR", "human whole-blood COX"]]}, {"text": " Valdecoxib  showed similar activity in the human whole-blood COX assay ( COX-2  IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)", "triple_list": [["Valdecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": " Valdecoxib  showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM;  COX-1  IC(50) = 21.9 microM)", "triple_list": [["Valdecoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": "The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing  prostaglandin  formation from  COX-1   Celecoxib and rofecoxib were among the molecules developed from these efforts", "triple_list": [["prostaglandin", "PRODUCT-OF", "COX-1"]]}, {"text": "An angiotensin II AT1 receptor antagonist,  telmisartan  augments glucose uptake and  GLUT4  protein expression in 3T3-L1 adipocytes", "triple_list": [["telmisartan", "ACTIVATOR", "GLUT4"]]}, {"text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with  telmisartan  caused a dose-dependent increase in mRNA levels for  PPARgamma  target genes such as aP2 and adiponectin", "triple_list": [["telmisartan", "ACTIVATOR", "PPARgamma"]]}, {"text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with  telmisartan  caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as  aP2  and adiponectin", "triple_list": [["telmisartan", "ACTIVATOR", "aP2"]]}, {"text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with  telmisartan  caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and  adiponectin   By contrast,  telmisartan  attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes", "triple_list": [["telmisartan", "ACTIVATOR", "adiponectin"]]}, {"text": "By contrast,  telmisartan  attenuated  11beta-hydroxysteroid dehydrogenase type 1  mRNA level in differentiated adipocytes", "triple_list": [["telmisartan", "ACTIVATOR", "11beta-hydroxysteroid dehydrogenase type 1"]]}, {"text": "Of note, we demonstrated for the first time that  telmisartan  augmented  GLUT4  protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.", "triple_list": [["telmisartan", "ACTIVATOR", "GLUT4"]]}, {"text": "An  angiotensin II AT1 receptor  antagonist,  telmisartan  augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes", "triple_list": [["telmisartan", "ANTAGONIST", "angiotensin II AT1 receptor"]]}, {"text": "An angiotensin II AT1 receptor antagonist, telmisartan augments  glucose  uptake and  GLUT4  protein expression in 3T3-L1 adipocytes", "triple_list": [["glucose", "PRODUCT-OF", "GLUT4"]]}, {"text": "Of note, we demonstrated for the first time that telmisartan augmented  GLUT4  protein expression and  2-deoxy glucose  uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.", "triple_list": [["2-deoxy glucose", "PRODUCT-OF", "GLUT4"]]}, {"text": "Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme  tyrosinase   as compared to the standard  tyrosinase  inhibitors  kojic acid  (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.", "triple_list": [["kojic acid", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme  tyrosinase   as compared to the standard  tyrosinase  inhibitors kojic acid (IC50=16.67 microM) and  L-mimosine  (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.", "triple_list": [["L-mimosine", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "In Experiment 2,  TT-235  induced a significant decrease (p<0.05) in  oxytocin receptor  number and binding affinity at both 0.5 and 4 hours compared with controls", "triple_list": [["TT-235", "DOWNREGULATOR", "oxytocin receptor"]]}, {"text": "In conclusion,  TT-235  may inhibit the uterine response to oxytocin by decreasing  oxytocin receptor  numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of  TT-235 .", "triple_list": [["TT-235", "DOWNREGULATOR", "oxytocin receptor"]]}, {"text": "In conclusion,  TT-235  may inhibit the uterine response to  oxytocin  by decreasing  oxytocin  receptor numbers and  oxytocin  binding affinity, which might explain the prolonged  oxytocin  antagonist activity of  TT-235 .", "triple_list": [["TT-235", "DOWNREGULATOR", "oxytocin"]]}, {"text": "The purpose of the present study was to confirm the duration of  TT-235  to block  oxytocin  induced uterine contractions in estrous rats", "triple_list": [["TT-235", "DOWNREGULATOR", "oxytocin"]]}, {"text": "Oxytocin antagonist (OTA),  TT-235   was developed by our group and shown to inhibit either spontaneous or  oxytocin  induced uterine contractions in primates", "triple_list": [["TT-235", "DOWNREGULATOR", "oxytocin"]]}, {"text": "In Experiment 1,  Antag I    Antag I I and TT-235 inhibited the integrated uterine response to  oxytocin  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)", "triple_list": [["Antag I", "DOWNREGULATOR", "oxytocin"]]}, {"text": "In Experiment 1, Antag I,  Antag II  and TT-235 inhibited the integrated uterine response to  oxytocin  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)", "triple_list": [["Antag II", "DOWNREGULATOR", "oxytocin"]]}, {"text": "In Experiment 1, Antag I, Antag II and  TT-235  inhibited the integrated uterine response to  oxytocin  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)", "triple_list": [["TT-235", "DOWNREGULATOR", "oxytocin"]]}, {"text": "In conclusion,  TT-235  may inhibit the uterine response to  oxytocin  by decreasing  oxytocin  receptor numbers and  oxytocin  binding affinity, which might explain the prolonged  oxytocin  antagonist activity of  TT-235  ", "triple_list": [["TT-235", "ANTAGONIST", "oxytocin"]]}, {"text": " Oxytocin  antagonist (OTA),  TT-235   was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates", "triple_list": [["TT-235", "ANTAGONIST", "Oxytocin"]]}, {"text": "This manuscript presents the preclinical profile of  lumiracoxib   a novel  cyclooxygenase-2  (COX-2) selective inhibitor", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "This manuscript presents the preclinical profile of  lumiracoxib   a novel cyclooxygenase-2 ( COX-2   selective inhibitor", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Ex vivo,  lumiracoxib  inhibited  COX-1  derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": "Preclinical pharmacology of  lumiracoxib   a novel selective inhibitor of  cyclooxygenase-2   1", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "However, consistent with its low  COX-1  inhibitory activity,  lumiracoxib  at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": " Lumiracoxib  inhibited purified  COX-1  and COX-2 with K(i) values of 3 and 0.06 microM, respectively", "triple_list": [["Lumiracoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": " Lumiracoxib  inhibited purified COX-1 and  COX-2  with K(i) values of 3 and 0.06 microM, respectively", "triple_list": [["Lumiracoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "However, consistent with its low  COX-1  inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than  diclofenac  (P<0.05)", "triple_list": [["diclofenac", "DOWNREGULATOR", "COX-1"]]}, {"text": " Lumiracoxib  is a highly selective  COX-2  inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.", "triple_list": [["Lumiracoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Lumiracoxib is a highly selective  COX-2  inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with  diclofenac   the reference NSAID, but with much improved gastrointestinal safety.", "triple_list": [["diclofenac", "DOWNREGULATOR", "COX-2"]]}, {"text": "In cellular assays,  lumiracoxib  had an IC(50) of 0.14 microM in  COX-2  expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "In a human whole blood assay, IC(50) values for  lumiracoxib  were 0.13 microM for  COX-2  and 67 microM for COX-1 (COX-1/ COX-2  selectivity ratio 515)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "In a human whole blood assay, IC(50) values for  lumiracoxib  were 0.13 microM for COX-2 and 67 microM for  COX-1  ( COX-1 /COX-2 selectivity ratio 515)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": "In a human whole blood assay, IC(50) values for  lumiracoxib  were 0.13 microM for COX-2 and 67 microM for  COX-1  ( COX-1  COX-2 selectivity ratio 515)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-1"]]}, {"text": "In a human whole blood assay, IC(50) values for  lumiracoxib  were 0.13 microM for  COX-2  and 67 microM for COX-1 (COX-1/ COX-2  selectivity ratio 515)", "triple_list": [["lumiracoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Ex vivo, lumiracoxib inhibited  COX-1  derived  thromboxane B(2)  (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)", "triple_list": [["thromboxane B(2)", "PRODUCT-OF", "COX-1"]]}, {"text": "Ex vivo, lumiracoxib inhibited  COX-1  derived thromboxane B(2) ( TxB(2)   generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)", "triple_list": [["TxB(2)", "PRODUCT-OF", "COX-1"]]}, {"text": "Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas  COX-2  derived production of  prostaglandin E(2)  (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)", "triple_list": [["prostaglandin E(2)", "PRODUCT-OF", "COX-2"]]}, {"text": "Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas  COX-2  derived production of prostaglandin E(2) ( PGE(2)   in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)", "triple_list": [["PGE(2)", "PRODUCT-OF", "COX-2"]]}, {"text": "As  thiamine  metabolism deficiencies have been seen in placental infarcts previously, these indicate that  PP20  hTPK may have a role in placental diseases", "triple_list": [["thiamine", "PRODUCT-OF", "PP20"]]}, {"text": "As  thiamine  metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/ hTPK  may have a role in placental diseases", "triple_list": [["thiamine", "PRODUCT-OF", "hTPK"]]}, {"text": " Denufosol  is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated  P2Y(2)  agonists", "triple_list": [["Denufosol", "AGONIST", "P2Y(2)"]]}, {"text": "Safety and tolerability of  denufosol tetrasodium  inhalation solution, a novel  P2Y2 receptor  agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis", "triple_list": [["denufosol tetrasodium", "AGONIST", "P2Y2 receptor"]]}, {"text": " Denufosol tetrasodium  (INS37217) is a selective  P2Y(2)  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF", "triple_list": [["Denufosol tetrasodium", "AGONIST", "P2Y(2)"]]}, {"text": "Denufosol tetrasodium ( INS37217   is a selective  P2Y(2)  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF", "triple_list": [["INS37217", "AGONIST", "P2Y(2)"]]}, {"text": "The  Cl(-)  secretory response is mediated via a non- CFTR  pathway, and the driving force for  Cl(-)  secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport", "triple_list": [["Cl(-)", "PRODUCT-OF", "CFTR"]]}, {"text": "Dimemorfan pre-treatment also attenuated the  KA  induced increases in c-fos/c-jun expression,  activator protein (AP)-1  DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus", "triple_list": [["KA", "ACTIVATOR", "activator protein (AP)-1"]]}, {"text": "The dextromethorphan analog  dimemorfan  attenuates kainate-induced seizures via  sigma1 receptor  activation: comparison with the effects of dextromethorphan", "triple_list": [["dimemorfan", "ACTIVATOR", "sigma1 receptor"]]}, {"text": "The  dextromethorphan  analog dimemorfan attenuates kainate-induced seizures via  sigma1 receptor  activation: comparison with the effects of  dextromethorphan ", "triple_list": [["dextromethorphan", "ACTIVATOR", "sigma1 receptor"]]}, {"text": "Dimemorfan pre-treatment also attenuated the  KA  induced increases in  c-fos  c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus", "triple_list": [["KA", "ACTIVATOR", "c-fos"]]}, {"text": "Dimemorfan pre-treatment also attenuated the  KA  induced increases in c-fos/ c-jun  expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus", "triple_list": [["KA", "ACTIVATOR", "c-jun"]]}, {"text": " Dimemorfan  pre-treatment also attenuated the KA-induced increases in  c-fos  c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus", "triple_list": [["Dimemorfan", "DOWNREGULATOR", "c-fos"]]}, {"text": " Dimemorfan  pre-treatment also attenuated the KA-induced increases in c-fos/ c-jun  expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus", "triple_list": [["Dimemorfan", "DOWNREGULATOR", "c-jun"]]}, {"text": " Dimemorfan  pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression,  activator protein (AP)-1  DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus", "triple_list": [["Dimemorfan", "DOWNREGULATOR", "activator protein (AP)-1"]]}, {"text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective  sigma1 receptor  antagonist  BD 1047   suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to  sigma1 receptor -activated modulation of AP-1 transcription factors", "triple_list": [["BD 1047", "ANTAGONIST", "sigma1 receptor"]]}, {"text": "We have analyzed binding domains of the  oxytocin  receptor for barusiban, a highly selective  oxytocin  receptor antagonist, in comparison to the combined vasopressin V1A/ oxytocin  receptor antagonist atosiban and the agonists  oxytocin  and carbetocin", "triple_list": [["oxytocin", "AGONIST", "vasopressin V1A/oxytocin receptor"]]}, {"text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  vasopressin V1A/oxytocin receptor  antagonist atosiban and the agonists oxytocin and  carbetocin   For this purpose, chimeric 'gain-in function' oxytocin/vasopressin V2 receptors were expressed in COS-7 cells", "triple_list": [["carbetocin", "AGONIST", "vasopressin V1A/oxytocin receptor"]]}, {"text": "Binding domains of the  oxytocin  receptor for the selective  oxytocin  receptor antagonist barusiban in comparison to the agonists  oxytocin  and carbetocin", "triple_list": [["oxytocin", "AGONIST", "oxytocin receptor"]]}, {"text": "Binding domains of the  oxytocin receptor  for the selective  oxytocin receptor  antagonist barusiban in comparison to the agonists oxytocin and  carbetocin   We have analyzed binding domains of the  oxytocin receptor  for barusiban, a highly selective  oxytocin receptor  antagonist, in comparison to the combined vasopressin V1A/ oxytocin receptor  antagonist atosiban and the agonists oxytocin and  carbetocin ", "triple_list": [["carbetocin", "AGONIST", "oxytocin receptor"]]}, {"text": "The binding domain of barusiban differs from the binding domain of the agonists and the nonselective  oxytocin receptor  antagonist  d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin  that has been used in previous studies", "triple_list": [["d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin", "ANTAGONIST", "oxytocin receptor"]]}, {"text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  vasopressin V1A/oxytocin receptor  antagonist  atosiban  and the agonists oxytocin and carbetocin", "triple_list": [["atosiban", "ANTAGONIST", "vasopressin V1A/oxytocin receptor"]]}, {"text": "We have analyzed binding domains of the  oxytocin receptor  for  barusiban   a highly selective  oxytocin receptor  antagonist, in comparison to the combined vasopressin V1A/ oxytocin receptor  antagonist atosiban and the agonists oxytocin and carbetocin", "triple_list": [["barusiban", "ANTAGONIST", "oxytocin receptor"]]}, {"text": "Binding domains of the  oxytocin receptor  for the selective  oxytocin receptor  antagonist  barusiban  in comparison to the agonists oxytocin and carbetocin", "triple_list": [["barusiban", "ANTAGONIST", "oxytocin receptor"]]}, {"text": "For the  vasopressin V1A/oxytocin receptor  antagonist  atosiban   none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor", "triple_list": [["atosiban", "ANTAGONIST", "vasopressin V1A/oxytocin receptor"]]}, {"text": "However, the flowcytometric analysis revealed that  AZC  and PCA decreased intracellular contents of  CD3-zeta chain  in these cells in dose dependent manner", "triple_list": [["AZC", "DOWNREGULATOR", "CD3-zeta chain"]]}, {"text": "However, the flowcytometric analysis revealed that AZC and  PCA  decreased intracellular contents of  CD3-zeta chain  in these cells in dose dependent manner", "triple_list": [["PCA", "DOWNREGULATOR", "CD3-zeta chain"]]}, {"text": "The compounds  5'-azacytidine  (AZC) and procainamide (PCA) belong to inhibitors of  DNMT1   whose low activity correlates with increase in transcription of various genes", "triple_list": [["5'-azacytidine", "DOWNREGULATOR", "DNMT1"]]}, {"text": "The compounds 5'-azacytidine ( AZC   and procainamide (PCA) belong to inhibitors of  DNMT1   whose low activity correlates with increase in transcription of various genes", "triple_list": [["AZC", "DOWNREGULATOR", "DNMT1"]]}, {"text": "The compounds 5'-azacytidine (AZC) and  procainamide  (PCA) belong to inhibitors of  DNMT1   whose low activity correlates with increase in transcription of various genes", "triple_list": [["procainamide", "DOWNREGULATOR", "DNMT1"]]}, {"text": "The compounds 5'-azacytidine (AZC) and procainamide ( PCA   belong to inhibitors of  DNMT1   whose low activity correlates with increase in transcription of various genes", "triple_list": [["PCA", "DOWNREGULATOR", "DNMT1"]]}, {"text": "These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to  TS  inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate ( FdUMP  ", "triple_list": [["FdUMP", "DOWNREGULATOR", "TS"]]}, {"text": "Clinical studies in cancer patients treated with the new  fluoropyrimidine  analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  thymidylate synthase  (TS)", "triple_list": [["fluoropyrimidine", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Clinical studies in cancer patients treated with the new  fluoropyrimidine  analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( TS  ", "triple_list": [["fluoropyrimidine", "DOWNREGULATOR", "TS"]]}, {"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue  capecitabine  (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  thymidylate synthase  (TS)", "triple_list": [["capecitabine", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue  capecitabine  (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( TS  ", "triple_list": [["capecitabine", "DOWNREGULATOR", "TS"]]}, {"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine ( N4-pentoxycarbonyl-5'-5-fluorocytidine   have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  thymidylate synthase  (TS)", "triple_list": [["N4-pentoxycarbonyl-5'-5-fluorocytidine", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine ( N4-pentoxycarbonyl-5'-5-fluorocytidine   have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( TS  ", "triple_list": [["N4-pentoxycarbonyl-5'-5-fluorocytidine", "DOWNREGULATOR", "TS"]]}, {"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma  2'-deoxyuridine  was significantly elevated after 1 week of treatment, consistent with inhibition of  thymidylate synthase  (TS)", "triple_list": [["2'-deoxyuridine", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma  2'-deoxyuridine  was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( TS  ", "triple_list": [["2'-deoxyuridine", "DOWNREGULATOR", "TS"]]}, {"text": "These findings suggest that the mechanism of antiproliferative toxicity of  capecitabine  is at least partly due to  TS  inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP)", "triple_list": [["capecitabine", "DOWNREGULATOR", "TS"]]}, {"text": "These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to  TS  inhibitory activity of its active metabolite  5-fluoro-2'-deoxyuridine monophosphate  (FdUMP)", "triple_list": [["5-fluoro-2'-deoxyuridine monophosphate", "DOWNREGULATOR", "TS"]]}, {"text": " Imatinib  induced changes were blocked with the  EGFR  antagonist cetuximab, which suggested direct involvement of  EGFR  in this process", "triple_list": [["Imatinib", "ACTIVATOR", "EGFR"]]}, {"text": "Western blot analysis of cells incubated with  imatinib  demonstrated activation of  EGFR  and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and  EGFR , but not Her2/ErbB2", "triple_list": [["imatinib", "ACTIVATOR", "EGFR"]]}, {"text": "Induction of heparin-binding EGF-like growth factor and activation of  EGF receptor  in  imatinib mesylate  treated squamous carcinoma cells", "triple_list": [["imatinib mesylate", "ACTIVATOR", "EGF receptor"]]}, {"text": "Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  imatinib  mediated  mitogen activated protein kinase  (MAPK) activation", "triple_list": [["imatinib", "ACTIVATOR", "mitogen activated protein kinase"]]}, {"text": "Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  imatinib  mediated mitogen activated protein kinase ( MAPK   activation", "triple_list": [["imatinib", "ACTIVATOR", "MAPK"]]}, {"text": " Imatinib  stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic  MAPK  activation", "triple_list": [["Imatinib", "ACTIVATOR", "MAPK"]]}, {"text": "Although,  imatinib  primarily inhibits tyrosine kinases, it also stimulates the activity of  EGFR  tyrosine kinase in head and neck squamous tumors", "triple_list": [["imatinib", "ACTIVATOR", "EGFR"]]}, {"text": "Although,  imatinib  primarily inhibits  tyrosine kinase s, it also stimulates the activity of EGFR  tyrosine kinase  in head and neck squamous tumors", "triple_list": [["imatinib", "ACTIVATOR", "tyrosine kinase"]]}, {"text": "Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of  imatinib  induced changes in cell morphology and growth similar to changes associated with  epidermal growth factor receptor  (EGFR) activation", "triple_list": [["imatinib", "ACTIVATOR", "epidermal growth factor receptor"]]}, {"text": "Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of  imatinib  induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor ( EGFR   activation", "triple_list": [["imatinib", "ACTIVATOR", "EGFR"]]}, {"text": "Western blot analysis of cells incubated with  imatinib  demonstrated activation of  EGFR  and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and  EGFR , but not Her2/ErbB2", "triple_list": [["imatinib", "ACTIVATOR", "EGFR"]]}, {"text": " Imatinib  stimulated the rapid release of soluble  HB-EGF  and the subsequent induction of membrane-bound  HB-EGF , which correlated with biphasic MAPK activation", "triple_list": [["Imatinib", "ACTIVATOR", "HB-EGF"]]}, {"text": " Imatinib  stimulated the rapid release of soluble  HB-EGF  and the subsequent induction of membrane-bound  HB-EGF   which correlated with biphasic MAPK activation", "triple_list": [["Imatinib", "ACTIVATOR", "HB-EGF"]]}, {"text": "Together, these results suggested that  imatinib  affects  EGFR  activation and signaling pathways through rapid release and increased expression of endogenous  EGFR  activating ligands", "triple_list": [["imatinib", "ACTIVATOR", "EGFR"]]}, {"text": " Imatinib mesylate  is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ( PDGFR  , and c-kit kinases", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "PDGFR"]]}, {"text": " Imatinib mesylate  is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and  c-kit  kinases", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "c-kit"]]}, {"text": " Imatinib mesylate  is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit  kinases   Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "kinases"]]}, {"text": " Imatinib mesylate  is a  tyrosine kinase  inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": " Imatinib mesylate  is a tyrosine kinase inhibitor of the  ABL   platelet-derived growth factor receptor (PDGFR), and c-kit kinases", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "ABL"]]}, {"text": " Imatinib mesylate  is a tyrosine kinase inhibitor of the ABL,  platelet-derived growth factor receptor  (PDGFR), and c-kit kinases", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "platelet-derived growth factor receptor"]]}, {"text": "Although,  imatinib  primarily inhibits  tyrosine kinases   it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors", "triple_list": [["imatinib", "DOWNREGULATOR", "tyrosine kinases"]]}, {"text": "The identity of the lung  beta-ADHs  was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by  4-methylpyrazole  or 1,10-phenanthroline", "triple_list": [["4-methylpyrazole", "DOWNREGULATOR", "beta-ADHs"]]}, {"text": "The identity of the lung  beta-ADHs  was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or  1,10-phenanthroline   The beta 2 allele, coding for beta 2 polypeptide, was found to be predominant in the lung specimens studied", "triple_list": [["1,10-phenanthroline", "DOWNREGULATOR", "beta-ADHs"]]}, {"text": "The results suggest that individuals with high Vmax  beta 2-ADH  and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with  acetaldehyde  accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "triple_list": [["acetaldehyde", "PRODUCT-OF", "beta 2-ADH"]]}, {"text": "The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial  ALDH2   accounting for approximately 45% of the Chinese population, may end up with  acetaldehyde  accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "triple_list": [["acetaldehyde", "PRODUCT-OF", "ALDH2"]]}, {"text": "These findings indicate that human pulmonary  ethanol  metabolizing activities differ significantly with respect to genetic polymorphism at both the  ADH2  and the ALDH2 loci", "triple_list": [["ethanol", "PRODUCT-OF", "ADH2"]]}, {"text": "These findings indicate that human pulmonary  ethanol  metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the  ALDH2  loci", "triple_list": [["ethanol", "PRODUCT-OF", "ALDH2"]]}, {"text": "The results suggest that individuals with high Vmax  beta 2-ADH  and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during  alcohol  consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "triple_list": [["alcohol", "PRODUCT-OF", "beta 2-ADH"]]}, {"text": "The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial  ALDH2   accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during  alcohol  consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "triple_list": [["alcohol", "PRODUCT-OF", "ALDH2"]]}, {"text": "The identity of the lung  beta-ADHs  was further demonstrated by their characteristic pH-activity profiles for  ethanol  oxidation, Km values for NAD and  ethanol , and inhibition by 4-methylpyrazole or 1,10-phenanthroline", "triple_list": [["ethanol", "PRODUCT-OF", "beta-ADHs"]]}, {"text": "The identity of the lung  beta-ADHs  was further demonstrated by their characteristic pH-activity profiles for  ethanol  oxidation, Km values for NAD and  ethanol   and inhibition by 4-methylpyrazole or 1,10-phenanthroline", "triple_list": [["ethanol", "PRODUCT-OF", "beta-ADHs"]]}, {"text": "The IL-18 production is located upstream of the  cytokine  cascade activated by  simvastatin   Moreover,  simvastatin  concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes", "triple_list": [["simvastatin", "ACTIVATOR", "cytokine"]]}, {"text": "In the presence of IL-18,  simvastatin  suppressed the expression of ICAM-1 and CD40 as well as the production of  IL-12   TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of  simvastatin ", "triple_list": [["simvastatin", "ACTIVATOR", "IL-12"]]}, {"text": "In the presence of IL-18,  simvastatin  suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12,  TNF-alpha  and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of  simvastatin ", "triple_list": [["simvastatin", "ACTIVATOR", "TNF-alpha"]]}, {"text": "In the presence of IL-18,  simvastatin  suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and  IFN-gamma  in PBMC, contributing to the anti-inflammatory effect of  simvastatin ", "triple_list": [["simvastatin", "ACTIVATOR", "IFN-gamma"]]}, {"text": " Simvastatin  induces  interleukin-18  production in human peripheral blood mononuclear cells", "triple_list": [["Simvastatin", "ACTIVATOR", "interleukin-18"]]}, {"text": " Simvastatin   an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of  interleukin (IL)-18   tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)", "triple_list": [["Simvastatin", "ACTIVATOR", "interleukin (IL)-18"]]}, {"text": " Simvastatin   an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18,  tumor necrosis factor (TNF)-alpha  and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)", "triple_list": [["Simvastatin", "ACTIVATOR", "tumor necrosis factor (TNF)-alpha"]]}, {"text": " Simvastatin   an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and  interferon (IFN)-gamma  in human peripheral blood mononuclear cells (PBMC)", "triple_list": [["Simvastatin", "ACTIVATOR", "interferon (IFN)-gamma"]]}, {"text": "The  IL-18  production is located upstream of the cytokine cascade activated by  simvastatin   Moreover,  simvastatin  concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes", "triple_list": [["simvastatin", "ACTIVATOR", "IL-18"]]}, {"text": "Moreover,  simvastatin  concentration-dependently inhibited the expression of ICAM-1 and induced the expression of  CD40  on monocytes", "triple_list": [["simvastatin", "ACTIVATOR", "CD40"]]}, {"text": "In the presence of IL-18,  simvastatin  suppressed the expression of  ICAM-1  and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of  simvastatin ", "triple_list": [["simvastatin", "DOWNREGULATOR", "ICAM-1"]]}, {"text": "In the presence of IL-18,  simvastatin  suppressed the expression of ICAM-1 and  CD40  as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of  simvastatin ", "triple_list": [["simvastatin", "DOWNREGULATOR", "CD40"]]}, {"text": "Moreover,  simvastatin  concentration-dependently inhibited the expression of  ICAM-1  and induced the expression of CD40 on monocytes", "triple_list": [["simvastatin", "DOWNREGULATOR", "ICAM-1"]]}, {"text": " Simvastatin   an  HMG-CoA reductase  inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)", "triple_list": [["Simvastatin", "DOWNREGULATOR", "HMG-CoA reductase"]]}, {"text": " Simvastatin   an HMG-CoA reductase inhibitor with mild inhibition of  LFA-1   induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)", "triple_list": [["Simvastatin", "DOWNREGULATOR", "LFA-1"]]}, {"text": "The effects of simvastatin were abolished by the addition of the product of the  HMG-CoA reductase    mevalonate   indicating the involvement of  HMG-CoA reductase  in the action of simvastatin.", "triple_list": [["mevalonate", "PRODUCT-OF", "HMG-CoA reductase"]]}, {"text": "However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater  COX-2  selectivity than at IC50, and meloxicam (-41.2%) and  carprofen  (-12.9%) had lower  COX-2  selectivity than at IC50", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-2"]]}, {"text": "We report on the inhibitory activity of the NSAIDs meloxicam,  carprofen   phenylbutazone and flunixin, on blood  cyclooxygenases  in the horse using in vitro enzyme-linked assays", "triple_list": [["carprofen", "DOWNREGULATOR", "cyclooxygenases"]]}, {"text": "We report on the inhibitory activity of the NSAIDs meloxicam, carprofen,  phenylbutazone  and flunixin, on blood  cyclooxygenases  in the horse using in vitro enzyme-linked assays", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "cyclooxygenases"]]}, {"text": "We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and  flunixin   on blood  cyclooxygenases  in the horse using in vitro enzyme-linked assays", "triple_list": [["flunixin", "DOWNREGULATOR", "cyclooxygenases"]]}, {"text": " COX-1  and COX-2 inhibition in horse blood by  phenylbutazone   flunixin, carprofen and meloxicam: an in vitro analysis", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "COX-1"]]}, {"text": "COX-1 and  COX-2  inhibition in horse blood by  phenylbutazone   flunixin, carprofen and meloxicam: an in vitro analysis", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "COX-2"]]}, {"text": " COX-1  and COX-2 inhibition in horse blood by phenylbutazone,  flunixin   carprofen and meloxicam: an in vitro analysis", "triple_list": [["flunixin", "DOWNREGULATOR", "COX-1"]]}, {"text": "COX-1 and  COX-2  inhibition in horse blood by phenylbutazone,  flunixin   carprofen and meloxicam: an in vitro analysis", "triple_list": [["flunixin", "DOWNREGULATOR", "COX-2"]]}, {"text": " COX-1  and COX-2 inhibition in horse blood by phenylbutazone, flunixin,  carprofen  and meloxicam: an in vitro analysis", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-1"]]}, {"text": "COX-1 and  COX-2  inhibition in horse blood by phenylbutazone, flunixin,  carprofen  and meloxicam: an in vitro analysis", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-2"]]}, {"text": " COX-1  and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and  meloxicam   an in vitro analysis", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-1"]]}, {"text": "COX-1 and  COX-2  inhibition in horse blood by phenylbutazone, flunixin, carprofen and  meloxicam   an in vitro analysis", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "As expected, comparison of IC50 indicated that  meloxicam  and carprofen are more selective inhibitors of  COX-2  than phenylbutazone and flunixin;  meloxicam  was the most advantageous for horses of four NSAIDs examined", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "As expected, comparison of IC50 indicated that meloxicam and  carprofen  are more selective inhibitors of  COX-2  than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-2"]]}, {"text": "As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of  COX-2  than  phenylbutazone  and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "COX-2"]]}, {"text": "As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of  COX-2  than phenylbutazone and  flunixin   meloxicam was the most advantageous for horses of four NSAIDs examined", "triple_list": [["flunixin", "DOWNREGULATOR", "COX-2"]]}, {"text": "However at IC80,  phenylbutazone  (+134.4%) and flunixin (+29.7%) had greater  COX-2  selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower  COX-2  selectivity than at IC50", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "COX-2"]]}, {"text": "However at IC80, phenylbutazone (+134.4%) and  flunixin  (+29.7%) had greater  COX-2  selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower  COX-2  selectivity than at IC50", "triple_list": [["flunixin", "DOWNREGULATOR", "COX-2"]]}, {"text": "However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater  COX-2  selectivity than at IC50, and  meloxicam  (-41.2%) and carprofen (-12.9%) had lower  COX-2  selectivity than at IC50", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "We report on the inhibitory activity of the NSAIDs  meloxicam   carprofen, phenylbutazone and flunixin, on blood  cyclooxygenases  in the horse using in vitro enzyme-linked assays", "triple_list": [["meloxicam", "DOWNREGULATOR", "cyclooxygenases"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and  NGF-beta  to the baseline values", "triple_list": [["carvedilol", "ACTIVATOR", "NGF-beta"]]}, {"text": " Carvedilol  prevents cardiac hypertrophy and overexpression of  hypoxia-inducible factor-1alpha  and vascular endothelial growth factor in pressure-overloaded rat heart", "triple_list": [["Carvedilol", "DOWNREGULATOR", "hypoxia-inducible factor-1alpha"]]}, {"text": " Carvedilol  prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and  vascular endothelial growth factor  in pressure-overloaded rat heart", "triple_list": [["Carvedilol", "DOWNREGULATOR", "vascular endothelial growth factor"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of  HIF-1alpha   VEGF, BNP, and NGF-beta to the baseline values", "triple_list": [["carvedilol", "DOWNREGULATOR", "HIF-1alpha"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of HIF-1alpha,  VEGF   BNP, and NGF-beta to the baseline values", "triple_list": [["carvedilol", "DOWNREGULATOR", "VEGF"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of HIF-1alpha, VEGF,  BNP   and NGF-beta to the baseline values", "triple_list": [["carvedilol", "DOWNREGULATOR", "BNP"]]}, {"text": "Increased immunohistochemical labeling of  HIF-1alpha   VEGF, and BNP in the ventricular myocardium was observed in the banding group and  carvedilol  again normalized the labeling", "triple_list": [["carvedilol", "DOWNREGULATOR", "HIF-1alpha"]]}, {"text": "Increased immunohistochemical labeling of HIF-1alpha,  VEGF   and BNP in the ventricular myocardium was observed in the banding group and  carvedilol  again normalized the labeling", "triple_list": [["carvedilol", "DOWNREGULATOR", "VEGF"]]}, {"text": "Increased immunohistochemical labeling of HIF-1alpha, VEGF, and  BNP  in the ventricular myocardium was observed in the banding group and  carvedilol  again normalized the labeling", "triple_list": [["carvedilol", "DOWNREGULATOR", "BNP"]]}, {"text": "Treatment with  carvedilol  is associated with a reversal of abnormal regulation of  HIF-1alpha   VEGF, BNP, and NGF-beta in the hypertrophic myocardium.", "triple_list": [["carvedilol", "DOWNREGULATOR", "HIF-1alpha"]]}, {"text": "Treatment with  carvedilol  is associated with a reversal of abnormal regulation of HIF-1alpha,  VEGF   BNP, and NGF-beta in the hypertrophic myocardium.", "triple_list": [["carvedilol", "DOWNREGULATOR", "VEGF"]]}, {"text": "Treatment with  carvedilol  is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF,  BNP   and NGF-beta in the hypertrophic myocardium.", "triple_list": [["carvedilol", "DOWNREGULATOR", "BNP"]]}, {"text": " Imatinib  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  KIT   ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Imatinib", "DOWNREGULATOR", "KIT"]]}, {"text": " Imatinib  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL   BCR- ABL , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Imatinib", "DOWNREGULATOR", "ABL"]]}, {"text": " Imatinib  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  BCR  ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Imatinib", "DOWNREGULATOR", "BCR"]]}, {"text": " Imatinib  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL , BCR- ABL   PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Imatinib", "DOWNREGULATOR", "ABL"]]}, {"text": " Imatinib  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  PDGFRA   and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Imatinib", "DOWNREGULATOR", "PDGFRA"]]}, {"text": " Imatinib  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  PDGFRB,  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Imatinib", "DOWNREGULATOR", "PDGFRB,"]]}, {"text": "Imatinib ( STI571   Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  KIT   ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["STI571", "DOWNREGULATOR", "KIT"]]}, {"text": "Imatinib ( STI571   Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL   BCR- ABL , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["STI571", "DOWNREGULATOR", "ABL"]]}, {"text": "Imatinib ( STI571   Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  BCR  ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["STI571", "DOWNREGULATOR", "BCR"]]}, {"text": "Imatinib ( STI571   Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL , BCR- ABL   PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["STI571", "DOWNREGULATOR", "ABL"]]}, {"text": "Imatinib ( STI571   Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  PDGFRA   and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["STI571", "DOWNREGULATOR", "PDGFRA"]]}, {"text": "Imatinib ( STI571   Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  PDGFRB,  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["STI571", "DOWNREGULATOR", "PDGFRB,"]]}, {"text": "Imatinib (STI571,  Gleevec   Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  KIT   ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Gleevec", "DOWNREGULATOR", "KIT"]]}, {"text": "Imatinib (STI571,  Gleevec   Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL   BCR- ABL , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Gleevec", "DOWNREGULATOR", "ABL"]]}, {"text": "Imatinib (STI571,  Gleevec   Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  BCR  ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Gleevec", "DOWNREGULATOR", "BCR"]]}, {"text": "Imatinib (STI571,  Gleevec   Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL , BCR- ABL   PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Gleevec", "DOWNREGULATOR", "ABL"]]}, {"text": "Imatinib (STI571,  Gleevec   Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  PDGFRA   and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Gleevec", "DOWNREGULATOR", "PDGFRA"]]}, {"text": "Imatinib (STI571,  Gleevec   Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  PDGFRB,  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Gleevec", "DOWNREGULATOR", "PDGFRB,"]]}, {"text": "Imatinib (STI571, Gleevec,  Glivec   Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  KIT   ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Glivec", "DOWNREGULATOR", "KIT"]]}, {"text": "Imatinib (STI571, Gleevec,  Glivec   Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL   BCR- ABL , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Glivec", "DOWNREGULATOR", "ABL"]]}, {"text": "Imatinib (STI571, Gleevec,  Glivec   Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  BCR  ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Glivec", "DOWNREGULATOR", "BCR"]]}, {"text": "Imatinib (STI571, Gleevec,  Glivec   Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  ABL , BCR- ABL   PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Glivec", "DOWNREGULATOR", "ABL"]]}, {"text": "Imatinib (STI571, Gleevec,  Glivec   Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  PDGFRA   and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Glivec", "DOWNREGULATOR", "PDGFRA"]]}, {"text": "Imatinib (STI571, Gleevec,  Glivec   Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  PDGFRB,  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs", "triple_list": [["Glivec", "DOWNREGULATOR", "PDGFRB,"]]}, {"text": "Moreover,  4-methylhistamine  potently activated the  hH(4)R  (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)", "triple_list": [["4-methylhistamine", "ACTIVATOR", "hH(4)R"]]}, {"text": "Most of the tested H(2)R agonists and  imidazole  based H(3)R ligands show micromolar-to-nanomolar range  hH(4)R  affinity, and these ligands exert different intrinsic  hH(4)R  activities, ranging from full agonists to inverse agonists", "triple_list": [["imidazole", "AGONIST", "hH(4)R"]]}, {"text": "Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine  H4 receptor : identification of  4-methylhistamine  as the first potent and selective  H4 receptor  agonist", "triple_list": [["4-methylhistamine", "AGONIST", "H4 receptor"]]}, {"text": "The identification of  4-methylhistamine  as a potent  H(4)R  agonist is of major importance for future studies to unravel the physiological roles of the  H(4)R .", "triple_list": [["4-methylhistamine", "AGONIST", "H(4)R"]]}, {"text": "Most of the tested H(2)R agonists and  imidazole  based H(3)R ligands show micromolar-to-nanomolar range  hH(4)R  affinity, and these ligands exert different intrinsic  hH(4)R  activities, ranging from full agonists to inverse agonists", "triple_list": [["imidazole", "AGONIST", "hH(4)R"]]}, {"text": "Moreover, 4-methylhistamine potently activated the h H(4)R  (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective  H(4)R  antagonist  JNJ 7777120  [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)", "triple_list": [["JNJ 7777120", "ANTAGONIST", "H(4)R"]]}, {"text": "Moreover, 4-methylhistamine potently activated the h H(4)R  (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective  H(4)R  antagonist JNJ 7777120 [ 1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine   (pA(2) = 7.8)", "triple_list": [["1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine", "ANTAGONIST", "H(4)R"]]}, {"text": "Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of  acetylcholinesterase  activity, which can be eliminated by administration of  atropine   Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to Topo I and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa", "triple_list": [["atropine", "ACTIVATOR", "acetylcholinesterase"]]}, {"text": " CPT-11  and SN-38 may also stimulate the production of pro-inflammatory  cytokines  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)", "triple_list": [["CPT-11", "ACTIVATOR", "cytokines"]]}, {"text": "CPT-11 and  SN-38  may also stimulate the production of pro-inflammatory  cytokines  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)", "triple_list": [["SN-38", "ACTIVATOR", "cytokines"]]}, {"text": "Irinotecan (CPT-11,  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin   has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting  DNA topoisomerase I  (Topo I)", "triple_list": [["7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin", "DOWNREGULATOR", "DNA topoisomerase I"]]}, {"text": "Irinotecan (CPT-11,  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin   has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ( Topo I  ", "triple_list": [["7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin", "DOWNREGULATOR", "Topo I"]]}, {"text": "Early-onset diarrhea is observed immediately after  CPT-11  infusion and probably due to the inhibition of  acetylcholinesterase  activity, which can be eliminated by administration of atropine", "triple_list": [["CPT-11", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": " Irinotecan  (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting  DNA topoisomerase I  (Topo I)", "triple_list": [["Irinotecan", "DOWNREGULATOR", "DNA topoisomerase I"]]}, {"text": " Irinotecan  (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ( Topo I  ", "triple_list": [["Irinotecan", "DOWNREGULATOR", "Topo I"]]}, {"text": "Irinotecan ( CPT-11   7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting  DNA topoisomerase I  (Topo I)", "triple_list": [["CPT-11", "DOWNREGULATOR", "DNA topoisomerase I"]]}, {"text": "Irinotecan ( CPT-11   7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ( Topo I  ", "triple_list": [["CPT-11", "DOWNREGULATOR", "Topo I"]]}, {"text": " (R)-Roscovitine  (CYC202, Seliciclib) is a relatively selective inhibitor of  cyclin-dependent kinases  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections", "triple_list": [["(R)-Roscovitine", "DOWNREGULATOR", "cyclin-dependent kinases"]]}, {"text": " (R)-Roscovitine  (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( CDKs  , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections", "triple_list": [["(R)-Roscovitine", "DOWNREGULATOR", "CDKs"]]}, {"text": "(R)-Roscovitine ( CYC202   Seliciclib) is a relatively selective inhibitor of  cyclin-dependent kinases  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections", "triple_list": [["CYC202", "DOWNREGULATOR", "cyclin-dependent kinases"]]}, {"text": "(R)-Roscovitine ( CYC202   Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( CDKs  , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections", "triple_list": [["CYC202", "DOWNREGULATOR", "CDKs"]]}, {"text": "(R)-Roscovitine (CYC202,  Seliciclib   is a relatively selective inhibitor of  cyclin-dependent kinases  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections", "triple_list": [["Seliciclib", "DOWNREGULATOR", "cyclin-dependent kinases"]]}, {"text": "(R)-Roscovitine (CYC202,  Seliciclib   is a relatively selective inhibitor of cyclin-dependent kinases ( CDKs  , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections", "triple_list": [["Seliciclib", "DOWNREGULATOR", "CDKs"]]}, {"text": " Pyridoxal kinase  (PDXK) catalyzes the phosphorylation of  pyridoxal   pyridoxamine, and pyridoxine in the presence of ATP and Zn2+", "triple_list": [["pyridoxal", "PRODUCT-OF", "Pyridoxal kinase"]]}, {"text": "Pyridoxal kinase ( PDXK   catalyzes the phosphorylation of  pyridoxal   pyridoxamine, and pyridoxine in the presence of ATP and Zn2+", "triple_list": [["pyridoxal", "PRODUCT-OF", "PDXK"]]}, {"text": " Pyridoxal kinase  (PDXK) catalyzes the phosphorylation of pyridoxal,  pyridoxamine   and pyridoxine in the presence of ATP and Zn2+", "triple_list": [["pyridoxamine", "PRODUCT-OF", "Pyridoxal kinase"]]}, {"text": "Pyridoxal kinase ( PDXK   catalyzes the phosphorylation of pyridoxal,  pyridoxamine   and pyridoxine in the presence of ATP and Zn2+", "triple_list": [["pyridoxamine", "PRODUCT-OF", "PDXK"]]}, {"text": " Pyridoxal kinase  (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and  pyridoxine  in the presence of ATP and Zn2+", "triple_list": [["pyridoxine", "PRODUCT-OF", "Pyridoxal kinase"]]}, {"text": "Pyridoxal kinase ( PDXK   catalyzes the phosphorylation of pyridoxal, pyridoxamine, and  pyridoxine  in the presence of ATP and Zn2+", "triple_list": [["pyridoxine", "PRODUCT-OF", "PDXK"]]}, {"text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as  adenylate cyclase  activator,  forskolin   The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059", "triple_list": [["forskolin", "ACTIVATOR", "adenylate cyclase"]]}, {"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  PP2   a selective inhibitor of tyrosine kinase Src responsible for ligand-independent  EGFR  autophosphorylation, but not by ERK inhibitor, PD98059", "triple_list": [["PP2", "ACTIVATOR", "EGFR"]]}, {"text": "Both inhibitors, moreover, blunted the  mucin  secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator,  forskolin   The gastric  mucin  secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059", "triple_list": [["forskolin", "DOWNREGULATOR", "mucin"]]}, {"text": "The  gastric mucin  secretory responses to isoproterenol, furthermore, were inhibited by  PP2   a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059", "triple_list": [["PP2", "DOWNREGULATOR", "gastric mucin"]]}, {"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on  mucin  secretion was inhibited by EGFR kinase inhibitor,  PD153035   as well as wortmannin, a specific inhibitor of PI3K", "triple_list": [["PD153035", "DOWNREGULATOR", "mucin"]]}, {"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on  mucin  secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as  wortmannin   a specific inhibitor of PI3K", "triple_list": [["wortmannin", "DOWNREGULATOR", "mucin"]]}, {"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  PP2   a selective inhibitor of  tyrosine kinase  Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059", "triple_list": [["PP2", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  PP2   a selective inhibitor of tyrosine kinase  Src  responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059", "triple_list": [["PP2", "DOWNREGULATOR", "Src"]]}, {"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by  ERK  inhibitor,  PD98059   The inhibition of  ERK , moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin", "triple_list": [["PD98059", "DOWNREGULATOR", "ERK"]]}, {"text": "The inhibition of  ERK   moreover, did not cause attenuation in mucin secretion in response to  cAMP  and forskolin", "triple_list": [["cAMP", "DOWNREGULATOR", "ERK"]]}, {"text": "The inhibition of  ERK   moreover, did not cause attenuation in mucin secretion in response to cAMP and  forskolin   The findings underline the role of EGFR as a convergence point in gastric mucin secretion triggered by beta-adrenergic GPCR activation, and demonstrate the requirement for Src kinase in EGFR transactivation.", "triple_list": [["forskolin", "DOWNREGULATOR", "ERK"]]}, {"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by  EGFR  kinase inhibitor,  PD153035   as well as wortmannin, a specific inhibitor of PI3K", "triple_list": [["PD153035", "DOWNREGULATOR", "EGFR"]]}, {"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR  kinase  inhibitor,  PD153035   as well as wortmannin, a specific inhibitor of PI3K", "triple_list": [["PD153035", "DOWNREGULATOR", "kinase"]]}, {"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as  wortmannin   a specific inhibitor of  PI3K   Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin", "triple_list": [["wortmannin", "DOWNREGULATOR", "PI3K"]]}, {"text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger,  cAMP  as well as  adenylate cyclase  activator, forskolin", "triple_list": [["cAMP", "PRODUCT-OF", "adenylate cyclase"]]}, {"text": " Losartan  is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the  AT(1) receptor  (non-competitive inhibition)", "triple_list": [["Losartan", "DOWNREGULATOR", "AT(1) receptor"]]}, {"text": "Clinical experience in heart failure is growing, and recent data suggest an improved survival with  losartan  versus captopril, a drug from the  angiotensin-converting-enzyme  inhibitor class with proven benefit in this population", "triple_list": [["losartan", "DOWNREGULATOR", "angiotensin-converting-enzyme"]]}, {"text": "Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus  captopril   a drug from the  angiotensin-converting-enzyme  inhibitor class with proven benefit in this population", "triple_list": [["captopril", "DOWNREGULATOR", "angiotensin-converting-enzyme"]]}, {"text": "The current comprehensive  losartan  clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the  AT(1) receptor  with  losartan  compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.", "triple_list": [["losartan", "DOWNREGULATOR", "AT(1) receptor"]]}, {"text": " Losartan   a selective  angiotensin II type 1 (AT1) receptor  antagonist for the treatment of heart failure", "triple_list": [["Losartan", "ANTAGONIST", "angiotensin II type 1 (AT1) receptor"]]}, {"text": " Losartan  (COZAAR) is the prototype of a new class of potent and selective  angiotensin II (AII) type 1 (AT(1)) receptor  antagonists with the largest published preclinical and clinical data base", "triple_list": [["Losartan", "ANTAGONIST", "angiotensin II (AII) type 1 (AT(1)) receptor"]]}, {"text": "Losartan ( COZAAR   is the prototype of a new class of potent and selective  angiotensin II (AII) type 1 (AT(1)) receptor  antagonists with the largest published preclinical and clinical data base", "triple_list": [["COZAAR", "ANTAGONIST", "angiotensin II (AII) type 1 (AT(1)) receptor"]]}, {"text": "Abrupt removal of  amrinone  or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented  TNF  production", "triple_list": [["amrinone", "ACTIVATOR", "TNF"]]}, {"text": "Abrupt removal of amrinone or  pentoxifylline  from the culture medium prior to LPS stimulation, however, caused significantly augmented  TNF  production", "triple_list": [["pentoxifylline", "ACTIVATOR", "TNF"]]}, {"text": "We now demonstrate that  amrinone   a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced  TNF  production at concentrations readily achieved in vivo", "triple_list": [["amrinone", "DOWNREGULATOR", "TNF"]]}, {"text": "Combined application of  dexamethasone  and amrinone caused additive inhibition of  TNF  biosynthesis in vitro", "triple_list": [["dexamethasone", "DOWNREGULATOR", "TNF"]]}, {"text": "Combined application of dexamethasone and  amrinone  caused additive inhibition of  TNF  biosynthesis in vitro", "triple_list": [["amrinone", "DOWNREGULATOR", "TNF"]]}, {"text": "Therefore, decreases of  PLK  and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with  gamma-aminobutyric acid  (GABA) function.", "triple_list": [["gamma-aminobutyric acid", "DOWNREGULATOR", "PLK"]]}, {"text": "Therefore, decreases of PLK and  PNPO  in the hippocampal CA1 region of aged brains may be involved in aging processes related with  gamma-aminobutyric acid  (GABA) function.", "triple_list": [["gamma-aminobutyric acid", "DOWNREGULATOR", "PNPO"]]}, {"text": "Therefore, decreases of  PLK  and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid ( GABA   function.", "triple_list": [["GABA", "DOWNREGULATOR", "PLK"]]}, {"text": "Therefore, decreases of PLK and  PNPO  in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid ( GABA   function.", "triple_list": [["GABA", "DOWNREGULATOR", "PNPO"]]}, {"text": "In the present study, age-related changes of  pyridoxal 5'-phosphate  (PLP) synthesizing enzymes, pyridoxal kinase ( PLK   and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["pyridoxal 5'-phosphate", "PRODUCT-OF", "PLK"]]}, {"text": "In the present study, age-related changes of  pyridoxal 5'-phosphate  (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and  pyridoxine 5'-phosphate oxidase  (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["pyridoxal 5'-phosphate", "PRODUCT-OF", "pyridoxine 5'-phosphate oxidase"]]}, {"text": "In the present study, age-related changes of  pyridoxal 5'-phosphate  (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase ( PNPO  , their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["pyridoxal 5'-phosphate", "PRODUCT-OF", "PNPO"]]}, {"text": "In the present study, age-related changes of  pyridoxal 5'-phosphate  (PLP) synthesizing enzymes,  pyridoxal kinase  (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["pyridoxal 5'-phosphate", "PRODUCT-OF", "pyridoxal kinase"]]}, {"text": "In the present study, age-related changes of pyridoxal 5'-phosphate ( PLP   synthesizing enzymes, pyridoxal kinase ( PLK   and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["PLP", "PRODUCT-OF", "PLK"]]}, {"text": "In the present study, age-related changes of pyridoxal 5'-phosphate ( PLP   synthesizing enzymes, pyridoxal kinase (PLK) and  pyridoxine 5'-phosphate oxidase  (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["PLP", "PRODUCT-OF", "pyridoxine 5'-phosphate oxidase"]]}, {"text": "In the present study, age-related changes of pyridoxal 5'-phosphate ( PLP   synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase ( PNPO  , their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["PLP", "PRODUCT-OF", "PNPO"]]}, {"text": "In the present study, age-related changes of pyridoxal 5'-phosphate ( PLP   synthesizing enzymes,  pyridoxal kinase  (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper", "triple_list": [["PLP", "PRODUCT-OF", "pyridoxal kinase"]]}, {"text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical  monocarboxylate transporter  (MCT) inhibitor,  alpha-cyano-4-hydroxycinnamic acid   suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system", "triple_list": [["alpha-cyano-4-hydroxycinnamic acid", "DOWNREGULATOR", "monocarboxylate transporter"]]}, {"text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter ( MCT   inhibitor,  alpha-cyano-4-hydroxycinnamic acid   suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system", "triple_list": [["alpha-cyano-4-hydroxycinnamic acid", "DOWNREGULATOR", "MCT"]]}, {"text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that  nicotinate  uptake by rat astrocytes is mediated by H(+)-coupled  monocarboxylate transport system   [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)", "triple_list": [["nicotinate", "PRODUCT-OF", "monocarboxylate transport system"]]}, {"text": "Because l-lactate reduced to 67% of the  nicotinate  uptake even at 10mM, it is unlikely that  nicotinate  uptake in rat astrocytes is mediated by  MCT1  and/or MCT2", "triple_list": [["nicotinate", "PRODUCT-OF", "MCT1"]]}, {"text": "Because l-lactate reduced to 67% of the  nicotinate  uptake even at 10mM, it is unlikely that  nicotinate  uptake in rat astrocytes is mediated by MCT1 and/or  MCT2   These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for  nicotinate  in rat cerebrocortical astrocytes.", "triple_list": [["nicotinate", "PRODUCT-OF", "MCT2"]]}, {"text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a  low-affinity monocarboxylate transporter  MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for  nicotinate  in rat cerebrocortical astrocytes.", "triple_list": [["nicotinate", "PRODUCT-OF", "low-affinity monocarboxylate transporter"]]}, {"text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter  MCT4  or other unknown H(+)-coupled monocarboxylate transport system, for  nicotinate  in rat cerebrocortical astrocytes.", "triple_list": [["nicotinate", "PRODUCT-OF", "MCT4"]]}, {"text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown  H(+)-coupled monocarboxylate transport system   for  nicotinate  in rat cerebrocortical astrocytes.", "triple_list": [["nicotinate", "PRODUCT-OF", "H(+)-coupled monocarboxylate transport system"]]}, {"text": "A review of the structural and functional features of  olmesartan medoxomil   an  angiotensin receptor  blocker", "triple_list": [["olmesartan medoxomil", "DOWNREGULATOR", "angiotensin receptor"]]}, {"text": "The marked antihypertensive efficacy of  olmesartan medoxomil  may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of  A-II   This review article characterizes the structural features of olmesartan that may be responsible for its clinical efficacy", "triple_list": [["olmesartan medoxomil", "DOWNREGULATOR", "A-II"]]}, {"text": "We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific  neutrophil elastase  inhibitor ( ONO-5046   on acid lung injury in rats", "triple_list": [["ONO-5046", "DOWNREGULATOR", "neutrophil elastase"]]}, {"text": "Effects of  granulocyte colony-stimulating factor  (G-CSF) and neutrophil elastase inhibitor ( ONO-5046   on acid-induced lung injury in rats", "triple_list": [["ONO-5046", "DOWNREGULATOR", "granulocyte colony-stimulating factor"]]}, {"text": "Effects of granulocyte colony-stimulating factor ( G-CSF   and neutrophil elastase inhibitor ( ONO-5046   on acid-induced lung injury in rats", "triple_list": [["ONO-5046", "DOWNREGULATOR", "G-CSF"]]}, {"text": "Effects of granulocyte colony-stimulating factor (G-CSF) and  neutrophil elastase  inhibitor ( ONO-5046   on acid-induced lung injury in rats", "triple_list": [["ONO-5046", "DOWNREGULATOR", "neutrophil elastase"]]}, {"text": " Miglustat   an imino sugar that reversibly inhibits  glucosylceramide synthase  and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option", "triple_list": [["Miglustat", "DOWNREGULATOR", "glucosylceramide synthase"]]}, {"text": "Miglustat, an  imino sugar  that reversibly inhibits  glucosylceramide synthase  and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option", "triple_list": [["imino sugar", "DOWNREGULATOR", "glucosylceramide synthase"]]}, {"text": "This effect was reverted in the presence of  atropine  (ATR; 0.1 microM), which blocks the pre-synaptic  muscarinic M2 receptor   After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist", "triple_list": [["atropine", "DOWNREGULATOR", "muscarinic M2 receptor"]]}, {"text": "This effect was reverted in the presence of atropine ( ATR   0.1 microM), which blocks the pre-synaptic  muscarinic M2 receptor   After that, a wide range of concentrations of drugs, concomitantly with  ATR  (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist", "triple_list": [["ATR", "DOWNREGULATOR", "muscarinic M2 receptor"]]}, {"text": "Nicotinic-receptor potentiator drugs, huprine X and  galantamine   increase ACh release by blocking  AChE  activity but not acting on nicotinic receptors", "triple_list": [["galantamine", "DOWNREGULATOR", "AChE"]]}, {"text": "To test the role of  nicotinic receptors  in the drugs' effects on [3H]-ACh release,  mecamylamine  (MEC) 100 microM was used to block such receptors", "triple_list": [["mecamylamine", "DOWNREGULATOR", "nicotinic receptors"]]}, {"text": "To test the role of  nicotinic receptors  in the drugs' effects on [3H]-ACh release, mecamylamine ( MEC   100 microM was used to block such receptors", "triple_list": [["MEC", "DOWNREGULATOR", "nicotinic receptors"]]}, {"text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of  haloperidol  (HAL; 0.01 microM), a  dopamine D2  antagonist", "triple_list": [["haloperidol", "ANTAGONIST", "dopamine D2"]]}, {"text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol ( HAL   0.01 microM), a  dopamine D2  antagonist", "triple_list": [["HAL", "ANTAGONIST", "dopamine D2"]]}, {"text": "mRNA levels for  RAR-alpha   RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with  retinoid  supplementation", "triple_list": [["retinoid", "DOWNREGULATOR", "RAR-alpha"]]}, {"text": "mRNA levels for RAR-alpha,  RAR-beta  and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with  retinoid  supplementation", "triple_list": [["retinoid", "DOWNREGULATOR", "RAR-beta"]]}, {"text": "mRNA levels for RAR-alpha, RAR-beta and  RAR-gamma   the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with  retinoid  supplementation", "triple_list": [["retinoid", "DOWNREGULATOR", "RAR-gamma"]]}, {"text": "mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the  nuclear receptors  for retinoic acid, decreased during activation of freshly isolated HSC even with  retinoid  supplementation", "triple_list": [["retinoid", "DOWNREGULATOR", "nuclear receptors"]]}, {"text": "Preincubation with 1 microM of the  protein kinase C  (PKC) activator phorbol 12-myristate 13-acetate ( PMA   caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization", "triple_list": [["PMA", "ACTIVATOR", "protein kinase C"]]}, {"text": "Preincubation with 1 microM of the protein kinase C ( PKC   activator phorbol 12-myristate 13-acetate ( PMA   caused a small but significant decrease in isoprenaline-induced E(max), indicating activated  PKC -mediated heterologous beta(2)-adrenoceptor desensitization", "triple_list": [["PMA", "ACTIVATOR", "PKC"]]}, {"text": "Preincubation with 1 microM of the protein kinase C ( PKC ) activator phorbol 12-myristate 13-acetate ( PMA   caused a small but significant decrease in isoprenaline-induced E(max), indicating activated  PKC  mediated heterologous beta(2)-adrenoceptor desensitization", "triple_list": [["PMA", "ACTIVATOR", "PKC"]]}, {"text": "Preincubation with 1 microM of the  protein kinase C  (PKC) activator  phorbol 12-myristate 13-acetate  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization", "triple_list": [["phorbol 12-myristate 13-acetate", "ACTIVATOR", "protein kinase C"]]}, {"text": "Preincubation with 1 microM of the protein kinase C ( PKC   activator  phorbol 12-myristate 13-acetate  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated  PKC -mediated heterologous beta(2)-adrenoceptor desensitization", "triple_list": [["phorbol 12-myristate 13-acetate", "ACTIVATOR", "PKC"]]}, {"text": "Preincubation with 1 microM of the protein kinase C ( PKC ) activator  phorbol 12-myristate 13-acetate  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated  PKC  mediated heterologous beta(2)-adrenoceptor desensitization", "triple_list": [["phorbol 12-myristate 13-acetate", "ACTIVATOR", "PKC"]]}, {"text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ( PMA   caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization", "triple_list": [["PMA", "DOWNREGULATOR", "beta(2)-adrenoceptor"]]}, {"text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of  fenoterol  decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the  beta(2)-adrenoceptor   Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization", "triple_list": [["fenoterol", "DOWNREGULATOR", "beta(2)-adrenoceptor"]]}, {"text": "Preincubation with 1 microM of the protein kinase C (PKC) activator  phorbol 12-myristate 13-acetate  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization", "triple_list": [["phorbol 12-myristate 13-acetate", "DOWNREGULATOR", "beta(2)-adrenoceptor"]]}, {"text": "Moreover, the specific  PKC  inhibitor  2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide  (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented", "triple_list": [["2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide", "DOWNREGULATOR", "PKC"]]}, {"text": "Moreover, the specific  PKC  inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide ( GF 109203X   markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented", "triple_list": [["GF 109203X", "DOWNREGULATOR", "PKC"]]}, {"text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  isoprenaline  induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization", "triple_list": [["isoprenaline", "AGONIST", "beta(2)-adrenoceptor"]]}, {"text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased  isoprenaline  induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the  beta(2)-adrenoceptor   Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  isoprenaline -induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization", "triple_list": [["isoprenaline", "AGONIST", "beta(2)-adrenoceptor"]]}, {"text": "Tyrosine kinase inhibitors are  quinazoline  derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including  EGFR , Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of  EGFR  signaling", "triple_list": [["quinazoline", "DOWNREGULATOR", "EGFR"]]}, {"text": " Tyrosine kinase  inhibitors are  quinazoline  derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling", "triple_list": [["quinazoline", "DOWNREGULATOR", "Tyrosine kinase"]]}, {"text": "Tyrosine kinase inhibitors are  quinazoline  derived, low molecular weight synthetic molecules that can block the intracellular  tyrosine kinase domain  of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling", "triple_list": [["quinazoline", "DOWNREGULATOR", "tyrosine kinase domain"]]}, {"text": "Tyrosine kinase inhibitors are  quinazoline  derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including  EGFR   Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of  EGFR  signaling", "triple_list": [["quinazoline", "DOWNREGULATOR", "EGFR"]]}, {"text": "Tyrosine kinase inhibitors are  quinazoline  derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR,  Erb2   and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling", "triple_list": [["quinazoline", "DOWNREGULATOR", "Erb2"]]}, {"text": "Tyrosine kinase inhibitors are  quinazoline  derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and  vascular endothelial growth factor receptor   and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling", "triple_list": [["quinazoline", "DOWNREGULATOR", "vascular endothelial growth factor receptor"]]}, {"text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of  proline   glycine, l-alanine and alpha-(methylamino)isobutyric acid", "triple_list": [["proline", "PRODUCT-OF", "rabbit PAT1"]]}, {"text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of proline,  glycine   l-alanine and alpha-(methylamino)isobutyric acid", "triple_list": [["glycine", "PRODUCT-OF", "rabbit PAT1"]]}, {"text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of proline, glycine,  l-alanine  and alpha-(methylamino)isobutyric acid", "triple_list": [["l-alanine", "PRODUCT-OF", "rabbit PAT1"]]}, {"text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and  alpha-(methylamino)isobutyric acid   Proline uptake was maximal at pH 5.0 (K(m) 2.2+/-0.7 mM)", "triple_list": [["alpha-(methylamino)isobutyric acid", "PRODUCT-OF", "rabbit PAT1"]]}, {"text": "In the presence of Na+ and under conditions in which  PAT1  transport function was suppressed, a second  proline  uptake system was detected that exhibited functional characteristics similar to those of the IMINO system", "triple_list": [["proline", "PRODUCT-OF", "PAT1"]]}, {"text": "The functional characteristics of rabbit  PAT1  in either mammalian cells or renal BBMV suggest that  PAT1  is the low-affinity transporter of  proline   glycine and hydroxy proline  believed to be defective in patients with iminoglycinuria.", "triple_list": [["proline", "PRODUCT-OF", "PAT1"]]}, {"text": "The functional characteristics of rabbit  PAT1  in either mammalian cells or renal BBMV suggest that  PAT1  is the low-affinity transporter of proline,  glycine  and hydroxyproline believed to be defective in patients with iminoglycinuria.", "triple_list": [["glycine", "PRODUCT-OF", "PAT1"]]}, {"text": "The functional characteristics of rabbit  PAT1  in either mammalian cells or renal BBMV suggest that  PAT1  is the low-affinity transporter of proline, glycine and  hydroxyproline  believed to be defective in patients with iminoglycinuria.", "triple_list": [["hydroxyproline", "PRODUCT-OF", "PAT1"]]}, {"text": "The fact that  trimipramine  also suppressed  IFN-gamma  production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake", "triple_list": [["trimipramine", "DOWNREGULATOR", "IFN-gamma"]]}, {"text": "The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean  leptin  level after 1 week of treatment with  cyproheptadine  (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05)", "triple_list": [["cyproheptadine", "ACTIVATOR", "leptin"]]}, {"text": "Given the treatment with three doses of  Captopril  (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of  PON1  and SOD in serum by single intragastric gavaged L-methionine", "triple_list": [["Captopril", "ACTIVATOR", "PON1"]]}, {"text": "Given the treatment with three doses of  Captopril  (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and  SOD  in serum by single intragastric gavaged L-methionine", "triple_list": [["Captopril", "ACTIVATOR", "SOD"]]}, {"text": "These results suggested that  Captopril  can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of  Captopril  may be related to attenuating the decrease in  PON1  activity and NO levels", "triple_list": [["Captopril", "ACTIVATOR", "PON1"]]}, {"text": "These results suggested that Captopril can protect the vascular endothelium against the damages induced by  L-methionine  in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in  PON1  activity and NO levels", "triple_list": [["L-methionine", "DOWNREGULATOR", "PON1"]]}, {"text": "We compared the effects of  Captopril  (an  ACE  inhibitor with -SH group), enalapril (an  ACE -inhibitor without -SH group), N-acetylcysteine (only -SH group not  ACE  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats", "triple_list": [["Captopril", "DOWNREGULATOR", "ACE"]]}, {"text": "We compared the effects of Captopril (an  ACE  inhibitor with - SH  group), enalapril (an  ACE -inhibitor without - SH  group), N-acetylcysteine (only - SH  group not  ACE  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats", "triple_list": [["SH", "DOWNREGULATOR", "ACE"]]}, {"text": "We compared the effects of Captopril (an  ACE  inhibitor with -SH group),  enalapril  (an  ACE  inhibitor without -SH group), N-acetylcysteine (only -SH group not  ACE  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats", "triple_list": [["enalapril", "DOWNREGULATOR", "ACE"]]}, {"text": "Comparison of  captopril  and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with  ACE  inhibitors in high dieted methionine mice", "triple_list": [["captopril", "DOWNREGULATOR", "ACE"]]}, {"text": "Comparison of captopril and  enalapril  to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with  ACE  inhibitors in high dieted methionine mice", "triple_list": [["enalapril", "DOWNREGULATOR", "ACE"]]}, {"text": "Comparison of captopril and enalapril to study the role of the  sulfhydryl  group in improvement of endothelial dysfunction with  ACE  inhibitors in high dieted methionine mice", "triple_list": [["sulfhydryl", "DOWNREGULATOR", "ACE"]]}, {"text": "It was found that a single intragastric gavage by  L-methionine  resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of  PON1  and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group", "triple_list": [["L-methionine", "DOWNREGULATOR", "PON1"]]}, {"text": "It was found that a single intragastric gavage by  L-methionine  resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and  SOD   similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group", "triple_list": [["L-methionine", "DOWNREGULATOR", "SOD"]]}, {"text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2,  VEGFR-3   platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT", "triple_list": [["sorafenib", "ACTIVATOR", "VEGFR-3"]]}, {"text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3,  platelet-derived growth factor (PDGFR)-beta  Flt-3, and c-KIT", "triple_list": [["sorafenib", "ACTIVATOR", "platelet-derived growth factor (PDGFR)-beta"]]}, {"text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta  Flt-3   and c-KIT", "triple_list": [["sorafenib", "ACTIVATOR", "Flt-3"]]}, {"text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and  c-KIT   Preclinically,  sorafenib  showed broad-spectrum antitumor activity in colon, breast and non-small-cell lung cancer xenograft models", "triple_list": [["sorafenib", "ACTIVATOR", "c-KIT"]]}, {"text": "In addition,  sorafenib  demonstrated significant activity against several  receptor tyrosine kinases  involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT", "triple_list": [["sorafenib", "ACTIVATOR", "receptor tyrosine kinases"]]}, {"text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including  vascular-endothelial growth factor (VEGFR)-2   VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT", "triple_list": [["sorafenib", "ACTIVATOR", "vascular-endothelial growth factor (VEGFR)-2"]]}, {"text": "Further characterization showed that  sorafenib  suppresses both wild-type and  V599E  mutant B-Raf activity in vitro", "triple_list": [["sorafenib", "DOWNREGULATOR", "V599E"]]}, {"text": "Further characterization showed that  sorafenib  suppresses both wild-type and V599E mutant  B-Raf  activity in vitro", "triple_list": [["sorafenib", "DOWNREGULATOR", "B-Raf"]]}, {"text": " Sorafenib   which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of  Raf-1  and its favorable kinase selectivity profile", "triple_list": [["Sorafenib", "DOWNREGULATOR", "Raf-1"]]}, {"text": " Sorafenib   which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable  kinase  selectivity profile", "triple_list": [["Sorafenib", "DOWNREGULATOR", "kinase"]]}, {"text": "Sorafenib, which belongs chemically to a class that can be described as  bis-aryl ureas   was selected for further pharmacologic characterization based on potent inhibition of  Raf-1  and its favorable kinase selectivity profile", "triple_list": [["bis-aryl ureas", "DOWNREGULATOR", "Raf-1"]]}, {"text": "Sorafenib, which belongs chemically to a class that can be described as  bis-aryl ureas   was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable  kinase  selectivity profile", "triple_list": [["bis-aryl ureas", "DOWNREGULATOR", "kinase"]]}, {"text": "The ability of  bexarotene  to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner  peroxisome proliferator-activated receptor gamma   Collectively, our results suggest a role of  bexarotene  in treatment of angiogenesis and metastasis in solid tumours.", "triple_list": [["bexarotene", "ACTIVATOR", "peroxisome proliferator-activated receptor gamma"]]}, {"text": "Analysis of tumour-conditioned medium indicated that  bexarotene  decreased the secretion of angiogenic factors and  matrix metalloproteinases  and increased the tissue inhibitor of  matrix metalloproteinases   The ability of  bexarotene  to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma", "triple_list": [["bexarotene", "ACTIVATOR", "matrix metalloproteinases"]]}, {"text": "Analysis of tumour-conditioned medium indicated that  bexarotene  decreased the secretion of angiogenic factors and  matrix metalloproteinases  and increased the tissue inhibitor of  matrix metalloproteinases ", "triple_list": [["bexarotene", "DOWNREGULATOR", "matrix metalloproteinases"]]}, {"text": "A selective  retinoid X receptor  agonist  bexarotene  (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours", "triple_list": [["bexarotene", "AGONIST", "retinoid X receptor"]]}, {"text": "A selective  retinoid X receptor  agonist bexarotene ( LGD1069   targretin) inhibits angiogenesis and metastasis in solid tumours", "triple_list": [["LGD1069", "AGONIST", "retinoid X receptor"]]}, {"text": "A selective  retinoid X receptor  agonist bexarotene (LGD1069,  targretin   inhibits angiogenesis and metastasis in solid tumours", "triple_list": [["targretin", "AGONIST", "retinoid X receptor"]]}, {"text": "The present study determined the influence of a  retinoid X receptor  agonist  bexarotene  on angiogenesis and metastasis in solid tumours", "triple_list": [["bexarotene", "AGONIST", "retinoid X receptor"]]}, {"text": "In subjects with dysmenorrhea the increase in pain following the administration of  vasopressin  was significantly lower during  atosiban  than during placebo infusion", "triple_list": [["atosiban", "DOWNREGULATOR", "vasopressin"]]}, {"text": "CONCLUSIONS:  Atosiban  reduces  vasopressin  induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea", "triple_list": [["Atosiban", "DOWNREGULATOR", "vasopressin"]]}, {"text": "Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the  acetylcholinesterase  inhibitor  tacrine   H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease", "triple_list": [["tacrine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of  acetylcholine sterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing  acetylcholine   Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine", "triple_list": [["acetylcholine", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of  acetylcholine sterase and of  butyrylcholinesterase  which is another catalytic enzyme hydrolysing  acetylcholine   Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine", "triple_list": [["acetylcholine", "PRODUCT-OF", "butyrylcholinesterase"]]}, {"text": "Novel highly affine  histamine  H3 receptor ligands with additional inhibitory effects on the main  histamine  metabolizing enzyme in the brain,  N-methyltransferase   chemically show structural elements of the acetylcholinesterase inhibitor tacrine", "triple_list": [["histamine", "PRODUCT-OF", "N-methyltransferase"]]}, {"text": "For some, pharmacologic inhibitors are available, including  sorafenib  for  BRAF   farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors", "triple_list": [["sorafenib", "DOWNREGULATOR", "BRAF"]]}, {"text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  PD-0325901  for  mitogen-activated protein kinase  extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors", "triple_list": [["PD-0325901", "DOWNREGULATOR", "mitogen-activated protein kinase"]]}, {"text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  PD-0325901  for mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase   rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors", "triple_list": [["PD-0325901", "DOWNREGULATOR", "extracellular signal-regulated kinase kinase"]]}, {"text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  rapamycin  analogues for mammalian target of  rapamycin   and agents that inhibit either vascular endothelial growth factor or its receptors", "triple_list": [["rapamycin", "DOWNREGULATOR", "mammalian target of rapamycin"]]}, {"text": "Similar to the  plasma membrane PS transporter   Atp8a1 is activated only by the naturally occurring  sn-1,2-glycerol  isomer of PS and not the sn-2,3-glycerol stereoisomer", "triple_list": [["sn-1,2-glycerol", "ACTIVATOR", "plasma membrane PS transporter"]]}, {"text": "Similar to the plasma membrane PS transporter,  Atp8a1  is activated only by the naturally occurring  sn-1,2-glycerol  isomer of PS and not the sn-2,3-glycerol stereoisomer", "triple_list": [["sn-1,2-glycerol", "ACTIVATOR", "Atp8a1"]]}, {"text": "Weakly translocated lipids ( PE   phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak  Atp8a1  activators", "triple_list": [["PE", "ACTIVATOR", "Atp8a1"]]}, {"text": "Weakly translocated lipids (PE,  phosphatidylhydroxypropionate   and phosphatidylhomoserine) are also weak  Atp8a1  activators", "triple_list": [["phosphatidylhydroxypropionate", "ACTIVATOR", "Atp8a1"]]}, {"text": "Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and  phosphatidylhomoserine   are also weak  Atp8a1  activators", "triple_list": [["phosphatidylhomoserine", "ACTIVATOR", "Atp8a1"]]}, {"text": "These results indicate that the  ATPase  activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ( PS  selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.", "triple_list": [["PS", "ACTIVATOR", "ATPase"]]}, {"text": "These results indicate that the ATPase activity of the secretory granule  Atp8a1  is activated by phospholipids binding to a specific site whose properties ( PS  selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.", "triple_list": [["PS", "ACTIVATOR", "Atp8a1"]]}, {"text": "The purified  Atp8a1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by  phosphatidylglycerol  or phosphatidylethanolamine (PE), and is maximally activated by PS", "triple_list": [["phosphatidylglycerol", "ACTIVATOR", "Atp8a1"]]}, {"text": "The purified  Atp8a1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or  phosphatidylethanolamine  (PE), and is maximally activated by PS", "triple_list": [["phosphatidylethanolamine", "ACTIVATOR", "Atp8a1"]]}, {"text": "The purified  Atp8a1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine ( PE  , and is maximally activated by PS", "triple_list": [["PE", "ACTIVATOR", "Atp8a1"]]}, {"text": "The purified  Atp8a1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by  PS   The selectivity for  PS  is dependent upon multiple elements of the lipid structure", "triple_list": [["PS", "ACTIVATOR", "Atp8a1"]]}, {"text": "Activation of  Atp8a1  is also reduced by these modifications;  phosphatidylserine-O-methyl ester   lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate  Atp8a1 ", "triple_list": [["phosphatidylserine-O-methyl ester", "DOWNREGULATOR", "Atp8a1"]]}, {"text": "Activation of  Atp8a1  is also reduced by these modifications; phosphatidylserine-O-methyl ester,  lysophosphatidylserine   glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate  Atp8a1 ", "triple_list": [["lysophosphatidylserine", "DOWNREGULATOR", "Atp8a1"]]}, {"text": "Activation of  Atp8a1  is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine,  glycerophosphoserine   and phosphoserine, which are not transported by the plasma membrane flippase, do not activate  Atp8a1 ", "triple_list": [["glycerophosphoserine", "DOWNREGULATOR", "Atp8a1"]]}, {"text": "Activation of  Atp8a1  is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycero phosphoserine , and  phosphoserine   which are not transported by the plasma membrane flippase, do not activate  Atp8a1 ", "triple_list": [["phosphoserine", "DOWNREGULATOR", "Atp8a1"]]}, {"text": "However,  N-methyl-phosphatidylserine   which is transported by the plasma membrane  flippase  at a rate equivalent to PS, is incapable of activating Atp8a1 activity", "triple_list": [["N-methyl-phosphatidylserine", "PRODUCT-OF", "flippase"]]}, {"text": "This aminophospholipid \" flippase   selectively transports  PS  to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents", "triple_list": [["PS", "PRODUCT-OF", "flippase"]]}, {"text": " Sorafenib  (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of  tyrosine kinases  that are known to be involved in tumor cell proliferation and tumor angiogenesis", "triple_list": [["Sorafenib", "DOWNREGULATOR", "tyrosine kinases"]]}, {"text": "Sorafenib ( BAY 43-9006   is a small-molecule inhibitor that has been shown to target members of multiple classes of  tyrosine kinases  that are known to be involved in tumor cell proliferation and tumor angiogenesis", "triple_list": [["BAY 43-9006", "DOWNREGULATOR", "tyrosine kinases"]]}, {"text": "Both  H(2)S  solution prepared by bubbling pure  H(2)S  gas and NaSH, a  H(2)S  donor, dose dependently induced HO-1 expression through the activation of the  extracellular signal-regulated kinase  (ERK)", "triple_list": [["H(2)S", "ACTIVATOR", "extracellular signal-regulated kinase"]]}, {"text": "Both  H(2)S  solution prepared by bubbling pure  H(2)S  gas and NaSH, a  H(2)S  donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase ( ERK  ", "triple_list": [["H(2)S", "ACTIVATOR", "ERK"]]}, {"text": "Both  H(2)S  solution prepared by bubbling pure  H(2)S  gas and NaSH, a  H(2)S  donor, dose dependently induced  HO-1  expression through the activation of the extracellular signal-regulated kinase (ERK)", "triple_list": [["H(2)S", "ACTIVATOR", "HO-1"]]}, {"text": " CO  treatment also inhibited LPS-induced NO production and  iNOS  expression via its inactivation of NF-kappaB", "triple_list": [["CO", "DOWNREGULATOR", "iNOS"]]}, {"text": "Here, we show that at noncytotoxic concentrations,  H(2)S  was able to inhibit NO production and  inducible NO synthase  (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)", "triple_list": [["H(2)S", "DOWNREGULATOR", "inducible NO synthase"]]}, {"text": "Here, we show that at noncytotoxic concentrations,  H(2)S  was able to inhibit NO production and inducible NO synthase ( iNOS   expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)", "triple_list": [["H(2)S", "DOWNREGULATOR", "iNOS"]]}, {"text": "Pretreatment with  H(2)S  or NaHS significantly inhibited LPS-induced  iNOS  expression and NO production", "triple_list": [["H(2)S", "DOWNREGULATOR", "iNOS"]]}, {"text": "Pretreatment with H(2)S or  NaHS  significantly inhibited LPS-induced  iNOS  expression and NO production", "triple_list": [["NaHS", "DOWNREGULATOR", "iNOS"]]}, {"text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  H(2)S  on  iNOS  expression and NO production, HO-1 overexpression produced the same inhibitory effects of  H(2)S ", "triple_list": [["H(2)S", "DOWNREGULATOR", "iNOS"]]}, {"text": " CO  treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of  NF-kappaB   Collectively, our results suggest that H(2)S can inhibit NO production and  NF-kappaB  activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/ CO .", "triple_list": [["CO", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Collectively, our results suggest that  H(2)S  can inhibit NO production and  NF-kappaB  activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.", "triple_list": [["H(2)S", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Moreover, NO production in LPS-stimulated macrophages that are expressing  CSE  mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective  CSE  inhibitor  beta-cyano-L-alanine  but not by the CBS inhibitor aminooxyacetic acid", "triple_list": [["beta-cyano-L-alanine", "DOWNREGULATOR", "CSE"]]}, {"text": " Hydrogen sulfide  inhibits nitric oxide production and  nuclear factor-kappaB  via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide", "triple_list": [["Hydrogen sulfide", "DOWNREGULATOR", "nuclear factor-kappaB"]]}, {"text": "Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the  CBS  inhibitor  aminooxyacetic acid   While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S", "triple_list": [["aminooxyacetic acid", "DOWNREGULATOR", "CBS"]]}, {"text": "In addition, LPS-induced nuclear factor  (NF)-kappaB  activation was diminished in RAW264.7 macrophages preincubated with  H(2)S   Interestingly, the inhibitory effect of  H(2)S  on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1", "triple_list": [["H(2)S", "DOWNREGULATOR", "(NF)-kappaB"]]}, {"text": "Interestingly, the inhibitory effect of  H(2)S  on  NF-kappaB  activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1", "triple_list": [["H(2)S", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with  HO-1  siRNA, but was mimicked by either  HO-1  gene transfection or treatment with  carbon monoxide  (CO), an end product of  HO-1   CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB", "triple_list": [["carbon monoxide", "PRODUCT-OF", "HO-1"]]}, {"text": "Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with  HO-1  siRNA, but was mimicked by either  HO-1  gene transfection or treatment with carbon monoxide ( CO  , an end product of  HO-1    CO  treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB", "triple_list": [["CO", "PRODUCT-OF", "HO-1"]]}, {"text": "CO treatment also inhibited LPS-induced  NO  production and i NO S expression via its inactivation of NF-kappaB", "triple_list": [["NO", "PRODUCT-OF", "iNOS"]]}, {"text": "Hydrogen sulfide ( H(2)S  , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( CSE   and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["H(2)S", "PRODUCT-OF", "CSE"]]}, {"text": "Hydrogen sulfide ( H(2)S  , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  cystathionine beta-synthase  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["H(2)S", "PRODUCT-OF", "cystathionine beta-synthase"]]}, {"text": "Hydrogen sulfide ( H(2)S  , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( CBS   from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["H(2)S", "PRODUCT-OF", "CBS"]]}, {"text": "Hydrogen sulfide ( H(2)S  , a regulatory gaseous molecule that is endogenously synthesized by  cystathionine gamma-lyase  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["H(2)S", "PRODUCT-OF", "cystathionine gamma-lyase"]]}, {"text": "Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of  HO-1   CO  ", "triple_list": [["CO", "PRODUCT-OF", "HO-1"]]}, {"text": " Hydrogen sulfide  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( CSE   and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["Hydrogen sulfide", "PRODUCT-OF", "CSE"]]}, {"text": " Hydrogen sulfide  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  cystathionine beta-synthase  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["Hydrogen sulfide", "PRODUCT-OF", "cystathionine beta-synthase"]]}, {"text": " Hydrogen sulfide  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( CBS   from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["Hydrogen sulfide", "PRODUCT-OF", "CBS"]]}, {"text": " Hydrogen sulfide  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  cystathionine gamma-lyase  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["Hydrogen sulfide", "PRODUCT-OF", "cystathionine gamma-lyase"]]}, {"text": "Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit  NO  production and inducible  NO  synthase (i NO S) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)", "triple_list": [["NO", "PRODUCT-OF", "inducible NO synthase"]]}, {"text": "Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit  NO  production and inducible  NO  synthase (i NO S  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)", "triple_list": [["NO", "PRODUCT-OF", "iNOS"]]}, {"text": "Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced i NO S expression and  NO  production", "triple_list": [["NO", "PRODUCT-OF", "iNOS"]]}, {"text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on i NO S expression and  NO  production, HO-1 overexpression produced the same inhibitory effects of H(2)S", "triple_list": [["NO", "PRODUCT-OF", "iNOS"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( CSE   and/or cystathionine beta-synthase (CBS) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-cysteine", "PRODUCT-OF", "CSE"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  cystathionine beta-synthase  (CBS) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-cysteine", "PRODUCT-OF", "cystathionine beta-synthase"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( CBS   from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-cysteine", "PRODUCT-OF", "CBS"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  cystathionine gamma-lyase  (CSE) and/or cystathionine beta-synthase (CBS) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-cysteine", "PRODUCT-OF", "cystathionine gamma-lyase"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( CSE   and/or cystathionine beta-synthase (CBS) from L-cysteine ( L-Cys   metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-Cys", "PRODUCT-OF", "CSE"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  cystathionine beta-synthase  (CBS) from L-cysteine ( L-Cys   metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-Cys", "PRODUCT-OF", "cystathionine beta-synthase"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( CBS   from L-cysteine ( L-Cys   metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-Cys", "PRODUCT-OF", "CBS"]]}, {"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  cystathionine gamma-lyase  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine ( L-Cys   metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored", "triple_list": [["L-Cys", "PRODUCT-OF", "cystathionine gamma-lyase"]]}, {"text": "Moreover, NO production in LPS-stimulated macrophages that are expressing  CSE  mRNA was significantly reduced by the addition of  L-Cys   a substrate for H(2)S, but enhanced by the selective  CSE  inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid", "triple_list": [["L-Cys", "PRODUCT-OF", "CSE"]]}, {"text": "However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of  arginase  activity by  urea  in the tissue lysates", "triple_list": [["urea", "DOWNREGULATOR", "arginase"]]}, {"text": "CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of  arginase   the inherent rise in  urea  concentration inhibits its enzymatic activity", "triple_list": [["urea", "DOWNREGULATOR", "arginase"]]}, {"text": "L-arg is converted to  urea  by  arginase I  in the liver and  arginase I I in the kidney", "triple_list": [["urea", "PRODUCT-OF", "arginase I"]]}, {"text": "L-arg is converted to  urea  by arginase I in the liver and  arginase II  in the kidney", "triple_list": [["urea", "PRODUCT-OF", "arginase II"]]}, {"text": "Sources of  L-arg  include dietary proteins and endogenous synthesis by  argininosuccinate synthetase  and argininosuccinate lyase", "triple_list": [["L-arg", "PRODUCT-OF", "argininosuccinate synthetase"]]}, {"text": "Sources of  L-arg  include dietary proteins and endogenous synthesis by argininosuccinate synthetase and  argininosuccinate lyase    L-arg  is converted to urea by arginase I in the liver and arginase II in the kidney", "triple_list": [["L-arg", "PRODUCT-OF", "argininosuccinate lyase"]]}, {"text": " L-arg  is converted to urea by  arginase I  in the liver and  arginase I I in the kidney", "triple_list": [["L-arg", "PRODUCT-OF", "arginase I"]]}, {"text": " L-arg  is converted to urea by arginase I in the liver and  arginase II  in the kidney", "triple_list": [["L-arg", "PRODUCT-OF", "arginase II"]]}, {"text": "We hypothesized that preservation of plasma  L-arg  in CRF may be, partly, due to downregulation/inhibition of  arginase   METHODS: Argininosuccinate synthetase,  arginase  I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation", "triple_list": [["L-arg", "PRODUCT-OF", "arginase"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are  VPA-985  (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463", "triple_list": [["VPA-985", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 ( lixivaptan  , YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463", "triple_list": [["lixivaptan", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan),  YM-087  (conivaptan), OPC-41061 (tolvaptan), and SR-121463", "triple_list": [["YM-087", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 ( conivaptan  , OPC-41061 (tolvaptan), and SR-121463", "triple_list": [["conivaptan", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan),  OPC-41061  (tolvaptan), and SR-121463", "triple_list": [["OPC-41061", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 ( tolvaptan  , and SR-121463", "triple_list": [["tolvaptan", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and  SR-121463   Prospective, randomized, placebo-controlled trials performed with these agents found that they corrected hyponatremia efficiently and safely", "triple_list": [["SR-121463", "ANTAGONIST", "vasopressin receptor"]]}, {"text": "Sedation and  histamine H1-receptor  antagonism: studies in man with the enantiomers of chlorpheniramine and  dimethindene   1", "triple_list": [["dimethindene", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": "Sedation and  histamine H1-receptor  antagonism: studies in man with the enantiomers of  chlorpheniramine  and dimethindene", "triple_list": [["chlorpheniramine", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": "BG also showed a protective effect in the presence of a  DNA polymerase beta  inhibitor ( cytosine arabinoside-3-phosphate   Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving  DNA polymerase beta .", "triple_list": [["cytosine arabinoside-3-phosphate", "DOWNREGULATOR", "DNA polymerase beta"]]}, {"text": "BG also showed a protective effect in the presence of a  DNA polymerase beta  inhibitor (cytosine arabinoside-3-phosphate,  Ara-C  , demonstrating that BG does not act through an anti-mutagenic mechanism of action involving  DNA polymerase beta .", "triple_list": [["Ara-C", "DOWNREGULATOR", "DNA polymerase beta"]]}, {"text": "Our purpose was to test the impact of single and/or combined treatment with the  AT(1)  receptor blocker  candesartan  and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats", "triple_list": [["candesartan", "DOWNREGULATOR", "AT(1)"]]}, {"text": "Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the  HMG-CoA reductase  inhibitor  rosuvastatin  and their combination", "triple_list": [["rosuvastatin", "DOWNREGULATOR", "HMG-CoA reductase"]]}, {"text": "Reduction of cerebral infarct size by the  AT1  receptor blocker  candesartan   the HMG-CoA reductase inhibitor rosuvastatin and their combination", "triple_list": [["candesartan", "DOWNREGULATOR", "AT1"]]}, {"text": "Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the  HMG-CoA reductase  inhibitor  rosuvastatin  on infarct size and neuroscore in transient cerebral ischemia in rats", "triple_list": [["rosuvastatin", "DOWNREGULATOR", "HMG-CoA reductase"]]}, {"text": "Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to  phosphatidic acid  by  DAG kinase  (DGK)", "triple_list": [["phosphatidic acid", "PRODUCT-OF", "DAG kinase"]]}, {"text": "Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to  phosphatidic acid  by DAG kinase ( DGK  ", "triple_list": [["phosphatidic acid", "PRODUCT-OF", "DGK"]]}, {"text": " Diacylglycerol  (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  DAG kinase  (DGK)", "triple_list": [["Diacylglycerol", "PRODUCT-OF", "DAG kinase"]]}, {"text": " Diacylglycerol  (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ( DGK  ", "triple_list": [["Diacylglycerol", "PRODUCT-OF", "DGK"]]}, {"text": "Diacylglycerol ( DAG   acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  DAG  kinase (DGK)", "triple_list": [["DAG", "PRODUCT-OF", "DAG kinase"]]}, {"text": "Diacylglycerol ( DAG   acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  DAG  kinase ( DGK  ", "triple_list": [["DAG", "PRODUCT-OF", "DGK"]]}, {"text": "Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of  acetylcholinesterase  against denaturation by heat or  guanidine  following phosphorylation by organophosphorus anticholinesterase compounds", "triple_list": [["guanidine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "Monoclonal antibody 25B1 generated against  diisopropyl phosphorofluoridate  inhibited fetal  bovine serum acetylcholinesterase  has been extensively characterized with respect to its anticholinesterase properties", "triple_list": [["diisopropyl phosphorofluoridate", "DOWNREGULATOR", "bovine serum acetylcholinesterase"]]}, {"text": "The  sordarins  group are protein synthesis inhibitors that work by blocking the function of  fungal translation elongation factor 2   Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402", "triple_list": [["sordarins", "DOWNREGULATOR", "fungal translation elongation factor 2"]]}, {"text": "It has been known for decades that  lithium chloride  (LiCl) leads to D-myo-inositol 1-phosphate accumulation on  GPCR  activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade", "triple_list": [["lithium chloride", "ACTIVATOR", "GPCR"]]}, {"text": "It has been known for decades that lithium chloride ( LiCl   leads to D-myo-inositol 1-phosphate accumulation on  GPCR  activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade", "triple_list": [["LiCl", "ACTIVATOR", "GPCR"]]}, {"text": "It has been known for decades that  lithium chloride  (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  inositol monophosphatase   the final enzyme of the IP3 metabolic cascade", "triple_list": [["lithium chloride", "DOWNREGULATOR", "inositol monophosphatase"]]}, {"text": "It has been known for decades that lithium chloride ( LiCl   leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  inositol monophosphatase   the final enzyme of the IP3 metabolic cascade", "triple_list": [["LiCl", "DOWNREGULATOR", "inositol monophosphatase"]]}, {"text": "Phospholipase C beta ( PLC-beta )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by  D-myo-inositol 1,4,5-trisphosphate  (IP3), a  PLC-beta  hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays", "triple_list": [["D-myo-inositol 1,4,5-trisphosphate", "PRODUCT-OF", "PLC-beta"]]}, {"text": "Phospholipase C beta ( PLC-beta )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ( IP3  , a  PLC-beta  hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays", "triple_list": [["IP3", "PRODUCT-OF", "PLC-beta"]]}, {"text": "Phospholipase C beta ( PLC-beta )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a  PLC-beta  hydrolysis product, or by measuring the production of  inositol phosphate  using cumbersome radioactive assays", "triple_list": [["inositol phosphate", "PRODUCT-OF", "PLC-beta"]]}, {"text": "It has been known for decades that lithium chloride (LiCl) leads to  D-myo-inositol 1-phosphate  accumulation on GPCR activation by inhibiting  inositol monophosphatase   the final enzyme of the IP3 metabolic cascade", "triple_list": [["D-myo-inositol 1-phosphate", "PRODUCT-OF", "inositol monophosphatase"]]}, {"text": "It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  inositol monophosphatase   the final enzyme of the  IP3  metabolic cascade", "triple_list": [["IP3", "PRODUCT-OF", "inositol monophosphatase"]]}, {"text": "Once formed, the molecule can be converted to  glycine  by  alanine-glyoxylate aminotransferase  (AGAT)", "triple_list": [["glycine", "PRODUCT-OF", "alanine-glyoxylate aminotransferase"]]}, {"text": "Once formed, the molecule can be converted to  glycine  by alanine-glyoxylate aminotransferase ( AGAT  ", "triple_list": [["glycine", "PRODUCT-OF", "AGAT"]]}, {"text": "inactivation of  cortisol  to cortisone) to prevent activation of the  mineralocorticoid receptor  (MR) by  cortisol   Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which  cortisol  activates the MR resulting in severe hypertension and hypokalemia", "triple_list": [["cortisol", "ACTIVATOR", "mineralocorticoid receptor"]]}, {"text": "inactivation of  cortisol  to cortisone) to prevent activation of the mineralocorticoid receptor ( MR   by  cortisol   Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which  cortisol  activates the  MR  resulting in severe hypertension and hypokalemia", "triple_list": [["cortisol", "ACTIVATOR", "MR"]]}, {"text": "Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which  cortisol  activates the  MR  resulting in severe hypertension and hypokalemia", "triple_list": [["cortisol", "ACTIVATOR", "MR"]]}, {"text": "Ingestion of competitive inhibitors of  11beta-HSD2  such as liquorice and  carbenoxolone  result in a similar but milder clinical phenotype", "triple_list": [["carbenoxolone", "DOWNREGULATOR", "11beta-HSD2"]]}, {"text": " 11Beta-HSD1  activates cortisone to  cortisol  to facilitate glucocorticoid receptor (GR)-mediated action", "triple_list": [["cortisol", "PRODUCT-OF", "11Beta-HSD1"]]}, {"text": " 11Beta-HSD1  activates  cortisone  to cortisol to facilitate glucocorticoid receptor (GR)-mediated action", "triple_list": [["cortisone", "PRODUCT-OF", "11Beta-HSD1"]]}, {"text": " ATRA  regulates gene expression via the activation of the  retinoic acid receptor (RAR)alpha  in human DCs, and RARalpha acutely regulates CD1d expression", "triple_list": [["ATRA", "ACTIVATOR", "retinoic acid receptor (RAR)alpha"]]}, {"text": " ATRA  regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and  RARalpha  acutely regulates CD1d expression", "triple_list": [["ATRA", "ACTIVATOR", "RARalpha"]]}, {"text": " ATRA  regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates  CD1d  expression", "triple_list": [["ATRA", "ACTIVATOR", "CD1d"]]}, {"text": "The  retinoic acid  induced elevated expression of  CD1d  is coupled to enhanced iNKT cell activation", "triple_list": [["retinoic acid", "ACTIVATOR", "CD1d"]]}, {"text": "Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit  retinoid  signaling leading to  CD1d  up-regulation", "triple_list": [["retinoid", "ACTIVATOR", "CD1d"]]}, {"text": "Here we demonstrate that PPARgamma, turns on  retinoic acid  synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as  retinol dehydrogenase 10  and retinaldehyde dehydrogenase type 2 (RALDH2)", "triple_list": [["retinoic acid", "PRODUCT-OF", "retinol dehydrogenase 10"]]}, {"text": "Here we demonstrate that PPARgamma, turns on  retinoic acid  synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and  retinaldehyde dehydrogenase type 2  (RALDH2)", "triple_list": [["retinoic acid", "PRODUCT-OF", "retinaldehyde dehydrogenase type 2"]]}, {"text": "Here we demonstrate that PPARgamma, turns on  retinoic acid  synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( RALDH2  ", "triple_list": [["retinoic acid", "PRODUCT-OF", "RALDH2"]]}, {"text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  retinol  and retinal metabolizing enzymes such as  retinol  dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)", "triple_list": [["retinol", "PRODUCT-OF", "retinol dehydrogenase 10"]]}, {"text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  retinol  and retinal metabolizing enzymes such as  retinol  dehydrogenase 10 and  retinaldehyde dehydrogenase type 2  (RALDH2)", "triple_list": [["retinol", "PRODUCT-OF", "retinaldehyde dehydrogenase type 2"]]}, {"text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  retinol  and retinal metabolizing enzymes such as  retinol  dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( RALDH2  ", "triple_list": [["retinol", "PRODUCT-OF", "RALDH2"]]}, {"text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  retinal  metabolizing enzymes such as  retinol dehydrogenase 10  and  retinal dehyde dehydrogenase type 2 (RALDH2)", "triple_list": [["retinal", "PRODUCT-OF", "retinol dehydrogenase 10"]]}, {"text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  retinal  metabolizing enzymes such as retinol dehydrogenase 10 and  retinal dehyde dehydrogenase type 2 (RALDH2)", "triple_list": [["retinal", "PRODUCT-OF", "retinaldehyde dehydrogenase type 2"]]}, {"text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  retinal  metabolizing enzymes such as retinol dehydrogenase 10 and  retinal dehyde dehydrogenase type 2 ( RALDH2  ", "triple_list": [["retinal", "PRODUCT-OF", "RALDH2"]]}, {"text": "CONTEXT:  Ramelteon  is a novel  MT1  and MT2 melatonin receptor selective agonist recently approved for insomnia treatment", "triple_list": [["Ramelteon", "AGONIST", "MT1"]]}, {"text": "CONTEXT:  Ramelteon  is a novel MT1 and  MT2 melatonin receptor  selective agonist recently approved for insomnia treatment", "triple_list": [["Ramelteon", "AGONIST", "MT2 melatonin receptor"]]}, {"text": "Late INa induced by the  VGSC  long QT mutant R1623Q was reduced by  resveratrol  and quercetin", "triple_list": [["resveratrol", "DOWNREGULATOR", "VGSC"]]}, {"text": "Late INa induced by the VGSC long QT mutant  R1623Q  was reduced by  resveratrol  and quercetin", "triple_list": [["resveratrol", "DOWNREGULATOR", "R1623Q"]]}, {"text": "Late INa induced by the  VGSC  long QT mutant R1623Q was reduced by resveratrol and  quercetin   Resveratrol and  quercetin  also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively", "triple_list": [["quercetin", "DOWNREGULATOR", "VGSC"]]}, {"text": "Late INa induced by the VGSC long QT mutant  R1623Q  was reduced by resveratrol and  quercetin   Resveratrol and  quercetin  also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively", "triple_list": [["quercetin", "DOWNREGULATOR", "R1623Q"]]}, {"text": "Enhancement of radiosensitivity by  topoisomerase II  inhibitor,  amrubicin  and  amrubicin ol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction", "triple_list": [["amrubicin", "DOWNREGULATOR", "topoisomerase II"]]}, {"text": "Enhancement of radiosensitivity by  topoisomerase II  inhibitor, amrubicin and  amrubicinol   in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction", "triple_list": [["amrubicinol", "DOWNREGULATOR", "topoisomerase II"]]}, {"text": "Similar to  AMR  and  AMR OH, adriamycin and etoposide (VP-16) are  DNA topoisomerase II  inhibitors", "triple_list": [["AMR", "DOWNREGULATOR", "DNA topoisomerase II"]]}, {"text": "Similar to AMR and  AMROH   adriamycin and etoposide (VP-16) are  DNA topoisomerase II  inhibitors", "triple_list": [["AMROH", "DOWNREGULATOR", "DNA topoisomerase II"]]}, {"text": "Similar to AMR and AMROH,  adriamycin  and etoposide (VP-16) are  DNA topoisomerase II  inhibitors", "triple_list": [["adriamycin", "DOWNREGULATOR", "DNA topoisomerase II"]]}, {"text": "Similar to AMR and AMROH, adriamycin and  etoposide  (VP-16) are  DNA topoisomerase II  inhibitors", "triple_list": [["etoposide", "DOWNREGULATOR", "DNA topoisomerase II"]]}, {"text": "Similar to AMR and AMROH, adriamycin and etoposide ( VP-16   are  DNA topoisomerase II  inhibitors", "triple_list": [["VP-16", "DOWNREGULATOR", "DNA topoisomerase II"]]}, {"text": "pylori may in fact, antagonize,  aspirin  induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from  COX-2  expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF", "triple_list": [["aspirin", "ACTIVATOR", "COX-2"]]}, {"text": "pylori may in fact, antagonize,  aspirin  induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as  TGF alpha  and VEGF", "triple_list": [["aspirin", "ACTIVATOR", "TGF alpha"]]}, {"text": "pylori may in fact, antagonize,  aspirin  induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and  VEGF   The present review summarizes and further addresses the issue of the interaction between these two major ulcer risk factors determined in the stomach of humans and experimental animals.", "triple_list": [["aspirin", "ACTIVATOR", "VEGF"]]}, {"text": "pylori may in fact, antagonize,  aspirin  induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from  COX-2  expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF", "triple_list": [["aspirin", "ACTIVATOR", "COX-2"]]}, {"text": "pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in  PGE(2)  possibly derived from  COX-2  expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF", "triple_list": [["PGE(2)", "PRODUCT-OF", "COX-2"]]}, {"text": "Based on selective nucleoside protection, TS was found to be the primary  pemetrexed  target in both cell lines with  GARFT  inhibition requiring 20- to 30-fold higher  pemetrexed  concentrations", "triple_list": [["pemetrexed", "DOWNREGULATOR", "GARFT"]]}, {"text": " Methylthioadenosine phosphorylase  (MTAP) salvages purines by releasing  adenine  from methylthioadenosine and is often deleted in mesothelioma", "triple_list": [["adenine", "PRODUCT-OF", "Methylthioadenosine phosphorylase"]]}, {"text": "Methylthioadenosine phosphorylase ( MTAP   salvages purines by releasing  adenine  from methylthioadenosine and is often deleted in mesothelioma", "triple_list": [["adenine", "PRODUCT-OF", "MTAP"]]}, {"text": " Methylthioadenosine phosphorylase  (MTAP) salvages purines by releasing adenine from  methylthioadenosine  and is often deleted in mesothelioma", "triple_list": [["methylthioadenosine", "PRODUCT-OF", "Methylthioadenosine phosphorylase"]]}, {"text": "Methylthioadenosine phosphorylase ( MTAP   salvages purines by releasing adenine from  methylthioadenosine  and is often deleted in mesothelioma", "triple_list": [["methylthioadenosine", "PRODUCT-OF", "MTAP"]]}, {"text": "The most active of these compounds,  gliquidone   is shown to be as potent as pioglitazone at inducing  PPARgamma  target gene expression", "triple_list": [["gliquidone", "ACTIVATOR", "PPARgamma"]]}, {"text": "The most active of these compounds, gliquidone, is shown to be as potent as  pioglitazone  at inducing  PPARgamma  target gene expression", "triple_list": [["pioglitazone", "ACTIVATOR", "PPARgamma"]]}, {"text": "Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating  insulin  release ( sulfonylureas   glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving  insulin  resistance (thiazolidinediones)", "triple_list": [["sulfonylureas", "ACTIVATOR", "insulin"]]}, {"text": "Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating  insulin  release (sulfonylureas,  glinides  , or target the peroxisome proliferator-activated receptor (PPARgamma) improving  insulin  resistance (thiazolidinediones)", "triple_list": [["glinides", "ACTIVATOR", "insulin"]]}, {"text": "Among the measured compounds,  gliquidone  and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment", "triple_list": [["gliquidone", "AGONIST", "PPARgamma"]]}, {"text": "Among the measured compounds, gliquidone and  glipizide  (two sulfonylureas), as well as nateglinide (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment", "triple_list": [["glipizide", "AGONIST", "PPARgamma"]]}, {"text": "Among the measured compounds, gliquidone and glipizide (two  sulfonylureas  , as well as nateglinide (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment", "triple_list": [["sulfonylureas", "AGONIST", "PPARgamma"]]}, {"text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as  nateglinide  (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment", "triple_list": [["nateglinide", "AGONIST", "PPARgamma"]]}, {"text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nate glinide  (a  glinide  , exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment", "triple_list": [["glinide", "AGONIST", "PPARgamma"]]}, {"text": " Glinides   sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new  PPARgamma  agonists", "triple_list": [["Glinides", "AGONIST", "PPARgamma"]]}, {"text": "Glinides,  sulfonylureas   and other acidified sulfonamides may be promising leads in the development of new  PPARgamma  agonists", "triple_list": [["sulfonylureas", "AGONIST", "PPARgamma"]]}, {"text": "Glinides, sulfonylureas, and other  acidified sulfonamides  may be promising leads in the development of new  PPARgamma  agonists", "triple_list": [["acidified sulfonamides", "AGONIST", "PPARgamma"]]}, {"text": "Our work shows that  sulfonylureas  and glinides additionally bind to  PPARgamma  and exhibit  PPARgamma  agonistic activity", "triple_list": [["sulfonylureas", "AGONIST", "PPARgamma"]]}, {"text": "Our work shows that sulfonylureas and  glinides  additionally bind to  PPARgamma  and exhibit  PPARgamma  agonistic activity", "triple_list": [["glinides", "AGONIST", "PPARgamma"]]}, {"text": "Such organization results in the local activation of  PKA  subsets through the generation of confined intracellular gradients of  cAMP   but the mechanisms responsible for limiting the diffusion of  cAMP  largely remain to be clarified", "triple_list": [["cAMP", "ACTIVATOR", "PKA"]]}, {"text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized  PDE4B  and PDE4D are responsible for selectively modulating the concentration of  cAMP  in individual subcellular compartments", "triple_list": [["cAMP", "PRODUCT-OF", "PDE4B"]]}, {"text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and  PDE4D  are responsible for selectively modulating the concentration of  cAMP  in individual subcellular compartments", "triple_list": [["cAMP", "PRODUCT-OF", "PDE4D"]]}, {"text": "We propose a model whereby compartmentalized  PDEs   rather than representing an enzymatic barrier to  cAMP  diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different  cAMP  concentrations irrespective of their distance from the site of  cAMP  synthesis.", "triple_list": [["cAMP", "PRODUCT-OF", "PDEs"]]}, {"text": "We propose a model whereby compartmentalized  PDEs   rather than representing an enzymatic barrier to  cAMP  diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different  cAMP  concentrations irrespective of their distance from the site of  cAMP  synthesis.", "triple_list": [["cAMP", "PRODUCT-OF", "PDEs"]]}, {"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors  doxorubicin  and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in  FAS promoter  activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["doxorubicin", "ACTIVATOR", "FAS promoter"]]}, {"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and  etopoxide  (VP-16) demonstrated a 2- to 3-fold increase in  FAS promoter  activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["etopoxide", "ACTIVATOR", "FAS promoter"]]}, {"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide ( VP-16   demonstrated a 2- to 3-fold increase in  FAS promoter  activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["VP-16", "ACTIVATOR", "FAS promoter"]]}, {"text": "SK-Br3 cells cultured in the presence of  topoisomerase IIalpha  (TOP2A) inhibitors  doxorubicin  and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["doxorubicin", "DOWNREGULATOR", "topoisomerase IIalpha"]]}, {"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha ( TOP2A   inhibitors  doxorubicin  and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["doxorubicin", "DOWNREGULATOR", "TOP2A"]]}, {"text": "SK-Br3 cells cultured in the presence of  topoisomerase IIalpha  (TOP2A) inhibitors doxorubicin and  etopoxide  (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["etopoxide", "DOWNREGULATOR", "topoisomerase IIalpha"]]}, {"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha ( TOP2A   inhibitors doxorubicin and  etopoxide  (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["etopoxide", "DOWNREGULATOR", "TOP2A"]]}, {"text": "SK-Br3 cells cultured in the presence of  topoisomerase IIalpha  (TOP2A) inhibitors doxorubicin and etopoxide ( VP-16   demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["VP-16", "DOWNREGULATOR", "topoisomerase IIalpha"]]}, {"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha ( TOP2A   inhibitors doxorubicin and etopoxide ( VP-16   demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions", "triple_list": [["VP-16", "DOWNREGULATOR", "TOP2A"]]}, {"text": "RESULT(S): The expression of endometrial  ERalpha   PRAB, PRB, and SRC-1 was increased significantly after 1 week of  mifepristone   but the increase was no longer seen after 10 weeks", "triple_list": [["mifepristone", "ACTIVATOR", "ERalpha"]]}, {"text": "RESULT(S): The expression of endometrial ERalpha,  PRAB   PRB, and SRC-1 was increased significantly after 1 week of  mifepristone   but the increase was no longer seen after 10 weeks", "triple_list": [["mifepristone", "ACTIVATOR", "PRAB"]]}, {"text": "RESULT(S): The expression of endometrial ERalpha, PRAB,  PRB   and SRC-1 was increased significantly after 1 week of  mifepristone   but the increase was no longer seen after 10 weeks", "triple_list": [["mifepristone", "ACTIVATOR", "PRB"]]}, {"text": "RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and  SRC-1  was increased significantly after 1 week of  mifepristone   but the increase was no longer seen after 10 weeks", "triple_list": [["mifepristone", "ACTIVATOR", "SRC-1"]]}, {"text": "CONCLUSION(S): Short-term exposure of  mifepristone  in new starters of DMPA increases the expression of endometrial  ERalpha   PRAB, PRB, and SRC-1 and promotes cell proliferation", "triple_list": [["mifepristone", "ACTIVATOR", "ERalpha"]]}, {"text": "CONCLUSION(S): Short-term exposure of  mifepristone  in new starters of DMPA increases the expression of endometrial ERalpha,  PRAB   PRB, and SRC-1 and promotes cell proliferation", "triple_list": [["mifepristone", "ACTIVATOR", "PRAB"]]}, {"text": "CONCLUSION(S): Short-term exposure of  mifepristone  in new starters of DMPA increases the expression of endometrial ERalpha, PRAB,  PRB   and SRC-1 and promotes cell proliferation", "triple_list": [["mifepristone", "ACTIVATOR", "PRB"]]}, {"text": "CONCLUSION(S): Short-term exposure of  mifepristone  in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and  SRC-1  and promotes cell proliferation", "triple_list": [["mifepristone", "ACTIVATOR", "SRC-1"]]}, {"text": "The cytosolic fraction obtained from pancreatic islets obtained from  GalN  treated rats had an increased  PTB  level compared to the levels obtained from the pancreatic islets of control rats", "triple_list": [["GalN", "ACTIVATOR", "PTB"]]}, {"text": "In the present study,  glucose  stimulated  insulin  secretion was significantly increased in GalN-treated rats compared to controls", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "In the present study, glucose-stimulated  insulin  secretion was significantly increased in  GalN  treated rats compared to controls", "triple_list": [["GalN", "ACTIVATOR", "insulin"]]}, {"text": "Levels of mRNA encoding  insulin 1   ICA512, and PC1/3 were increased in the pancreatic islets of  GalN  treated rats", "triple_list": [["GalN", "ACTIVATOR", "insulin 1"]]}, {"text": "Levels of mRNA encoding insulin 1,  ICA512   and PC1/3 were increased in the pancreatic islets of  GalN  treated rats", "triple_list": [["GalN", "ACTIVATOR", "ICA512"]]}, {"text": "When the  PTB-binding site  in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from  GalN  treated rats compared to the level in control rats", "triple_list": [["GalN", "ACTIVATOR", "PTB-binding site"]]}, {"text": "When the PTB-binding site in  insulin 1  mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from  GalN  treated rats compared to the level in control rats", "triple_list": [["GalN", "ACTIVATOR", "insulin 1"]]}, {"text": "RESULTS: In the  NMDA  injured brain, the  CysLT1 receptor  mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes", "triple_list": [["NMDA", "ACTIVATOR", "CysLT1 receptor"]]}, {"text": "CONCLUSION:  CysLT1 receptor  expression in neurons is upregulated after  NMDA  injection, and  NMDA -induced responses are inhibited by  CysLT1 receptor  antagonists, indicating that the increased  CysLT1 receptor  is involved in  NMDA  excitotoxicity.", "triple_list": [["NMDA", "ACTIVATOR", "CysLT1 receptor"]]}, {"text": "CONCLUSION:  CysLT1 receptor  expression in neurons is upregulated after  NMDA  injection, and  NMDA -induced responses are inhibited by  CysLT1 receptor  antagonists, indicating that the increased  CysLT1 receptor  is involved in  NMDA  excitotoxicity.", "triple_list": [["NMDA", "ACTIVATOR", "CysLT1 receptor"]]}, {"text": "Pranlukast, ketamine and edaravone decreased NMDA-induced injury;  pranlukast  (0.1 mg/kg) and ketamine inhibited the upregulated expression of the  CysLT1 receptor   CONCLUSION:  CysLT1 receptor  expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by  CysLT1 receptor  antagonists, indicating that the increased  CysLT1 receptor  is involved in NMDA excitotoxicity.", "triple_list": [["pranlukast", "DOWNREGULATOR", "CysLT1 receptor"]]}, {"text": "Pranlukast,  ketamine  and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and  ketamine  inhibited the upregulated expression of the  CysLT1 receptor   CONCLUSION:  CysLT1 receptor  expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by  CysLT1 receptor  antagonists, indicating that the increased  CysLT1 receptor  is involved in NMDA excitotoxicity.", "triple_list": [["ketamine", "DOWNREGULATOR", "CysLT1 receptor"]]}, {"text": "The changes in  CysLT1 receptor  expression 24 h after NMDA injection and the effects of a  CysLT1 receptor  antagonist,  pranlukast  (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed", "triple_list": [["pranlukast", "ANTAGONIST", "CysLT1 receptor"]]}, {"text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an  NMDA receptor  antagonist,  ketamine  (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed", "triple_list": [["ketamine", "ANTAGONIST", "NMDA receptor"]]}, {"text": "We have previously demonstrated that phosphorylation of  Fas-associated death domain-containing protein  (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  paclitaxel   In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens", "triple_list": [["paclitaxel", "ACTIVATOR", "Fas-associated death domain-containing protein"]]}, {"text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein ( FADD   at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/ FADD  plays an important role in cell growth suppression by  paclitaxel   In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated  FADD /JNK (P- FADD /JNK) was analyzed immunohistochemically using 107 human breast cancer specimens", "triple_list": [["paclitaxel", "ACTIVATOR", "FADD"]]}, {"text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through  c-jun NH2-terminal kinase  (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  paclitaxel   In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens", "triple_list": [["paclitaxel", "ACTIVATOR", "c-jun NH2-terminal kinase"]]}, {"text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase ( JNK   activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of  JNK /FADD plays an important role in cell growth suppression by  paclitaxel   In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/ JNK  (P-FADD/ JNK ) was analyzed immunohistochemically using 107 human breast cancer specimens", "triple_list": [["paclitaxel", "ACTIVATOR", "JNK"]]}, {"text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase ( JNK ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of  JNK  FADD plays an important role in cell growth suppression by  paclitaxel   In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/ JNK  (P-FADD/ JNK ) was analyzed immunohistochemically using 107 human breast cancer specimens", "triple_list": [["paclitaxel", "ACTIVATOR", "JNK"]]}, {"text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein ( FADD ) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/ FADD  plays an important role in cell growth suppression by  paclitaxel   In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated  FADD /JNK (P- FADD /JNK) was analyzed immunohistochemically using 107 human breast cancer specimens", "triple_list": [["paclitaxel", "ACTIVATOR", "FADD"]]}, {"text": "Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the  beta 1 adrenoceptor  mediated positive chronotropic response to  isoproterenol   This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II", "triple_list": [["isoproterenol", "ACTIVATOR", "beta 1 adrenoceptor"]]}, {"text": "The vasopressor response to the  calcium channel  activator,  BAY-K-8644   which is mediated through the opening of voltage dependent  calcium channel s and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  calcium channel  antagonist, consistent with our previous in vitro studies", "triple_list": [["BAY-K-8644", "ACTIVATOR", "calcium channel"]]}, {"text": "The vasopressor response to the calcium channel activator,  BAY-K-8644   which is mediated through the opening of  voltage dependent calcium channels  and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies", "triple_list": [["BAY-K-8644", "ACTIVATOR", "voltage dependent calcium channels"]]}, {"text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of  voltage dependent calcium channels  and the subsequent translocation of extracellular calcium, was significantly inhibited by  carvedilol  (1 mg/kg, iv), suggesting that  carvedilol  is also a calcium channel antagonist, consistent with our previous in vitro studies", "triple_list": [["carvedilol", "DOWNREGULATOR", "voltage dependent calcium channels"]]}, {"text": "Thus,  carvedilol  blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the  beta 1 adrenoceptor  subtype", "triple_list": [["carvedilol", "DOWNREGULATOR", "beta 1 adrenoceptor"]]}, {"text": " Carvedilol  (0.3 mg/kg, iv) produced a significant inhibition of the  beta 1 adrenoceptor  mediated positive chronotropic response to isoproterenol", "triple_list": [["Carvedilol", "DOWNREGULATOR", "beta 1 adrenoceptor"]]}, {"text": "This same dose of  carvedilol  also inhibited, but to a lesser degree, the  beta 2 adrenoceptor  mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II", "triple_list": [["carvedilol", "DOWNREGULATOR", "beta 2 adrenoceptor"]]}, {"text": " Carvedilol  produced significant inhibition of the  alpha 1 adrenoceptor  mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an  alpha 1 adrenoceptor  antagonist at antihypertensive doses", "triple_list": [["Carvedilol", "DOWNREGULATOR", "alpha 1 adrenoceptor"]]}, {"text": "The vasopressor response to the  calcium channel  activator, BAY-K-8644, which is mediated through the opening of voltage dependent  calcium channel s and the subsequent translocation of extracellular calcium, was significantly inhibited by  carvedilol  (1 mg/kg, iv), suggesting that  carvedilol  is also a  calcium channel  antagonist, consistent with our previous in vitro studies", "triple_list": [["carvedilol", "ANTAGONIST", "calcium channel"]]}, {"text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the  alpha 1 adrenoceptor  antagonist,  prazosin  (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and  alpha 1 adrenoceptor s", "triple_list": [["prazosin", "ANTAGONIST", "alpha 1 adrenoceptor"]]}, {"text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective  beta adrenoceptor  antagonist,  propranolol  (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors", "triple_list": [["propranolol", "ANTAGONIST", "beta adrenoceptor"]]}, {"text": "We therefore conclude that  carvedilol   at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of  calcium channels  in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)", "triple_list": [["carvedilol", "ANTAGONIST", "calcium channels"]]}, {"text": "The mechanism(s) responsible for arterial vasodilation observed following acute administration of  racemic carvedilol   a novel vasodilator/ beta adrenoceptor  antagonist, has been investigated in rats", "triple_list": [["racemic carvedilol", "ANTAGONIST", "beta adrenoceptor"]]}, {"text": "Carvedilol produced significant inhibition of the  alpha 1 adrenoceptor  mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that  carvedilol  is also an  alpha 1 adrenoceptor  antagonist at antihypertensive doses", "triple_list": [["carvedilol", "ANTAGONIST", "alpha 1 adrenoceptor"]]}, {"text": "The vasopressor response to the  calcium  channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent  calcium  channels and the subsequent translocation of extracellular  calcium   was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  calcium  channel antagonist, consistent with our previous in vitro studies", "triple_list": [["calcium", "PRODUCT-OF", "voltage dependent calcium channels"]]}, {"text": " 5-HT3 receptor  antagonism with  alosetron  reduced responses to 5-HT in controls but not during inflammation", "triple_list": [["alosetron", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": "These results highlight the importance of  PR  activation of the Src/MAPK signaling pathway for  progesterone  induced transcription of select target genes and cell cycle progression.", "triple_list": [["progesterone", "ACTIVATOR", "PR"]]}, {"text": "These results highlight the importance of PR activation of the  Src  MAPK signaling pathway for  progesterone  induced transcription of select target genes and cell cycle progression.", "triple_list": [["progesterone", "ACTIVATOR", "Src"]]}, {"text": "These results highlight the importance of PR activation of the Src/ MAPK  signaling pathway for  progesterone  induced transcription of select target genes and cell cycle progression.", "triple_list": [["progesterone", "ACTIVATOR", "MAPK"]]}, {"text": " Progestin  activation of  Src  MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear", "triple_list": [["Progestin", "ACTIVATOR", "Src"]]}, {"text": " Progestin  activation of Src/ MAPK  occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear", "triple_list": [["Progestin", "ACTIVATOR", "MAPK"]]}, {"text": " Progestin  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on  PR  activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with  PR  activation of Src", "triple_list": [["Progestin", "ACTIVATOR", "PR"]]}, {"text": " Progestin  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the  Src  MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of  Src ", "triple_list": [["Progestin", "ACTIVATOR", "Src"]]}, {"text": " Progestin  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/ MAPK  pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src", "triple_list": [["Progestin", "ACTIVATOR", "MAPK"]]}, {"text": "injection of a subthreshold dose of  picrotoxin   a use-dependent  gamma-aminobutyric acid receptor  antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice", "triple_list": [["picrotoxin", "ANTAGONIST", "gamma-aminobutyric acid receptor"]]}, {"text": "MicroPET imaging in nonhuman primates with [ 11C  1 and [ 11C ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the  SERT  rich brain regions and peak uptake being achieved in about 55 min postinjection", "triple_list": [["11C", "PRODUCT-OF", "SERT"]]}, {"text": "MicroPET imaging in nonhuman primates with [ 11C ]1 and [ 11C  2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the  SERT  rich brain regions and peak uptake being achieved in about 55 min postinjection", "triple_list": [["11C", "PRODUCT-OF", "SERT"]]}, {"text": "This trial investigated the possibility of pharmacokinetic interactions between the  AT1 receptor  antagonist  olmesartan medoxomil  and the thiazide diuretic hydrochlorothiazide in healthy subjects", "triple_list": [["olmesartan medoxomil", "ANTAGONIST", "AT1 receptor"]]}, {"text": " SecS  required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate  selenocysteyl  tRNA([Ser]Sec)", "triple_list": [["selenocysteyl", "PRODUCT-OF", "SecS"]]}, {"text": "In addition, we found that  selenophosphate synthetase 2  could synthesize  monoselenophosphate  in vitro but selenophosphate synthetase 1 could not", "triple_list": [["monoselenophosphate", "PRODUCT-OF", "selenophosphate synthetase 2"]]}, {"text": " SecS  required selenophosphate and  O-phosphoseryl  tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)", "triple_list": [["O-phosphoseryl", "PRODUCT-OF", "SecS"]]}, {"text": " SecS  required  selenophosphate  and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)", "triple_list": [["selenophosphate", "PRODUCT-OF", "SecS"]]}, {"text": " Triflusal  (30 mg/kg) also significantly decreased the protein levels of  IL-Ibeta  but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion", "triple_list": [["Triflusal", "DOWNREGULATOR", "IL-Ibeta"]]}, {"text": "The  GRIP1  reduction was inhibited by  MK-801   an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist", "triple_list": [["MK-801", "ACTIVATOR", "GRIP1"]]}, {"text": " EGTA  and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  GRIP1  degradation", "triple_list": [["EGTA", "ACTIVATOR", "GRIP1"]]}, {"text": "EGTA and  1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis  (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  GRIP1  degradation", "triple_list": [["1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis", "ACTIVATOR", "GRIP1"]]}, {"text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis ( BAPTA  , two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  GRIP1  degradation", "triple_list": [["BAPTA", "ACTIVATOR", "GRIP1"]]}, {"text": "Our results suggest that  glutamate  induces  GRIP1  degradation by proteasome through an NMDA receptor-Ca2+ pathway and that  GRIP1  degradation may play an important role in regulating GluR2 surface expression.", "triple_list": [["glutamate", "DOWNREGULATOR", "GRIP1"]]}, {"text": "Our results suggest that  glutamate  induces  GRIP1  degradation by proteasome through an NMDA receptor-Ca2+ pathway and that  GRIP1  degradation may play an important role in regulating GluR2 surface expression.", "triple_list": [["glutamate", "DOWNREGULATOR", "GRIP1"]]}, {"text": " Glutamate  stimulates  glutamate receptor interacting protein 1  degradation by ubiquitin-proteasome system to regulate surface expression of GluR2", "triple_list": [["Glutamate", "DOWNREGULATOR", "glutamate receptor interacting protein 1"]]}, {"text": "Down-regulation of  GRIP1  by  glutamate  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin", "triple_list": [["glutamate", "DOWNREGULATOR", "GRIP1"]]}, {"text": "Furthermore, MG132 prevented  glutamate  stimulated reduction in surface amount of  GluR2   and knockdown of GRIP1 by RNAi against GRIP1 reduced surface  GluR2  in neurons", "triple_list": [["glutamate", "DOWNREGULATOR", "GluR2"]]}, {"text": "Here we report that  glutamate  stimulation caused a rapid reduction in protein levels of  GRIP1   but not that of  glutamate  receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures", "triple_list": [["glutamate", "DOWNREGULATOR", "GRIP1"]]}, {"text": "Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ( MG132  , a  proteasome  inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin", "triple_list": [["MG132", "DOWNREGULATOR", "proteasome"]]}, {"text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not  nifedipine   an  L-type Ca2+ channel  blocker, prevented GRIP1 degradation", "triple_list": [["nifedipine", "DOWNREGULATOR", "L-type Ca2+ channel"]]}, {"text": "Down-regulation of GRIP1 by glutamate was blocked by  carbobenzoxyl-leucinyl-leucinyl-leucinal  (MG132), a  proteasome  inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin", "triple_list": [["carbobenzoxyl-leucinyl-leucinyl-leucinal", "DOWNREGULATOR", "proteasome"]]}, {"text": "The GRIP1 reduction was inhibited by  MK-801   an  N-methyl-d-aspartate (NMDA) receptor  antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist", "triple_list": [["MK-801", "ANTAGONIST", "N-methyl-d-aspartate (NMDA) receptor"]]}, {"text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by  6-cyano-7-nitroquinoxaline-2,3-dione  (CNQX), an  AMPA receptor  antagonist", "triple_list": [["6-cyano-7-nitroquinoxaline-2,3-dione", "ANTAGONIST", "AMPA receptor"]]}, {"text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione ( CNQX  , an  AMPA receptor  antagonist", "triple_list": [["CNQX", "ANTAGONIST", "AMPA receptor"]]}, {"text": "RESULTS:  Leukotriene D(4)  upregulated  MUC2/5AC  gene expression and mucin secretion in a dose dependent pattern", "triple_list": [["Leukotriene D(4)", "ACTIVATOR", "MUC2/5AC"]]}, {"text": "RESULTS:  Leukotriene D(4)  upregulated MUC2/5AC gene expression and  mucin  secretion in a dose dependent pattern", "triple_list": [["Leukotriene D(4)", "ACTIVATOR", "mucin"]]}, {"text": "The inhibitory effect of the leukotriene receptor antagonist on  leukotriene D4  induced MUC2/5AC gene expression and  mucin  secretion in human airway epithelial cells", "triple_list": [["leukotriene D4", "ACTIVATOR", "mucin"]]}, {"text": "The inhibitory effect of the leukotriene receptor antagonist on  leukotriene D4  induced  MUC2/5AC  gene expression and mucin secretion in human airway epithelial cells", "triple_list": [["leukotriene D4", "ACTIVATOR", "MUC2/5AC"]]}, {"text": "Pranlukast hydrate (ONO-1078, 100 microM) downregulated the  leukotriene D(4)  induced  MUC2/5AC  gene expression and mucin secretion", "triple_list": [["leukotriene D(4)", "ACTIVATOR", "MUC2/5AC"]]}, {"text": "Pranlukast hydrate (ONO-1078, 100 microM) downregulated the  leukotriene D(4)  induced MUC2/5AC gene expression and  mucin  secretion", "triple_list": [["leukotriene D(4)", "ACTIVATOR", "mucin"]]}, {"text": " Pranlukast hydrate  (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced  MUC2/5AC  gene expression and mucin secretion", "triple_list": [["Pranlukast hydrate", "DOWNREGULATOR", "MUC2/5AC"]]}, {"text": " Pranlukast hydrate  (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and  mucin  secretion", "triple_list": [["Pranlukast hydrate", "DOWNREGULATOR", "mucin"]]}, {"text": "Pranlukast hydrate ( ONO-1078   100 microM) downregulated the leukotriene D(4)-induced  MUC2/5AC  gene expression and mucin secretion", "triple_list": [["ONO-1078", "DOWNREGULATOR", "MUC2/5AC"]]}, {"text": "Pranlukast hydrate ( ONO-1078   100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and  mucin  secretion", "triple_list": [["ONO-1078", "DOWNREGULATOR", "mucin"]]}, {"text": "METHODS: The effect of leukotriene D(4) and the  leukotriene receptor  antagonist,  pranlukast hydrate  (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells", "triple_list": [["pranlukast hydrate", "ANTAGONIST", "leukotriene receptor"]]}, {"text": "METHODS: The effect of leukotriene D(4) and the  leukotriene receptor  antagonist, pranlukast hydrate ( ONO-1078   on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells", "triple_list": [["ONO-1078", "ANTAGONIST", "leukotriene receptor"]]}, {"text": "CONCLUSION: In postmenopausal women, isolated  isoflavone  treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating  pre-beta high-density lipoprotein  level, which could provide beneficial vascular effects.", "triple_list": [["isoflavone", "ACTIVATOR", "pre-beta high-density lipoprotein"]]}, {"text": "However, as a novel finding,  isoflavone  treatment increased a subclass of  high-density lipoprotein   the pre-beta  high-density lipoprotein  levels by 18% without affecting any other serum lipid concentrations", "triple_list": [["isoflavone", "ACTIVATOR", "high-density lipoprotein"]]}, {"text": "However, as a novel finding,  isoflavone  treatment increased a subclass of high-density lipoprotein, the  pre-beta high-density lipoprotein  levels by 18% without affecting any other serum lipid concentrations", "triple_list": [["isoflavone", "ACTIVATOR", "pre-beta high-density lipoprotein"]]}, {"text": "CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect  ABCA1  dependent  cholesterol  efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse  cholesterol  transport as evaluated by  adenosine triphosphate-binding cassette A1   (ABCA1), dependent  cholesterol  efflux from macrophages", "triple_list": [["cholesterol", "PRODUCT-OF", "adenosine triphosphate-binding cassette A1"]]}, {"text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse  cholesterol  transport as evaluated by adenosine triphosphate-binding cassette A1- ( ABCA1  , dependent  cholesterol  efflux from macrophages", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "[H]-Cholesterol-labeled J774 macrophage cells, with and without  ABCA1  up-regulation, were incubated with the samples, and  ABCA1  dependent  cholesterol  efflux and serum lipid and lipoprotein levels were assessed", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "Thus, isoflavone supplementation did not affect  ABCA1  dependent  cholesterol  efflux to serum", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": " ABCA1  facilitated  cholesterol  efflux and lipid parameters did not differ between equol-producing and non-equol-producing women", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "We investigated the efficacy of  sorafenib  at inhibiting mutants of the  receptor tyrosine kinases  PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies", "triple_list": [["sorafenib", "DOWNREGULATOR", "receptor tyrosine kinases"]]}, {"text": "We investigated the efficacy of  sorafenib  at inhibiting mutants of the receptor tyrosine kinases  PDGFRbeta   KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies", "triple_list": [["sorafenib", "DOWNREGULATOR", "PDGFRbeta"]]}, {"text": "We investigated the efficacy of  sorafenib  at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta,  KIT   and FLT3, which are implicated in the pathogenesis of myeloid malignancies", "triple_list": [["sorafenib", "DOWNREGULATOR", "KIT"]]}, {"text": "We investigated the efficacy of  sorafenib  at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and  FLT3   which are implicated in the pathogenesis of myeloid malignancies", "triple_list": [["sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": "The ability of  sorafenib  to inhibit oncogenic  PDGFRbeta  and FLT3 mutants and overcome resistance to other small molecule inhibitors", "triple_list": [["sorafenib", "DOWNREGULATOR", "PDGFRbeta"]]}, {"text": "The ability of  sorafenib  to inhibit oncogenic PDGFRbeta and  FLT3  mutants and overcome resistance to other small molecule inhibitors", "triple_list": [["sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": "RESULTS: We show that  sorafenib  is a potent inhibitor of  ETV6  PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors", "triple_list": [["sorafenib", "DOWNREGULATOR", "ETV6"]]}, {"text": "RESULTS: We show that  sorafenib  is a potent inhibitor of ETV6- PDGFRbeta  and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors", "triple_list": [["sorafenib", "DOWNREGULATOR", "PDGFRbeta"]]}, {"text": "RESULTS: We show that  sorafenib  is a potent inhibitor of ETV6-PDGFRbeta and  FLT3  mutants, including some of the mutants that confer resistance to PKC412 and other  FLT3  inhibitors", "triple_list": [["sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": "RESULTS: We show that  sorafenib  is a potent inhibitor of ETV6-PDGFRbeta and  FLT3  mutants, including some of the mutants that confer resistance to PKC412 and other  FLT3  inhibitors", "triple_list": [["sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": " Sorafenib  induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing  FLT3  with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines", "triple_list": [["Sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": " Sorafenib  (BAY43-9006, Nexavar) is a small molecule  B-RAF  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families", "triple_list": [["Sorafenib", "DOWNREGULATOR", "B-RAF"]]}, {"text": "INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of  sorafenib  for the treatment of myeloid malignancies expressing activated forms of  PDGFRbeta  and FLT3.", "triple_list": [["sorafenib", "DOWNREGULATOR", "PDGFRbeta"]]}, {"text": "INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of  sorafenib  for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and  FLT3  ", "triple_list": [["sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": "Sorafenib ( BAY43-9006   Nexavar) is a small molecule  B-RAF  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families", "triple_list": [["BAY43-9006", "DOWNREGULATOR", "B-RAF"]]}, {"text": "Sorafenib (BAY43-9006,  Nexavar   is a small molecule  B-RAF  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families", "triple_list": [["Nexavar", "DOWNREGULATOR", "B-RAF"]]}, {"text": "Exposure to  mifepristone  (a  glucocorticoid receptor  antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA", "triple_list": [["mifepristone", "ANTAGONIST", "glucocorticoid receptor"]]}, {"text": "Exposure to mifepristone (a glucocorticoid receptor antagonist), but not  spironolactone  (a  mineralocorticoid receptor  antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA", "triple_list": [["spironolactone", "ANTAGONIST", "mineralocorticoid receptor"]]}, {"text": "All three  salicylates  inhibited the diabetes-induced translocation of  p50  (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of  p50  and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections", "triple_list": [["salicylates", "DOWNREGULATOR", "p50"]]}, {"text": "All three  salicylates  inhibited the diabetes-induced translocation of  p50  (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of  p50  and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections", "triple_list": [["salicylates", "DOWNREGULATOR", "p50"]]}, {"text": "All three  salicylates  inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and  p65  into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections", "triple_list": [["salicylates", "DOWNREGULATOR", "p65"]]}, {"text": "Oral  aspirin  (as a representative of the salicylate family) inhibited diabetes-induced increase in  NF-kappaB  DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina", "triple_list": [["aspirin", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Oral aspirin (as a representative of the  salicylate  family) inhibited diabetes-induced increase in  NF-kappaB  DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina", "triple_list": [["salicylate", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "All three  salicylates  inhibited the diabetes-induced translocation of p50 (a subunit of  NF-kappaB   into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections", "triple_list": [["salicylates", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": " Sulfasalazine  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by  NF-kappaB   including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": " Sulfasalazine  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule,  intracellular adhesion molecule-1   inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "intracellular adhesion molecule-1"]]}, {"text": " Sulfasalazine  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1,  inducible nitric oxide synthase   and cyclooxygenase-2 in whole-retinal lysate", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "inducible nitric oxide synthase"]]}, {"text": " Sulfasalazine  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and  cyclooxygenase-2  in whole-retinal lysate", "triple_list": [["Sulfasalazine", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Sulfasalazine (also as a representative of the  salicylates   inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by  NF-kappaB   including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate", "triple_list": [["salicylates", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": " Salicylates   in doses administrated in our experiments, inhibited  NF-kappa   and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.", "triple_list": [["Salicylates", "DOWNREGULATOR", "NF-kappa"]]}, {"text": "In addition, activation of protein kinase C and increases in intracellular  cAMP  also enhance cholinergic activity in T cells, and  lymphocyte function associated antigen-1  (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation", "triple_list": [["cAMP", "ACTIVATOR", "lymphocyte function associated antigen-1"]]}, {"text": "In addition, activation of protein kinase C and increases in intracellular  cAMP  also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 ( LFA-1   CD11a/CD18) is an important mediator of leukocyte migration and T cell activation", "triple_list": [["cAMP", "ACTIVATOR", "LFA-1"]]}, {"text": "In addition, activation of protein kinase C and increases in intracellular  cAMP  also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1;  CD11a  CD18) is an important mediator of leukocyte migration and T cell activation", "triple_list": [["cAMP", "ACTIVATOR", "CD11a"]]}, {"text": "In addition, activation of protein kinase C and increases in intracellular  cAMP  also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/ CD18   is an important mediator of leukocyte migration and T cell activation", "triple_list": [["cAMP", "ACTIVATOR", "CD18"]]}, {"text": "We found that  simvastatin  abolishes anti- CD11a  mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity", "triple_list": [["simvastatin", "DOWNREGULATOR", "CD11a"]]}, {"text": "Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( ACh  ;  choline acetyltransferase  (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic  ACh  receptors (m ACh Rs and n ACh Rs, respectively)", "triple_list": [["ACh", "PRODUCT-OF", "choline acetyltransferase"]]}, {"text": "Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( ACh  ; choline acetyltransferase ( ChAT  , its synthesizing enzyme; and both muscarinic and nicotinic  ACh  receptors (m ACh Rs and n ACh Rs, respectively)", "triple_list": [["ACh", "PRODUCT-OF", "ChAT"]]}, {"text": "Lymphocytes possess the essential components of a cholinergic system, including  acetylcholine  (ACh);  choline acetyltransferase  (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)", "triple_list": [["acetylcholine", "PRODUCT-OF", "choline acetyltransferase"]]}, {"text": "Lymphocytes possess the essential components of a cholinergic system, including  acetylcholine  (ACh); choline acetyltransferase ( ChAT  , its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)", "triple_list": [["acetylcholine", "PRODUCT-OF", "ChAT"]]}, {"text": " PR isoform B  levels were low in virgin control mice and increased after  progestin  treatment in both strains", "triple_list": [["progestin", "ACTIVATOR", "PR isoform B"]]}, {"text": "INTRODUCTION: Medroxyprogesterone acetate ( MPA   induces estrogen receptor (ER)-positive and progesterone receptor ( PR  -positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["MPA", "ACTIVATOR", "PR"]]}, {"text": "INTRODUCTION: Medroxyprogesterone acetate ( MPA   induces  estrogen receptor  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["MPA", "ACTIVATOR", "estrogen receptor"]]}, {"text": "INTRODUCTION: Medroxyprogesterone acetate ( MPA   induces estrogen receptor ( ER  -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["MPA", "ACTIVATOR", "ER"]]}, {"text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces estrogen receptor (ER)-positive and progesterone receptor ( PR  -positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["Medroxyprogesterone acetate", "ACTIVATOR", "PR"]]}, {"text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces  estrogen receptor  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["Medroxyprogesterone acetate", "ACTIVATOR", "estrogen receptor"]]}, {"text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces estrogen receptor ( ER  -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["Medroxyprogesterone acetate", "ACTIVATOR", "ER"]]}, {"text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces estrogen receptor (ER)-positive and  progesterone receptor  (PR)-positive ductal invasive mammary carcinomas in BALB/c mice", "triple_list": [["Medroxyprogesterone acetate", "ACTIVATOR", "progesterone receptor"]]}, {"text": "The expression of  ER-alpha  and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in  progestin  treated BALB/c mice (P < 0.05)", "triple_list": [["progestin", "DOWNREGULATOR", "ER-alpha"]]}, {"text": "The expression of ER-alpha and  PR isoform A  in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in  progestin  treated BALB/c mice (P < 0.05)", "triple_list": [["progestin", "DOWNREGULATOR", "PR isoform A"]]}, {"text": "Various genes controlled by  estrogen   including  X-inactive-specific transcript   anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed", "triple_list": [["estrogen", "ACTIVATOR", "X-inactive-specific transcript"]]}, {"text": "Various genes controlled by  estrogen   including X-inactive-specific transcript,  anterior gradient-2   trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed", "triple_list": [["estrogen", "ACTIVATOR", "anterior gradient-2"]]}, {"text": "Various genes controlled by  estrogen   including X-inactive-specific transcript, anterior gradient-2,  trefoil factor-1   CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed", "triple_list": [["estrogen", "ACTIVATOR", "trefoil factor-1"]]}, {"text": "Various genes controlled by  estrogen   including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1,  CRP-ductin   ghrelin, and small proline-rich protein-2A, were dramatically over-expressed", "triple_list": [["estrogen", "ACTIVATOR", "CRP-ductin"]]}, {"text": "Various genes controlled by  estrogen   including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin,  ghrelin   and small proline-rich protein-2A, were dramatically over-expressed", "triple_list": [["estrogen", "ACTIVATOR", "ghrelin"]]}, {"text": "Various genes controlled by  estrogen   including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and  small proline-rich protein-2A   were dramatically over-expressed", "triple_list": [["estrogen", "ACTIVATOR", "small proline-rich protein-2A"]]}, {"text": " Estrogen  regulated genes including cytokeratin 1-19 and  Cyp2a4  were over-expressed, although Cyp3a25 was suppressed", "triple_list": [["Estrogen", "ACTIVATOR", "Cyp2a4"]]}, {"text": " Estrogen  regulated genes including  cytokeratin 1-19  and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed", "triple_list": [["Estrogen", "ACTIVATOR", "cytokeratin 1-19"]]}, {"text": " Estrogen  regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although  Cyp3a25  was suppressed", "triple_list": [["Estrogen", "DOWNREGULATOR", "Cyp3a25"]]}, {"text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of  17beta-hydroxysteroid dehydrogenase-7  (HSD17beta7; involved in  estradiol  production) and decreased expression of HSD17beta5 (involved in testosterone production)", "triple_list": [["estradiol", "PRODUCT-OF", "17beta-hydroxysteroid dehydrogenase-7"]]}, {"text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 ( HSD17beta7   involved in  estradiol  production) and decreased expression of HSD17beta5 (involved in testosterone production)", "triple_list": [["estradiol", "PRODUCT-OF", "HSD17beta7"]]}, {"text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of  HSD17beta5  (involved in  testosterone  production)", "triple_list": [["testosterone", "PRODUCT-OF", "HSD17beta5"]]}, {"text": "The expression of key genes important in  methionine  metabolism, such as  methionine  adenosyltransferase-1a  betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed", "triple_list": [["methionine", "PRODUCT-OF", "methionine adenosyltransferase-1a"]]}, {"text": "The expression of key genes important in  methionine  metabolism, such as  methionine  adenosyltransferase-1a,  betaine-homocysteine methyltransferase  and thioether S-methyltransferase, were suppressed", "triple_list": [["methionine", "PRODUCT-OF", "betaine-homocysteine methyltransferase"]]}, {"text": "The expression of key genes important in  methionine  metabolism, such as  methionine  adenosyltransferase-1a, betaine-homocysteine methyltransferase and  thioether S-methyltransferase   were suppressed", "triple_list": [["methionine", "PRODUCT-OF", "thioether S-methyltransferase"]]}, {"text": " Monosodium urate  crystals stimulate monocytes and macrophages to release  IL-1beta  through the NALP3 component of the inflammasome", "triple_list": [["Monosodium urate", "ACTIVATOR", "IL-1beta"]]}, {"text": "We identified  suramin  as a compound that binds to human SIRT5 and showed that it inhibits  SIRT5 NAD(+)-dependent deacetylase  activity with an IC(50) value of 22 microM", "triple_list": [["suramin", "DOWNREGULATOR", "SIRT5 NAD(+)-dependent deacetylase"]]}, {"text": "Structural basis of inhibition of the  human NAD+-dependent deacetylase SIRT5  by  suramin   Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer", "triple_list": [["suramin", "DOWNREGULATOR", "human NAD+-dependent deacetylase SIRT5"]]}, {"text": "In humans,  methionine synthase  deficiency results in the accumulation of  methyltetrahydrofolate  at the expense of folate derivatives required for purine and thymidylate biosynthesis", "triple_list": [["methyltetrahydrofolate", "PRODUCT-OF", "methionine synthase"]]}, {"text": "In summary,  phenformin  and metformin increase  AMPK  activity and phosphorylation in the isolated heart", "triple_list": [["phenformin", "ACTIVATOR", "AMPK"]]}, {"text": "In summary, phenformin and  metformin  increase  AMPK  activity and phosphorylation in the isolated heart", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "Cytosolic [ AMP ] reported metabolically active  AMP   which triggered increased  AMP K activity, but measures of total  AMP  did not.", "triple_list": [["AMP", "ACTIVATOR", "AMPK"]]}, {"text": " Metformin  and phenformin, which are biguanides, have been reported to increase  AMPK  activity without increasing AMP/ATP", "triple_list": [["Metformin", "ACTIVATOR", "AMPK"]]}, {"text": "Metformin and  phenformin   which are biguanides, have been reported to increase  AMPK  activity without increasing AMP/ATP", "triple_list": [["phenformin", "ACTIVATOR", "AMPK"]]}, {"text": "Metformin and phenformin, which are  biguanides   have been reported to increase  AMPK  activity without increasing AMP/ATP", "triple_list": [["biguanides", "ACTIVATOR", "AMPK"]]}, {"text": "In hearts treated with  phenformin  for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and  AMPK  activity was elevated at 36 min", "triple_list": [["phenformin", "ACTIVATOR", "AMPK"]]}, {"text": "In hearts treated with  metformin   [AMP] was increased at 50 min and  AMPK  activity, phosphorylated  AMPK , and phosphorylated acetyl-CoA carboxylase were elevated at 61 min", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "In hearts treated with  metformin   [AMP] was increased at 50 min and  AMPK  activity, phosphorylated  AMPK   and phosphorylated acetyl-CoA carboxylase were elevated at 61 min", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "In hearts treated with  metformin   [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and  phosphorylated acetyl-CoA carboxylase  were elevated at 61 min", "triple_list": [["metformin", "ACTIVATOR", "phosphorylated acetyl-CoA carboxylase"]]}, {"text": " Metformin  and phenformin activate  AMP-activated protein kinase  in the heart by increasing cytosolic AMP concentration", "triple_list": [["Metformin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "Metformin and  phenformin  activate  AMP-activated protein kinase  in the heart by increasing cytosolic AMP concentration", "triple_list": [["phenformin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "In the current project, we found that the selective  H(1)  antagonist pyrilamine also reversed the  dizocilpine  induced impairment in PPI of tactile startle with an auditory prepulse", "triple_list": [["dizocilpine", "ACTIVATOR", "H(1)"]]}, {"text": "In summary, the therapeutic effect of  clozapine  in reversing PPI impairment was mimicked by the  H(1)  antagonist pyrilamine, while pyrilamine had a mixed effect on cognition", "triple_list": [["clozapine", "DOWNREGULATOR", "H(1)"]]}, {"text": " Histamine H(1)  blockade is one of the more prominent actions of the multi-receptor acting antipsychotic  clozapine   It is currently not known how much this H(1) antagonism of  clozapine  contributes to the therapeutic or adverse side effects of  clozapine ", "triple_list": [["clozapine", "DOWNREGULATOR", "Histamine H(1)"]]}, {"text": "Thus,  H(1)  antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as  clozapine  ", "triple_list": [["clozapine", "ANTAGONIST", "H(1)"]]}, {"text": "It is currently not known how much this  H(1)  antagonism of  clozapine  contributes to the therapeutic or adverse side effects of  clozapine ", "triple_list": [["clozapine", "ANTAGONIST", "H(1)"]]}, {"text": "In the current project, we found that the selective  H(1)  antagonist  pyrilamine  also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse", "triple_list": [["pyrilamine", "ANTAGONIST", "H(1)"]]}, {"text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the  H(1)  antagonist  pyrilamine   while  pyrilamine  had a mixed effect on cognition", "triple_list": [["pyrilamine", "ANTAGONIST", "H(1)"]]}, {"text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the  H(1)  antagonist  pyrilamine , while  pyrilamine  had a mixed effect on cognition", "triple_list": [["pyrilamine", "ANTAGONIST", "H(1)"]]}, {"text": "Furthermore, the enzymatic activity of  alanine aminotransferase  (ALT), which converts the critical gluconeogenic amino acid alanine into  pyruvate   is decreased (approximately 50%) in KLF15-/- hepatocytes", "triple_list": [["pyruvate", "PRODUCT-OF", "alanine aminotransferase"]]}, {"text": "Furthermore, the enzymatic activity of alanine aminotransferase ( ALT  , which converts the critical gluconeogenic amino acid alanine into  pyruvate   is decreased (approximately 50%) in KLF15-/- hepatocytes", "triple_list": [["pyruvate", "PRODUCT-OF", "ALT"]]}, {"text": "Furthermore, the enzymatic activity of  alanine aminotransferase  (ALT), which converts the critical gluconeogenic  amino acid  alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes", "triple_list": [["amino acid", "PRODUCT-OF", "alanine aminotransferase"]]}, {"text": "Furthermore, the enzymatic activity of alanine aminotransferase ( ALT  , which converts the critical gluconeogenic  amino acid  alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes", "triple_list": [["amino acid", "PRODUCT-OF", "ALT"]]}, {"text": "Furthermore, the enzymatic activity of  alanine  aminotransferase (ALT), which converts the critical gluconeogenic amino acid  alanine  into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes", "triple_list": [["alanine", "PRODUCT-OF", "alanine aminotransferase"]]}, {"text": "Furthermore, the enzymatic activity of  alanine  aminotransferase ( ALT  , which converts the critical gluconeogenic amino acid  alanine  into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes", "triple_list": [["alanine", "PRODUCT-OF", "ALT"]]}, {"text": "TGF-beta1 and high  D-glucose  increased p42/44(mapk) and  Smad2  phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)", "triple_list": [["D-glucose", "ACTIVATOR", "Smad2"]]}, {"text": " D-glucose  stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and  Smad2  requiring functional type II TGF-beta receptors in human umbilical vein endothelium", "triple_list": [["D-glucose", "ACTIVATOR", "Smad2"]]}, {"text": "High  D-glucose  increases L-arginine transport and eNOS expression following  TbetaRII  activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC", "triple_list": [["D-glucose", "ACTIVATOR", "TbetaRII"]]}, {"text": "High  D-glucose  increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and  Smad2  in HUVEC", "triple_list": [["D-glucose", "ACTIVATOR", "Smad2"]]}, {"text": " TGF-beta1  release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal)  D-glucose    TGF-beta1  increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal  D-glucose , but did not alter high  D-glucose -increased L-arginine transport", "triple_list": [["D-glucose", "ACTIVATOR", "TGF-beta1"]]}, {"text": "TGF-beta1 and high  D-glucose  increased  hCAT-1  mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation", "triple_list": [["D-glucose", "ACTIVATOR", "hCAT-1"]]}, {"text": "High  D-glucose  increases L-arginine transport and  eNOS  expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC", "triple_list": [["D-glucose", "ACTIVATOR", "eNOS"]]}, {"text": "Elevated extracellular  D-glucose  increases  transforming growth factor beta1  (TGF-beta1) release from human umbilical vein endothelium (HUVEC)", "triple_list": [["D-glucose", "ACTIVATOR", "transforming growth factor beta1"]]}, {"text": "Elevated extracellular  D-glucose  increases transforming growth factor beta1 ( TGF-beta1   release from human umbilical vein endothelium (HUVEC)", "triple_list": [["D-glucose", "ACTIVATOR", "TGF-beta1"]]}, {"text": "TGF-beta1 and high D-glucose increased p42/44(mapk) and  Smad2  phosphorylation, an effect blocked by  PD-98059  (MEK1/2 inhibitor)", "triple_list": [["PD-98059", "DOWNREGULATOR", "Smad2"]]}, {"text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  NO  synthesis) and endothelial  NO  synthase (e NO S) protein abundance, but did not alter e NO S phosphorylation", "triple_list": [["NO", "PRODUCT-OF", "endothelial NO synthase"]]}, {"text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  NO  synthesis) and endothelial  NO  synthase (e NO S  protein abundance, but did not alter e NO S phosphorylation", "triple_list": [["NO", "PRODUCT-OF", "eNOS"]]}, {"text": "Moreover stimulation of  COX-2 promoter  activity was increased by those  PUFAs  or rosiglitazone", "triple_list": [["PUFAs", "ACTIVATOR", "COX-2 promoter"]]}, {"text": "Moreover stimulation of  COX-2 promoter  activity was increased by those PUFAs or  rosiglitazone   The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of  COX-2 promoter  activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction", "triple_list": [["rosiglitazone", "ACTIVATOR", "COX-2 promoter"]]}, {"text": " n-3 and n-6 polyunsaturated fatty acids  induce the expression of COX-2 via  PPARgamma  activation in human keratinocyte HaCaT cells", "triple_list": [["n-3 and n-6 polyunsaturated fatty acids", "ACTIVATOR", "PPARgamma"]]}, {"text": "Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of  AA  metabolites in  PPAR  activation", "triple_list": [["AA", "ACTIVATOR", "PPAR"]]}, {"text": "These findings demonstrate that  n-3 and n-6 PUFA  increased  PPARgamma  activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells", "triple_list": [["n-3 and n-6 PUFA", "ACTIVATOR", "PPARgamma"]]}, {"text": "These findings demonstrate that  n-3 and n-6 PUFA  increased PPARgamma activity is necessary for the  COX-2  induction in HaCaT human keratinocyte cells", "triple_list": [["n-3 and n-6 PUFA", "ACTIVATOR", "COX-2"]]}, {"text": "Given the anti-inflammatory properties of EPA, we suggest that induction of  COX-2  in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of  PUFAs n-3  or n-6.", "triple_list": [["PUFAs n-3", "ACTIVATOR", "COX-2"]]}, {"text": "We demonstrate that only treatment of HaCaT with  GLA  and EPA or a PPARgamma ligand (roziglitazone), induced  COX-2  expression (protein and mRNA)", "triple_list": [["GLA", "ACTIVATOR", "COX-2"]]}, {"text": "We demonstrate that only treatment of HaCaT with GLA and  EPA  or a PPARgamma ligand (roziglitazone), induced  COX-2  expression (protein and mRNA)", "triple_list": [["EPA", "ACTIVATOR", "COX-2"]]}, {"text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand ( roziglitazone  , induced  COX-2  expression (protein and mRNA)", "triple_list": [["roziglitazone", "ACTIVATOR", "COX-2"]]}, {"text": " n-3 and n-6 polyunsaturated fatty acids  induce the expression of  COX-2  via PPARgamma activation in human keratinocyte HaCaT cells", "triple_list": [["n-3 and n-6 polyunsaturated fatty acids", "ACTIVATOR", "COX-2"]]}, {"text": "Finally,  PLA2  inhibitor methyl  arachidonyl fluorophosphonate  blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation", "triple_list": [["arachidonyl fluorophosphonate", "DOWNREGULATOR", "PLA2"]]}, {"text": "Finally, PLA2 inhibitor methyl  arachidonyl fluorophosphonate  blocked the PUFA effects on  COX-2  induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation", "triple_list": [["arachidonyl fluorophosphonate", "DOWNREGULATOR", "COX-2"]]}, {"text": "The inhibitory effects of  GW9662  and T0070907 ( PPARgamma  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that  PPARgamma  is implicated in COX-2 induction", "triple_list": [["GW9662", "ANTAGONIST", "PPARgamma"]]}, {"text": "The inhibitory effects of GW9662 and  T0070907  ( PPARgamma  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that  PPARgamma  is implicated in COX-2 induction", "triple_list": [["T0070907", "ANTAGONIST", "PPARgamma"]]}, {"text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting  beta(2)-adrenergic  agonist that is the  [R,R] isomer of formoterol   and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)", "triple_list": [["[R,R] isomer of formoterol", "AGONIST", "beta(2)-adrenergic"]]}, {"text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized  arformoterol tartrate  (a selective, long-acting  beta(2)-adrenergic  agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)", "triple_list": [["arformoterol tartrate", "AGONIST", "beta(2)-adrenergic"]]}, {"text": "The cytosolic  ACC1  is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in  fatty acid  biosynthesis", "triple_list": [["fatty acid", "PRODUCT-OF", "ACC1"]]}, {"text": "The mitochondrial  ACC2  is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of  fatty acid  oxidation", "triple_list": [["fatty acid", "PRODUCT-OF", "ACC2"]]}, {"text": " Acetyl-coenzyme A carboxylase  (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in  fatty acid  biosynthesis and oxidation", "triple_list": [["fatty acid", "PRODUCT-OF", "Acetyl-coenzyme A carboxylase"]]}, {"text": "Acetyl-coenzyme A carboxylase ( ACC   enzymes exist as two isoforms,  ACC 1 and  ACC 2, which play critical roles in  fatty acid  biosynthesis and oxidation", "triple_list": [["fatty acid", "PRODUCT-OF", "ACC"]]}, {"text": "Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms,  ACC1  and ACC2, which play critical roles in  fatty acid  biosynthesis and oxidation", "triple_list": [["fatty acid", "PRODUCT-OF", "ACC1"]]}, {"text": "Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and  ACC2   which play critical roles in  fatty acid  biosynthesis and oxidation", "triple_list": [["fatty acid", "PRODUCT-OF", "ACC2"]]}, {"text": "In contrast, the  RA  catabolising enzymes  Cyp26A1  and Cyp26B1 which are known to be  RA -responsive were not expressed at all in the developing eye", "triple_list": [["RA", "PRODUCT-OF", "Cyp26A1"]]}, {"text": "In contrast, the  RA  catabolising enzymes Cyp26A1 and  Cyp26B1  which are known to be  RA -responsive were not expressed at all in the developing eye", "triple_list": [["RA", "PRODUCT-OF", "Cyp26B1"]]}, {"text": "Incretin-receptor activation leads to  glucose  dependent  insulin  secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "This report reviews published and unpublished data that suggest that  aripiprazole  acts as a selective partial agonist at the  dopamine D(2) receptor  and does not affect 5-HT receptors at therapeutic doses.", "triple_list": [["aripiprazole", "AGONIST", "dopamine D(2) receptor"]]}, {"text": " Mifepriston'e  blocks  glucocorticoid receptor  activation without modifying cortisol synthesis", "triple_list": [["Mifepriston'e", "DOWNREGULATOR", "glucocorticoid receptor"]]}, {"text": "The present findings confirm that PVN  CB1 receptors , localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of  CB1 receptors  by  SR 141716A  increases the density of these receptors in the PVN", "triple_list": [["SR 141716A", "DOWNREGULATOR", "CB1 receptors"]]}, {"text": "[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ( SR 141716A  , a selective  cannabinoid CB1 receptor  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection", "triple_list": [["SR 141716A", "ANTAGONIST", "cannabinoid CB1 receptor"]]}, {"text": "[ N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide   (SR 141716A), a selective  cannabinoid CB1 receptor  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection", "triple_list": [["N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide", "ANTAGONIST", "cannabinoid CB1 receptor"]]}, {"text": "Modulation of the function of CD36 (CD36-/- mice),  p38  MAPK) ( SB203580  , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition", "triple_list": [["SB203580", "DOWNREGULATOR", "p38"]]}, {"text": "Modulation of the function of CD36 (CD36-/- mice), p38( MAPK   ( SB203580  , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition", "triple_list": [["SB203580", "DOWNREGULATOR", "MAPK"]]}, {"text": "Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580),  COX-1  ( indomethacin  , and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition", "triple_list": [["indomethacin", "DOWNREGULATOR", "COX-1"]]}, {"text": "We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that  human type 12 RDH  reduces dihydrotestosterone to  androstanediol   and is thus also involved in steroid metabolism", "triple_list": [["androstanediol", "PRODUCT-OF", "human type 12 RDH"]]}, {"text": "The  sibutramine  group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial  peptide YY  compared with the placebo group", "triple_list": [["sibutramine", "ACTIVATOR", "peptide YY"]]}, {"text": "CONCLUSIONS: Weight reduction with  sibutramine  is associated with altered gastric functions and increased  peptide YY  and is significantly associated with SLC6A4 genotype", "triple_list": [["sibutramine", "ACTIVATOR", "peptide YY"]]}, {"text": "An investigation of the absolute configuration of the potent  histamine H3 receptor  antagonist  GT-2331  using vibrational circular dichroism", "triple_list": [["GT-2331", "ANTAGONIST", "histamine H3 receptor"]]}, {"text": "In this study the neuromuscular blocking drug  vecuronium  and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  human muscarinic M2 receptors  K(off) values min(-1);  vecuronium  (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)", "triple_list": [["vecuronium", "DOWNREGULATOR", "human muscarinic M2 receptors"]]}, {"text": "In this study the neuromuscular blocking drug vecuronium and the controls  gallamine  and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  human muscarinic M2 receptors  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02;  gallamine  (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)", "triple_list": [["gallamine", "DOWNREGULATOR", "human muscarinic M2 receptors"]]}, {"text": "In this study the neuromuscular blocking drug vecuronium and the controls gallamine and  pancuronium  slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  human muscarinic M2 receptors  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04;  pancuronium (21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)", "triple_list": [["pancuronium", "DOWNREGULATOR", "human muscarinic M2 receptors"]]}, {"text": "Patients with acute vitiligo have low epidermal  catalase  expression/activities and accumulate 10(-3) M  H(2)O(2)   One consequence of this severe oxidative stress is an altered calcium homeostasis in epidermal keratinocytes and melanocytes", "triple_list": [["H(2)O(2)", "PRODUCT-OF", "catalase"]]}, {"text": "However, upon addition of NO to  CDO  in the presence of substrate  l-cysteine   a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops", "triple_list": [["l-cysteine", "PRODUCT-OF", "CDO"]]}, {"text": "Mammalian  cysteine  dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative  cysteine  catabolism", "triple_list": [["cysteine", "PRODUCT-OF", "Mammalian cysteine dioxygenase"]]}, {"text": "Mammalian  cysteine  dioxygenase ( CDO   is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative  cysteine  catabolism", "triple_list": [["cysteine", "PRODUCT-OF", "CDO"]]}, {"text": "The transcriptional activity of torafugu  PPARalpha1  was enhanced 4.5- and 11.5-fold by  Wy-14643  and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively", "triple_list": [["Wy-14643", "ACTIVATOR", "PPARalpha1"]]}, {"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by  Wy-14643  and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of  PPARalpha2   4.5- and 7.3-fold at the same concentration of the respective ligands, respectively", "triple_list": [["Wy-14643", "ACTIVATOR", "PPARalpha2"]]}, {"text": "The transcriptional activity of torafugu  PPARalpha1  was enhanced 4.5- and 11.5-fold by Wy-14643 and  5,8,11,14-eicosatetraynoic acid  (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively", "triple_list": [["5,8,11,14-eicosatetraynoic acid", "ACTIVATOR", "PPARalpha1"]]}, {"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and  5,8,11,14-eicosatetraynoic acid  (ETYA) each at 10 microM, respectively, whereas that of  PPARalpha2   4.5- and 7.3-fold at the same concentration of the respective ligands, respectively", "triple_list": [["5,8,11,14-eicosatetraynoic acid", "ACTIVATOR", "PPARalpha2"]]}, {"text": "The transcriptional activity of torafugu  PPARalpha1  was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ( ETYA   each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively", "triple_list": [["ETYA", "ACTIVATOR", "PPARalpha1"]]}, {"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ( ETYA   each at 10 microM, respectively, whereas that of  PPARalpha2   4.5- and 7.3-fold at the same concentration of the respective ligands, respectively", "triple_list": [["ETYA", "ACTIVATOR", "PPARalpha2"]]}, {"text": "Furthermore, the activities of the two  torafugu PPARalphas  were enhanced 4.3- and 7.6-fold by  arachidonic acid   4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively", "triple_list": [["arachidonic acid", "ACTIVATOR", "torafugu PPARalphas"]]}, {"text": "Furthermore, the activities of the two  torafugu PPARalphas  were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by  docosahexaenoic acid   and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively", "triple_list": [["docosahexaenoic acid", "ACTIVATOR", "torafugu PPARalphas"]]}, {"text": "Furthermore, the activities of the two  torafugu PPARalphas  were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by  eicosapentaenoic acid  each at 50 microM, respectively", "triple_list": [["eicosapentaenoic acid", "ACTIVATOR", "torafugu PPARalphas"]]}, {"text": "Combination chemotherapy with a  substance P receptor  antagonist ( aprepitant   and melarsoprol in a mouse model of human African trypanosomiasis", "triple_list": [["aprepitant", "ANTAGONIST", "substance P receptor"]]}, {"text": "Combination chemotherapy with a  substance P receptor  antagonist (aprepitant) and  melarsoprol  in a mouse model of human African trypanosomiasis", "triple_list": [["melarsoprol", "ANTAGONIST", "substance P receptor"]]}, {"text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a  humanised SP receptor  antagonist  aprepitant  (EMEND) in this mouse model", "triple_list": [["aprepitant", "ANTAGONIST", "humanised SP receptor"]]}, {"text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a  humanised SP receptor  antagonist aprepitant ( EMEND   in this mouse model", "triple_list": [["EMEND", "ANTAGONIST", "humanised SP receptor"]]}, {"text": "It is thought to play a critical role in the visual cycle by functioning as an acceptor of  11-cis-retinol  from the  isomerohydrolase  reaction", "triple_list": [["11-cis-retinol", "PRODUCT-OF", "isomerohydrolase"]]}, {"text": "Using this assay, we found that both  superoxide  and nitric oxide inhibit renal cortical  DDAH  activity in vitro.", "triple_list": [["superoxide", "DOWNREGULATOR", "DDAH"]]}, {"text": "Using this assay, we found that both superoxide and  nitric oxide  inhibit renal cortical  DDAH  activity in vitro.", "triple_list": [["nitric oxide", "DOWNREGULATOR", "DDAH"]]}, {"text": "Our optimized  L-citrulline  production assay to measure  DDAH  activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption", "triple_list": [["L-citrulline", "PRODUCT-OF", "DDAH"]]}, {"text": " Dimethylarginine dimethylaminohydrolase  (DDAH) metabolizes asymmetric dimethylarginine to generate  L-citrulline  and is present in large quantities in the kidney", "triple_list": [["L-citrulline", "PRODUCT-OF", "Dimethylarginine dimethylaminohydrolase"]]}, {"text": "Dimethylarginine dimethylaminohydrolase ( DDAH   metabolizes asymmetric dimethylarginine to generate  L-citrulline  and is present in large quantities in the kidney", "triple_list": [["L-citrulline", "PRODUCT-OF", "DDAH"]]}, {"text": "We present a new study that optimizes the Prescott-Jones colorimetric assay to measure  DDAH  dependent  L-citrulline  generation in kidney homogenates", "triple_list": [["L-citrulline", "PRODUCT-OF", "DDAH"]]}, {"text": "Our optimized L-citrulline production assay to measure  DDAH  activity correlated closely with the direct measure of the rate of asymmetric  dimethylarginine  consumption", "triple_list": [["dimethylarginine", "PRODUCT-OF", "DDAH"]]}, {"text": "We found that the removal of  urea  with  urea se is necessary since  urea  also produces a positive reaction", "triple_list": [["urea", "PRODUCT-OF", "urease"]]}, {"text": " Dimethylarginine dimethylaminohydrolase  (DDAH) metabolizes asymmetric  dimethylarginine  to generate L-citrulline and is present in large quantities in the kidney", "triple_list": [["dimethylarginine", "PRODUCT-OF", "Dimethylarginine dimethylaminohydrolase"]]}, {"text": "Dimethylarginine dimethylaminohydrolase ( DDAH   metabolizes asymmetric  dimethylarginine  to generate L-citrulline and is present in large quantities in the kidney", "triple_list": [["dimethylarginine", "PRODUCT-OF", "DDAH"]]}, {"text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting  HER2  neu as well as the epidermal growth factor receptor (EGFR),  lapatinib   Other trials are investigating differences in duration", "triple_list": [["lapatinib", "DOWNREGULATOR", "HER2"]]}, {"text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/ neu  as well as the epidermal growth factor receptor (EGFR),  lapatinib   Other trials are investigating differences in duration", "triple_list": [["lapatinib", "DOWNREGULATOR", "neu"]]}, {"text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the  epidermal growth factor receptor  (EGFR),  lapatinib   Other trials are investigating differences in duration", "triple_list": [["lapatinib", "DOWNREGULATOR", "epidermal growth factor receptor"]]}, {"text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor ( EGFR  ,  lapatinib   Other trials are investigating differences in duration", "triple_list": [["lapatinib", "DOWNREGULATOR", "EGFR"]]}, {"text": "Exposure of Jurkat cells to either  (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine  [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin", "triple_list": [["(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine", "ANTAGONIST", "NMDA receptor"]]}, {"text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [ (+)-MK 801   or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin", "triple_list": [["(+)-MK 801", "ANTAGONIST", "NMDA receptor"]]}, {"text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or  D-(-)-2-amino-5-phosphonopentanoic acid  (D-AP5), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin", "triple_list": [["D-(-)-2-amino-5-phosphonopentanoic acid", "ANTAGONIST", "NMDA receptor"]]}, {"text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid ( D-AP5  , two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin", "triple_list": [["D-AP5", "ANTAGONIST", "NMDA receptor"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for  DVS  at sites labeled by [(3)H]NIS was found to distinguish  DVS , the  DVS  analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["DVS", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog  rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol  (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol ( WY-46824  , methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["WY-46824", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824),  methylphenidate   and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["methylphenidate", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the  cocaine  analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and  cocaine ", "triple_list": [["cocaine", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog  3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester  (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ( RTI-55   from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["RTI-55", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H] NIS  was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as  NIS   mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["NIS", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS,  mazindol   tricyclic antidepressants, and cocaine", "triple_list": [["mazindol", "ANTAGONIST", "hNET"]]}, {"text": " Desvenlafaxine succinate  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ( hNET  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause", "triple_list": [["Desvenlafaxine succinate", "ANTAGONIST", "hNET"]]}, {"text": " Desvenlafaxine succinate  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and  hSERT   respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause", "triple_list": [["Desvenlafaxine succinate", "ANTAGONIST", "hSERT"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol,  tricyclic  antidepressants, and cocaine", "triple_list": [["tricyclic", "ANTAGONIST", "hNET"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the  cocaine  analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and  cocaine   These differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct  hNET  binding sites", "triple_list": [["cocaine", "ANTAGONIST", "hNET"]]}, {"text": " Desvenlafaxine succinate  identifies novel antagonist binding determinants in the  human norepinephrine transporter    Desvenlafaxine succinate  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause", "triple_list": [["Desvenlafaxine succinate", "ANTAGONIST", "human norepinephrine transporter"]]}, {"text": "Desvenlafaxine succinate ( DVS   is a recently introduced antagonist of the human norepinephrine and serotonin transporters ( hNET  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause", "triple_list": [["DVS", "ANTAGONIST", "hNET"]]}, {"text": "Desvenlafaxine succinate ( DVS   is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and  hSERT   respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause", "triple_list": [["DVS", "ANTAGONIST", "hSERT"]]}, {"text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for  DVS  at sites labeled by [(3)H]NIS was found to distinguish  DVS   the  DVS  analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine", "triple_list": [["DVS", "ANTAGONIST", "hNET"]]}, {"text": " Sorafenib  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ( VEGFR-2   VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor", "triple_list": [["Sorafenib", "DOWNREGULATOR", "VEGFR-2"]]}, {"text": " Sorafenib  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2,  VEGFR-3   and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor", "triple_list": [["Sorafenib", "DOWNREGULATOR", "VEGFR-3"]]}, {"text": " Sorafenib  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and  platelet-derived growth factor receptor beta  (PDGFR-beta), while temsirolimus is an mTOR inhibitor", "triple_list": [["Sorafenib", "DOWNREGULATOR", "platelet-derived growth factor receptor beta"]]}, {"text": " Sorafenib  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ( PDGFR-beta  , while temsirolimus is an mTOR inhibitor", "triple_list": [["Sorafenib", "DOWNREGULATOR", "PDGFR-beta"]]}, {"text": "Sorafenib and  sunitinib  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ( VEGFR-2   VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor", "triple_list": [["sunitinib", "DOWNREGULATOR", "VEGFR-2"]]}, {"text": "Sorafenib and  sunitinib  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2,  VEGFR-3   and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor", "triple_list": [["sunitinib", "DOWNREGULATOR", "VEGFR-3"]]}, {"text": "Sorafenib and  sunitinib  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and  platelet-derived growth factor receptor beta  (PDGFR-beta), while temsirolimus is an mTOR inhibitor", "triple_list": [["sunitinib", "DOWNREGULATOR", "platelet-derived growth factor receptor beta"]]}, {"text": "Sorafenib and  sunitinib  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ( PDGFR-beta  , while temsirolimus is an mTOR inhibitor", "triple_list": [["sunitinib", "DOWNREGULATOR", "PDGFR-beta"]]}, {"text": "Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  temsirolimus  is an  mTOR  inhibitor", "triple_list": [["temsirolimus", "DOWNREGULATOR", "mTOR"]]}, {"text": "One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes,  RAR-alpha , -beta and -gamma, without measurable receptor binding, whereas  tazarotene  preferentially binds to and activates RAR-beta and -gamma in preference to  RAR-alpha   The other is that there is already increased formation of retinoic acid in the psoriatic lesion", "triple_list": [["tazarotene", "ACTIVATOR", "RAR-alpha"]]}, {"text": "Rasagiline [ N-propargyl-l(R)-aminoindan   is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain  MAO-B  and is specifically designed for the treatment of Parkinson's disease (PD)", "triple_list": [["N-propargyl-l(R)-aminoindan", "DOWNREGULATOR", "MAO-B"]]}, {"text": "Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation  propargylamine  pharmacophore that selectively and irreversibly inhibits brain  MAO-B  and is specifically designed for the treatment of Parkinson's disease (PD)", "triple_list": [["propargylamine", "DOWNREGULATOR", "MAO-B"]]}, {"text": "Comprehensive review of  rasagiline   a second-generation  monoamine oxidase  inhibitor, for the treatment of Parkinson's disease", "triple_list": [["rasagiline", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Based on the results from those studies, we concluded that  rasagiline  PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited  MAO-B   Pharmacologically,  rasagiline  was found to be < or =10-fold more potent than selegiline and was not metabolized to amphetamine derivatives", "triple_list": [["rasagiline", "DOWNREGULATOR", "MAO-B"]]}, {"text": " Rasagiline  [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain  MAO-B  and is specifically designed for the treatment of Parkinson's disease (PD)", "triple_list": [["Rasagiline", "DOWNREGULATOR", "MAO-B"]]}, {"text": "This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to  factor Xa  ( rivaroxaban  and apixaban) and IIa (dabigatran)", "triple_list": [["rivaroxaban", "DOWNREGULATOR", "factor Xa"]]}, {"text": "This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to  factor Xa  (rivaroxaban and  apixaban   and IIa (dabigatran)", "triple_list": [["apixaban", "DOWNREGULATOR", "factor Xa"]]}, {"text": "INTERVENTIONS: In the 8-week run-in period, all participants received the  ACE  inhibitor  cilazapril  (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg", "triple_list": [["cilazapril", "DOWNREGULATOR", "ACE"]]}, {"text": "Two  imidazoquinoline  molecules, imiquimod and gardiquimod, markedly activated both  porcine TLR7  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands", "triple_list": [["imidazoquinoline", "ACTIVATOR", "porcine TLR7"]]}, {"text": "Two  imidazoquinoline  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and  TLR8  whereas only human TLR7, but not  TLR8 , was activated by the ligands", "triple_list": [["imidazoquinoline", "ACTIVATOR", "TLR8"]]}, {"text": "Two  imidazoquinoline  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only  human TLR7   but not TLR8, was activated by the ligands", "triple_list": [["imidazoquinoline", "ACTIVATOR", "human TLR7"]]}, {"text": "Two imidazoquinoline molecules,  imiquimod  and gardiquimod, markedly activated both  porcine TLR7  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands", "triple_list": [["imiquimod", "ACTIVATOR", "porcine TLR7"]]}, {"text": "Two imidazoquinoline molecules,  imiquimod  and gardiquimod, markedly activated both porcine TLR7 and  TLR8  whereas only human TLR7, but not  TLR8 , was activated by the ligands", "triple_list": [["imiquimod", "ACTIVATOR", "TLR8"]]}, {"text": "Two imidazoquinoline molecules,  imiquimod  and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only  human TLR7   but not TLR8, was activated by the ligands", "triple_list": [["imiquimod", "ACTIVATOR", "human TLR7"]]}, {"text": "Two imidazoquinoline molecules, imiquimod and  gardiquimod   markedly activated both  porcine TLR7  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands", "triple_list": [["gardiquimod", "ACTIVATOR", "porcine TLR7"]]}, {"text": "Two imidazoquinoline molecules, imiquimod and  gardiquimod   markedly activated both porcine TLR7 and  TLR8  whereas only human TLR7, but not  TLR8 , was activated by the ligands", "triple_list": [["gardiquimod", "ACTIVATOR", "TLR8"]]}, {"text": "Two imidazoquinoline molecules, imiquimod and  gardiquimod   markedly activated both porcine TLR7 and TLR8 whereas only  human TLR7   but not TLR8, was activated by the ligands", "triple_list": [["gardiquimod", "ACTIVATOR", "human TLR7"]]}, {"text": "Porcine TLR8 and  TLR7  are both activated by a selective  TLR7  ligand,  imiquimod   Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)", "triple_list": [["imiquimod", "ACTIVATOR", "TLR7"]]}, {"text": "Porcine  TLR8  and TLR7 are both activated by a selective TLR7 ligand,  imiquimod   Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)", "triple_list": [["imiquimod", "ACTIVATOR", "TLR8"]]}, {"text": "Moreover, activation of transfected cells and porcine PBMC by  TLR7  ligands was inhibited by  bafilomycin A(1)  indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.", "triple_list": [["bafilomycin A(1)", "DOWNREGULATOR", "TLR7"]]}, {"text": "The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for  4-chloropropofol  in  Na(V)1.2   Membrane depolarization inducing inactivation strongly increased the blocking potency of all compounds", "triple_list": [["4-chloropropofol", "DOWNREGULATOR", "Na(V)1.2"]]}, {"text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for  4-iodopropofol   4-bromopropofol and 4-chloropropofol in  Na(V)1.4   and 450 nM for 4-chloropropofol in Na(V)1.2", "triple_list": [["4-iodopropofol", "DOWNREGULATOR", "Na(V)1.4"]]}, {"text": "High-affinity blockade of  voltage-operated skeletal muscle and neuronal sodium channels  by  halogenated propofol  analogues", "triple_list": [["halogenated propofol", "DOWNREGULATOR", "voltage-operated skeletal muscle and neuronal sodium channels"]]}, {"text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol,  4-bromopropofol  and 4-chloropropofol in  Na(V)1.4   and 450 nM for 4-chloropropofol in Na(V)1.2", "triple_list": [["4-bromopropofol", "DOWNREGULATOR", "Na(V)1.4"]]}, {"text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and  4-chloropropofol  in  Na(V)1.4   and 450 nM for  4-chloropropofol  in Na(V)1.2", "triple_list": [["4-chloropropofol", "DOWNREGULATOR", "Na(V)1.4"]]}, {"text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and  4-chloropropofol  in Na(V)1.4, and 450 nM for  4-chloropropofol  in  Na(V)1.2   Recovery from fast inactivation was prolonged in the presence of drug leading to an accumulation of block during repetitive stimulation at high frequencies (100 Hz)", "triple_list": [["4-chloropropofol", "DOWNREGULATOR", "Na(V)1.2"]]}, {"text": "CONCLUSIONS AND IMPLICATIONS:  Halogenated propofol  analogues constitute a novel class of  sodium channel  blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine", "triple_list": [["Halogenated propofol", "DOWNREGULATOR", "sodium channel"]]}, {"text": " Irbesartan  (Aprovel, Avapro, Irbetan, Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension", "triple_list": [["Irbesartan", "ANTAGONIST", "angiotensin II receptor type 1"]]}, {"text": "Irbesartan ( Aprovel   Avapro, Irbetan, Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension", "triple_list": [["Aprovel", "ANTAGONIST", "angiotensin II receptor type 1"]]}, {"text": "Irbesartan (Aprovel,  Avapro   Irbetan, Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension", "triple_list": [["Avapro", "ANTAGONIST", "angiotensin II receptor type 1"]]}, {"text": "Irbesartan (Aprovel, Avapro,  Irbetan   Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension", "triple_list": [["Irbetan", "ANTAGONIST", "angiotensin II receptor type 1"]]}, {"text": "Irbesartan (Aprovel, Avapro, Irbetan,  Karvea  , an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension", "triple_list": [["Karvea", "ANTAGONIST", "angiotensin II receptor type 1"]]}, {"text": " RTX  treatment also induced foci of  RAD51   gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied", "triple_list": [["RTX", "ACTIVATOR", "RAD51"]]}, {"text": " RTX  treatment also induced foci of RAD51,  gamma-H2AX   phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied", "triple_list": [["RTX", "ACTIVATOR", "gamma-H2AX"]]}, {"text": " RTX  treatment also induced foci of RAD51, gamma-H2AX,  phospho-Chk1   and phospho-NBS1, although the extent of co-localization with RPA2 foci varied", "triple_list": [["RTX", "ACTIVATOR", "phospho-Chk1"]]}, {"text": " RTX  treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and  phospho-NBS1   although the extent of co-localization with RPA2 foci varied", "triple_list": [["RTX", "ACTIVATOR", "phospho-NBS1"]]}, {"text": "When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ( RTX  , which specifically inhibits  TS   To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to thymidylate deprivation", "triple_list": [["RTX", "DOWNREGULATOR", "TS"]]}, {"text": "DNA damage is accepted as a consequence of  thymidylate  deprivation induced by chemotherapeutic inhibitors of  thymidylate  synthase (TS), but the types of damage and signaling responses remain incompletely understood", "triple_list": [["thymidylate", "PRODUCT-OF", "thymidylate synthase"]]}, {"text": "DNA damage is accepted as a consequence of  thymidylate  deprivation induced by chemotherapeutic inhibitors of  thymidylate  synthase ( TS  , but the types of damage and signaling responses remain incompletely understood", "triple_list": [["thymidylate", "PRODUCT-OF", "TS"]]}, {"text": " Nicotinic acid  (NA), a widely used drug to lower elevated plasma lipid levels, induced  NNMT  enzyme activity in white adipose tissue of mice", "triple_list": [["Nicotinic acid", "ACTIVATOR", "NNMT"]]}, {"text": "Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the  NNMT  inhibitor  1-methylnicotinamide   Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced  NNMT  enzyme activity in white adipose tissue of mice", "triple_list": [["1-methylnicotinamide", "DOWNREGULATOR", "NNMT"]]}, {"text": " Nicotinamide N-methyltransferase  (NNMT) catalyses the conversion of nicotinamide to  1-methylnicotinamide  and plays an important role in hepatic detoxification reactions", "triple_list": [["1-methylnicotinamide", "PRODUCT-OF", "Nicotinamide N-methyltransferase"]]}, {"text": "Nicotinamide N-methyltransferase ( NNMT   catalyses the conversion of nicotinamide to  1-methylnicotinamide  and plays an important role in hepatic detoxification reactions", "triple_list": [["1-methylnicotinamide", "PRODUCT-OF", "NNMT"]]}, {"text": "These data support the concept that adipose tissue  NNMT  contributes to the increased plasma  homocysteine  levels in patients treated with NA.", "triple_list": [["homocysteine", "PRODUCT-OF", "NNMT"]]}, {"text": " Homocysteine   the atherogenic product of the  NNMT  catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures", "triple_list": [["Homocysteine", "PRODUCT-OF", "NNMT"]]}, {"text": " Nicotinamide N-methyltransferase  (NNMT) catalyses the conversion of  nicotinamide  to 1-methyl nicotinamide  and plays an important role in hepatic detoxification reactions", "triple_list": [["nicotinamide", "PRODUCT-OF", "Nicotinamide N-methyltransferase"]]}, {"text": "Nicotinamide N-methyltransferase ( NNMT   catalyses the conversion of  nicotinamide  to 1-methyl nicotinamide  and plays an important role in hepatic detoxification reactions", "triple_list": [["nicotinamide", "PRODUCT-OF", "NNMT"]]}, {"text": "A comparison of bosutinib with  dasatinib  across the whole  kinase  panel revealed overlapping, but distinct, inhibition profiles", "triple_list": [["dasatinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Global target profile of the  kinase  inhibitor  bosutinib  in primary chronic myeloid leukemia cells", "triple_list": [["bosutinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Finally,  bosutinib  is the first  kinase  inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.", "triple_list": [["bosutinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Finally,  bosutinib  is the first kinase inhibitor shown to target  CAMK2G   recently implicated in myeloid leukemia cell proliferation.", "triple_list": [["bosutinib", "DOWNREGULATOR", "CAMK2G"]]}, {"text": "Here, we characterized the target profile of the dual  SRC  ABL inhibitor  bosutinib  employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel", "triple_list": [["bosutinib", "DOWNREGULATOR", "SRC"]]}, {"text": "Here, we characterized the target profile of the dual SRC/ ABL  inhibitor  bosutinib  employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel", "triple_list": [["bosutinib", "DOWNREGULATOR", "ABL"]]}, {"text": "A comparison of  bosutinib  with dasatinib across the whole  kinase  panel revealed overlapping, but distinct, inhibition profiles", "triple_list": [["bosutinib", "DOWNREGULATOR", "kinase"]]}, {"text": "The affinity labeling  nucleotide  analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the  dehydrogenase  and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)", "triple_list": [["nucleotide", "DOWNREGULATOR", "dehydrogenase"]]}, {"text": "The affinity labeling nucleotide analog,  5'-[p-(fluorosulfonyl)benzoyl]adenosine  (FSA), inactivates the  dehydrogenase  and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)", "triple_list": [["5'-[p-(fluorosulfonyl)benzoyl]adenosine", "DOWNREGULATOR", "dehydrogenase"]]}, {"text": "The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine ( FSA  , inactivates the  dehydrogenase  and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)", "triple_list": [["FSA", "DOWNREGULATOR", "dehydrogenase"]]}, {"text": "The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as  dehydrogenase  from inactivation by  FSA   These observations are evidence for a single cofactor binding region which services both enzyme activities.", "triple_list": [["FSA", "DOWNREGULATOR", "dehydrogenase"]]}, {"text": "Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the  dehydrogenase  and isomerase substrate  steroids  bind at different sites on the same protein", "triple_list": [["steroids", "PRODUCT-OF", "dehydrogenase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( SU 11248   Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["SU 11248", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( SU 11248   Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["SU 11248", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  Sutent   specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Sutent", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  Sutent   specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["Sutent", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase,  AMN107  (Nilotinib) and INNO-406 (NS-187) specific for  c-KIT  kinase", "triple_list": [["AMN107", "DOWNREGULATOR", "c-KIT"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ( Nilotinib   and INNO-406 (NS-187) specific for  c-KIT  kinase", "triple_list": [["Nilotinib", "DOWNREGULATOR", "c-KIT"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and  INNO-406  (NS-187) specific for  c-KIT  kinase", "triple_list": [["INNO-406", "DOWNREGULATOR", "c-KIT"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ( NS-187   specific for  c-KIT  kinase", "triple_list": [["NS-187", "DOWNREGULATOR", "c-KIT"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development:  Lapatinib  ( Lapatinib  ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Lapatinib", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib ( Lapatinib ditosylate   Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Lapatinib ditosylate", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate,  Tykerb   GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Tykerb", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb,  GW-572016  , Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["GW-572016", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016),  Canertinib  (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Canertinib", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib ( CI-1033  , Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["CI-1033", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033),  Zactima  (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Zactima", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima ( ZD6474  , Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["ZD6474", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474),  Vatalanib  (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Vatalanib", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib ( P TK 787  ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["PTK787", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ ZK 222584  , Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["ZK 222584", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584),  Sorafenib  (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Sorafenib", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib ( Bay 43-9006   Nexavar), and Leflunomide (SU101, Arava)", "triple_list": [["Bay 43-9006", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006,  Nexavar  , and Leflunomide (SU101, Arava)", "triple_list": [["Nexavar", "DOWNREGULATOR", "TK"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include  Dasatinib  (BMS-354825) specific for  ABL  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Dasatinib", "DOWNREGULATOR", "ABL"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include  Dasatinib  (BMS-354825) specific for ABL  non-receptor cytoplasmic kinase   Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Dasatinib", "DOWNREGULATOR", "non-receptor cytoplasmic kinase"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and  Leflunomide  (SU101, Arava)", "triple_list": [["Leflunomide", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide ( SU101   Arava)", "triple_list": [["SU101", "DOWNREGULATOR", "TK"]]}, {"text": "The following  TK  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (P TK 787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101,  Arava  ", "triple_list": [["Arava", "DOWNREGULATOR", "TK"]]}, {"text": "The most successful example of  kinase  blockers is  Imatinib  ( Imatinib  mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Imatinib", "DOWNREGULATOR", "kinase"]]}, {"text": "The most successful example of kinase blockers is  Imatinib  ( Imatinib  mesylate, Gleevec, STI571), the inhibitor of  Bcr  Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Imatinib", "DOWNREGULATOR", "Bcr"]]}, {"text": "The most successful example of kinase blockers is  Imatinib  ( Imatinib  mesylate, Gleevec, STI571), the inhibitor of Bcr/ Abl  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Imatinib", "DOWNREGULATOR", "Abl"]]}, {"text": "The most successful example of  kinase  blockers is Imatinib ( Imatinib mesylate   Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "kinase"]]}, {"text": "The most successful example of kinase blockers is Imatinib ( Imatinib mesylate   Gleevec, STI571), the inhibitor of  Bcr  Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "Bcr"]]}, {"text": "The most successful example of kinase blockers is Imatinib ( Imatinib mesylate   Gleevec, STI571), the inhibitor of Bcr/ Abl  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Imatinib mesylate", "DOWNREGULATOR", "Abl"]]}, {"text": "The most successful example of  kinase  blockers is Imatinib (Imatinib mesylate,  Gleevec   STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Gleevec", "DOWNREGULATOR", "kinase"]]}, {"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate,  Gleevec   STI571), the inhibitor of  Bcr  Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Gleevec", "DOWNREGULATOR", "Bcr"]]}, {"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate,  Gleevec   STI571), the inhibitor of Bcr/ Abl  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["Gleevec", "DOWNREGULATOR", "Abl"]]}, {"text": "The most successful example of  kinase  blockers is Imatinib (Imatinib mesylate, Gleevec,  STI571  , the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["STI571", "DOWNREGULATOR", "kinase"]]}, {"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec,  STI571  , the inhibitor of  Bcr  Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["STI571", "DOWNREGULATOR", "Bcr"]]}, {"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec,  STI571  , the inhibitor of Bcr/ Abl  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia", "triple_list": [["STI571", "DOWNREGULATOR", "Abl"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib ( BMS-354825   specific for  ABL  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["BMS-354825", "DOWNREGULATOR", "ABL"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase,  Gefitinib  (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Gefitinib", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase ,  Gefitinib  (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["Gefitinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ( Iressa  , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Iressa", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib ( Iressa  , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["Iressa", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa),  Erlotinib  (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Erlotinib", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib (Iressa),  Erlotinib  (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["Erlotinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ( OSI-774   Tarceva) and Sunitinib (SU 11248, Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["OSI-774", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib (Iressa), Erlotinib ( OSI-774   Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["OSI-774", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774,  Tarceva   and Sunitinib (SU 11248, Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Tarceva", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib (Iressa), Erlotinib (OSI-774,  Tarceva   and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["Tarceva", "DOWNREGULATOR", "kinase"]]}, {"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  Sunitinib  (SU 11248, Sutent) specific for  VEGF receptor  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase", "triple_list": [["Sunitinib", "DOWNREGULATOR", "VEGF receptor"]]}, {"text": "Others  kinase  inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic  kinase , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  Sunitinib  (SU 11248, Sutent) specific for VEGF receptor  kinase   AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT  kinase ", "triple_list": [["Sunitinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Currently, the use of orally administered  MAO  inhibitor antidepressants (eg,  phenelzine   tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine", "triple_list": [["phenelzine", "DOWNREGULATOR", "MAO"]]}, {"text": "Currently, the use of orally administered  MAO  inhibitor antidepressants (eg, phenelzine,  tranylcypromine   is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "MAO"]]}, {"text": " CYP2D6  inhibitors, such as  paroxetine   are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor  CYP2D6  metabolizers", "triple_list": [["paroxetine", "DOWNREGULATOR", "CYP2D6"]]}, {"text": "It undergoes extensive biotransformation, which is affected by poor metabolism by  cytochrome P450 (CYP) 2D6  in a small percentage of the population; these patients have greater exposure to and slower elimination of  atomoxetine  than extensive metabolizers", "triple_list": [["atomoxetine", "PRODUCT-OF", "cytochrome P450 (CYP) 2D6"]]}, {"text": " CYP2D6  inhibitors, such as paroxetine, are associated with changes in  atomoxetine  pharmacokinetics similar to those observed among poor  CYP2D6  metabolizers", "triple_list": [["atomoxetine", "PRODUCT-OF", "CYP2D6"]]}, {"text": " Atomoxetine  appeared better tolerated among extensive  CYP2D6  metabolizers than among poor metabolizers", "triple_list": [["Atomoxetine", "PRODUCT-OF", "CYP2D6"]]}, {"text": "The recently discovered hyper insulin ism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by  GTP  causes excessive secretion of  insulin   Subsequent studies demonstrated that wild-type and hyper insulin emia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate", "triple_list": [["GTP", "ACTIVATOR", "insulin"]]}, {"text": "Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of  GDH  are inhibited by the green tea polyphenols,  epigallocatechin gallate  and epicatechin gallate", "triple_list": [["epigallocatechin gallate", "DOWNREGULATOR", "GDH"]]}, {"text": "Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of  GDH  are inhibited by the green tea polyphenols, epigallocatechin gallate and  epicatechin gallate   This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol", "triple_list": [["epicatechin gallate", "DOWNREGULATOR", "GDH"]]}, {"text": " Mammalian glutamate dehydrogenase  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to  2-oxoglutarate  using NAD(P)(+) as coenzyme", "triple_list": [["2-oxoglutarate", "PRODUCT-OF", "Mammalian glutamate dehydrogenase"]]}, {"text": "Mammalian glutamate dehydrogenase ( GDH   is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to  2-oxoglutarate  using NAD(P)(+) as coenzyme", "triple_list": [["2-oxoglutarate", "PRODUCT-OF", "GDH"]]}, {"text": " Mammalian glutamate dehydrogenase  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of  l-glutamate  to 2-oxoglutarate using NAD(P)(+) as coenzyme", "triple_list": [["l-glutamate", "PRODUCT-OF", "Mammalian glutamate dehydrogenase"]]}, {"text": "Mammalian glutamate dehydrogenase ( GDH   is a homohexameric enzyme that catalyzes the reversible oxidative deamination of  l-glutamate  to 2-oxoglutarate using NAD(P)(+) as coenzyme", "triple_list": [["l-glutamate", "PRODUCT-OF", "GDH"]]}, {"text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord  COX-2  (cyclooxygenase-2), with a subsequent increase in central  prostaglandin E2  (PGE2) levels associated with the development of hyperalgesia", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "COX-2"]]}, {"text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 ( cyclooxygenase-2  , with a subsequent increase in central  prostaglandin E2  (PGE2) levels associated with the development of hyperalgesia", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "cyclooxygenase-2"]]}, {"text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord  COX-2  (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 ( PGE2   levels associated with the development of hyperalgesia", "triple_list": [["PGE2", "PRODUCT-OF", "COX-2"]]}, {"text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 ( cyclooxygenase-2  , with a subsequent increase in central prostaglandin E2 ( PGE2   levels associated with the development of hyperalgesia", "triple_list": [["PGE2", "PRODUCT-OF", "cyclooxygenase-2"]]}, {"text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  alpha 1a-adrenoceptor  selective agonist  methoxamine  induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil", "triple_list": [["methoxamine", "AGONIST", "alpha 1a-adrenoceptor"]]}, {"text": "The Schild plots for the competitive antagonists  WB4101  and 5-methyl-urapidil against  alpha 1a-adrenoceptor  selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for  WB4101  and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil", "triple_list": [["WB4101", "ANTAGONIST", "alpha 1a-adrenoceptor"]]}, {"text": "The Schild plots for the competitive antagonists WB4101 and  5-methyl-urapidil  against  alpha 1a-adrenoceptor  selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for  5-methyl-urapidil   However, the Schilod plots for these antagonists against norepinephrine were curvilinear", "triple_list": [["5-methyl-urapidil", "ANTAGONIST", "alpha 1a-adrenoceptor"]]}, {"text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  alpha 1-adrenoceptor  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for  WB4101  and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both  WB4101  and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)", "triple_list": [["WB4101", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  alpha 1-adrenoceptor  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for  5-methyl-urapidil   and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and  5-methyl-urapidil ), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)", "triple_list": [["5-methyl-urapidil", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and  5-methyl-urapidil   we have examined the possible heterogeneity in the  alpha 1-adrenoceptor  populations in rabbit aorta", "triple_list": [["5-methyl-urapidil", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists  chlorethylclonidine  (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the  alpha 1-adrenoceptor  populations in rabbit aorta", "triple_list": [["chlorethylclonidine", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "Radioligand binding studies with the nonselective  alpha 1-adrenoceptor  antagonist radioligand  125I-BE2254  showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)", "triple_list": [["125I-BE2254", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists chlorethylclonidine ( CEC  , WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the  alpha 1-adrenoceptor  populations in rabbit aorta", "triple_list": [["CEC", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists chlorethylclonidine (CEC),  WB4101   and 5-methyl-urapidil, we have examined the possible heterogeneity in the  alpha 1-adrenoceptor  populations in rabbit aorta", "triple_list": [["WB4101", "ANTAGONIST", "alpha 1-adrenoceptor"]]}, {"text": "The Schild plots for the competitive antagonists  WB4101  and 5-methyl-urapidil against  alpha 1a-adrenoceptor  selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for  WB4101  and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil", "triple_list": [["WB4101", "ANTAGONIST", "alpha 1a-adrenoceptor"]]}, {"text": "The Schild plots for the competitive antagonists WB4101 and  5-methyl-urapidil  against  alpha 1a-adrenoceptor  selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for  5-methyl-urapidil ", "triple_list": [["5-methyl-urapidil", "ANTAGONIST", "alpha 1a-adrenoceptor"]]}, {"text": " Ambrisentan  is an  endothelin receptor  antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH)", "triple_list": [["Ambrisentan", "ANTAGONIST", "endothelin receptor"]]}, {"text": " Ambrisentan  is the first  ET(A)  selective ERA approved for use in the US", "triple_list": [["Ambrisentan", "ANTAGONIST", "ET(A)"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone,  promegestone   nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["promegestone", "DOWNREGULATOR", "sulfatase"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone,  promegestone   nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["promegestone", "DOWNREGULATOR", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone,  nomegestrol acetate  and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["nomegestrol acetate", "DOWNREGULATOR", "sulfatase"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone,  nomegestrol acetate  and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["nomegestrol acetate", "DOWNREGULATOR", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and  norelgestromin  can reduce intratissular levels of estradiol in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["norelgestromin", "DOWNREGULATOR", "sulfatase"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and  norelgestromin  can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["norelgestromin", "DOWNREGULATOR", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": "As discussed in this review, various  progestogens  including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["progestogens", "DOWNREGULATOR", "sulfatase"]]}, {"text": "As discussed in this review, various  progestogens  including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["progestogens", "DOWNREGULATOR", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": "As discussed in this review, various progestogens including  dydrogesterone  and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["dydrogesterone", "DOWNREGULATOR", "sulfatase"]]}, {"text": "As discussed in this review, various progestogens including  dydrogesterone  and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["dydrogesterone", "DOWNREGULATOR", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative,  medrogestone   promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["medrogestone", "DOWNREGULATOR", "sulfatase"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative,  medrogestone   promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["medrogestone", "DOWNREGULATOR", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of  estradiol  in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities", "triple_list": [["estradiol", "PRODUCT-OF", "sulfatase"]]}, {"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of  estradiol  in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities", "triple_list": [["estradiol", "PRODUCT-OF", "17beta-hydroxysteroid-dehydrogenase type 1"]]}, {"text": " Mitiglinide  reduced fasting plasma glucose and  GA  levels after 4 weeks and Hb(A1c) levels after 8 weeks", "triple_list": [["Mitiglinide", "DOWNREGULATOR", "GA"]]}, {"text": " Mitiglinide  reduced fasting plasma glucose and GA levels after 4 weeks and  Hb(A1c)  levels after 8 weeks", "triple_list": [["Mitiglinide", "DOWNREGULATOR", "Hb(A1c)"]]}, {"text": " Ibuprofen  activates  PPARgamma  in neuron-like PC12 and B104 cells", "triple_list": [["Ibuprofen", "ACTIVATOR", "PPARgamma"]]}, {"text": "In addition, another study suggests that  ibuprofen  reduces generation of  amyloid-beta42  peptide via inactivation of RhoA signaling, although it may also regulate  amyloid-beta42  formation by direct inhibition of the gamma-secretase complex", "triple_list": [["ibuprofen", "ACTIVATOR", "amyloid-beta42"]]}, {"text": "Recently, we have demonstrated that  ibuprofen  inhibits intracellular signaling of  RhoA  and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "In addition, another study suggests that  ibuprofen  reduces generation of  amyloid-beta42  peptide via inactivation of RhoA signaling, although it may also regulate  amyloid-beta42  formation by direct inhibition of the gamma-secretase complex", "triple_list": [["ibuprofen", "DOWNREGULATOR", "amyloid-beta42"]]}, {"text": "In addition, another study suggests that  ibuprofen  reduces generation of amyloid-beta42 peptide via inactivation of  RhoA  signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "The molecular mechanisms by which  ibuprofen  inhibits the  RhoA  signal in neurons, however, remain unclear", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling  ibuprofen  to  RhoA  inhibition and subsequent neurite growth promotion in neurons", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "A molecular mechanism for  ibuprofen  mediated  RhoA  inhibition in neurons", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": " Ibuprofen  is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of  cyclooxygenases   Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents", "triple_list": [["Ibuprofen", "DOWNREGULATOR", "cyclooxygenases"]]}, {"text": "Activation of PPARgamma with traditional agonists mimics the  RhoA  inhibiting properties of  ibuprofen  in PC12 cells and, like  ibuprofen , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "These findings support that PPARgamma plays an essential role in mediating the  RhoA  inhibiting effect of  ibuprofen   Elucidation of the novel molecular mechanisms linking  ibuprofen  to  RhoA  inhibition may provide additional therapeutic targets to the disorders characterized by  RhoA  activation, including spinal cord injuries and Alzheimer's disease.", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "Elucidation of the novel molecular mechanisms linking  ibuprofen  to  RhoA  inhibition may provide additional therapeutic targets to the disorders characterized by  RhoA  activation, including spinal cord injuries and Alzheimer's disease.", "triple_list": [["ibuprofen", "DOWNREGULATOR", "RhoA"]]}, {"text": "In addition, another study suggests that  ibuprofen  reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the  gamma-secretase complex   The molecular mechanisms by which  ibuprofen  inhibits the RhoA signal in neurons, however, remain unclear", "triple_list": [["ibuprofen", "DOWNREGULATOR", "gamma-secretase complex"]]}, {"text": "Of these, the  thrombin  inhibitor  dabigatran  and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe", "triple_list": [["dabigatran", "DOWNREGULATOR", "thrombin"]]}, {"text": "Of these, the thrombin inhibitor dabigatran and  factor Xa  inhibitor  rivaroxaban  have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe", "triple_list": [["rivaroxaban", "DOWNREGULATOR", "factor Xa"]]}, {"text": "In addition, the  factor Xa  inhibitor  apixaban  is in late-stage clinical development", "triple_list": [["apixaban", "DOWNREGULATOR", "factor Xa"]]}, {"text": "We determined whether an  angiotensin-converting enzyme  (ACE) inhibitor,  captopril   inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2- captopril  complex", "triple_list": [["captopril", "DOWNREGULATOR", "angiotensin-converting enzyme"]]}, {"text": "We determined whether an angiotensin-converting enzyme ( ACE   inhibitor,  captopril   inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2- captopril  complex", "triple_list": [["captopril", "DOWNREGULATOR", "ACE"]]}, {"text": "METHODS: The inhibitory effect of  captopril  on  MMP-2  activity was measured in peritoneal effluents from 17 patients on CAPD", "triple_list": [["captopril", "DOWNREGULATOR", "MMP-2"]]}, {"text": "RESULTS:  Captopril  directly inhibited  MMP-2  activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the  MMP-2  active site could be formed in each complex model without molecular distortion", "triple_list": [["Captopril", "DOWNREGULATOR", "MMP-2"]]}, {"text": "CONCLUSION: ACE inhibitors, such as  captopril   may be applied as important compounds for  MMP-2  inhibition in inflammation caused by CAPD.", "triple_list": [["captopril", "DOWNREGULATOR", "MMP-2"]]}, {"text": "CONCLUSION:  ACE  inhibitors, such as  captopril   may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.", "triple_list": [["captopril", "DOWNREGULATOR", "ACE"]]}, {"text": " Captopril  directly inhibits  matrix metalloproteinase-2  activity in continuous ambulatory peritoneal dialysis therapy", "triple_list": [["Captopril", "DOWNREGULATOR", "matrix metalloproteinase-2"]]}, {"text": " Phenformin  reduced the open probability of  Kir6.1  SUR2B channels by approximately 90% in inside-out patches", "triple_list": [["Phenformin", "DOWNREGULATOR", "Kir6.1"]]}, {"text": " Phenformin  reduced the open probability of Kir6.1/ SUR2B  channels by approximately 90% in inside-out patches", "triple_list": [["Phenformin", "DOWNREGULATOR", "SUR2B"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of  K(ATP)  including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)", "triple_list": [["Phenformin", "DOWNREGULATOR", "K(ATP)"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ( Kir6.1  SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)", "triple_list": [["Phenformin", "DOWNREGULATOR", "Kir6.1"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/ SUR2B  and Kir6.2/ SUR2B ) and pancreatic beta-cells (Kir6.2/SUR1)", "triple_list": [["Phenformin", "DOWNREGULATOR", "SUR2B"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and  Kir6.2  SUR2B) and pancreatic beta-cells ( Kir6.2 /SUR1)", "triple_list": [["Phenformin", "DOWNREGULATOR", "Kir6.2"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/ SUR2B  and Kir6.2/ SUR2B   and pancreatic beta-cells (Kir6.2/SUR1)", "triple_list": [["Phenformin", "DOWNREGULATOR", "SUR2B"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and  Kir6.2 /SUR2B) and pancreatic beta-cells ( Kir6.2  SUR1)", "triple_list": [["Phenformin", "DOWNREGULATOR", "Kir6.2"]]}, {"text": " Phenformin  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/ SUR1  ", "triple_list": [["Phenformin", "DOWNREGULATOR", "SUR1"]]}, {"text": " Phenformin  has a direct inhibitory effect on the  ATP-sensitive potassium channel   The biguanides, phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating AMPK activity", "triple_list": [["Phenformin", "DOWNREGULATOR", "ATP-sensitive potassium channel"]]}, {"text": "The extent and rate of inhibition are similar to that seen with the known  K(ATP)  blocker  PNU 37883A   Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM", "triple_list": [["PNU 37883A", "DOWNREGULATOR", "K(ATP)"]]}, {"text": "Additionally,  phenformin  inhibited the current elicited through the  Kir6.2DeltaC26  (functional without SUR) channel with an IC50 of 1.78 mM", "triple_list": [["phenformin", "DOWNREGULATOR", "Kir6.2DeltaC26"]]}, {"text": "In pig parathyroid cells,  paricalcitol  and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although  paricalcitol  induced the expression of  CaSR  mRNA more effectively", "triple_list": [["paricalcitol", "ACTIVATOR", "CaSR"]]}, {"text": "Different VDRAs are known to have differential effects on serum calcium ( Ca ), which may also affect serum  PTH  levels since serum  Ca  regulates  PTH  secretion mediated by the  Ca -sensing receptor ( Ca SR)", "triple_list": [["Ca", "ACTIVATOR", "PTH"]]}, {"text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed  PTH  mRNA expression and serum  PTH  effectively in the 5/6 NX rats, but  paricalcitol  was less potent in raising serum Ca than doxercalciferol", "triple_list": [["paricalcitol", "DOWNREGULATOR", "PTH"]]}, {"text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed  PTH  mRNA expression and serum  PTH  effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than  doxercalciferol   In pig parathyroid cells, paricalcitol and the active form of  doxercalciferol  induced VDR translocation from the cytoplasm into the nucleus, suppressed  PTH  mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively", "triple_list": [["doxercalciferol", "DOWNREGULATOR", "PTH"]]}, {"text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed  PTH  mRNA expression and serum  PTH  effectively in the 5/6 NX rats, but  paricalcitol  was less potent in raising serum Ca than doxercalciferol", "triple_list": [["paricalcitol", "DOWNREGULATOR", "PTH"]]}, {"text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed  PTH  mRNA expression and serum  PTH  effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than  doxercalciferol   In pig parathyroid cells, paricalcitol and the active form of  doxercalciferol  induced VDR translocation from the cytoplasm into the nucleus, suppressed  PTH  mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively", "triple_list": [["doxercalciferol", "DOWNREGULATOR", "PTH"]]}, {"text": "In pig parathyroid cells,  paricalcitol  and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed  PTH  mRNA expression and inhibited cell proliferation in a similar manner, although  paricalcitol  induced the expression of CaSR mRNA more effectively", "triple_list": [["paricalcitol", "DOWNREGULATOR", "PTH"]]}, {"text": "In pig parathyroid cells, paricalcitol and the active form of  doxercalciferol  induced VDR translocation from the cytoplasm into the nucleus, suppressed  PTH  mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively", "triple_list": [["doxercalciferol", "DOWNREGULATOR", "PTH"]]}, {"text": " Thalidomide  initiates its teratogenic effects by binding to CRBN and inhibiting the associated  ubiquitin ligase  activity", "triple_list": [["Thalidomide", "DOWNREGULATOR", "ubiquitin ligase"]]}, {"text": " Telmisartan  is an  angiotensin II receptor  blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure", "triple_list": [["Telmisartan", "DOWNREGULATOR", "angiotensin II receptor"]]}, {"text": "With the pentapeptide linked through the C7alpha position of  estradiol   the resulting PROTAC shows the most effective  ER  degradation and highest affinity for the estrogen receptor", "triple_list": [["estradiol", "DOWNREGULATOR", "ER"]]}, {"text": "Recent studies indicate that  tamoxifen  initially acts as an antagonist, but later functions as an  ER  agonist, promoting tumor growth", "triple_list": [["tamoxifen", "AGONIST", "ER"]]}, {"text": "Recent studies indicate that  tamoxifen  initially acts as an antagonist, but later functions as an  ER  agonist, promoting tumor growth", "triple_list": [["tamoxifen", "ANTAGONIST", "ER"]]}, {"text": " salmeterol  and formoterol, for the  beta(2)-adrenoceptor  over the beta(1) or beta(3)), while others (e.g", "triple_list": [["salmeterol", "AGONIST", "beta(2)-adrenoceptor"]]}, {"text": " salmeterol  and formoterol, for the beta(2)-adrenoceptor over the  beta(1)  or beta(3)), while others (e.g", "triple_list": [["salmeterol", "AGONIST", "beta(1)"]]}, {"text": "salmeterol and  formoterol   for the  beta(2)-adrenoceptor  over the beta(1) or beta(3)), while others (e.g", "triple_list": [["formoterol", "AGONIST", "beta(2)-adrenoceptor"]]}, {"text": "salmeterol and  formoterol   for the beta(2)-adrenoceptor over the beta(1) or  beta(3)  , while others (e.g", "triple_list": [["formoterol", "AGONIST", "beta(3)"]]}, {"text": "However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the  N-propargyl  moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating  Bcl-2  family proteins", "triple_list": [["N-propargyl", "ACTIVATOR", "Bcl-2"]]}, {"text": " Rasagiline   a novel anti-Parkinsonian  monoamine oxidase-B  inhibitor with neuroprotective activity", "triple_list": [["Rasagiline", "DOWNREGULATOR", "monoamine oxidase-B"]]}, {"text": " Rasagiline  (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible  monoamine oxidase (MAO)-B  inhibitor, anti-Parkinsonian drug", "triple_list": [["Rasagiline", "DOWNREGULATOR", "monoamine oxidase (MAO)-B"]]}, {"text": "Rasagiline ( N-propargyl-1-(R)-aminoindan   is a novel, highly potent irreversible  monoamine oxidase (MAO)-B  inhibitor, anti-Parkinsonian drug", "triple_list": [["N-propargyl-1-(R)-aminoindan", "DOWNREGULATOR", "monoamine oxidase (MAO)-B"]]}, {"text": "Its S-isomer,  TVP1022  is thousand times less potent as an  MAO-B  inhibitor", "triple_list": [["TVP1022", "DOWNREGULATOR", "MAO-B"]]}, {"text": "However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of  rasagiline  does not depend on inhibition of  MAO-B   but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins", "triple_list": [["rasagiline", "DOWNREGULATOR", "MAO-B"]]}, {"text": "Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum  TSH  level with high dose of  levothyroxine  might be optimum for normal growth.", "triple_list": [["levothyroxine", "ACTIVATOR", "TSH"]]}, {"text": "With exposure to  rofecoxib   a selective  COX-2  inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective  COX-2  inhibitors in breast cancer prophylaxis.", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "With exposure to  rofecoxib   a selective  COX-2  inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective  COX-2  inhibitors in breast cancer prophylaxis.", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "METHODS: We conducted a case-control study to measure the association between selective  cox-2  inhibitors, particularly  celecoxib   rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk", "triple_list": [["celecoxib", "DOWNREGULATOR", "cox-2"]]}, {"text": "METHODS: We conducted a case-control study to measure the association between selective  cox-2  inhibitors, particularly celecoxib,  rofecoxib   valdecoxib and non-specific NSAID subgroups, and breast cancer risk", "triple_list": [["rofecoxib", "DOWNREGULATOR", "cox-2"]]}, {"text": "METHODS: We conducted a case-control study to measure the association between selective  cox-2  inhibitors, particularly celecoxib, rofecoxib,  valdecoxib  and non-specific NSAID subgroups, and breast cancer risk", "triple_list": [["valdecoxib", "DOWNREGULATOR", "cox-2"]]}, {"text": "BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non- steroidal  anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of  cyclooxygenase-2  (COX-2)", "triple_list": [["steroidal", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non- steroidal  anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 ( COX-2  ", "triple_list": [["steroidal", "DOWNREGULATOR", "COX-2"]]}, {"text": "The suppressive effect of  ceruletide  on barrel rotation could be partially countered by MK-329, a selective peripheral  CCK  ( CCK -A) receptor antagonist", "triple_list": [["ceruletide", "DOWNREGULATOR", "CCK"]]}, {"text": "The suppressive effect of  ceruletide  on barrel rotation could be partially countered by MK-329, a selective peripheral CCK  (CCK-A) receptor  antagonist", "triple_list": [["ceruletide", "DOWNREGULATOR", "(CCK-A) receptor"]]}, {"text": "These findings suggest that  ceruletide  specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through  CCK-A receptor  ", "triple_list": [["ceruletide", "DOWNREGULATOR", "CCK-A receptor"]]}, {"text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by  MK-329   a selective peripheral  CCK  ( CCK -A) receptor antagonist", "triple_list": [["MK-329", "ANTAGONIST", "CCK"]]}, {"text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by  MK-329   a selective peripheral CCK  (CCK-A) receptor  antagonist", "triple_list": [["MK-329", "ANTAGONIST", "(CCK-A) receptor"]]}, {"text": "BACKGROUND: The effects of  histamine H1  antagonist  chlorcyclizine  on rat palate development were characterized following in utero exposure", "triple_list": [["chlorcyclizine", "ANTAGONIST", "histamine H1"]]}, {"text": "Effects of the  histamine H1  antagonist  chlorcyclizine  on rat fetal palate development", "triple_list": [["chlorcyclizine", "ANTAGONIST", "histamine H1"]]}, {"text": "The smooth muscle relaxant,  W-7   which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced  PRL  secretion in a dose-dependent manner (r = -0.991, p less than 0.01)", "triple_list": [["W-7", "DOWNREGULATOR", "PRL"]]}, {"text": "Removing medium Ca2+, blocking  Ca2+ channels  with 50 mumol/l  verapamil   or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion", "triple_list": [["verapamil", "DOWNREGULATOR", "Ca2+ channels"]]}, {"text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  calmodulin  activation with 20 mumol/l  trifluoperazine   10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion", "triple_list": [["trifluoperazine", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  calmodulin  activation with 20 mumol/l trifluoperazine, 10 mumol/l  chlorpromazine  or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion", "triple_list": [["chlorpromazine", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  calmodulin  activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l  pimozide  almost completely blocked hyposmolarity-induced secretion", "triple_list": [["pimozide", "DOWNREGULATOR", "calmodulin"]]}, {"text": "An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement  spermine  and this can be accomplished by breeding with CAG- SMS  mice that express SpmS from a ubiquitous promoter", "triple_list": [["spermine", "PRODUCT-OF", "SMS"]]}, {"text": "An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement  spermine  and this can be accomplished by breeding with CAG-SMS mice that express  SpmS  from a ubiquitous promoter", "triple_list": [["spermine", "PRODUCT-OF", "SpmS"]]}, {"text": "Importantly, treatment with  cabozantinib  did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of  VEGF  signaling that do not target MET", "triple_list": [["cabozantinib", "DOWNREGULATOR", "VEGF"]]}, {"text": "Collectively, these data suggest that  cabozantinib  is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated  MET  and VEGFR signaling.", "triple_list": [["cabozantinib", "DOWNREGULATOR", "MET"]]}, {"text": "Collectively, these data suggest that  cabozantinib  is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and  VEGFR  signaling.", "triple_list": [["cabozantinib", "DOWNREGULATOR", "VEGFR"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule  kinase  inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine  kinase s that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "kinase"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward  MET  and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "MET"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and  VEGF receptor 2  (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "VEGF receptor 2"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 ( VEGFR2  , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "VEGFR2"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other  receptor tyrosine kinases  that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "receptor tyrosine kinases"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including  RET   KIT, AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "RET"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET,  KIT   AXL, and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "KIT"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT,  AXL   and FLT3", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "AXL"]]}, {"text": " Cabozantinib  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and  FLT3   Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "FLT3"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule  kinase  inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine  kinase s that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "kinase"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward  MET  and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "MET"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and  VEGF receptor 2  (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "VEGF receptor 2"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 ( VEGFR2  , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "VEGFR2"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other  receptor tyrosine kinases  that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "receptor tyrosine kinases"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including  RET   KIT, AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "RET"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET,  KIT   AXL, and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "KIT"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT,  AXL   and FLT3", "triple_list": [["XL184", "DOWNREGULATOR", "AXL"]]}, {"text": "Cabozantinib ( XL184   is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and  FLT3   Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro", "triple_list": [["XL184", "DOWNREGULATOR", "FLT3"]]}, {"text": "Treatment with  cabozantinib  inhibited  MET  and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro", "triple_list": [["cabozantinib", "DOWNREGULATOR", "MET"]]}, {"text": "Treatment with  cabozantinib  inhibited MET and  VEGFR2  phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro", "triple_list": [["cabozantinib", "DOWNREGULATOR", "VEGFR2"]]}, {"text": " Cabozantinib  (XL184), a novel  MET  and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "MET"]]}, {"text": " Cabozantinib  (XL184), a novel MET and  VEGFR2  inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "VEGFR2"]]}, {"text": "Cabozantinib ( XL184  , a novel  MET  and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth", "triple_list": [["XL184", "DOWNREGULATOR", "MET"]]}, {"text": "Cabozantinib ( XL184  , a novel MET and  VEGFR2  inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth", "triple_list": [["XL184", "DOWNREGULATOR", "VEGFR2"]]}, {"text": "Inhibition of the  NF-kappaB  pathway was responsible for this effect since the  colchicoside  inhibited RANKL-induced  NF-kappaB  activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of  NF-kappaB alpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of  NF-kappaB ", "triple_list": [["colchicoside", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the  colchicoside  inhibited RANKL-induced NF-kappaB activation, activation of  IkappaB kinase  (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB", "triple_list": [["colchicoside", "DOWNREGULATOR", "IkappaB kinase"]]}, {"text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the  colchicoside  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase ( IKK   and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB", "triple_list": [["colchicoside", "DOWNREGULATOR", "IKK"]]}, {"text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the  colchicoside  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of  NF-kappaBalpha  (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB", "triple_list": [["colchicoside", "DOWNREGULATOR", "NF-kappaBalpha"]]}, {"text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the  colchicoside  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha ( IkappaBalpha   phosphorylation and degradation, an inhibitor of NF-kappaB", "triple_list": [["colchicoside", "DOWNREGULATOR", "IkappaBalpha"]]}, {"text": "Inhibition of the  NF-kappaB  pathway was responsible for this effect since the  colchicoside  inhibited RANKL-induced  NF-kappaB  activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of  NF-kappaB alpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of  NF-kappaB   Furthermore, an inhibitor of the IkappaBalpha kinase gamma or  NF-kappaB  essential modulator, the regulatory component of the IKK complex, demonstrated that the  NF-kappaB  signalling pathway is mandatory for osteoclastogenesis induced by RANKL", "triple_list": [["colchicoside", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the  colchicoside  inhibited  RANKL  induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB", "triple_list": [["colchicoside", "DOWNREGULATOR", "RANKL"]]}, {"text": "CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that  thiocolchicoside  significantly suppressed osteoclastogenesis induced by  RANKL  and tumour cells via the NF-kappaB signalling pathway", "triple_list": [["thiocolchicoside", "DOWNREGULATOR", "RANKL"]]}, {"text": "CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that  thiocolchicoside  significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the  NF-kappaB  signalling pathway", "triple_list": [["thiocolchicoside", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "Although genetic polymorphisms in the endothelial nitric oxide synthase (e NO S  gene may impair endogenous  NO  formation, there is little information about how e NO S polymorphisms and haplotypes affect the responses to sildenafil", "triple_list": [["NO", "PRODUCT-OF", "eNOS"]]}, {"text": "Although genetic polymorphisms in the  endothelial nitric oxide synthase  (e NO S) gene may impair endogenous  NO  formation, there is little information about how e NO S polymorphisms and haplotypes affect the responses to sildenafil", "triple_list": [["NO", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": "Here, we report biochemical evidence that  mercury  alone induces  NF-\u03baB  activation, resulting in the induced expression of COX-2 and iNOS", "triple_list": [["mercury", "ACTIVATOR", "NF-\u03baB"]]}, {"text": "Here, we report biochemical evidence that  mercury  alone induces NF-\u03baB activation, resulting in the induced expression of  COX-2  and iNOS", "triple_list": [["mercury", "ACTIVATOR", "COX-2"]]}, {"text": "Here, we report biochemical evidence that  mercury  alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and  iNOS   The results suggest that  mercury  can induce inflammatory diseases by lowering host defense.", "triple_list": [["mercury", "ACTIVATOR", "iNOS"]]}, {"text": " Mercury  induces the expression of  cyclooxygenase-2  and inducible nitric oxide synthase", "triple_list": [["Mercury", "ACTIVATOR", "cyclooxygenase-2"]]}, {"text": " Mercury  induces the expression of cyclooxygenase-2 and  inducible nitric oxide synthase   Nuclear factor-\u03baB (NF-\u03baB) is a transcription factor that mediates the inducible expression of a variety of genes involved in immune and inflammatory responses", "triple_list": [["Mercury", "ACTIVATOR", "inducible nitric oxide synthase"]]}, {"text": "Unexpectedly, both the  mGluR(5)  pecific agonist,  CHPG   and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization", "triple_list": [["CHPG", "AGONIST", "mGluR(5)"]]}, {"text": "Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the  group II mGluR  (mGlu(2/3)) agonist,  LY379268  (LY), induced a TTX-insensitive outward current/hyperpolarization", "triple_list": [["LY379268", "AGONIST", "group II mGluR"]]}, {"text": "Both outward currents were significantly reduced by the  mGluR  antagonist  MCPG  and the CHPG-induced current was blocked by the specific  mGluR (5) antagonist MTEP", "triple_list": [["MCPG", "ANTAGONIST", "mGluR"]]}, {"text": "Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific  mGluR(5)  antagonist  MTEP   Concurrent Ca(2+)imaging revealed that while CHPG actions did include release of Ca(2+) from CPA/thapsigargin-sensitive intracellular stores, actions of LY did not", "triple_list": [["MTEP", "ANTAGONIST", "mGluR(5)"]]}, {"text": "We have examined the effectiveness of two novel  Chk1  selective inhibitors,  AR323  and AR678, in a panel of melanoma cell lines and normal cell types", "triple_list": [["AR323", "DOWNREGULATOR", "Chk1"]]}, {"text": "We have examined the effectiveness of two novel  Chk1  selective inhibitors, AR323 and  AR678   in a panel of melanoma cell lines and normal cell types", "triple_list": [["AR678", "DOWNREGULATOR", "Chk1"]]}, {"text": "Aspirin and  metformin  (an activator of  AMPK   increased inhibition of mTOR and Akt, as well as autophagy in CRC cells", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "CONCLUSIONS:  Aspirin  is an inhibitor of mTOR and an activator of  AMPK   targeting regulators of intracellular energy homeostasis and metabolism", "triple_list": [["Aspirin", "ACTIVATOR", "AMPK"]]}, {"text": " Aspirin  inhibits mTOR signaling, activates  AMP-activated protein kinase   and induces autophagy in colorectal cancer cells", "triple_list": [["Aspirin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": " Aspirin  changed nucleotide ratios and activated  AMPK  in CRC cells", "triple_list": [["Aspirin", "ACTIVATOR", "AMPK"]]}, {"text": " Aspirin  and metformin (an activator of  AMPK   increased inhibition of mTOR and Akt, as well as autophagy in CRC cells", "triple_list": [["Aspirin", "ACTIVATOR", "AMPK"]]}, {"text": "RESULTS:  Aspirin  reduced  mTOR  signaling in CRC cells by inhibiting the  mTOR  effectors S6K1 and 4E-BP1", "triple_list": [["Aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": " Aspirin  inhibits  mTOR  signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells", "triple_list": [["Aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": "Aspirin and  metformin  (an activator of AMPK) increased inhibition of  mTOR  and Akt, as well as autophagy in CRC cells", "triple_list": [["metformin", "DOWNREGULATOR", "mTOR"]]}, {"text": "Aspirin and  metformin  (an activator of AMPK) increased inhibition of mTOR and  Akt   as well as autophagy in CRC cells", "triple_list": [["metformin", "DOWNREGULATOR", "Akt"]]}, {"text": "Rectal mucosal samples from patients given  aspirin  had reduced phosphorylation of  S6K1  and S6", "triple_list": [["aspirin", "DOWNREGULATOR", "S6K1"]]}, {"text": "Rectal mucosal samples from patients given  aspirin  had reduced phosphorylation of  S6 K1 and  S6   CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism", "triple_list": [["aspirin", "DOWNREGULATOR", "S6"]]}, {"text": "CONCLUSIONS:  Aspirin  is an inhibitor of  mTOR  and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism", "triple_list": [["Aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": "RESULTS:  Aspirin  reduced  mTOR  signaling in CRC cells by inhibiting the  mTOR  effectors S6K1 and 4E-BP1", "triple_list": [["Aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": "RESULTS:  Aspirin  reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors  S6K1  and 4E-BP1", "triple_list": [["Aspirin", "DOWNREGULATOR", "S6K1"]]}, {"text": "RESULTS:  Aspirin  reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and  4E-BP1    Aspirin  changed nucleotide ratios and activated AMPK in CRC cells", "triple_list": [["Aspirin", "DOWNREGULATOR", "4E-BP1"]]}, {"text": " mTOR  was still inhibited by  aspirin  in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of  aspirin -induced inhibition of  mTOR ", "triple_list": [["aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": " mTOR  was still inhibited by  aspirin  in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of  aspirin  induced inhibition of  mTOR   Aspirin induced autophagy, a feature of  mTOR  inhibition", "triple_list": [["aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": " Aspirin  induced autophagy, a feature of  mTOR  inhibition", "triple_list": [["Aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": " Aspirin  and metformin (an activator of AMPK) increased inhibition of  mTOR  and Akt, as well as autophagy in CRC cells", "triple_list": [["Aspirin", "DOWNREGULATOR", "mTOR"]]}, {"text": " Aspirin  and metformin (an activator of AMPK) increased inhibition of mTOR and  Akt   as well as autophagy in CRC cells", "triple_list": [["Aspirin", "DOWNREGULATOR", "Akt"]]}, {"text": "Exogenous stimulation of  PKA  activity, achieved by  forskolin  treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels", "triple_list": [["forskolin", "ACTIVATOR", "PKA"]]}, {"text": "Exogenous stimulation of PKA activity, achieved by  forskolin  treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced  complex I  activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels", "triple_list": [["forskolin", "ACTIVATOR", "complex I"]]}, {"text": "Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected  K-ras  transformed cells from apoptosis induced by  glucose  deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels", "triple_list": [["glucose", "DOWNREGULATOR", "K-ras"]]}, {"text": " SB203580  (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of  collagen type I  and \u03b1-SMA in TGF-\u03b21-induced NPDFs", "triple_list": [["SB203580", "DOWNREGULATOR", "collagen type I"]]}, {"text": " SB203580  (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and  \u03b1-SMA  in TGF-\u03b21-induced NPDFs", "triple_list": [["SB203580", "DOWNREGULATOR", "\u03b1-SMA"]]}, {"text": " SB203580  (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in  TGF-\u03b21  induced NPDFs", "triple_list": [["SB203580", "DOWNREGULATOR", "TGF-\u03b21"]]}, {"text": "In  TGF-\u03b21  induced NPDFs,  berberine  significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels", "triple_list": [["berberine", "DOWNREGULATOR", "TGF-\u03b21"]]}, {"text": "In TGF-\u03b21-induced NPDFs,  berberine  significantly inhibited the expression of  \u03b1-SMA  and collagen type I mRNA and reduced  \u03b1-SMA  and collagen protein levels", "triple_list": [["berberine", "DOWNREGULATOR", "\u03b1-SMA"]]}, {"text": "In TGF-\u03b21-induced NPDFs,  berberine  significantly inhibited the expression of \u03b1-SMA and  collagen type I  mRNA and reduced \u03b1-SMA and collagen protein levels", "triple_list": [["berberine", "DOWNREGULATOR", "collagen type I"]]}, {"text": "In TGF-\u03b21-induced NPDFs,  berberine  significantly inhibited the expression of  \u03b1-SMA  and collagen type I mRNA and reduced  \u03b1-SMA  and collagen protein levels", "triple_list": [["berberine", "DOWNREGULATOR", "\u03b1-SMA"]]}, {"text": "In TGF-\u03b21-induced NPDFs,  berberine  significantly inhibited the expression of \u03b1-SMA and  collagen  type I mRNA and reduced \u03b1-SMA and  collagen  protein levels", "triple_list": [["berberine", "DOWNREGULATOR", "collagen"]]}, {"text": " Berberine  only suppressed the expression of  pp38  among the evaluated signaling molecules", "triple_list": [["Berberine", "DOWNREGULATOR", "pp38"]]}, {"text": " SB203580  (a specific inhibitor of  p38  kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs", "triple_list": [["SB203580", "DOWNREGULATOR", "p38"]]}, {"text": " SB203580  (a specific inhibitor of p38  kinase   markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs", "triple_list": [["SB203580", "DOWNREGULATOR", "kinase"]]}, {"text": "CRBN mediated antiproliferative activities of  lenalidomide  and pomalidomide in myeloma cells, as well as  lenalidomide   and pomalidomide-induced  cytokine  production in T cells", "triple_list": [["lenalidomide", "ACTIVATOR", "cytokine"]]}, {"text": "CRBN mediated antiproliferative activities of lenalidomide and  pomalidomide  in myeloma cells, as well as lenalidomide- and  pomalidomide  induced  cytokine  production in T cells", "triple_list": [["pomalidomide", "ACTIVATOR", "cytokine"]]}, {"text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  pomalidomide  mediated reductions in c-myc and IRF4 expression and increases in p21( WAF-1   expression", "triple_list": [["pomalidomide", "ACTIVATOR", "WAF-1"]]}, {"text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  pomalidomide  mediated reductions in c-myc and IRF4 expression and increases in  p21  WAF-1) expression", "triple_list": [["pomalidomide", "ACTIVATOR", "p21"]]}, {"text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  pomalidomide  mediated reductions in  c-myc  and IRF4 expression and increases in p21(WAF-1) expression", "triple_list": [["pomalidomide", "DOWNREGULATOR", "c-myc"]]}, {"text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  pomalidomide  mediated reductions in c-myc and  IRF4  expression and increases in p21(WAF-1) expression", "triple_list": [["pomalidomide", "DOWNREGULATOR", "IRF4"]]}, {"text": "Long-term selection for  lenalidomide  resistance in H929 myeloma cell lines was accompanied by a reduction in  CRBN   while in DF15R myeloma cells resistant to both pomalidomide and  lenalidomide ,  CRBN  protein was undetectable", "triple_list": [["lenalidomide", "DOWNREGULATOR", "CRBN"]]}, {"text": " Lenalidomide  and pomalidomide inhibited autoubiquitination of  CRBN  in HEK293T cells expressing thalidomide-binding competent wild-type  CRBN , but not thalidomide-binding defective  CRBN (YW/AA)", "triple_list": [["Lenalidomide", "DOWNREGULATOR", "CRBN"]]}, {"text": " Lenalidomide  and pomalidomide inhibited autoubiquitination of  CRBN  in HEK293T cells expressing thalidomide-binding competent wild-type  CRBN   but not thalidomide-binding defective  CRBN (YW/AA)", "triple_list": [["Lenalidomide", "DOWNREGULATOR", "CRBN"]]}, {"text": "Lenalidomide and  pomalidomide  inhibited autoubiquitination of  CRBN  in HEK293T cells expressing thalidomide-binding competent wild-type  CRBN , but not thalidomide-binding defective  CRBN (YW/AA)", "triple_list": [["pomalidomide", "DOWNREGULATOR", "CRBN"]]}, {"text": "Lenalidomide and  pomalidomide  inhibited autoubiquitination of  CRBN  in HEK293T cells expressing thalidomide-binding competent wild-type  CRBN   but not thalidomide-binding defective  CRBN (YW/AA)", "triple_list": [["pomalidomide", "DOWNREGULATOR", "CRBN"]]}, {"text": "These  polyphenols   but not GvEx, showed a certain level of inhibition of human-cDNA-expressed  CYPs   In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of CYP activities and of midazolam 1'-hydroxylation than grapefruit juice", "triple_list": [["polyphenols", "DOWNREGULATOR", "CYPs"]]}, {"text": " Crizotinib  is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the  ALK  fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing  ALK ", "triple_list": [["Crizotinib", "DOWNREGULATOR", "ALK"]]}, {"text": " Crizotinib  is an oral  tyrosine kinase  inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK", "triple_list": [["Crizotinib", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": " Enprofylline   a weak adenosine antagonist but potent inhibitor of  cyclic AMP phosphodiesterase   did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions", "triple_list": [["Enprofylline", "DOWNREGULATOR", "cyclic AMP phosphodiesterase"]]}, {"text": " adenosine  agonists,  N6-(R-phenylisopropyl) adenosine   (R-PIA), N6-(S-phenylisopropyl) adenosine , 5'-(N-cyclopropyl)-carboxamido adenosine , antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["N6-(R-phenylisopropyl)adenosine", "AGONIST", "adenosine"]]}, {"text": " adenosine  agonists, N6-(R-phenylisopropyl) adenosine  ( R-PIA  , N6-(S-phenylisopropyl) adenosine , 5'-(N-cyclopropyl)-carboxamido adenosine , antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["R-PIA", "AGONIST", "adenosine"]]}, {"text": " adenosine  agonists, N6-(R-phenylisopropyl) adenosine  (R-PIA),  N6-(S-phenylisopropyl) adenosine    5'-(N-cyclopropyl)-carboxamido adenosine , antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["N6-(S-phenylisopropyl)adenosine", "AGONIST", "adenosine"]]}, {"text": " adenosine  agonists, N6-(R-phenylisopropyl) adenosine  (R-PIA), N6-(S-phenylisopropyl) adenosine ,  5'-(N-cyclopropyl)-carboxamido adenosine    antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["5'-(N-cyclopropyl)-carboxamidoadenosine", "AGONIST", "adenosine"]]}, {"text": " adenosine  agonists, N6-(R-phenylisopropyl) adenosine  (R-PIA), N6-(S-phenylisopropyl) adenosine , 5'-(N-cyclopropyl)-carboxamido adenosine , antagonists,  theophylline  and 8-p-(sulfophenyl) theophylline  as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["theophylline", "ANTAGONIST", "adenosine"]]}, {"text": " adenosine  agonists, N6-(R-phenylisopropyl) adenosine  (R-PIA), N6-(S-phenylisopropyl) adenosine , 5'-(N-cyclopropyl)-carboxamido adenosine , antagonists, theophylline and  8-p-(sulfophenyl)theophylline  as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["8-p-(sulfophenyl)theophylline", "ANTAGONIST", "adenosine"]]}, {"text": " adenosine  agonists, N6-(R-phenylisopropyl) adenosine  (R-PIA), N6-(S-phenylisopropyl) adenosine , 5'-(N-cyclopropyl)-carboxamido adenosine , antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as  enprofylline  on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod", "triple_list": [["enprofylline", "ANTAGONIST", "adenosine"]]}, {"text": " Enprofylline   a weak  adenosine  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  adenosine  receptor mechanism(s) in ethanol- adenosine  interactions", "triple_list": [["Enprofylline", "ANTAGONIST", "adenosine"]]}, {"text": " Celastrol  also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and  Annexin V  markers of apoptosis", "triple_list": [["Celastrol", "ACTIVATOR", "Annexin V"]]}, {"text": " Celastrol   a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased  TGF-\u03b21  induced phosphorylation of TAK1 and RELA, and suppressed basal,  TGF-\u03b21 - and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "TGF-\u03b21"]]}, {"text": " Celastrol   a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased  TGF-\u03b21 -induced phosphorylation of TAK1 and RELA, and suppressed basal,  TGF-\u03b21   and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "TGF-\u03b21"]]}, {"text": " Celastrol   a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and  tumor necrosis factor-alpha  (TNF-\u03b1)-induced NF-\u03baB reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "tumor necrosis factor-alpha"]]}, {"text": " Celastrol   a  TAK1  inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of  TAK1  and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "TAK1"]]}, {"text": " Celastrol   a  TAK1  inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of  TAK1  and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "TAK1"]]}, {"text": " Celastrol   a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and  RELA   and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "RELA"]]}, {"text": " Celastrol   a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced  NF-\u03baB  reporter gene activity", "triple_list": [["Celastrol", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": " Celastrol  highlights the therapeutic potential of agents targeting  TAK1  as a key node in this pro-oncogenic TGF-\u03b2-NF-\u03baB signal pathway.", "triple_list": [["Celastrol", "DOWNREGULATOR", "TAK1"]]}, {"text": "When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of  p38  MAPK and ERK1/2 phosphorylation by  dynorphin A   CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors", "triple_list": [["dynorphin A", "ACTIVATOR", "p38"]]}, {"text": "When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38  MAPK  and ERK1/2 phosphorylation by  dynorphin A   CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors", "triple_list": [["dynorphin A", "ACTIVATOR", "MAPK"]]}, {"text": "CONCLUSIONS AND IMPLICATIONS: In different cell systems,  mianserin  directly activates  kappa-opioid receptors   displaying partial agonist activity at brain receptors", "triple_list": [["mianserin", "ACTIVATOR", "kappa-opioid receptors"]]}, {"text": "In [(35)S]GTPgammaS assays,  mianserin  selectively activated  kappa-opioid receptors   The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI)", "triple_list": [["mianserin", "ACTIVATOR", "kappa-opioid receptors"]]}, {"text": "The agonist activity was antagonized by the selective  kappa-opioid  blocker  nor-binaltorphimine  (nor-BNI)", "triple_list": [["nor-binaltorphimine", "DOWNREGULATOR", "kappa-opioid"]]}, {"text": "The agonist activity was antagonized by the selective  kappa-opioid  blocker nor-binaltorphimine ( nor-BNI  ", "triple_list": [["nor-BNI", "DOWNREGULATOR", "kappa-opioid"]]}, {"text": "When combined,  mianserin  antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of  p38  MAPK and ERK1/2 phosphorylation by dynorphin A", "triple_list": [["mianserin", "DOWNREGULATOR", "p38"]]}, {"text": "When combined,  mianserin  antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38  MAPK  and ERK1/2 phosphorylation by dynorphin A", "triple_list": [["mianserin", "DOWNREGULATOR", "MAPK"]]}, {"text": "We previously reported that  tricyclic  antidepressants act as agonists at distinct  opioid receptors   Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native  opioid receptors ", "triple_list": [["tricyclic", "AGONIST", "opioid receptors"]]}, {"text": "CONCLUSIONS AND IMPLICATIONS: In different cell systems,  mianserin  directly activates  kappa-opioid receptors   displaying partial agonist activity at brain receptors", "triple_list": [["mianserin", "AGONIST", "kappa-opioid receptors"]]}, {"text": "The  mianserin  analogue mirtazapine also displayed  kappa-opioid  agonist activity", "triple_list": [["mianserin", "AGONIST", "kappa-opioid"]]}, {"text": "The mianserin analogue  mirtazapine  also displayed  kappa-opioid  agonist activity", "triple_list": [["mirtazapine", "AGONIST", "kappa-opioid"]]}, {"text": "The atypical antidepressant  mianserin  exhibits agonist activity at  kappa-opioid receptors   BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood", "triple_list": [["mianserin", "AGONIST", "kappa-opioid receptors"]]}, {"text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  kappa-opioid  agonists  (-)-U50,488  and dynorphin A", "triple_list": [["(-)-U50,488", "AGONIST", "kappa-opioid"]]}, {"text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  kappa-opioid  agonists (-)-U50,488 and  dynorphin A   When combined, mianserin antagonized the effects of the full  kappa-opioid  receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by  dynorphin A ", "triple_list": [["dynorphin A", "AGONIST", "kappa-opioid"]]}, {"text": "The agonist activity was antagonized by the selective  kappa-opioid  blocker  nor-binaltorphimine  (nor-BNI)", "triple_list": [["nor-binaltorphimine", "ANTAGONIST", "kappa-opioid"]]}, {"text": "The agonist activity was antagonized by the selective  kappa-opioid  blocker nor-binaltorphimine ( nor-BNI  ", "triple_list": [["nor-BNI", "ANTAGONIST", "kappa-opioid"]]}, {"text": "When combined,  mianserin  antagonized the effects of the full  kappa-opioid receptor  agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A", "triple_list": [["mianserin", "ANTAGONIST", "kappa-opioid receptor"]]}, {"text": "In the present study we tested whether  propranolol   a  \u03b2-receptor  antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)", "triple_list": [["propranolol", "ANTAGONIST", "\u03b2-receptor"]]}, {"text": "The purpose of this review is to summarize current knowledge about  oxysterol  dependent activation by  LXR  of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of  oxysterol  generation for expression of  LXR -dependent genes.", "triple_list": [["oxysterol", "ACTIVATOR", "LXR"]]}, {"text": " LXRs  are thought to be activated predominantly by  oxysterols  generated enzymatically from cholesterol in different cell organelles", "triple_list": [["oxysterols", "ACTIVATOR", "LXRs"]]}, {"text": "Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in  sterol-27-hydroxylase  activity lead to specific blocks in  oxysterol  production and impaired LXR-dependent gene activation", "triple_list": [["oxysterol", "PRODUCT-OF", "sterol-27-hydroxylase"]]}, {"text": "Mass spectral analysis of  CBDP  inhibited  BChE  digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438", "triple_list": [["CBDP", "DOWNREGULATOR", "BChE"]]}, {"text": " CBDP  irreversibly inhibits  butyrylcholinesterase  (BChE) in human plasma by forming adducts on the active site serine (Ser-198)", "triple_list": [["CBDP", "DOWNREGULATOR", "butyrylcholinesterase"]]}, {"text": " CBDP  irreversibly inhibits butyrylcholinesterase ( BChE   in human plasma by forming adducts on the active site serine (Ser-198)", "triple_list": [["CBDP", "DOWNREGULATOR", "BChE"]]}, {"text": "We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by  \u03b1-tocopherol  in the rat dentate gyrus, increasing  cyclic adenosine monophosphate response element binding protein  phosphorylation", "triple_list": [["\u03b1-tocopherol", "ACTIVATOR", "cyclic adenosine monophosphate response element binding protein"]]}, {"text": " Galantamine  is a reversible, competitive  acetylcholinesterase  (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids", "triple_list": [["Galantamine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": " Galantamine  is a reversible, competitive acetylcholinesterase ( AChE   inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids", "triple_list": [["Galantamine", "DOWNREGULATOR", "AChE"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  ER\u03b2  agonist- DPN  [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  ER\u03b2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["DPN", "AGONIST", "ER\u03b2"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  ER\u03b2  agonist-DPN [ 2,3-bis(4-hydroxyphenyl)-propionitrile  , a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  ER\u03b2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["2,3-bis(4-hydroxyphenyl)-propionitrile", "AGONIST", "ER\u03b2"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist- PPT  [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["PPT", "AGONIST", "ER\u03b1"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist-PPT [ 4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol  , a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol", "AGONIST", "ER\u03b1"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist- MPP  [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["MPP", "ANTAGONIST", "ER\u03b1"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist-MPP [ 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol  -1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol", "ANTAGONIST", "ER\u03b1"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]- 1H-pyrazole dihydrochloride   or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["1H-pyrazole dihydrochloride", "ANTAGONIST", "ER\u03b1"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  ER\u03b2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  ER\u03b2  antagonist- PHTPP  (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)", "triple_list": [["PHTPP", "ANTAGONIST", "ER\u03b2"]]}, {"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  ER\u03b2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  ER\u03b2  antagonist-PHTPP ( 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol  ", "triple_list": [["4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol", "ANTAGONIST", "ER\u03b2"]]}, {"text": "Modulation of the  nitric oxide  producing system (demonstrated via the  NADPH-diaphorase  histochemical reaction) by oestradiol has been established in several structures of the rat brain", "triple_list": [["nitric oxide", "PRODUCT-OF", "NADPH-diaphorase"]]}, {"text": "Furthermore,  salubrinal   a specific  eIF2\u03b1  phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA", "triple_list": [["salubrinal", "ACTIVATOR", "eIF2\u03b1"]]}, {"text": "Furthermore,  salubrinal   a specific eIF2\u03b1 phosphorylation-inducing agent, increased  CHOP  and DR5 expression in the presence of VA", "triple_list": [["salubrinal", "ACTIVATOR", "CHOP"]]}, {"text": "Furthermore,  salubrinal   a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and  DR5  expression in the presence of VA", "triple_list": [["salubrinal", "ACTIVATOR", "DR5"]]}, {"text": " Verrucarin A  sensitizes TRAIL-induced apoptosis via the upregulation of  DR5  in an eIF2\u03b1/CHOP-dependent manner", "triple_list": [["Verrucarin A", "ACTIVATOR", "DR5"]]}, {"text": " Verrucarin A  sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an  eIF2\u03b1  CHOP-dependent manner", "triple_list": [["Verrucarin A", "ACTIVATOR", "eIF2\u03b1"]]}, {"text": " Verrucarin A  sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1/ CHOP  dependent manner", "triple_list": [["Verrucarin A", "ACTIVATOR", "CHOP"]]}, {"text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  glucose  transporter isoform 4 (GLUT4) and  glucose  uptake", "triple_list": [["glucose", "PRODUCT-OF", "glucose transporter isoform 4"]]}, {"text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  glucose  transporter isoform 4 ( GLUT4   and  glucose  uptake", "triple_list": [["glucose", "PRODUCT-OF", "GLUT4"]]}, {"text": "Our data also indicate that  NMDA receptor  pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since  AP7  microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO", "triple_list": [["AP7", "DOWNREGULATOR", "NMDA receptor"]]}, {"text": "Other groups received either an infusion of the selective  NMDA receptor  antagonist ( AP7   10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)", "triple_list": [["AP7", "ANTAGONIST", "NMDA receptor"]]}, {"text": "The acetylation of  TETA  is increased in  SSAT1  overexpressing mice compared with wild-type mice", "triple_list": [["TETA", "PRODUCT-OF", "SSAT1"]]}, {"text": "However, SSAT1-deficient mice metabolize  TETA  at the same rate as the wild-type mice, indicating the existence of another  N-acetylase  respons 2ible for its metabolism in mice", "triple_list": [["TETA", "PRODUCT-OF", "N-acetylase"]]}, {"text": "Here, we show that siRNA-mediated knockdown of  SSAT2  in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of  TETA  to MAT", "triple_list": [["TETA", "PRODUCT-OF", "SSAT2"]]}, {"text": "By contrast,  1,12-diamino-3,6,9-triazadodecane  SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  SSAT1  in HEPG2 cells and in wild-type primary hepatocytes", "triple_list": [["1,12-diamino-3,6,9-triazadodecane", "PRODUCT-OF", "SSAT1"]]}, {"text": "By contrast,  1,12-diamino-3,6,9-triazadodecane  SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of  human recombinant SSAT2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes", "triple_list": [["1,12-diamino-3,6,9-triazadodecane", "PRODUCT-OF", "human recombinant SSAT2"]]}, {"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane( SpmTrien  , a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  SSAT1  in HEPG2 cells and in wild-type primary hepatocytes", "triple_list": [["SpmTrien", "PRODUCT-OF", "SSAT1"]]}, {"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane( SpmTrien  , a charge-deficient spermine analog, was an extremely poor substrate of  human recombinant SSAT2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes", "triple_list": [["SpmTrien", "PRODUCT-OF", "human recombinant SSAT2"]]}, {"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient  spermine  analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  SSAT1  in HEPG2 cells and in wild-type primary hepatocytes", "triple_list": [["spermine", "PRODUCT-OF", "SSAT1"]]}, {"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient  spermine  analog, was an extremely poor substrate of  human recombinant SSAT2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes", "triple_list": [["spermine", "PRODUCT-OF", "human recombinant SSAT2"]]}, {"text": "Metabolism of  triethylenetetramine  and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and  thialysine acetyltransferase   Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine", "triple_list": [["triethylenetetramine", "PRODUCT-OF", "thialysine acetyltransferase"]]}, {"text": "Metabolism of  triethylenetetramine  and 1,12-diamino-3,6,9-triazadodecane by the  spermidine/spermine-N(1)-acetyltransferase  and thialysine acetyltransferase", "triple_list": [["triethylenetetramine", "PRODUCT-OF", "spermidine/spermine-N(1)-acetyltransferase"]]}, {"text": "Metabolism of triethylenetetramine and  1,12-diamino-3,6,9-triazadodecane  by the spermidine/spermine-N(1)-acetyltransferase and  thialysine acetyltransferase   Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine", "triple_list": [["1,12-diamino-3,6,9-triazadodecane", "PRODUCT-OF", "thialysine acetyltransferase"]]}, {"text": "Metabolism of triethylenetetramine and  1,12-diamino-3,6,9-triazadodecane  by the  spermidine/spermine-N(1)-acetyltransferase  and thialysine acetyltransferase", "triple_list": [["1,12-diamino-3,6,9-triazadodecane", "PRODUCT-OF", "spermidine/spermine-N(1)-acetyltransferase"]]}, {"text": "Thus, despite the similar structures of  TETA  and SpmTrien,  SSAT2  is the main acetylator of  TETA   whereas SpmTrien is primarily acetylated by SSAT1.", "triple_list": [["TETA", "PRODUCT-OF", "SSAT2"]]}, {"text": "Thus, despite the similar structures of TETA and  SpmTrien , SSAT2 is the main acetylator of TETA, whereas  SpmTrien  is primarily acetylated by  SSAT1  ", "triple_list": [["SpmTrien", "PRODUCT-OF", "SSAT1"]]}, {"text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme  spermidine/spermine-N(1)-acetyltransferase  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)", "triple_list": [["TETA", "PRODUCT-OF", "spermidine/spermine-N(1)-acetyltransferase"]]}, {"text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ( SSAT1   and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)", "triple_list": [["TETA", "PRODUCT-OF", "SSAT1"]]}, {"text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  thialysine acetyltransferase  (SSAT2) to its monoacetylated derivative (MAT)", "triple_list": [["TETA", "PRODUCT-OF", "thialysine acetyltransferase"]]}, {"text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ( SSAT2   to its monoacetylated derivative (MAT)", "triple_list": [["TETA", "PRODUCT-OF", "SSAT2"]]}, {"text": "We recently showed that TETA is metabolized in vitro by  polyamine  catabolic enzyme  spermidine/spermine-N(1)-acetyltransferase  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)", "triple_list": [["polyamine", "PRODUCT-OF", "spermidine/spermine-N(1)-acetyltransferase"]]}, {"text": "We recently showed that TETA is metabolized in vitro by  polyamine  catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ( SSAT1   and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)", "triple_list": [["polyamine", "PRODUCT-OF", "SSAT1"]]}, {"text": "In vitro metabolism of the  5-hydroxytryptamine1B  receptor antagonist  elzasonan   The metabolism of  elzasonan  has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (rCYP)", "triple_list": [["elzasonan", "ANTAGONIST", "5-hydroxytryptamine1B"]]}, {"text": "Cytochrome b5 has shown to be an essential component in  P450 3A4  catalyzed  5-hydroxyelzasonan  formation and provides insights on the disconnect between human liver microsomes data and that of rCYP", "triple_list": [["5-hydroxyelzasonan", "PRODUCT-OF", "P450 3A4"]]}, {"text": "The  rCYP  data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each  rCYP  in the metabolism of  elzasonan   Results demonstrated the involvement of CYP3A4 in the pathways leading to M3a, M3, M5 and M6 and CYP2C8 in the formation of M4", "triple_list": [["elzasonan", "PRODUCT-OF", "rCYP"]]}, {"text": "The signaling of both  Sox9  and Runx2, key regulators of chondrogenesis, was downregulated by  VPA   In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes", "triple_list": [["VPA", "DOWNREGULATOR", "Sox9"]]}, {"text": "The signaling of both Sox9 and  Runx2   key regulators of chondrogenesis, was downregulated by  VPA   In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes", "triple_list": [["VPA", "DOWNREGULATOR", "Runx2"]]}, {"text": " VPA  caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its  HDAC  inhibitory effect", "triple_list": [["VPA", "DOWNREGULATOR", "HDAC"]]}, {"text": "In utero exposure to  valproic acid  (VPA), a  histone deacetylase  (HDAC) inhibitor, causes neural tube, heart, and limb defects", "triple_list": [["valproic acid", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "In utero exposure to  valproic acid  (VPA), a histone deacetylase ( HDAC   inhibitor, causes neural tube, heart, and limb defects", "triple_list": [["valproic acid", "DOWNREGULATOR", "HDAC"]]}, {"text": "In utero exposure to valproic acid ( VPA  , a  histone deacetylase  (HDAC) inhibitor, causes neural tube, heart, and limb defects", "triple_list": [["VPA", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "In utero exposure to valproic acid ( VPA  , a histone deacetylase ( HDAC   inhibitor, causes neural tube, heart, and limb defects", "triple_list": [["VPA", "DOWNREGULATOR", "HDAC"]]}, {"text": "In summary, activation of  caspases  and oxidative stress were observed after  AMD  TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated  AMD /TNF-induced cytotoxicity.", "triple_list": [["AMD", "ACTIVATOR", "caspases"]]}, {"text": " \u03b1-TOCO  plus a  pancaspase  inhibitor completely abolished AMD/TNF-induced cytotoxicity", "triple_list": [["\u03b1-TOCO", "DOWNREGULATOR", "pancaspase"]]}, {"text": "Human serum butyrylcholinesterase ( HuBChE   is currently the most suitable bioscavenger for the prophylaxis of highly toxic  organophosphate  (OP) nerve agents", "triple_list": [["organophosphate", "PRODUCT-OF", "HuBChE"]]}, {"text": " Human serum butyrylcholinesterase  (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic  organophosphate  (OP) nerve agents", "triple_list": [["organophosphate", "PRODUCT-OF", "Human serum butyrylcholinesterase"]]}, {"text": "Cu-dependent  tyrosinase  activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate  l-DOPA   These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.", "triple_list": [["l-DOPA", "PRODUCT-OF", "tyrosinase"]]}, {"text": "Protein expression of  Ugt1a6  also decreased and corresponded with reduced in vitro glucuronidation of  bisphenol A  in S9 fractions from livers of pregnant mice", "triple_list": [["bisphenol A", "DOWNREGULATOR", "Ugt1a6"]]}, {"text": "Results showed that  DMF  increased nuclear levels of  Nrf2   and both  DMF  and adenovirus-mediated overexpression of  Nrf2  (Ad- Nrf2 ) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "ACTIVATOR", "Nrf2"]]}, {"text": "Results showed that  DMF  increased nuclear levels of  Nrf2 , and both  DMF  and adenovirus-mediated overexpression of  Nrf2  (Ad- Nrf2 ) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "ACTIVATOR", "Nrf2"]]}, {"text": "Finally,  DMF  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of  Nrf2  and phospho-Smad3, respectively", "triple_list": [["DMF", "ACTIVATOR", "Nrf2"]]}, {"text": "Additionally,  DMF  and Ad-Nrf2 repressed  TGF-beta  stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression", "triple_list": [["DMF", "DOWNREGULATOR", "TGF-beta"]]}, {"text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  DMF  on  TGF-beta  induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  DMF ", "triple_list": [["DMF", "DOWNREGULATOR", "TGF-beta"]]}, {"text": "Results showed that  DMF  increased nuclear levels of Nrf2, and both  DMF  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased  PAI-1   alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "DOWNREGULATOR", "PAI-1"]]}, {"text": "Results showed that  DMF  increased nuclear levels of Nrf2, and both  DMF  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1,  alpha-smooth muscle actin  (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "DOWNREGULATOR", "alpha-smooth muscle actin"]]}, {"text": "Results showed that  DMF  increased nuclear levels of Nrf2, and both  DMF  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin ( alpha-SMA  , fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "DOWNREGULATOR", "alpha-SMA"]]}, {"text": "Results showed that  DMF  increased nuclear levels of Nrf2, and both  DMF  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA),  fibronectin  and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "DOWNREGULATOR", "fibronectin"]]}, {"text": "Results showed that  DMF  increased nuclear levels of Nrf2, and both  DMF  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and  type 1 collagen  expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)", "triple_list": [["DMF", "DOWNREGULATOR", "type 1 collagen"]]}, {"text": " Dimethylfumarate  attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/ Smad  signaling", "triple_list": [["Dimethylfumarate", "DOWNREGULATOR", "Smad"]]}, {"text": " Dimethylfumarate  attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of  transforming growth factor-beta  Smad signaling", "triple_list": [["Dimethylfumarate", "DOWNREGULATOR", "transforming growth factor-beta"]]}, {"text": "Finally,  DMF  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and  alpha-SMA   fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively", "triple_list": [["DMF", "DOWNREGULATOR", "alpha-SMA"]]}, {"text": "Finally,  DMF  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA,  fibronectin  and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively", "triple_list": [["DMF", "DOWNREGULATOR", "fibronectin"]]}, {"text": "Finally,  DMF  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and  type 1 collagen  expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively", "triple_list": [["DMF", "DOWNREGULATOR", "type 1 collagen"]]}, {"text": "Finally,  DMF  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and  phospho-Smad3   respectively", "triple_list": [["DMF", "DOWNREGULATOR", "phospho-Smad3"]]}, {"text": "In summary,  DMF  attenuated renal fibrosis via the Nrf2-mediated inhibition of  TGF-beta  Smad3 signaling in an ARE-independent manner, suggesting that  DMF  could be used to treat renal fibrosis.", "triple_list": [["DMF", "DOWNREGULATOR", "TGF-beta"]]}, {"text": "In summary,  DMF  attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/ Smad3  signaling in an ARE-independent manner, suggesting that  DMF  could be used to treat renal fibrosis.", "triple_list": [["DMF", "DOWNREGULATOR", "Smad3"]]}, {"text": "Additionally,  DMF  and Ad-Nrf2 repressed TGF-beta-stimulated  Smad3  activity by inhibiting  Smad3  phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression", "triple_list": [["DMF", "DOWNREGULATOR", "Smad3"]]}, {"text": "Additionally,  DMF  and Ad-Nrf2 repressed TGF-beta-stimulated  Smad3  activity by inhibiting  Smad3  phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression", "triple_list": [["DMF", "DOWNREGULATOR", "Smad3"]]}, {"text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while  osteocalcin  (OCN) was augmented in CCL3(-/-) and  Met  RANTES-treated mice", "triple_list": [["Met", "ACTIVATOR", "osteocalcin"]]}, {"text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin ( OCN   was augmented in CCL3(-/-) and  Met  RANTES-treated mice", "triple_list": [["Met", "ACTIVATOR", "OCN"]]}, {"text": "The expression of the osteoblast markers runt-related transcription factor 2 ( RUNX2   and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and  Met  RANTES-treated mice", "triple_list": [["Met", "DOWNREGULATOR", "RUNX2"]]}, {"text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and  periostin  was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and  Met  RANTES-treated mice", "triple_list": [["Met", "DOWNREGULATOR", "periostin"]]}, {"text": "The expression of the osteoblast markers  runt-related transcription factor 2  (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and  Met  RANTES-treated mice", "triple_list": [["Met", "DOWNREGULATOR", "runt-related transcription factor 2"]]}, {"text": "mRNA levels of  receptor activator of nuclear factor kappa-B  (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "receptor activator of nuclear factor kappa-B"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B ( RANK  , its ligand  RANK L, tumor necrosis factor alpha (TNF-\u03b1) and  RANK L/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "RANK"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand  RANKL   tumor necrosis factor alpha (TNF-\u03b1) and  RANKL /osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "RANKL"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL,  tumor necrosis factor alpha  (TNF-\u03b1) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "tumor necrosis factor alpha"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha ( TNF-\u03b1   and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "TNF-\u03b1"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand  RANKL , tumor necrosis factor alpha (TNF-\u03b1) and  RANKL  osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "RANKL"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/ osteoprotegerin  (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "osteoprotegerin"]]}, {"text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/osteoprotegerin ( OPG   ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  Met  RANTES", "triple_list": [["Met", "DOWNREGULATOR", "OPG"]]}, {"text": " Met  RANTES treatment also reduced the levels of  cathepsin K  and metalloproteinase 13 (MMP13)", "triple_list": [["Met", "DOWNREGULATOR", "cathepsin K"]]}, {"text": " Met  RANTES treatment also reduced the levels of cathepsin K and  metalloproteinase 13  (MMP13)", "triple_list": [["Met", "DOWNREGULATOR", "metalloproteinase 13"]]}, {"text": " Met  RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 ( MMP13  ", "triple_list": [["Met", "DOWNREGULATOR", "MMP13"]]}, {"text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  Met  RANTES (an antagonist of  CCR5  and CCR1)", "triple_list": [["Met", "ANTAGONIST", "CCR5"]]}, {"text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and  CCR1 (-/-) mice and in animals treated with  Met  RANTES (an antagonist of CCR5 and  CCR1  ", "triple_list": [["Met", "ANTAGONIST", "CCR1"]]}, {"text": "The quinolizidine alkaloids (natural products) such as oxy matrine , sophoridine, sophocarpine and  matrine  carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  hERG  blocking activity", "triple_list": [["matrine", "DOWNREGULATOR", "hERG"]]}, {"text": "The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of  O=C=N-C-C-C-N  that possessed positive ionotropic effect and  hERG  blocking activity", "triple_list": [["O=C=N-C-C-C-N", "DOWNREGULATOR", "hERG"]]}, {"text": "The  quinolizidine alkaloids  (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  hERG  blocking activity", "triple_list": [["quinolizidine alkaloids", "DOWNREGULATOR", "hERG"]]}, {"text": "The quinolizidine alkaloids (natural products) such as  oxymatrine   sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  hERG  blocking activity", "triple_list": [["oxymatrine", "DOWNREGULATOR", "hERG"]]}, {"text": "The quinolizidine alkaloids (natural products) such as oxymatrine,  sophoridine   sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  hERG  blocking activity", "triple_list": [["sophoridine", "DOWNREGULATOR", "hERG"]]}, {"text": "The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine,  sophocarpine  and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  hERG  blocking activity", "triple_list": [["sophocarpine", "DOWNREGULATOR", "hERG"]]}, {"text": "Several effects of  polyphenols  are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors,  AMPK  activators, calorie-restriction mimetics or epigenetic regulators", "triple_list": [["polyphenols", "ACTIVATOR", "AMPK"]]}, {"text": "Several effects of  polyphenols  are useful in this scenario, including a reduction in the activities of  cytokines  and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators", "triple_list": [["polyphenols", "DOWNREGULATOR", "cytokines"]]}, {"text": "Several effects of  polyphenols  are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through  histone deacetylase  inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators", "triple_list": [["polyphenols", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": " NFD  suppressed  EGF  mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity", "triple_list": [["NFD", "DOWNREGULATOR", "EGF"]]}, {"text": " NFD  abrogated  EGF  induced phosphorylation of  EGF  receptor ( EGF R) and phosphatidylinositol 3-kinase (PI3K)/Akt", "triple_list": [["NFD", "DOWNREGULATOR", "EGF"]]}, {"text": "Furthermore, the EGFR inhibitor  AG1478  inhibited EGF-induced  MMP-9  expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation", "triple_list": [["AG1478", "DOWNREGULATOR", "MMP-9"]]}, {"text": "These findings suggest that  NFD  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent  PI3K  Akt signaling, leading to the down-regulation of MMP-9 expression", "triple_list": [["NFD", "DOWNREGULATOR", "PI3K"]]}, {"text": "These findings suggest that  NFD  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/ Akt  signaling, leading to the down-regulation of MMP-9 expression", "triple_list": [["NFD", "DOWNREGULATOR", "Akt"]]}, {"text": "These findings suggest that  NFD  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of  MMP-9  expression", "triple_list": [["NFD", "DOWNREGULATOR", "MMP-9"]]}, {"text": " NFD  suppressed EGF-mediated protein levels of  c-Jun  and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity", "triple_list": [["NFD", "DOWNREGULATOR", "c-Jun"]]}, {"text": " NFD  suppressed EGF-mediated protein levels of c-Jun and  c-Fos   and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity", "triple_list": [["NFD", "DOWNREGULATOR", "c-Fos"]]}, {"text": " NFD  suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced  MMP-9  expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity", "triple_list": [["NFD", "DOWNREGULATOR", "MMP-9"]]}, {"text": "Furthermore, the EGFR inhibitor  AG1478  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of  PI3K /Akt, suggesting that  PI3K  Akt activation occur downstream of EGFR activation", "triple_list": [["AG1478", "DOWNREGULATOR", "PI3K"]]}, {"text": "Furthermore, the EGFR inhibitor  AG1478  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/ Akt , suggesting that PI3K/ Akt  activation occur downstream of EGFR activation", "triple_list": [["AG1478", "DOWNREGULATOR", "Akt"]]}, {"text": "Furthermore, the  EGFR  inhibitor  AG1478  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of  EGFR  activation", "triple_list": [["AG1478", "DOWNREGULATOR", "EGFR"]]}, {"text": "Furthermore, the  EGFR  inhibitor  AG1478  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of  EGFR  activation", "triple_list": [["AG1478", "DOWNREGULATOR", "EGFR"]]}, {"text": "Furthermore, the  EGF R inhibitor  AG1478  inhibited  EGF  induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of  EGF R activation", "triple_list": [["AG1478", "DOWNREGULATOR", "EGF"]]}, {"text": "Furthermore, the EGFR inhibitor  AG1478  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of  PI3K  Akt, suggesting that  PI3K /Akt activation occur downstream of EGFR activation", "triple_list": [["AG1478", "DOWNREGULATOR", "PI3K"]]}, {"text": "Furthermore, the EGFR inhibitor  AG1478  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/ Akt   suggesting that PI3K/ Akt  activation occur downstream of EGFR activation", "triple_list": [["AG1478", "DOWNREGULATOR", "Akt"]]}, {"text": "Inhibition of  EGF   EGF R activation with  naphtho[1,2-b]furan-4,5-dione  blocks migration and invasion of MDA-MB-231 cells", "triple_list": [["naphtho[1,2-b]furan-4,5-dione", "DOWNREGULATOR", "EGF"]]}, {"text": "Inhibition of EGF/ EGFR  activation with  naphtho[1,2-b]furan-4,5-dione  blocks migration and invasion of MDA-MB-231 cells", "triple_list": [["naphtho[1,2-b]furan-4,5-dione", "DOWNREGULATOR", "EGFR"]]}, {"text": "These findings suggest that  NFD  inhibited the  EGF  induced invasion and migration of MDA-MB-231 cells via  EGF R-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression", "triple_list": [["NFD", "DOWNREGULATOR", "EGF"]]}, {"text": "These findings suggest that  NFD  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via  EGFR  dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression", "triple_list": [["NFD", "DOWNREGULATOR", "EGFR"]]}, {"text": " NFD  suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced  MMP-9  expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity", "triple_list": [["NFD", "DOWNREGULATOR", "MMP-9"]]}, {"text": " NFD  abrogated EGF-induced phosphorylation of  EGF receptor  (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt", "triple_list": [["NFD", "DOWNREGULATOR", "EGF receptor"]]}, {"text": " NFD  abrogated EGF-induced phosphorylation of EGF receptor ( EGFR   and phosphatidylinositol 3-kinase (PI3K)/Akt", "triple_list": [["NFD", "DOWNREGULATOR", "EGFR"]]}, {"text": " NFD  abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  phosphatidylinositol 3-kinase  (PI3K)/Akt", "triple_list": [["NFD", "DOWNREGULATOR", "phosphatidylinositol 3-kinase"]]}, {"text": " NFD  abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase ( PI3K  /Akt", "triple_list": [["NFD", "DOWNREGULATOR", "PI3K"]]}, {"text": " NFD  abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/ Akt   The specific PI3K inhibitor, wortmannin, blocked significantly EGF-induced cell migration and invasion", "triple_list": [["NFD", "DOWNREGULATOR", "Akt"]]}, {"text": "The specific  PI3K  inhibitor,  wortmannin   blocked significantly EGF-induced cell migration and invasion", "triple_list": [["wortmannin", "DOWNREGULATOR", "PI3K"]]}, {"text": "The specific PI3K inhibitor,  wortmannin   blocked significantly  EGF  induced cell migration and invasion", "triple_list": [["wortmannin", "DOWNREGULATOR", "EGF"]]}, {"text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated  insulin  secretion in pancreatic \u03b2 cells", "triple_list": [["3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "DOWNREGULATOR", "insulin"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09  , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated  insulin  secretion in pancreatic \u03b2 cells", "triple_list": [["ESI-09", "DOWNREGULATOR", "insulin"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated  insulin  secretion in pancreatic \u03b2 cells", "triple_list": [["nucleotide", "DOWNREGULATOR", "insulin"]]}, {"text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular  EPAC  mediated Rap1 activation and Akt phosphorylation, as well as  EPAC -mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "DOWNREGULATOR", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated  Rap1  activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "DOWNREGULATOR", "Rap1"]]}, {"text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and  Akt  phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "DOWNREGULATOR", "Akt"]]}, {"text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular  EPAC -mediated Rap1 activation and Akt phosphorylation, as well as  EPAC  mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "DOWNREGULATOR", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09  , a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular  EPAC  mediated Rap1 activation and Akt phosphorylation, as well as  EPAC -mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["ESI-09", "DOWNREGULATOR", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09  , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated  Rap1  activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["ESI-09", "DOWNREGULATOR", "Rap1"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09  , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and  Akt  phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["ESI-09", "DOWNREGULATOR", "Akt"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09  , a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular  EPAC -mediated Rap1 activation and Akt phosphorylation, as well as  EPAC  mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["ESI-09", "DOWNREGULATOR", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide   EPAC  antagonist that is capable of specifically blocking intracellular  EPAC  mediated Rap1 activation and Akt phosphorylation, as well as  EPAC -mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["nucleotide", "DOWNREGULATOR", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated  Rap1  activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["nucleotide", "DOWNREGULATOR", "Rap1"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and  Akt  phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["nucleotide", "DOWNREGULATOR", "Akt"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide   EPAC  antagonist that is capable of specifically blocking intracellular  EPAC -mediated Rap1 activation and Akt phosphorylation, as well as  EPAC  mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["nucleotide", "DOWNREGULATOR", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular  EPAC -mediated Rap1 activation and Akt phosphorylation, as well as  EPAC -mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "ANTAGONIST", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09  , a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular  EPAC -mediated Rap1 activation and Akt phosphorylation, as well as  EPAC -mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["ESI-09", "ANTAGONIST", "EPAC"]]}, {"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide   EPAC  antagonist that is capable of specifically blocking intracellular  EPAC -mediated Rap1 activation and Akt phosphorylation, as well as  EPAC -mediated insulin secretion in pancreatic \u03b2 cells", "triple_list": [["nucleotide", "ANTAGONIST", "EPAC"]]}, {"text": "Furthermore, the  AMPK  activator  5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide  (AICAR) significantly inhibited ghrelin secretion", "triple_list": [["5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide", "ACTIVATOR", "AMPK"]]}, {"text": "Furthermore, the  AMPK  activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide ( AICAR   significantly inhibited ghrelin secretion", "triple_list": [["AICAR", "ACTIVATOR", "AMPK"]]}, {"text": "Finally,  Metformin  treatment caused a significant increase in the level of  phosphorylated (active) AMPK   Our results show that  Metformin  directly inhibits stomach ghrelin production and secretion through AMPK", "triple_list": [["Metformin", "ACTIVATOR", "phosphorylated (active) AMPK"]]}, {"text": "Metformin significantly reduced  ghrelin  secretion and pro ghrelin  mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor  compound C   Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited  ghrelin  secretion", "triple_list": [["compound C", "ACTIVATOR", "ghrelin"]]}, {"text": "Metformin significantly reduced ghrelin secretion and  proghrelin  mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor  compound C   Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion", "triple_list": [["compound C", "ACTIVATOR", "proghrelin"]]}, {"text": "Our results show that  Metformin  directly inhibits stomach  ghrelin  production and secretion through AMPK", "triple_list": [["Metformin", "DOWNREGULATOR", "ghrelin"]]}, {"text": " Metformin  treatment is also associated with lower circulating levels of the  orexigenic hormone  ghrelin", "triple_list": [["Metformin", "DOWNREGULATOR", "orexigenic hormone"]]}, {"text": " Metformin  treatment is also associated with lower circulating levels of the orexigenic hormone  ghrelin   To test whether  Metformin  directly affects  ghrelin  cells, rat primary stomach cells were treated with  Metformin  and the levels of  ghrelin  secretion, pro ghrelin  gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined", "triple_list": [["Metformin", "DOWNREGULATOR", "ghrelin"]]}, {"text": " Metformin  directly inhibits  ghrelin  secretion through AMP-activated protein kinase in rat primary gastric cells", "triple_list": [["Metformin", "DOWNREGULATOR", "ghrelin"]]}, {"text": " Metformin  significantly reduced  ghrelin  secretion and pro ghrelin  mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C", "triple_list": [["Metformin", "DOWNREGULATOR", "ghrelin"]]}, {"text": " Metformin  significantly reduced ghrelin secretion and  proghrelin  mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C", "triple_list": [["Metformin", "DOWNREGULATOR", "proghrelin"]]}, {"text": "Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide ( AICAR   significantly inhibited  ghrelin  secretion", "triple_list": [["AICAR", "DOWNREGULATOR", "ghrelin"]]}, {"text": "Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the  AMPK  inhibitor  compound C   Furthermore, the  AMPK  activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion", "triple_list": [["compound C", "DOWNREGULATOR", "AMPK"]]}, {"text": "Induction of AhR by  TCDD  and prochloraz resulted in a time- and dose-dependent increase of  ABCG2  gene expression and transporter protein levels", "triple_list": [["TCDD", "ACTIVATOR", "ABCG2"]]}, {"text": "Induction of AhR by TCDD and  prochloraz  resulted in a time- and dose-dependent increase of  ABCG2  gene expression and transporter protein levels", "triple_list": [["prochloraz", "ACTIVATOR", "ABCG2"]]}, {"text": "Fungicide  prochloraz  and environmental pollutant dioxin induce the  ABCG2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway", "triple_list": [["prochloraz", "ACTIVATOR", "ABCG2"]]}, {"text": "Fungicide prochloraz and environmental pollutant  dioxin  induce the  ABCG2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway", "triple_list": [["dioxin", "ACTIVATOR", "ABCG2"]]}, {"text": "Induction of  AhR  by  TCDD  and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels", "triple_list": [["TCDD", "ACTIVATOR", "AhR"]]}, {"text": "Induction of  AhR  by TCDD and  prochloraz  resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels", "triple_list": [["prochloraz", "ACTIVATOR", "AhR"]]}, {"text": "This effect was almost completely reversed by specific  ABCG2  inhibitor  Ko143   In further mechanistic studies, we showed that this induction was due to binding of activated AhR to DRE sequences in the  ABCG2  5'-UTR", "triple_list": [["Ko143", "DOWNREGULATOR", "ABCG2"]]}, {"text": "As these regulatory motifs mediate regulation of target genes by  AhR  agonists including  TCDD  and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells", "triple_list": [["TCDD", "AGONIST", "AhR"]]}, {"text": "As these regulatory motifs mediate regulation of target genes by  AhR  agonists including TCDD and  prochloraz   we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells", "triple_list": [["prochloraz", "AGONIST", "AhR"]]}, {"text": "Receptor binding was significantly reduced by specific  AhR  antagonist  salicyl amide   Induction of  AhR  by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels", "triple_list": [["salicyl amide", "ANTAGONIST", "AhR"]]}, {"text": "TCDD or prochloraz doubled  ABCG2  mediated  Hoechst H33342  secretion", "triple_list": [["Hoechst H33342", "PRODUCT-OF", "ABCG2"]]}, {"text": "We observed similar effects of  Ag  NPs on inflammatory mediator expression in vitro and in vivo with increase of  interleukin-8  (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro", "triple_list": [["Ag", "ACTIVATOR", "interleukin-8"]]}, {"text": "We observed similar effects of  Ag  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 ( IL-8  /macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased  IL-8  protein release in vitro", "triple_list": [["Ag", "ACTIVATOR", "IL-8"]]}, {"text": "We observed similar effects of  Ag  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/ macrophage inflammatory protein 2   IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro", "triple_list": [["Ag", "ACTIVATOR", "macrophage inflammatory protein 2"]]}, {"text": "We observed similar effects of  Ag  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2,  IL-1RI   and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro", "triple_list": [["Ag", "ACTIVATOR", "IL-1RI"]]}, {"text": "We observed similar effects of  Ag  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and  tumor necrosis factor-\u03b1  expression in both models and increased IL-8 protein release in vitro", "triple_list": [["Ag", "ACTIVATOR", "tumor necrosis factor-\u03b1"]]}, {"text": "We observed similar effects of  Ag  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 ( IL-8 )/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased  IL-8  protein release in vitro", "triple_list": [["Ag", "ACTIVATOR", "IL-8"]]}, {"text": "We found that  Ag  NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 \u03bcg/cm(2)) and affected hepatocyte homeostasis by reducing  albumin  release", "triple_list": [["Ag", "DOWNREGULATOR", "albumin"]]}, {"text": "Blood pressure was increased in rats exposed to IH, and treatment with the  PDK-1  inhibitor  OSU-03012  [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats", "triple_list": [["OSU-03012", "DOWNREGULATOR", "PDK-1"]]}, {"text": "Blood pressure was increased in rats exposed to IH, and treatment with the  PDK-1  inhibitor OSU-03012 [ 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide   (33 mg/day) lowered blood pressure in IH but not sham group rats", "triple_list": [["2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide", "DOWNREGULATOR", "PDK-1"]]}, {"text": "Following  CdCl\u2082  treatment,  ICAM2  was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for  ICAM2  by 6-16 h", "triple_list": [["CdCl\u2082", "ACTIVATOR", "ICAM2"]]}, {"text": "Interestingly, there was a loss in the binding of ICAM2 to  actin  during  CdCl\u2082  induced germ cell loss, suggesting that a loss of ICAM2- actin  interactions might have facilitated junction restructuring", "triple_list": [["CdCl\u2082", "DOWNREGULATOR", "actin"]]}, {"text": "The reaction was inhibited by the specific  CYP2D  inhibitors  quinine  and fluoxetine", "triple_list": [["quinine", "DOWNREGULATOR", "CYP2D"]]}, {"text": "The reaction was inhibited by the specific  CYP2D  inhibitors quinine and  fluoxetine   Human liver microsomes of the wild-type  CYP2D 6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective  CYP2D 6*4*4 ones", "triple_list": [["fluoxetine", "DOWNREGULATOR", "CYP2D"]]}, {"text": "Of the rat CYP isoforms studied,  CYP2D  isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to  serotonin   but they were less effective than the human isoform  CYP2D 6", "triple_list": [["serotonin", "PRODUCT-OF", "CYP2D"]]}, {"text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to  serotonin   but they were less effective than the  human isoform CYP2D6   Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to  serotonin ", "triple_list": [["serotonin", "PRODUCT-OF", "human isoform CYP2D6"]]}, {"text": "The catalytic competence of  cytochrome P450  in the synthesis of  serotonin  from 5-methoxytryptamine in the brain: an in vitro study", "triple_list": [["serotonin", "PRODUCT-OF", "cytochrome P450"]]}, {"text": "Human liver microsomes of the wild-type  CYP2D6  metabolized 5-methoxytryptamine to  serotonin  more effectively than did the defective  CYP2D6 *4*4 ones", "triple_list": [["serotonin", "PRODUCT-OF", "CYP2D6"]]}, {"text": "Human liver microsomes of the wild-type  CYP2D6  metabolized 5-methoxytryptamine to  serotonin  more effectively than did the defective  CYP2D6  4*4 ones", "triple_list": [["serotonin", "PRODUCT-OF", "CYP2D6"]]}, {"text": "The obtained results indicate that  rat brain CYP2D  isoforms catalyze the formation of  serotonin  from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect  serotonin  metabolism in the brain", "triple_list": [["serotonin", "PRODUCT-OF", "rat brain CYP2D"]]}, {"text": "The obtained results indicate that rat brain  CYP2D  isoforms catalyze the formation of  serotonin  from 5-methoxytryptamine, and that the deficit or genetic defect of  CYP2D  may affect  serotonin  metabolism in the brain", "triple_list": [["serotonin", "PRODUCT-OF", "CYP2D"]]}, {"text": " O f the rat CYP isoforms studied,  CYP2D  isoforms were the most efficient in catalyzing the  O  demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform  CYP2D 6", "triple_list": [["O", "PRODUCT-OF", "CYP2D"]]}, {"text": " O f the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the  O  demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the  human isoform CYP2D6   Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin", "triple_list": [["O", "PRODUCT-OF", "human isoform CYP2D6"]]}, {"text": "Of the rat CYP isoforms studied,  CYP2D  isoforms were the most efficient in catalyzing the O-demethylation of  5-methoxytryptamine  to serotonin, but they were less effective than the human isoform  CYP2D 6", "triple_list": [["5-methoxytryptamine", "PRODUCT-OF", "CYP2D"]]}, {"text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of  5-methoxytryptamine  to serotonin, but they were less effective than the  human isoform CYP2D6   Microsomes from different brain regions were capable of metabolizing  5-methoxytryptamine  to serotonin", "triple_list": [["5-methoxytryptamine", "PRODUCT-OF", "human isoform CYP2D6"]]}, {"text": "The catalytic competence of  cytochrome P450  in the synthesis of serotonin from  5-methoxytryptamine  in the brain: an in vitro study", "triple_list": [["5-methoxytryptamine", "PRODUCT-OF", "cytochrome P450"]]}, {"text": "Human liver microsomes of the wild-type  CYP2D6  metabolized  5-methoxytryptamine  to serotonin more effectively than did the defective  CYP2D6 *4*4 ones", "triple_list": [["5-methoxytryptamine", "PRODUCT-OF", "CYP2D6"]]}, {"text": "Human liver microsomes of the wild-type  CYP2D6  metabolized  5-methoxytryptamine  to serotonin more effectively than did the defective  CYP2D6  4*4 ones", "triple_list": [["5-methoxytryptamine", "PRODUCT-OF", "CYP2D6"]]}, {"text": "The obtained results indicate that  rat brain CYP2D  isoforms catalyze the formation of serotonin from  5-methoxytryptamine   and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain", "triple_list": [["5-methoxytryptamine", "PRODUCT-OF", "rat brain CYP2D"]]}, {"text": " Toosendanin  induces apoptosis through suppression of  JNK  signaling pathway in HL-60 cells", "triple_list": [["Toosendanin", "DOWNREGULATOR", "JNK"]]}, {"text": "Western blot analysis indicated that  TSN  inhibits the  CDC42  MEKK1/JNK pathway", "triple_list": [["TSN", "DOWNREGULATOR", "CDC42"]]}, {"text": "Western blot analysis indicated that  TSN  inhibits the CDC42/ MEKK1  JNK pathway", "triple_list": [["TSN", "DOWNREGULATOR", "MEKK1"]]}, {"text": "Western blot analysis indicated that  TSN  inhibits the CDC42/MEKK1/ JNK  pathway", "triple_list": [["TSN", "DOWNREGULATOR", "JNK"]]}, {"text": "Administration of low, but not high, doses of oral  nicotine  in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of  tumor necrosis factor-\u03b1   However, the anti-inflammatory effect of  nicotine  was not seen after chronic s.c", "triple_list": [["nicotine", "ACTIVATOR", "tumor necrosis factor-\u03b1"]]}, {"text": "The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by  orexin-A , and this effect of  orexin-A  was reversed by the administration of  SB334867  as well as by hypothalamic BDNF knockdown", "triple_list": [["SB334867", "DOWNREGULATOR", "orexin-A"]]}, {"text": "The MCAO-induced decrease in  insulin receptor  levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of  SB334867  as well as by hypothalamic BDNF knockdown", "triple_list": [["SB334867", "DOWNREGULATOR", "insulin receptor"]]}, {"text": "Small interfering RNA directed BDNF, orexin-A, and  SB334867  [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific  orexin-1 receptor  antagonist] were administered directly into the hypothalamus", "triple_list": [["SB334867", "ANTAGONIST", "orexin-1 receptor"]]}, {"text": "Small interfering RNA directed BDNF, orexin-A, and SB334867 [ N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea   a specific  orexin-1 receptor  antagonist] were administered directly into the hypothalamus", "triple_list": [["N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea", "ANTAGONIST", "orexin-1 receptor"]]}, {"text": "Moreover,  5-ASA  treatment restored membranous expression of adhesion molecules  E-cadherin  and \u03b2-catenin", "triple_list": [["5-ASA", "ACTIVATOR", "E-cadherin"]]}, {"text": "Moreover,  5-ASA  treatment restored membranous expression of adhesion molecules E-cadherin and  \u03b2-catenin   Role of PAK1 as a mediator of mesalamine activity was validated in vitro and in vivo", "triple_list": [["5-ASA", "ACTIVATOR", "\u03b2-catenin"]]}, {"text": " PAK1  expression was elevated in APC(min) polyps and  5-ASA  treatment reduced its expression", "triple_list": [["5-ASA", "DOWNREGULATOR", "PAK1"]]}, {"text": "We propose that inhibition of  PAK1  expression by  5-ASA  can impede with neoplastic progression in colorectal carcinogenesis", "triple_list": [["5-ASA", "DOWNREGULATOR", "PAK1"]]}, {"text": " Mesalamine  modulates intercellular adhesion through inhibition of  p-21 activated kinase-1    Mesalamine  (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon", "triple_list": [["Mesalamine", "DOWNREGULATOR", "p-21 activated kinase-1"]]}, {"text": "The mechanism of  PAK1  inhibition and induction of membranous translocation of adhesion proteins by  5-ASA  might be independent of its known anti-inflammatory action.", "triple_list": [["5-ASA", "DOWNREGULATOR", "PAK1"]]}, {"text": "This study shows ability of  EGCG  to raise plasma bile acid concentrations, mainly through  Cyp7a1  upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow", "triple_list": [["EGCG", "ACTIVATOR", "Cyp7a1"]]}, {"text": "In contrast,  EGCG  markedly downregulated major  bile acid transporters  (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum", "triple_list": [["EGCG", "DOWNREGULATOR", "bile acid transporters"]]}, {"text": "In contrast,  EGCG  markedly downregulated major bile acid transporters ( Asbt  and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum", "triple_list": [["EGCG", "DOWNREGULATOR", "Asbt"]]}, {"text": "In contrast,  EGCG  markedly downregulated major bile acid transporters (Asbt and  Ost\u03b1   and regulatory molecules (Shp and Fgf15) in the ileum", "triple_list": [["EGCG", "DOWNREGULATOR", "Ost\u03b1"]]}, {"text": "In contrast,  EGCG  markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules ( Shp  and Fgf15) in the ileum", "triple_list": [["EGCG", "DOWNREGULATOR", "Shp"]]}, {"text": "In contrast,  EGCG  markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and  Fgf15   in the ileum", "triple_list": [["EGCG", "DOWNREGULATOR", "Fgf15"]]}, {"text": "Data at transcriptional level also demonstrated that  catalpol  potently attenuated gene expressions involved in inflammation, such as  iNOS   COX-2 and TLR4", "triple_list": [["catalpol", "DOWNREGULATOR", "iNOS"]]}, {"text": "Data at transcriptional level also demonstrated that  catalpol  potently attenuated gene expressions involved in inflammation, such as iNOS,  COX-2  and TLR4", "triple_list": [["catalpol", "DOWNREGULATOR", "COX-2"]]}, {"text": "Data at transcriptional level also demonstrated that  catalpol  potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and  TLR4   In addition, our exploration further revealed that the suppressive action of  catalpol  on inflammation was mediated via inhibiting nuclear factor-\u03baB (NF-\u03baB) activation", "triple_list": [["catalpol", "DOWNREGULATOR", "TLR4"]]}, {"text": "In addition, our exploration further revealed that the suppressive action of  catalpol  on inflammation was mediated via inhibiting nuclear factor-\u03baB ( NF-\u03baB   activation", "triple_list": [["catalpol", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": "In addition, our exploration further revealed that the suppressive action of  catalpol  on inflammation was mediated via inhibiting  nuclear factor-\u03baB  (NF-\u03baB) activation", "triple_list": [["catalpol", "DOWNREGULATOR", "nuclear factor-\u03baB"]]}, {"text": " Catalpol  inhibits LPS plus  IFN-\u03b3  induced inflammatory response in astrocytes primary cultures", "triple_list": [["Catalpol", "DOWNREGULATOR", "IFN-\u03b3"]]}, {"text": "Collectively, these results suggest that  catalpol  can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of  NF-\u03baB  could be the major determinant for its anti-inflammatory mechanism", "triple_list": [["catalpol", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": "Biochemical analyses showed that NO and ROS production and  iNOS  activity were significantly reduced by  catalpol   Data at transcriptional level also demonstrated that  catalpol  potently attenuated gene expressions involved in inflammation, such as  iNOS , COX-2 and TLR4", "triple_list": [["catalpol", "DOWNREGULATOR", "iNOS"]]}, {"text": " Protein tyrosine phosphatase 1B  inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum  saponins    Protein tyrosine phosphatase 1B  (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity", "triple_list": [["saponins", "DOWNREGULATOR", "Protein tyrosine phosphatase 1B"]]}, {"text": " Protein tyrosine phosphatase 1B  inhibitory effect by  dammarane  type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins", "triple_list": [["dammarane", "DOWNREGULATOR", "Protein tyrosine phosphatase 1B"]]}, {"text": " Protein tyrosine phosphatase 1B  inhibitory effect by dammarane-type  triterpenes  from hydrolyzate of total Gynostemma pentaphyllum saponins", "triple_list": [["triterpenes", "DOWNREGULATOR", "Protein tyrosine phosphatase 1B"]]}, {"text": "Therefore, the present results show that the earlier cerebellar responses to  (PhTe)(2)  include disruption of cytoskeletal homeostasis that could be related with  MAPK  and PKA activation and reactive astrogliosis", "triple_list": [["(PhTe)(2)", "ACTIVATOR", "MAPK"]]}, {"text": "Therefore, the present results show that the earlier cerebellar responses to  (PhTe)(2)  include disruption of cytoskeletal homeostasis that could be related with MAPK and  PKA  activation and reactive astrogliosis", "triple_list": [["(PhTe)(2)", "ACTIVATOR", "PKA"]]}, {"text": "Also, reactive astrogliosis takes part of the early responses to the insult with  (PhTe)(2)   evidenced by upregulated  GFAP  in Western blot, PCR and immunofluorescence analysis", "triple_list": [["(PhTe)(2)", "ACTIVATOR", "GFAP"]]}, {"text": "Six days after  (PhTe)(2)  injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in  NeuN  positive population evidenced by flow cytometry and reduced immunofluorescence for  NeuN   suggesting that the in vivo exposure to  (PhTe)(2)  progressed to neuronal death", "triple_list": [["(PhTe)(2)", "DOWNREGULATOR", "NeuN"]]}, {"text": "Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased  Akt  immunoreactivity, however phospho-GSK-3-\u03b2 (Ser9) was not altered in  (PhTe)(2)  injected rat", "triple_list": [["(PhTe)(2)", "DOWNREGULATOR", "Akt"]]}, {"text": "Fluorescence of the reporter dye is turned on by rapid removal of the  quinone  quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted  quinone  substrate by the cancer-associated human NAD(P)H: quinone  oxidoreductase isozyme 1 (hNQO1)", "triple_list": [["quinone", "PRODUCT-OF", "human NAD(P)H:quinone oxidoreductase isozyme 1"]]}, {"text": "Fluorescence of the reporter dye is turned on by rapid removal of the  quinone  quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted  quinone  substrate by the cancer-associated human NAD(P)H: quinone  oxidoreductase isozyme 1 ( hNQO1  ", "triple_list": [["quinone", "PRODUCT-OF", "hNQO1"]]}, {"text": "Synthesis, biological evaluation, and molecular modeling of  glycyrrhizin  derivatives as potent  high-mobility group box-1  inhibitors with anti-heart-failure activity in vivo", "triple_list": [["glycyrrhizin", "DOWNREGULATOR", "high-mobility group box-1"]]}, {"text": "Within the  TPBP  scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan- mAChR  antagonism, which was demonstrated to be mediated via the orthosteric site", "triple_list": [["TPBP", "ANTAGONIST", "mAChR"]]}, {"text": "Within the TPBP scaffold, either electronic or steric perturbations to the central  piperidine  ring led to a loss of selective M(1) allosteric agonism and afforded pan- mAChR  antagonism, which was demonstrated to be mediated via the orthosteric site", "triple_list": [["piperidine", "ANTAGONIST", "mAChR"]]}, {"text": "Additional SAR around a related M(1) allosteric agonist family ( VU0357017   identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan- mAChR  orthosteric antagonism", "triple_list": [["VU0357017", "ANTAGONIST", "mAChR"]]}, {"text": "2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  P-gp  substrate,  risperidone   and its major metabolite, 9-hydroxy risperidone , in rats", "triple_list": [["risperidone", "PRODUCT-OF", "P-gp"]]}, {"text": "2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  P-gp  substrate, risperidone, and its major metabolite,  9-hydroxyrisperidone   in rats", "triple_list": [["9-hydroxyrisperidone", "PRODUCT-OF", "P-gp"]]}, {"text": "On the other hand, peptides modified with  (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid   apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to  arginine vasopressin   The results of this study provide useful information about the structure-activity relationship of  arginine vasopressin  analogues and can help to design compounds with desired biological properties.", "triple_list": [["(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid", "ANTAGONIST", "arginine vasopressin"]]}, {"text": " Liver X Receptor (LXR) \u03b1  and LXR \u03b2 are nuclear receptors activated by  oxysterols   oxidized derivatives of cholesterol", "triple_list": [["oxysterols", "ACTIVATOR", "Liver X Receptor (LXR) \u03b1"]]}, {"text": "Liver X Receptor (LXR) \u03b1 and  LXR \u03b2  are nuclear receptors activated by  oxysterols   oxidized derivatives of cholesterol", "triple_list": [["oxysterols", "ACTIVATOR", "LXR \u03b2"]]}, {"text": "\u03b2-catenin regulates  GnRH  induced  FSH\u03b2  gene expression", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "Furthermore, knockdown of Brms1L significantly attenuated  GnRH  induced  FSH\u03b2  expression", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "Thus, our findings indicate that the expression of Brms1L depends on \u03b2-catenin activity and contributes to  FSH\u03b2  induction by  GnRH  ", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": " GnRH  caused a sustained increase in nuclear  \u03b2-catenin  levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition", "triple_list": [["GnRH", "ACTIVATOR", "\u03b2-catenin"]]}, {"text": "Small interfering RNA-mediated knockdown of \u03b2-catenin mRNA demonstrated that induction of  FSH\u03b2  mRNA by  GnRH  depended on \u03b2-catenin and that regulation of  FSH\u03b2  by \u03b2-catenin occurred independently of the JNK-c-jun pathway", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "In conclusion, in this cellular model,  DOX  effectively protects against PQ toxicity by inducing  P-gp  and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.", "triple_list": [["DOX", "ACTIVATOR", "P-gp"]]}, {"text": "The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether  doxorubicin  (DOX), a known  P-gp  inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario", "triple_list": [["doxorubicin", "ACTIVATOR", "P-gp"]]}, {"text": "The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin ( DOX  , a known  P-gp  inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario", "triple_list": [["DOX", "ACTIVATOR", "P-gp"]]}, {"text": "The herbicide  paraquat  (PQ) is a  P-gp  substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote", "triple_list": [["paraquat", "PRODUCT-OF", "P-gp"]]}, {"text": " P505-15  successfully inhibited SYK-mediated  B-cell receptor  signaling and decreased cell viability in NHL and CLL", "triple_list": [["P505-15", "DOWNREGULATOR", "B-cell receptor"]]}, {"text": "The selective  SYK  inhibitor  P505-15  (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia", "triple_list": [["P505-15", "DOWNREGULATOR", "SYK"]]}, {"text": "The selective  SYK  inhibitor P505-15 ( PRT062607   inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia", "triple_list": [["PRT062607", "DOWNREGULATOR", "SYK"]]}, {"text": " P505-15  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule  SYK  inhibitor ( SYK  IC(50) = 1 nM) with anti- SYK  activity that is at least 80-fold greater than its affinity for other kinases", "triple_list": [["P505-15", "DOWNREGULATOR", "SYK"]]}, {"text": " P505-15  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule  SYK  inhibitor ( SYK  IC(50) = 1 nM) with anti- SYK  activity that is at least 80-fold greater than its affinity for other kinases", "triple_list": [["P505-15", "DOWNREGULATOR", "SYK"]]}, {"text": " P505-15  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule  SYK  inhibitor ( SYK  IC(50) = 1 nM) with anti- SYK  activity that is at least 80-fold greater than its affinity for other kinases", "triple_list": [["P505-15", "DOWNREGULATOR", "SYK"]]}, {"text": "P505-15 (also known as  PRT062607   is a novel, highly selective, and orally bioavailable small molecule  SYK  inhibitor ( SYK  IC(50) = 1 nM) with anti- SYK  activity that is at least 80-fold greater than its affinity for other kinases", "triple_list": [["PRT062607", "DOWNREGULATOR", "SYK"]]}, {"text": "P505-15 (also known as  PRT062607   is a novel, highly selective, and orally bioavailable small molecule  SYK  inhibitor ( SYK  IC(50) = 1 nM) with anti- SYK  activity that is at least 80-fold greater than its affinity for other kinases", "triple_list": [["PRT062607", "DOWNREGULATOR", "SYK"]]}, {"text": "P505-15 (also known as  PRT062607   is a novel, highly selective, and orally bioavailable small molecule  SYK  inhibitor ( SYK  IC(50) = 1 nM) with anti- SYK  activity that is at least 80-fold greater than its affinity for other kinases", "triple_list": [["PRT062607", "DOWNREGULATOR", "SYK"]]}, {"text": " P505-15  successfully inhibited  SYK  mediated B-cell receptor signaling and decreased cell viability in NHL and CLL", "triple_list": [["P505-15", "DOWNREGULATOR", "SYK"]]}, {"text": "Although treatment with  17-AAG  reduced  AhR  levels and  AhR -regulated gene expression in lung AD cells,  AhR  expression increased anticancer activity of  17-AAG ", "triple_list": [["17-AAG", "DOWNREGULATOR", "AhR"]]}, {"text": "Although treatment with  17-AAG  reduced  AhR  levels and  AhR  regulated gene expression in lung AD cells,  AhR  expression increased anticancer activity of  17-AAG ", "triple_list": [["17-AAG", "DOWNREGULATOR", "AhR"]]}, {"text": "In addition,  17-AAG  treatment reduced cell viability,  CDK2   CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells", "triple_list": [["17-AAG", "DOWNREGULATOR", "CDK2"]]}, {"text": "In addition,  17-AAG  treatment reduced cell viability, CDK2,  CDK4   cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells", "triple_list": [["17-AAG", "DOWNREGULATOR", "CDK4"]]}, {"text": "In addition,  17-AAG  treatment reduced cell viability, CDK2, CDK4,  cyclin E   cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells", "triple_list": [["17-AAG", "DOWNREGULATOR", "cyclin E"]]}, {"text": "In addition,  17-AAG  treatment reduced cell viability, CDK2, CDK4, cyclin E,  cyclin D1   and phosphorylated Rb levels in AhR-expressing lung AD cells", "triple_list": [["17-AAG", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "In addition,  17-AAG  treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and  phosphorylated Rb  levels in AhR-expressing lung AD cells", "triple_list": [["17-AAG", "DOWNREGULATOR", "phosphorylated Rb"]]}, {"text": " 17-Allylamino-17-demethoxygeldanamycin  (17-AAG), an  Hsp90  inhibitor, is currently under evaluation for its anticancer activity in clinical trials", "triple_list": [["17-Allylamino-17-demethoxygeldanamycin", "DOWNREGULATOR", "Hsp90"]]}, {"text": "17-Allylamino-17-demethoxygeldanamycin ( 17-AAG  , an  Hsp90  inhibitor, is currently under evaluation for its anticancer activity in clinical trials", "triple_list": [["17-AAG", "DOWNREGULATOR", "Hsp90"]]}, {"text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "CDA"]]}, {"text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "Lys27Gln"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr   and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "Ala70Thr"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "DCK"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val   Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "Ile24Val"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly   and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "Ala119Gly"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser   were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C  , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["Ara-C", "PRODUCT-OF", "Pro122Ser"]]}, {"text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "CDA"]]}, {"text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "Lys27Gln"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr   and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "Ala70Thr"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "DCK"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val   Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "Ile24Val"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly   and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "Ala119Gly"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser   were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC   and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["dFdC", "PRODUCT-OF", "Pro122Ser"]]}, {"text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "CDA"]]}, {"text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "Lys27Gln"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr   and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "Ala70Thr"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "DCK"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val   Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "Ile24Val"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly   and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "Ala119Gly"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser   were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates", "triple_list": [["2',2'-difluorodeoxyuridine", "PRODUCT-OF", "Pro122Ser"]]}, {"text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( dFdU   as substrates", "triple_list": [["dFdU", "PRODUCT-OF", "CDA"]]}, {"text": "All three  CDA  proteins showed similar K(m) and V(max) for  Ara-C  and dFdC deamination, except for  CDA 70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for  Ara-C  deamination", "triple_list": [["Ara-C", "PRODUCT-OF", "CDA"]]}, {"text": "All three  CDA  proteins showed similar K(m) and V(max) for Ara-C and  dFdC  deamination, except for  CDA 70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination", "triple_list": [["dFdC", "PRODUCT-OF", "CDA"]]}, {"text": "All three  CDA  proteins showed similar K(m) and V(max) for  Ara-C  and dFdC deamination, except for  CDA  0Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for  Ara-C  deamination", "triple_list": [["Ara-C", "PRODUCT-OF", "CDA"]]}, {"text": "All four  DCK  proteins yielded comparable metabolic activity for  Ara-C  and dFdC monophosphorylation, except for  DCK 24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)", "triple_list": [["Ara-C", "PRODUCT-OF", "DCK"]]}, {"text": "All four  DCK  proteins yielded comparable metabolic activity for Ara-C and  dFdC  monophosphorylation, except for  DCK 24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of  dFdC  monophosphorylation due to a 40% decrease in K(m) (P < 0.05)", "triple_list": [["dFdC", "PRODUCT-OF", "DCK"]]}, {"text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( DCK  , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["Gemcitabine", "PRODUCT-OF", "DCK"]]}, {"text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  cytidine deaminase  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["Gemcitabine", "PRODUCT-OF", "cytidine deaminase"]]}, {"text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ( CDA   and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["Gemcitabine", "PRODUCT-OF", "CDA"]]}, {"text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  deoxycytidine kinase  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["Gemcitabine", "PRODUCT-OF", "deoxycytidine kinase"]]}, {"text": "All four  DCK  proteins yielded comparable metabolic activity for Ara-C and  dFdC  monophosphorylation, except for  DCK  4Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of  dFdC  monophosphorylation due to a 40% decrease in K(m) (P < 0.05)", "triple_list": [["dFdC", "PRODUCT-OF", "DCK"]]}, {"text": "In conclusion, the  Lys27Gln  substitution does not significantly modulate CDA activity toward  dFdC   and therefore would not contribute to interindividual variability in response to gemcitabine", "triple_list": [["dFdC", "PRODUCT-OF", "Lys27Gln"]]}, {"text": "In conclusion, the Lys27Gln substitution does not significantly modulate  CDA  activity toward  dFdC   and therefore would not contribute to interindividual variability in response to gemcitabine", "triple_list": [["dFdC", "PRODUCT-OF", "CDA"]]}, {"text": "Gemcitabine ( dFdC   2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( DCK  , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["dFdC", "PRODUCT-OF", "DCK"]]}, {"text": "Gemcitabine ( dFdC   2',2'-difluorodeoxycytidine) is metabolized by  cytidine deaminase  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["dFdC", "PRODUCT-OF", "cytidine deaminase"]]}, {"text": "Gemcitabine ( dFdC   2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ( CDA   and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["dFdC", "PRODUCT-OF", "CDA"]]}, {"text": "Gemcitabine ( dFdC   2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  deoxycytidine kinase  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["dFdC", "PRODUCT-OF", "deoxycytidine kinase"]]}, {"text": "The higher in vitro catalytic efficiency of  DCK  4Val toward  dFdC  monophosphorylation may be relevant to  dFdC  clinical response", "triple_list": [["dFdC", "PRODUCT-OF", "DCK"]]}, {"text": "The higher in vitro catalytic efficiency of  DCK  4Val toward  dFdC  monophosphorylation may be relevant to  dFdC  clinical response", "triple_list": [["dFdC", "PRODUCT-OF", "DCK"]]}, {"text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine   is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( DCK  , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["2',2'-difluorodeoxycytidine", "PRODUCT-OF", "DCK"]]}, {"text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine   is metabolized by  cytidine deaminase  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["2',2'-difluorodeoxycytidine", "PRODUCT-OF", "cytidine deaminase"]]}, {"text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine   is metabolized by cytidine deaminase ( CDA   and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["2',2'-difluorodeoxycytidine", "PRODUCT-OF", "CDA"]]}, {"text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine   is metabolized by cytidine deaminase (CDA) and  deoxycytidine kinase  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear", "triple_list": [["2',2'-difluorodeoxycytidine", "PRODUCT-OF", "deoxycytidine kinase"]]}, {"text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "CDA"]]}, {"text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "Lys27Gln"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr   and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "Ala70Thr"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "DCK"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val   Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "Ile24Val"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly   and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "Ala119Gly"]]}, {"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser   were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates", "triple_list": [["cytarabine", "PRODUCT-OF", "Pro122Ser"]]}, {"text": "A series of compounds based on a  4-phenyl-2-phenylaminopyridine  scaffold that are potent and selective inhibitors of  Traf2- and Nck-interacting kinase  (TNIK) activity are described", "triple_list": [["4-phenyl-2-phenylaminopyridine", "DOWNREGULATOR", "Traf2- and Nck-interacting kinase"]]}, {"text": "A series of compounds based on a  4-phenyl-2-phenylaminopyridine  scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase ( TNIK   activity are described", "triple_list": [["4-phenyl-2-phenylaminopyridine", "DOWNREGULATOR", "TNIK"]]}, {"text": "Discovery of  4-phenyl-2-phenylaminopyridine  based  TNIK  inhibitors", "triple_list": [["4-phenyl-2-phenylaminopyridine", "DOWNREGULATOR", "TNIK"]]}, {"text": "Here we present  boronic  and borinic acid derivatives as a new class of potent and nontoxic  APT  inhibitors", "triple_list": [["boronic", "DOWNREGULATOR", "APT"]]}, {"text": "Here we present boronic and  borinic acid  derivatives as a new class of potent and nontoxic  APT  inhibitors", "triple_list": [["borinic acid", "DOWNREGULATOR", "APT"]]}, {"text": " Boron  based inhibitors of  acyl protein thioesterases 1 and 2   Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues", "triple_list": [["Boron", "DOWNREGULATOR", "acyl protein thioesterases 1 and 2"]]}, {"text": "Furthermore,  thrombin  diminished cAMP production in ECs, which were prevented by treatment with  genistein   These findings demonstrated that  genistein  improves  thrombin -induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling.", "triple_list": [["genistein", "DOWNREGULATOR", "thrombin"]]}, {"text": "Here, we report that  genistein  at physiologically relevant concentrations (0.1-10 \u03bcM) significantly inhibited  thrombin  induced increase in endothelial monolayer permeability", "triple_list": [["genistein", "DOWNREGULATOR", "thrombin"]]}, {"text": " Genistein  also reduced the formation of stress fibers by  thrombin  and suppressed  thrombin -induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)", "triple_list": [["Genistein", "DOWNREGULATOR", "thrombin"]]}, {"text": " Genistein  also reduced the formation of stress fibers by  thrombin  and suppressed  thrombin  induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)", "triple_list": [["Genistein", "DOWNREGULATOR", "thrombin"]]}, {"text": " Genistein  also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of  myosin light chain  (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)", "triple_list": [["Genistein", "DOWNREGULATOR", "myosin light chain"]]}, {"text": " Genistein  also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain ( MLC   on Ser(19)/Thr(18) in endothelial cells (ECs)", "triple_list": [["Genistein", "DOWNREGULATOR", "MLC"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards  CYPs  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "CYPs"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs ( CYP1A2   2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "CYP1A2"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2,  2C9   2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "2C9"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9,  2C19   2D6, 3A4), Pgp, OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "2C19"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19,  2D6   3A4), Pgp, OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "2D6"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  3A4  , Pgp, OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "3A4"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  Pgp   OATP1B3, or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "Pgp"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  OATP1B3   or OCT2", "triple_list": [["GSK1292263", "DOWNREGULATOR", "OATP1B3"]]}, {"text": "3.\u2002In vitro,  GSK1292263  demonstrated little/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  OCT2   However,  GSK1292263  inhibited BCRP and OATP1B1, which are transporters involved in statin disposition", "triple_list": [["GSK1292263", "DOWNREGULATOR", "OCT2"]]}, {"text": "However,  GSK1292263  inhibited  BCRP  and OATP1B1, which are transporters involved in statin disposition", "triple_list": [["GSK1292263", "DOWNREGULATOR", "BCRP"]]}, {"text": "However,  GSK1292263  inhibited BCRP and  OATP1B1   which are transporters involved in statin disposition", "triple_list": [["GSK1292263", "DOWNREGULATOR", "OATP1B1"]]}, {"text": "4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with  GSK1292263   which is consistent with an inhibitory effect on intestinal BCRP and  CYP3A4   In contrast,  GSK1292263  did not inhibit OATP1B1 based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)]", "triple_list": [["GSK1292263", "DOWNREGULATOR", "CYP3A4"]]}, {"text": "4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with  GSK1292263   which is consistent with an inhibitory effect on intestinal  BCRP  and CYP3A4", "triple_list": [["GSK1292263", "DOWNREGULATOR", "BCRP"]]}, {"text": "1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the  HMG-coA reductase  inhibitors  simvastatin  and rosuvastatin", "triple_list": [["simvastatin", "DOWNREGULATOR", "HMG-coA reductase"]]}, {"text": "This study provides a mechanistic understanding of the in vivo inhibition of  transporters  and enzymes by  GSK1292263  ", "triple_list": [["GSK1292263", "DOWNREGULATOR", "transporters"]]}, {"text": "1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the  HMG-coA reductase  inhibitors simvastatin and  rosuvastatin   2.\u2002In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and  rosuvastatin  (10\u2009mg single dose)", "triple_list": [["rosuvastatin", "DOWNREGULATOR", "HMG-coA reductase"]]}, {"text": "2.\u2002In vitro experiments assessed the inhibition of  transporters  and CYP enzymes by  GSK1292263   and a clinical drug interaction study investigated the effect of  GSK1292263  (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)", "triple_list": [["GSK1292263", "DOWNREGULATOR", "transporters"]]}, {"text": "2.\u2002In vitro experiments assessed the inhibition of transporters and  CYP  enzymes by  GSK1292263   and a clinical drug interaction study investigated the effect of  GSK1292263  (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)", "triple_list": [["GSK1292263", "DOWNREGULATOR", "CYP"]]}, {"text": "1.\u2002This work investigated the drug interaction potential of  GSK1292263   a novel  GPR119  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin", "triple_list": [["GSK1292263", "AGONIST", "GPR119"]]}, {"text": "Evaluation of drug interactions of  GSK1292263  (a  GPR119  agonist) with statins: from in vitro data to clinical study design", "triple_list": [["GSK1292263", "AGONIST", "GPR119"]]}, {"text": "The presence of  steroid  hormones most probably causes the degradation of the  Tat2  permease and impairment of tryptophan import.", "triple_list": [["steroid", "DOWNREGULATOR", "Tat2"]]}, {"text": "Further study showed that  icariin  dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory  cytokine  levels of activated T cells", "triple_list": [["icariin", "DOWNREGULATOR", "cytokine"]]}, {"text": "Inhibition of Th1/Th17 responses via suppression of  STAT1  and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside  icariin   Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells", "triple_list": [["icariin", "DOWNREGULATOR", "STAT1"]]}, {"text": "Inhibition of Th1/Th17 responses via suppression of STAT1 and  STAT3  activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside  icariin   Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells", "triple_list": [["icariin", "DOWNREGULATOR", "STAT3"]]}, {"text": "Moreover,  icariin  treatment inhibited the phosphorylations of  STAT1  and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively", "triple_list": [["icariin", "DOWNREGULATOR", "STAT1"]]}, {"text": "Moreover,  icariin  treatment inhibited the phosphorylations of STAT1 and  STAT3  in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively", "triple_list": [["icariin", "DOWNREGULATOR", "STAT3"]]}, {"text": "Inhibition of Th1/Th17 responses via suppression of  STAT1  and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural  flavonoid  glucoside icariin", "triple_list": [["flavonoid", "DOWNREGULATOR", "STAT1"]]}, {"text": "Inhibition of Th1/Th17 responses via suppression of STAT1 and  STAT3  activation contributes to the amelioration of murine experimental colitis by a natural  flavonoid  glucoside icariin", "triple_list": [["flavonoid", "DOWNREGULATOR", "STAT3"]]}, {"text": "Pharmacological inhibition of MTORC1 with  rapamycin  abrogated the  insulin  induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6", "triple_list": [["rapamycin", "DOWNREGULATOR", "insulin"]]}, {"text": "Furthermore,  insulin  stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by  rapamycin   Taken together, the present studies show that  insulin  stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.", "triple_list": [["rapamycin", "DOWNREGULATOR", "insulin"]]}, {"text": "Furthermore, insulin-stimulated T-I cell proliferation and the expression of  cell cycle regulatory proteins  CDK4, CCND3 and PCNA were also blocked by  rapamycin   Taken together, the present studies show that insulin stimulates cell proliferation and  cell cycle regulatory proteins  in T-I cells via activation of the MTORC1 signaling pathway.", "triple_list": [["rapamycin", "DOWNREGULATOR", "cell cycle regulatory proteins"]]}, {"text": "Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins  CDK4   CCND3 and PCNA were also blocked by  rapamycin   Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.", "triple_list": [["rapamycin", "DOWNREGULATOR", "CDK4"]]}, {"text": "Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4,  CCND3  and PCNA were also blocked by  rapamycin   Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.", "triple_list": [["rapamycin", "DOWNREGULATOR", "CCND3"]]}, {"text": "Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and  PCNA  were also blocked by  rapamycin   Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.", "triple_list": [["rapamycin", "DOWNREGULATOR", "PCNA"]]}, {"text": "Pharmacological inhibition of  MTORC1  with  rapamycin  abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6", "triple_list": [["rapamycin", "DOWNREGULATOR", "MTORC1"]]}, {"text": "Pharmacological inhibition of MTORC1 with  rapamycin  abrogated the insulin-induced phosphorylation of  EIF4EBP1   RPS6KB1 and its downstream effector, RPS6", "triple_list": [["rapamycin", "DOWNREGULATOR", "EIF4EBP1"]]}, {"text": "Pharmacological inhibition of MTORC1 with  rapamycin  abrogated the insulin-induced phosphorylation of EIF4EBP1,  RPS6KB1  and its downstream effector, RPS6", "triple_list": [["rapamycin", "DOWNREGULATOR", "RPS6KB1"]]}, {"text": "Pharmacological inhibition of MTORC1 with  rapamycin  abrogated the insulin-induced phosphorylation of EIF4EBP1,  RPS6 KB1 and its downstream effector,  RPS6   These results were further confirmed by demonstrating that knockdown of Mtor using siRNA reduced the insulin-stimulated MTORC1 signaling", "triple_list": [["rapamycin", "DOWNREGULATOR", "RPS6"]]}, {"text": "We report the discovery of novel series of highly potent  TLR7  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various  tertiary amines  onto the N(9)-position of the adenine moiety", "triple_list": [["tertiary amines", "AGONIST", "TLR7"]]}, {"text": "We report the discovery of novel series of highly potent  TLR7  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the  N  9)-position of the adenine moiety", "triple_list": [["N", "AGONIST", "TLR7"]]}, {"text": "We report the discovery of novel series of highly potent  TLR7  agonists based on 8-oxo adenine s, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the  adenine  moiety", "triple_list": [["adenine", "AGONIST", "TLR7"]]}, {"text": "The introduction of the  amino  group resulted in not only improved water solubility but also enhanced  TLR7  agonistic activity", "triple_list": [["amino", "AGONIST", "TLR7"]]}, {"text": "We report the discovery of novel series of highly potent  TLR7  agonists based on  8-oxoadenines   1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety", "triple_list": [["8-oxoadenines", "AGONIST", "TLR7"]]}, {"text": "Synthesis and evaluation of  8-oxoadenine  derivatives as potent  Toll-like receptor 7  agonists with high water solubility", "triple_list": [["8-oxoadenine", "AGONIST", "Toll-like receptor 7"]]}, {"text": "Inhibitors based on a  benzo-fused spirocyclic oxazepine  scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 ( SCD1   and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model", "triple_list": [["benzo-fused spirocyclic oxazepine", "DOWNREGULATOR", "SCD1"]]}, {"text": "Inhibitors based on a  benzo-fused spirocyclic oxazepine  scaffold were discovered for  stearoyl-coenzyme A (CoA) desaturase 1  (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model", "triple_list": [["benzo-fused spirocyclic oxazepine", "DOWNREGULATOR", "stearoyl-coenzyme A (CoA) desaturase 1"]]}, {"text": "The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited  human Hsp60  chaperone activity (IC(50): 6.80 \u00b1 0.25 \u03bcM) and this inhibition activity was higher than that of  ETB  (IC(50): 10.9 \u00b1 0.63 \u03bcM).", "triple_list": [["ETB", "DOWNREGULATOR", "human Hsp60"]]}, {"text": " Apocynin  and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated  p66Shc  in rat testes", "triple_list": [["Apocynin", "DOWNREGULATOR", "p66Shc"]]}, {"text": "Apocynin and  raisanberine  alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated  p66Shc  in rat testes", "triple_list": [["raisanberine", "DOWNREGULATOR", "p66Shc"]]}, {"text": "We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase ( NOX ), therefore,  APO  (apocynin) an inhibitor of  NOX  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis", "triple_list": [["APO", "DOWNREGULATOR", "NOX"]]}, {"text": "We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase ( NOX ), therefore, APO ( apocynin   an inhibitor of  NOX  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis", "triple_list": [["apocynin", "DOWNREGULATOR", "NOX"]]}, {"text": " APO  and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and  p66Shc  in testes.", "triple_list": [["APO", "DOWNREGULATOR", "p66Shc"]]}, {"text": "Apocynin and  raisanberine  alleviate intermittent hypoxia induced abnormal StAR and  3\u03b2-HSD  and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes", "triple_list": [["raisanberine", "PRODUCT-OF", "3\u03b2-HSD"]]}, {"text": "Furthermore, we found that  arsenic trioxide  activates the  Pirh2 promoter  and consequently induces Pirh2 expression", "triple_list": [["arsenic trioxide", "ACTIVATOR", "Pirh2 promoter"]]}, {"text": "Furthermore, we found that  arsenic trioxide  activates the  Pirh2  promoter and consequently induces  Pirh2  expression", "triple_list": [["arsenic trioxide", "ACTIVATOR", "Pirh2"]]}, {"text": "Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances,  arsenic  induced degradation of  \u0394Np63  protein", "triple_list": [["arsenic", "DOWNREGULATOR", "\u0394Np63"]]}, {"text": "Together, these data suggest that  arsenic  degrades  \u0394Np63  protein at least in part via Pirh2-dependent proteolysis and that inhibition of  \u0394Np63  expression facilitates tumor cells to  arsenic -induced death.", "triple_list": [["arsenic", "DOWNREGULATOR", "\u0394Np63"]]}, {"text": "Together, these data suggest that  arsenic  degrades  \u0394Np63  protein at least in part via Pirh2-dependent proteolysis and that inhibition of  \u0394Np63  expression facilitates tumor cells to  arsenic -induced death.", "triple_list": [["arsenic", "DOWNREGULATOR", "\u0394Np63"]]}, {"text": "Here we found that  arsenic trioxide   a frontline agent for acute promyelocytic leukemia, inhibits  \u0394Np63  but not TAp63 expression in time- and dose-dependent manners", "triple_list": [["arsenic trioxide", "DOWNREGULATOR", "\u0394Np63"]]}, {"text": "In addition, we found that  arsenic trioxide  decreases the stability of  \u0394Np63  protein via a proteasome-dependent pathway but has little effect on the level of  \u0394Np63  transcript", "triple_list": [["arsenic trioxide", "DOWNREGULATOR", "\u0394Np63"]]}, {"text": "Additional mechanistic studies revealed that  jaceosidin  treatment resulted in an increase in phosphorylation of  Cdc25C  and ATM-Chk1/2", "triple_list": [["jaceosidin", "ACTIVATOR", "Cdc25C"]]}, {"text": "Additional mechanistic studies revealed that  jaceosidin  treatment resulted in an increase in phosphorylation of Cdc25C and  ATM  Chk1/2", "triple_list": [["jaceosidin", "ACTIVATOR", "ATM"]]}, {"text": " Jaceosidin   isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via  ATM  Chk1/2 activation", "triple_list": [["Jaceosidin", "ACTIVATOR", "ATM"]]}, {"text": " Jaceosidin   isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating  cdc25C  cdc2 via ATM-Chk1/2 activation", "triple_list": [["Jaceosidin", "DOWNREGULATOR", "cdc25C"]]}, {"text": " Jaceosidin   isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating  cdc2 5C- cdc2  via ATM-Chk1/2 activation", "triple_list": [["Jaceosidin", "DOWNREGULATOR", "cdc2"]]}, {"text": "Moreover, jaceosidin treatment resulted in phosphorylation of  ERK , and pretreatment with the  ERK  inhibitor,  PD98059   attenuated cell growth inhibition by jaceosidin", "triple_list": [["PD98059", "DOWNREGULATOR", "ERK"]]}, {"text": "These data suggest that  jaceosidin   isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the  Cdc2  cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.", "triple_list": [["jaceosidin", "DOWNREGULATOR", "Cdc2"]]}, {"text": "These data suggest that  jaceosidin   isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2- cyclin B1  complex, followed by G2/M cell cycle arrest in endometrial cancer cells.", "triple_list": [["jaceosidin", "DOWNREGULATOR", "cyclin B1"]]}, {"text": "Exogenous  ATP  transiently activated  Akt  and, inhibiting phosphatidylinositol 3-kinase (PI3K) or  Akt  as well as dominant-negative  Akt  mutant, reduced  ATP -dependent 2-NBDG uptake and  Akt  phosphorylation", "triple_list": [["ATP", "ACTIVATOR", "Akt"]]}, {"text": "Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  adenosine-phosphate phosphatase  and by purinergic receptor blockade ( suramin  ", "triple_list": [["suramin", "DOWNREGULATOR", "adenosine-phosphate phosphatase"]]}, {"text": "Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by  purinergic receptor  blockade ( suramin  ", "triple_list": [["suramin", "DOWNREGULATOR", "purinergic receptor"]]}, {"text": "Electrical stimulation transiently elevated extracellular ATP and caused  Akt  phosphorylation that was additive to insulin and inhibited by  suramin   Exogenous ATP transiently activated  Akt  and, inhibiting phosphatidylinositol 3-kinase (PI3K) or  Akt  as well as dominant-negative  Akt  mutant, reduced ATP-dependent 2-NBDG uptake and  Akt  phosphorylation", "triple_list": [["suramin", "DOWNREGULATOR", "Akt"]]}, {"text": "ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the  phosphatidylinositol 3-kinase-\u03b3  (PI3K\u03b3) inhibitor  AS605240   ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3K\u03b3 kinase-dead mutants, and potentiated by myristoylated PI3K\u03b3", "triple_list": [["AS605240", "DOWNREGULATOR", "phosphatidylinositol 3-kinase-\u03b3"]]}, {"text": "ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the phosphatidylinositol 3-kinase-\u03b3 ( PI3K\u03b3   inhibitor  AS605240   ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or  PI3K\u03b3  kinase-dead mutants, and potentiated by myristoylated  PI3K\u03b3 ", "triple_list": [["AS605240", "DOWNREGULATOR", "PI3K\u03b3"]]}, {"text": "Electrical Stimuli Release ATP to Increase  GLUT4  Translocation and  Glucose  Uptake via PI3K\u03b3-Akt-AS160 in Skeletal Muscle Cells", "triple_list": [["Glucose", "PRODUCT-OF", "GLUT4"]]}, {"text": "A series of  anthra[1,2-d]imidazole-6,11-dione  derivatives were synthesized and evaluated for  telomerase  inhibition, hTERT expression and suppression of cancer cell growth in vitro", "triple_list": [["anthra[1,2-d]imidazole-6,11-dione", "DOWNREGULATOR", "telomerase"]]}, {"text": "Structure-based design, synthesis and evaluation of novel  anthra[1,2-d]imidazole-6,11-dione  derivatives as  telomerase  inhibitors and potential for cancer polypharmacology", "triple_list": [["anthra[1,2-d]imidazole-6,11-dione", "DOWNREGULATOR", "telomerase"]]}, {"text": "Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the  NF-E2-related factor 2  antioxidant response element (Nrf2-ARE) activator  sulforaphane   or small interfering RNA", "triple_list": [["sulforaphane", "ACTIVATOR", "NF-E2-related factor 2"]]}, {"text": "Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2- antioxidant response element  (Nrf2-ARE) activator  sulforaphane   or small interfering RNA", "triple_list": [["sulforaphane", "ACTIVATOR", "antioxidant response element"]]}, {"text": "Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element ( Nrf2  ARE) activator  sulforaphane   or small interfering RNA", "triple_list": [["sulforaphane", "ACTIVATOR", "Nrf2"]]}, {"text": "Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- ARE   activator  sulforaphane   or small interfering RNA", "triple_list": [["sulforaphane", "ACTIVATOR", "ARE"]]}, {"text": "In conclusion, this study provides the first evidence implicating that  TSA  inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced  Nrf2  ARE signaling.", "triple_list": [["TSA", "ACTIVATOR", "Nrf2"]]}, {"text": "In conclusion, this study provides the first evidence implicating that  TSA  inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2- ARE  signaling.", "triple_list": [["TSA", "ACTIVATOR", "ARE"]]}, {"text": " Trichostatin A  inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced  NF-E2-related factor 2  antioxidant response element signaling", "triple_list": [["Trichostatin A", "ACTIVATOR", "NF-E2-related factor 2"]]}, {"text": " Trichostatin A  inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2- antioxidant response element  signaling", "triple_list": [["Trichostatin A", "ACTIVATOR", "antioxidant response element"]]}, {"text": "In addition,  TSA  induced  Nrf2  nuclear translocation and up-regulated the expression of  Nrf2  ARE downstream antioxidant genes, whereas  Nrf2  knockdown by RNA interference blocked the inhibition of  TSA  on myofibroblast differentiation", "triple_list": [["TSA", "ACTIVATOR", "Nrf2"]]}, {"text": "In addition,  TSA  induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2- ARE  downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of  TSA  on myofibroblast differentiation", "triple_list": [["TSA", "ACTIVATOR", "ARE"]]}, {"text": "In conclusion, this study provides the first evidence implicating that  TSA  inhibits  TGF-\u03b2  induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.", "triple_list": [["TSA", "DOWNREGULATOR", "TGF-\u03b2"]]}, {"text": "Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the  NAD(P)H oxidase  inhibitor  diphenyleneiodonium  (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA", "triple_list": [["diphenyleneiodonium", "DOWNREGULATOR", "NAD(P)H oxidase"]]}, {"text": "Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the  NAD(P)H oxidase  inhibitor diphenyleneiodonium ( DPI  , the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA", "triple_list": [["DPI", "DOWNREGULATOR", "NAD(P)H oxidase"]]}, {"text": "Treatment with  TSA  and the Nrf2-ARE activator resulted in increased inhibition of the  TGF-\u03b2  induced myofibroblast differentiation as compared with treatment with DPI or NAC", "triple_list": [["TSA", "DOWNREGULATOR", "TGF-\u03b2"]]}, {"text": " Trichostatin A  inhibits  transforming growth factor-\u03b2  induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling", "triple_list": [["Trichostatin A", "DOWNREGULATOR", "transforming growth factor-\u03b2"]]}, {"text": "Furthermore,  TSA  also decreased cellular ROS and H(2)O(2) accumulation induced by  TGF-\u03b2   whereas it elevated intracellular GSH level and cellular total antioxidant capacity", "triple_list": [["TSA", "DOWNREGULATOR", "TGF-\u03b2"]]}, {"text": "Results indicate that  AM4054  serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  AM4054  dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  AM4054 ", "triple_list": [["AM4054", "ACTIVATOR", "CB(1)"]]}, {"text": "In the present studies, the  CB(1)  inverse agonist SR141716A (rimonabant) and the  CB(1)  neutral antagonist AM4113 were compared for their ability to modify  CB(1)  receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  CB(1)  full agonist  AM4054   Results indicate that  AM4054  serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  AM4054  dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  AM4054 ", "triple_list": [["AM4054", "AGONIST", "CB(1)"]]}, {"text": "Results indicate that AM4054 serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist  \u0394(9)-tetrahydrocannabinol   and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054", "triple_list": [["\u0394(9)-tetrahydrocannabinol", "AGONIST", "CB(1)"]]}, {"text": "Results indicate that  AM4054  serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  AM4054  dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  AM4054 ", "triple_list": [["AM4054", "AGONIST", "CB(1)"]]}, {"text": "Results indicate that  AM4054  serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  AM4054  dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  AM4054   Schild analyses further show that rimonabant and AM4113 produce highly similar antagonist effects, as evident in comparable pA(2) values (6.9)", "triple_list": [["AM4054", "AGONIST", "CB(1)"]]}, {"text": "Results indicate that AM4054 serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist  rimonabant  and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054", "triple_list": [["rimonabant", "AGONIST", "CB(1)"]]}, {"text": "In the present studies, the  CB(1)  inverse agonist  SR141716A  (rimonabant) and the  CB(1)  neutral antagonist AM4113 were compared for their ability to modify  CB(1)  receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  CB(1)  full agonist AM4054", "triple_list": [["SR141716A", "AGONIST", "CB(1)"]]}, {"text": "In the present studies, the  CB(1)  inverse agonist SR141716A ( rimonabant   and the  CB(1)  neutral antagonist AM4113 were compared for their ability to modify  CB(1)  receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  CB(1)  full agonist AM4054", "triple_list": [["rimonabant", "AGONIST", "CB(1)"]]}, {"text": " Cannabinoid receptor 1  (CB(1)) inverse agonists (e.g.,  rimonabant   have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications", "triple_list": [["rimonabant", "AGONIST", "Cannabinoid receptor 1"]]}, {"text": "Cannabinoid receptor 1 ( CB(1)   inverse agonists (e.g.,  rimonabant   have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications", "triple_list": [["rimonabant", "AGONIST", "CB(1)"]]}, {"text": "In the present studies, the  CB(1)  inverse agonist SR141716A (rimonabant) and the  CB(1)  neutral antagonist  AM4113  were compared for their ability to modify  CB(1)  receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  CB(1)  full agonist AM4054", "triple_list": [["AM4113", "ANTAGONIST", "CB(1)"]]}, {"text": "Results indicate that AM4054 serves as an effective  CB(1)  discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist  AM4113  produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054", "triple_list": [["AM4113", "ANTAGONIST", "CB(1)"]]}, {"text": " Dabigatran  has an advantage over the indirect  thrombin  inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound  thrombin ", "triple_list": [["Dabigatran", "DOWNREGULATOR", "thrombin"]]}, {"text": " Dabigatran  has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and  fibrin  bound thrombin", "triple_list": [["Dabigatran", "DOWNREGULATOR", "fibrin"]]}, {"text": " Dabigatran  has an advantage over the indirect  thrombin  inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound  thrombin   The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent  thrombin  inhibitors, e.g", "triple_list": [["Dabigatran", "DOWNREGULATOR", "thrombin"]]}, {"text": "The reversible binding of  dabigatran  may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent  thrombin  inhibitors, e.g", "triple_list": [["dabigatran", "DOWNREGULATOR", "thrombin"]]}, {"text": " rivaroxaban  and apixaban, are potent, oral direct inhibitors of  prothrombinase  bound, clot-associated or free FXa", "triple_list": [["rivaroxaban", "DOWNREGULATOR", "prothrombinase"]]}, {"text": " rivaroxaban  and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free  FXa   Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations", "triple_list": [["rivaroxaban", "DOWNREGULATOR", "FXa"]]}, {"text": "rivaroxaban and  apixaban   are potent, oral direct inhibitors of  prothrombinase  bound, clot-associated or free FXa", "triple_list": [["apixaban", "DOWNREGULATOR", "prothrombinase"]]}, {"text": "rivaroxaban and  apixaban   are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free  FXa   Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations", "triple_list": [["apixaban", "DOWNREGULATOR", "FXa"]]}, {"text": "Although parenteral oral direct  thrombin  inhibitors (DTIs), such as  argatroban  and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic  thrombin  antagonists", "triple_list": [["argatroban", "DOWNREGULATOR", "thrombin"]]}, {"text": "Although parenteral oral direct  thrombin  inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as  dabigatran  are novel synthetic  thrombin  antagonists", "triple_list": [["dabigatran", "ANTAGONIST", "thrombin"]]}, {"text": "This shift in conformational population at higher  Mg(2+)  ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the  ALDH1  pocket", "triple_list": [["Mg(2+)", "DOWNREGULATOR", "ALDH1"]]}, {"text": "As the  Mg(2+)  ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 \u03bcM  Mg(2+) ) to 0.050 s(-1) (6000 \u03bcM  Mg(2+) ) and a distinct shift in steady-state conformational population from one that favors the  ALDH1  NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the  ALDH1 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 \u03bcM  Mg(2+) ", "triple_list": [["Mg(2+)", "DOWNREGULATOR", "ALDH1"]]}, {"text": "Physiologic levels of  Mg(2+)  ions decrease  ALDH1  activity in part by increasing NADH binding affinity to the enzyme", "triple_list": [["Mg(2+)", "DOWNREGULATOR", "ALDH1"]]}, {"text": " Aldehyde dehydrogenase 1  (ALDH1A1) catalyzes the oxidation of toxic aldehydes to  carboxylic acids   Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme", "triple_list": [["carboxylic acids", "PRODUCT-OF", "Aldehyde dehydrogenase 1"]]}, {"text": "Aldehyde dehydrogenase 1 ( ALDH1A1   catalyzes the oxidation of toxic aldehydes to  carboxylic acids   Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme", "triple_list": [["carboxylic acids", "PRODUCT-OF", "ALDH1A1"]]}, {"text": " Aldehyde dehydrogenase 1  (ALDH1A1) catalyzes the oxidation of toxic  aldehydes  to carboxylic acids", "triple_list": [["aldehydes", "PRODUCT-OF", "Aldehyde dehydrogenase 1"]]}, {"text": "Aldehyde dehydrogenase 1 ( ALDH1A1   catalyzes the oxidation of toxic  aldehydes  to carboxylic acids", "triple_list": [["aldehydes", "PRODUCT-OF", "ALDH1A1"]]}, {"text": "Moreover,  Acrolein  resulted in activation of astrocytes, up-regulation of  BACE-1  in cortex and down-regulation of ADAM-10 in hippocampus and cortex", "triple_list": [["Acrolein", "ACTIVATOR", "BACE-1"]]}, {"text": "Interestingly,  Acrolein  increased proteins' levels of  amyloid precursor protein  (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels", "triple_list": [["Acrolein", "ACTIVATOR", "amyloid precursor protein"]]}, {"text": "Interestingly,  Acrolein  increased proteins' levels of amyloid precursor protein (APP),  \u03b2-secretase  (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels", "triple_list": [["Acrolein", "ACTIVATOR", "\u03b2-secretase"]]}, {"text": "Interestingly,  Acrolein  increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase ( BACE-1   and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels", "triple_list": [["Acrolein", "ACTIVATOR", "BACE-1"]]}, {"text": "Interestingly,  Acrolein  increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the  amyloid \u03b2-peptide transporter  receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels", "triple_list": [["Acrolein", "ACTIVATOR", "amyloid \u03b2-peptide transporter"]]}, {"text": "Interestingly,  Acrolein  increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter  receptor for advanced glycation end products   and decreased A-disintegrin and metalloprotease (ADAM) 10 levels", "triple_list": [["Acrolein", "ACTIVATOR", "receptor for advanced glycation end products"]]}, {"text": "Moreover,  Acrolein  resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of  ADAM-10  in hippocampus and cortex", "triple_list": [["Acrolein", "DOWNREGULATOR", "ADAM-10"]]}, {"text": "Interestingly,  Acrolein  increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased  A-disintegrin and metalloprotease (ADAM) 10  levels", "triple_list": [["Acrolein", "DOWNREGULATOR", "A-disintegrin and metalloprotease (ADAM) 10"]]}, {"text": "Regulation of sexual reproduction by  estradiol  involves the activation of  estrogen receptors  (ERs) in the hypothalamus", "triple_list": [["estradiol", "ACTIVATOR", "estrogen receptors"]]}, {"text": "Regulation of sexual reproduction by  estradiol  involves the activation of estrogen receptors ( ERs   in the hypothalamus", "triple_list": [["estradiol", "ACTIVATOR", "ERs"]]}, {"text": "Using surface biotinylation, we observed that treatment of N-38 neurons with  estradiol  or with a membrane impermeant  estradiol  elevated plasma membrane  ER\u03b1  protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane", "triple_list": [["estradiol", "ACTIVATOR", "ER\u03b1"]]}, {"text": "These results indicate that membrane  ER\u03b1  levels in N-38 neurons are dynamically autoregulated by  estradiol  ", "triple_list": [["estradiol", "ACTIVATOR", "ER\u03b1"]]}, {"text": "Using surface biotinylation, we observed that treatment of N-38 neurons with  estradiol  or with a membrane impermeant  estradiol  elevated plasma membrane  ER\u03b1  protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane", "triple_list": [["estradiol", "ACTIVATOR", "ER\u03b1"]]}, {"text": "Insertion of  ER\u03b1  was blocked by the ER antagonist  ICI 182,780  or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)", "triple_list": [["ICI 182,780", "DOWNREGULATOR", "ER\u03b1"]]}, {"text": "Insertion of  ER\u03b1  was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor  bisindolylmaleimide  (BIS)", "triple_list": [["bisindolylmaleimide", "DOWNREGULATOR", "ER\u03b1"]]}, {"text": "Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the  protein kinase C  (PKC) pathway inhibitor  bisindolylmaleimide  (BIS)", "triple_list": [["bisindolylmaleimide", "DOWNREGULATOR", "protein kinase C"]]}, {"text": "Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C ( PKC   pathway inhibitor  bisindolylmaleimide  (BIS)", "triple_list": [["bisindolylmaleimide", "DOWNREGULATOR", "PKC"]]}, {"text": "Insertion of  ER\u03b1  was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide ( BIS  ", "triple_list": [["BIS", "DOWNREGULATOR", "ER\u03b1"]]}, {"text": "Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the  protein kinase C  (PKC) pathway inhibitor bisindolylmaleimide ( BIS  ", "triple_list": [["BIS", "DOWNREGULATOR", "protein kinase C"]]}, {"text": "Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C ( PKC   pathway inhibitor bisindolylmaleimide ( BIS  ", "triple_list": [["BIS", "DOWNREGULATOR", "PKC"]]}, {"text": "Insertion of  ER \u03b1 was blocked by the  ER  antagonist  ICI 182,780  or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)", "triple_list": [["ICI 182,780", "ANTAGONIST", "ER"]]}, {"text": "Reductions in striatal dopamine and  tyrosine hydroxylase  content were also less pronounced with  EHT  treatment", "triple_list": [["EHT", "ACTIVATOR", "tyrosine hydroxylase"]]}, {"text": "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of  phosphoprotein phosphatase 2A  (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by  EHT   These findings indicate that the neuroprotective effect of  EHT  against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A", "triple_list": [["EHT", "ACTIVATOR", "phosphoprotein phosphatase 2A"]]}, {"text": "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A ( PP2A  , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by  EHT   These findings indicate that the neuroprotective effect of  EHT  against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of  PP2A ", "triple_list": [["EHT", "ACTIVATOR", "PP2A"]]}, {"text": "Additionally, in SH-SY5Y cells,  MPP(+)  induced demethylation of  phosphoprotein phosphatase 2A  (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT", "triple_list": [["MPP(+)", "DOWNREGULATOR", "phosphoprotein phosphatase 2A"]]}, {"text": "Additionally, in SH-SY5Y cells,  MPP(+)  induced demethylation of phosphoprotein phosphatase 2A ( PP2A  , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT", "triple_list": [["MPP(+)", "DOWNREGULATOR", "PP2A"]]}, {"text": "The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and  JNK  activation were significantly prevented with  EHT   In cultured primary microglia and astrocytes,  EHT  had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, iNOS induction, and nitric oxide production", "triple_list": [["EHT", "DOWNREGULATOR", "JNK"]]}, {"text": "In cultured primary microglia and astrocytes,  EHT  had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced  NF\u03baB  activation, iNOS induction, and nitric oxide production", "triple_list": [["EHT", "DOWNREGULATOR", "NF\u03baB"]]}, {"text": "In cultured primary microglia and astrocytes,  EHT  had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation,  iNOS  induction, and nitric oxide production", "triple_list": [["EHT", "DOWNREGULATOR", "iNOS"]]}, {"text": "Substantial evidence shows that  H(2)S  is involved in aging by inhibiting free-radical reactions, activating  SIRT1   and probably interacting with the age-related gene Klotho", "triple_list": [["H(2)S", "ACTIVATOR", "SIRT1"]]}, {"text": "Induction of  HO-1  through p38 MAPK/Nrf2 signaling pathway by  ethanol  extract of Inula helenium L", "triple_list": [["ethanol", "ACTIVATOR", "HO-1"]]}, {"text": "Induction of HO-1 through  p38  MAPK/Nrf2 signaling pathway by  ethanol  extract of Inula helenium L", "triple_list": [["ethanol", "ACTIVATOR", "p38"]]}, {"text": "Induction of HO-1 through p38  MAPK  Nrf2 signaling pathway by  ethanol  extract of Inula helenium L", "triple_list": [["ethanol", "ACTIVATOR", "MAPK"]]}, {"text": "The induction of  HO-1  by EIH was inhibited by  SB203580  but not by SP600125, PD98059, nor LY294002", "triple_list": [["SB203580", "DOWNREGULATOR", "HO-1"]]}, {"text": "FMO3 expression is induced by dietary  bile acid s by a mechanism that involves the  farnesoid X receptor  (FXR), a  bile acid  activated nuclear receptor", "triple_list": [["bile acid", "ACTIVATOR", "farnesoid X receptor"]]}, {"text": "FMO3 expression is induced by dietary  bile acid s by a mechanism that involves the farnesoid X receptor ( FXR  , a  bile acid  activated nuclear receptor", "triple_list": [["bile acid", "ACTIVATOR", "FXR"]]}, {"text": " FMO3  expression is induced by dietary  bile acids  by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor", "triple_list": [["bile acids", "ACTIVATOR", "FMO3"]]}, {"text": "In mice, this reduction in  FMO3  expression is due primarily to downregulation by  androgens    FMO3  expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor", "triple_list": [["androgens", "DOWNREGULATOR", "FMO3"]]}, {"text": "Analysis of natural genetic variation among inbred strains of mice indicates that  FMO3  and  TMAO  are significantly correlated, and  TMAO  levels explain 11% of the variation in atherosclerosis.", "triple_list": [["TMAO", "PRODUCT-OF", "FMO3"]]}, {"text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to  TMAO   Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1", "triple_list": [["TMAO", "PRODUCT-OF", "flavin mono-oxygenase"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to  TMAO   Further, we show that FMO3 exhibits 10-fold higher specific activity than  FMO1 ", "triple_list": [["TMAO", "PRODUCT-OF", "FMO1"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3   oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to  TMAO   Further, we show that  FMO3  exhibits 10-fold higher specific activity than FMO1", "triple_list": [["TMAO", "PRODUCT-OF", "FMO3"]]}, {"text": " FMO3  overexpression in mice significantly increases plasma  TMAO  levels while silencing  FMO3  decreases  TMAO  levels", "triple_list": [["TMAO", "PRODUCT-OF", "FMO3"]]}, {"text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize  trimethylamine  (TMA), derived from gut flora metabolism of choline, to TMAO", "triple_list": [["trimethylamine", "PRODUCT-OF", "flavin mono-oxygenase"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize  trimethylamine  (TMA), derived from gut flora metabolism of choline, to TMAO", "triple_list": [["trimethylamine", "PRODUCT-OF", "FMO1"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3   oxidize  trimethylamine  (TMA), derived from gut flora metabolism of choline, to TMAO", "triple_list": [["trimethylamine", "PRODUCT-OF", "FMO3"]]}, {"text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize trimethylamine ( TMA  , derived from gut flora metabolism of choline, to  TMA O", "triple_list": [["TMA", "PRODUCT-OF", "flavin mono-oxygenase"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize trimethylamine ( TMA  , derived from gut flora metabolism of choline, to  TMA O", "triple_list": [["TMA", "PRODUCT-OF", "FMO1"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3   oxidize trimethylamine ( TMA  , derived from gut flora metabolism of choline, to  TMA O", "triple_list": [["TMA", "PRODUCT-OF", "FMO3"]]}, {"text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of  choline   to TMAO", "triple_list": [["choline", "PRODUCT-OF", "flavin mono-oxygenase"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of  choline   to TMAO", "triple_list": [["choline", "PRODUCT-OF", "FMO1"]]}, {"text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3   oxidize trimethylamine (TMA), derived from gut flora metabolism of  choline   to TMAO", "triple_list": [["choline", "PRODUCT-OF", "FMO3"]]}, {"text": " FMO3  overexpression in mice significantly increases plasma  TMAO  levels while silencing  FMO3  decreases  TMAO  levels", "triple_list": [["TMAO", "PRODUCT-OF", "FMO3"]]}, {"text": "Synthesis of  quinoline  derivatives: discovery of a potent and selective  phosphodiesterase 5  inhibitor for the treatment of Alzheimer's disease", "triple_list": [["quinoline", "DOWNREGULATOR", "phosphodiesterase 5"]]}, {"text": "Phosphodiesterase type 5 ( PDE5   mediates the degradation of  cGMP  in a variety of tissues including brain", "triple_list": [["cGMP", "PRODUCT-OF", "PDE5"]]}, {"text": " Phosphodiesterase type 5  (PDE5) mediates the degradation of  cGMP  in a variety of tissues including brain", "triple_list": [["cGMP", "PRODUCT-OF", "Phosphodiesterase type 5"]]}, {"text": "A novel potent compound,  N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide  (12c), which binds  Mcl-1  with an IC(50) value of 54 nM was obtained", "triple_list": [["N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide", "DOWNREGULATOR", "Mcl-1"]]}, {"text": "We have previously reported a nanomolar inhibitor of antiapoptotic  Mcl-1  protein,  3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile  (S1)", "triple_list": [["3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile", "DOWNREGULATOR", "Mcl-1"]]}, {"text": "Fragment-based design, synthesis, and biological evaluation of  N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide  derivatives as novel  Mcl-1  inhibitors", "triple_list": [["N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide", "DOWNREGULATOR", "Mcl-1"]]}, {"text": " Peginesatide   a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the  erythropoietin receptor  dimer that governs erythropoiesis", "triple_list": [["Peginesatide", "ACTIVATOR", "erythropoietin receptor"]]}, {"text": "Peginesatide, a  polyethylene glycol  (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the  erythropoietin receptor  dimer that governs erythropoiesis", "triple_list": [["polyethylene glycol", "ACTIVATOR", "erythropoietin receptor"]]}, {"text": "Peginesatide, a polyethylene glycol ( PEG  ylated peptide-based erythropoiesis-stimulating agent, stimulates the  erythropoietin receptor  dimer that governs erythropoiesis", "triple_list": [["PEG", "ACTIVATOR", "erythropoietin receptor"]]}, {"text": " LPA 1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of  LPA  by driving MRTF-dependent  CTGF  expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J", "triple_list": [["LPA", "ACTIVATOR", "CTGF"]]}, {"text": " Bile acids  are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor,  constitutive androstane receptor   and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism", "triple_list": [["Bile acids", "ACTIVATOR", "constitutive androstane receptor"]]}, {"text": " Bile acids  are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  vitamin D receptor   and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism", "triple_list": [["Bile acids", "ACTIVATOR", "vitamin D receptor"]]}, {"text": " Bile acids  are signaling molecules that activate  nuclear receptors   such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism", "triple_list": [["Bile acids", "ACTIVATOR", "nuclear receptors"]]}, {"text": " Bile acids  are signaling molecules that activate nuclear receptors, such as  farnesoid X receptor   pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism", "triple_list": [["Bile acids", "ACTIVATOR", "farnesoid X receptor"]]}, {"text": " Bile acids  are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  pregnane X receptor   constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism", "triple_list": [["Bile acids", "ACTIVATOR", "pregnane X receptor"]]}, {"text": "Results confirmed that  YR-11  peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of  NF-\u03baB   The results obtained in this study substantiate the therapeutic benefit of this novel peptide in the prevention of bone loss and inflammation in rheumatoid arthritis with reduced side effects.", "triple_list": [["YR-11", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": "The peptide  YR-11  (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK- RANKL  binding, and  RANKL  induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity", "triple_list": [["YR-11", "DOWNREGULATOR", "RANKL"]]}, {"text": "The peptide  YR-11  (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced  TRAP  activity and formation of multinucleated osteoclasts without any cytotoxicity", "triple_list": [["YR-11", "DOWNREGULATOR", "TRAP"]]}, {"text": "The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of  cysteine  with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK- RANKL  binding, and  RANKL  induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity", "triple_list": [["cysteine", "DOWNREGULATOR", "RANKL"]]}, {"text": "The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of  cysteine  with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced  TRAP  activity and formation of multinucleated osteoclasts without any cytotoxicity", "triple_list": [["cysteine", "DOWNREGULATOR", "TRAP"]]}, {"text": "The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a  serine  residue in the template sequence, significantly (p<0.05) inhibited RANK- RANKL  binding, and  RANKL  induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity", "triple_list": [["serine", "DOWNREGULATOR", "RANKL"]]}, {"text": "The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a  serine  residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced  TRAP  activity and formation of multinucleated osteoclasts without any cytotoxicity", "triple_list": [["serine", "DOWNREGULATOR", "TRAP"]]}, {"text": "Results confirmed that  YR-11  peptide inhibited pro-inflammatory  cytokines  in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-\u03baB", "triple_list": [["YR-11", "DOWNREGULATOR", "cytokines"]]}, {"text": "Results confirmed that  YR-11  peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on  RANKL  induced nuclear translocation of NF-\u03baB", "triple_list": [["YR-11", "DOWNREGULATOR", "RANKL"]]}, {"text": "The activation of  Rac1  was induced by  silica  nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation", "triple_list": [["silica", "ACTIVATOR", "Rac1"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an  ATM  inhibitor", "triple_list": [["ATO", "ACTIVATOR", "ATM"]]}, {"text": "Osteoblasts survive the  arsenic trioxide  treatment by activation of  ATM  mediated pathway", "triple_list": [["arsenic trioxide", "ACTIVATOR", "ATM"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX,  Chk1   Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "Chk1"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX, Chk1,  Chk2   p53, and p21(waf1/cip1) were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "Chk2"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX, Chk1, Chk2,  p53   and p21(waf1/cip1) were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "p53"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX, Chk1, Chk2, p53, and  p21  waf1/cip1) were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "p21"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX, Chk1, Chk2, p53, and p21( waf1  cip1) were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "waf1"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1/ cip1   were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "cip1"]]}, {"text": "Additionally, these effects of  ATO  on \u03b3- H2AX   Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor", "triple_list": [["ATO", "ACTIVATOR", "H2AX"]]}, {"text": "Furthermore, a mixture of  isoflavonoid  parent compounds, and a mixture of  isoflavonoid  metabolites were found to have  PPAR\u03b3  activating abilities", "triple_list": [["isoflavonoid", "ACTIVATOR", "PPAR\u03b3"]]}, {"text": "Furthermore, a mixture of  isoflavonoid  parent compounds, and a mixture of  isoflavonoid  metabolites were found to have  PPAR\u03b3  activating abilities", "triple_list": [["isoflavonoid", "ACTIVATOR", "PPAR\u03b3"]]}, {"text": "In monocytes, both  EPA  and DHA increased  interleukin (IL)-10  without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6", "triple_list": [["EPA", "ACTIVATOR", "interleukin (IL)-10"]]}, {"text": "In monocytes, both EPA and  DHA  increased  interleukin (IL)-10  without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6", "triple_list": [["DHA", "ACTIVATOR", "interleukin (IL)-10"]]}, {"text": "Both  fatty acids   but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of  cytokine  expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells", "triple_list": [["fatty acids", "DOWNREGULATOR", "cytokine"]]}, {"text": "Both fatty acids, but  DHA  to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of  cytokine  expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells", "triple_list": [["DHA", "DOWNREGULATOR", "cytokine"]]}, {"text": "Both fatty acids, but DHA to a lesser extent compared with  EPA   selectively and dose-dependently reduced the percentage of  cytokine  expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells", "triple_list": [["EPA", "DOWNREGULATOR", "cytokine"]]}, {"text": "In the in vitro model we observed high permeability of  imperatorin  and iso imperatorin  with the  P-gp  mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82", "triple_list": [["imperatorin", "PRODUCT-OF", "P-gp"]]}, {"text": "In the in vitro model we observed high permeability of imperatorin and  isoimperatorin  with the  P-gp  mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82", "triple_list": [["isoimperatorin", "PRODUCT-OF", "P-gp"]]}, {"text": "In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the  P-gp  mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of  cnidilin  with 0.82", "triple_list": [["cnidilin", "PRODUCT-OF", "P-gp"]]}, {"text": "In agreement with these data, the exogenous treatment of  SAH  or inhibition of  SAH H by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on  Src   the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and  Src ", "triple_list": [["SAH", "DOWNREGULATOR", "Src"]]}, {"text": "Through immunoblotting analysis, it was found that  AdOx  was capable of indirectly diminishing the phosphorylation of oncogenic  Src  and its kinase activity", "triple_list": [["AdOx", "DOWNREGULATOR", "Src"]]}, {"text": "Interestingly,  AdOx  disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of  Src  and p85/PI3K, which is linked to various tumorigenic responses", "triple_list": [["AdOx", "DOWNREGULATOR", "Src"]]}, {"text": "Interestingly,  AdOx  disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and  p85  PI3K, which is linked to various tumorigenic responses", "triple_list": [["AdOx", "DOWNREGULATOR", "p85"]]}, {"text": "Interestingly,  AdOx  disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/ PI3K   which is linked to various tumorigenic responses", "triple_list": [["AdOx", "DOWNREGULATOR", "PI3K"]]}, {"text": "Through immunoblotting analysis, it was found that  AdOx  was capable of indirectly diminishing the phosphorylation of oncogenic Src and its  kinase  activity", "triple_list": [["AdOx", "DOWNREGULATOR", "kinase"]]}, {"text": "Interestingly,  AdOx  disrupted  actin  cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses", "triple_list": [["AdOx", "DOWNREGULATOR", "actin"]]}, {"text": "In agreement with these data, the exogenous treatment of SAH or inhibition of  SAHH  by specific siRNA or another type of inhibitor,  3-deazaadenosine  (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src", "triple_list": [["3-deazaadenosine", "DOWNREGULATOR", "SAHH"]]}, {"text": "In agreement with these data, the exogenous treatment of SAH or inhibition of  SAHH  by specific siRNA or another type of inhibitor, 3-deazaadenosine ( DAZA  , similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src", "triple_list": [["DAZA", "DOWNREGULATOR", "SAHH"]]}, {"text": "Treatment with  adenosine dialdehyde  (AdOx), an inhibitor of transmethylation-suppressive  adenosylhomocysteine (SAH) hydrolase  (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner", "triple_list": [["adenosine dialdehyde", "DOWNREGULATOR", "adenosylhomocysteine (SAH) hydrolase"]]}, {"text": "Treatment with  adenosine dialdehyde  (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase ( SAHH  , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner", "triple_list": [["adenosine dialdehyde", "DOWNREGULATOR", "SAHH"]]}, {"text": "Treatment with adenosine dialdehyde ( AdOx  , an inhibitor of transmethylation-suppressive  adenosylhomocysteine (SAH) hydrolase  (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner", "triple_list": [["AdOx", "DOWNREGULATOR", "adenosylhomocysteine (SAH) hydrolase"]]}, {"text": "Treatment with adenosine dialdehyde ( AdOx  , an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase ( SAHH  , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner", "triple_list": [["AdOx", "DOWNREGULATOR", "SAHH"]]}, {"text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine ( SAH ) hydrolase ( SAH H), enhanced the level of  SAH  and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner", "triple_list": [["SAH", "PRODUCT-OF", "adenosylhomocysteine (SAH) hydrolase"]]}, {"text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine ( SAH ) hydrolase ( SAH H , enhanced the level of  SAH  and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner", "triple_list": [["SAH", "PRODUCT-OF", "SAHH"]]}, {"text": "A series of  MMP-1  inhibitors have been identified based upon a  methyl rosmarinate  scaffold using structure-based drug design methods", "triple_list": [["methyl rosmarinate", "DOWNREGULATOR", "MMP-1"]]}, {"text": "Synthesis of derivatives of  methyl rosmarinate  and their inhibitory activities against matrix metalloproteinase-1 ( MMP-1  ", "triple_list": [["methyl rosmarinate", "DOWNREGULATOR", "MMP-1"]]}, {"text": "Synthesis of derivatives of  methyl rosmarinate  and their inhibitory activities against  matrix metalloproteinase-1  (MMP-1)", "triple_list": [["methyl rosmarinate", "DOWNREGULATOR", "matrix metalloproteinase-1"]]}, {"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as  cyclooxygenase-2  (COX-2)-derived  prostaglandin E2  (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "cyclooxygenase-2"]]}, {"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 ( COX-2  -derived  prostaglandin E2  (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "COX-2"]]}, {"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as  cyclooxygenase-2  (COX-2)-derived prostaglandin E2 ( PGE2   inhibitory activity of murine macrophage RAW 264.7 cell line", "triple_list": [["PGE2", "PRODUCT-OF", "cyclooxygenase-2"]]}, {"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 ( COX-2  -derived prostaglandin E2 ( PGE2   inhibitory activity of murine macrophage RAW 264.7 cell line", "triple_list": [["PGE2", "PRODUCT-OF", "COX-2"]]}, {"text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the  lipoxygenase  (LOX)-pathway (one having as precursors the  polyunsaturated fatty acids  containing a cis-cis-1,4-pentadiene system)", "triple_list": [["polyunsaturated fatty acids", "PRODUCT-OF", "lipoxygenase"]]}, {"text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase ( LOX  -pathway (one having as precursors the  polyunsaturated fatty acids  containing a cis-cis-1,4-pentadiene system)", "triple_list": [["polyunsaturated fatty acids", "PRODUCT-OF", "LOX"]]}, {"text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the  lipoxygenase  (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a  cis-cis-1,4-pentadiene  system)", "triple_list": [["cis-cis-1,4-pentadiene", "PRODUCT-OF", "lipoxygenase"]]}, {"text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase ( LOX  -pathway (one having as precursors the polyunsaturated fatty acids containing a  cis-cis-1,4-pentadiene  system)", "triple_list": [["cis-cis-1,4-pentadiene", "PRODUCT-OF", "LOX"]]}, {"text": "In general, antiproliferative activity is greatly enhanced by low levels of the  glutathione synthase  inhibitor  l-buthionine sulfoxime   The work illustrates how subtle changes to the design of low-spin d(6) metal complexes can lead to major changes in cellular metabolism and to potent complexes with novel mechanisms of anticancer activity.", "triple_list": [["l-buthionine sulfoxime", "DOWNREGULATOR", "glutathione synthase"]]}, {"text": "The recent identification of  zinc  permeability of the lysosomal ion channel  TRPML1  (transient receptor potential mucolipin 1), and the evidence of abnormal  zinc  levels in cells deficient in  TRPML1 , suggested a role for  TRPML1 \u00a0in  zinc  transport", "triple_list": [["zinc", "PRODUCT-OF", "TRPML1"]]}, {"text": "The recent identification of  zinc  permeability of the lysosomal ion channel TRPML1 ( transient receptor potential mucolipin 1  , and the evidence of abnormal  zinc  levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in  zinc  transport", "triple_list": [["zinc", "PRODUCT-OF", "transient receptor potential mucolipin 1"]]}, {"text": "The recent identification of  zinc  permeability of the lysosomal ion channel  TRPML1  (transient receptor potential mucolipin 1), and the evidence of abnormal  zinc  levels in cells deficient in  TRPML1 , suggested a role for  TRPML1  in  zinc  transport", "triple_list": [["zinc", "PRODUCT-OF", "TRPML1"]]}, {"text": "Cellular  zinc  is controlled by  zinc -chelating proteins and by  zinc  transporters", "triple_list": [["zinc", "PRODUCT-OF", "zinc-chelating proteins"]]}, {"text": "Cellular  zinc  is controlled by  zinc -chelating proteins and by  zinc  transporters  The recent identification of  zinc  permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal  zinc  levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in  zinc  transport", "triple_list": [["zinc", "PRODUCT-OF", "zinc transporters"]]}, {"text": "These results underscore a role for  TRPML1  in  zinc  metabolism", "triple_list": [["zinc", "PRODUCT-OF", "TRPML1"]]}, {"text": "Furthermore, they suggest that  TRPML1  works in concert with ZnT4 to regulate  zinc  translocation between the cytoplasm and lysosomes.", "triple_list": [["zinc", "PRODUCT-OF", "TRPML1"]]}, {"text": "Furthermore, they suggest that TRPML1 works in concert with  ZnT4  to regulate  zinc  translocation between the cytoplasm and lysosomes.", "triple_list": [["zinc", "PRODUCT-OF", "ZnT4"]]}, {"text": "Importantly, expression of the acute-phase reactant  serum amyloid A  (SAA) significantly increased after  ritodrine  injection, with values indicating the largest fold-change", "triple_list": [["ritodrine", "ACTIVATOR", "serum amyloid A"]]}, {"text": "Importantly, expression of the acute-phase reactant serum amyloid A ( SAA   significantly increased after  ritodrine  injection, with values indicating the largest fold-change", "triple_list": [["ritodrine", "ACTIVATOR", "SAA"]]}, {"text": " Serum amyloid A  upsurge precedes standard biomarkers of hepatotoxicity in  ritodrine  injected mice", "triple_list": [["ritodrine", "ACTIVATOR", "Serum amyloid A"]]}, {"text": "The increase in  SAA  expression is specific to  ritodrine  induced liver damage, because  SAA  expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin", "triple_list": [["ritodrine", "ACTIVATOR", "SAA"]]}, {"text": "Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the  ritodrine  induced  SAA  increase", "triple_list": [["ritodrine", "ACTIVATOR", "SAA"]]}, {"text": "Pharmacodynamic data suggest that  ceftazidime  avibactam is rapidly bactericidal versus  \u03b2-lactamase  producing Gram-negative bacilli that are not inhibited by  ceftazidime  alone.Clinical trials to date have reported that  ceftazidime -avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates", "triple_list": [["ceftazidime", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "Pharmacodynamic data suggest that ceftazidime- avibactam  is rapidly bactericidal versus  \u03b2-lactamase  producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime- avibactam  is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates", "triple_list": [["avibactam", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "Avibactam (formerly  NXL104   AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some  Ambler class D  enzymes", "triple_list": [["NXL104", "DOWNREGULATOR", "Ambler class D"]]}, {"text": "Avibactam (formerly  NXL104   AVE1330A) is a synthetic non-\u03b2-lactam,  \u03b2-lactamase  inhibitor that inhibits the activities of Ambler class A and C  \u03b2-lactamase s and some Ambler class D enzymes", "triple_list": [["NXL104", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": " Avibactam  (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some  Ambler class D  enzymes", "triple_list": [["Avibactam", "DOWNREGULATOR", "Ambler class D"]]}, {"text": " Avibactam  (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam,  \u03b2-lactamase  inhibitor that inhibits the activities of Ambler class A and C  \u03b2-lactamase s and some Ambler class D enzymes", "triple_list": [["Avibactam", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "Ceftazidime- avibactam  appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion,  avibactam  serves to broaden the spectrum of ceftazidime versus  \u00df-lactamase  producing Gram-negative bacilli", "triple_list": [["avibactam", "DOWNREGULATOR", "\u00df-lactamase"]]}, {"text": "Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of  ceftazidime  versus  \u00df-lactamase  producing Gram-negative bacilli", "triple_list": [["ceftazidime", "DOWNREGULATOR", "\u00df-lactamase"]]}, {"text": "Avibactam (formerly NXL104,  AVE1330A   is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some  Ambler class D  enzymes", "triple_list": [["AVE1330A", "DOWNREGULATOR", "Ambler class D"]]}, {"text": "Avibactam (formerly NXL104,  AVE1330A   is a synthetic non-\u03b2-lactam,  \u03b2-lactamase  inhibitor that inhibits the activities of Ambler class A and C  \u03b2-lactamase s and some Ambler class D enzymes", "triple_list": [["AVE1330A", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "The addition of  avibactam  greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of  \u03b2-lactamase  enzyme(s)", "triple_list": [["avibactam", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of  ceftazidime  versus most species of Enterobacteriaceae depending on the presence or absence of  \u03b2-lactamase  enzyme(s)", "triple_list": [["ceftazidime", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": " Ceftazidime  avibactam: a novel cephalosporin/ \u03b2-lactamase  inhibitor combination", "triple_list": [["Ceftazidime", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "Ceftazidime- avibactam   a novel cephalosporin/ \u03b2-lactamase  inhibitor combination", "triple_list": [["avibactam", "DOWNREGULATOR", "\u03b2-lactamase"]]}, {"text": "Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective  cyclooxygenase-2  inhibitor,  celecoxib   improved vascular function, and also attenuated obesity", "triple_list": [["celecoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": " Upamostat  (Mesupron\u00ae) is a new small molecule  serine protease  inhibitor", "triple_list": [["Upamostat", "DOWNREGULATOR", "serine protease"]]}, {"text": "Upamostat ( Mesupron  ) is a new small molecule  serine protease  inhibitor", "triple_list": [["Mesupron", "DOWNREGULATOR", "serine protease"]]}, {"text": "Interestingly, GPx1a was the most sensitive to  selenium  availability in non stressful conditions, whereas  GPx1b1  and GPx1b2 were highly induced by exposure to  selenium  levels that had some toxic effects on the cells", "triple_list": [["selenium", "ACTIVATOR", "GPx1b1"]]}, {"text": "Interestingly, GPx1a was the most sensitive to  selenium  availability in non stressful conditions, whereas GPx1b1 and  GPx1b2  were highly induced by exposure to  selenium  levels that had some toxic effects on the cells", "triple_list": [["selenium", "ACTIVATOR", "GPx1b2"]]}, {"text": "These findings are the first to show that long-term exposure to  Mn  during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers,  p38  MAPK) phosphorylation and caspase activity in the striatum", "triple_list": [["Mn", "ACTIVATOR", "p38"]]}, {"text": "These findings are the first to show that long-term exposure to  Mn  during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38( MAPK   phosphorylation and caspase activity in the striatum", "triple_list": [["Mn", "ACTIVATOR", "MAPK"]]}, {"text": "These findings are the first to show that long-term exposure to  Mn  during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and  caspase  activity in the striatum", "triple_list": [["Mn", "ACTIVATOR", "caspase"]]}, {"text": " Mn  exposure (20\u00a0mg/kg) increased  p38  MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation", "triple_list": [["Mn", "ACTIVATOR", "p38"]]}, {"text": " Mn  exposure (20\u00a0mg/kg) increased p38( MAPK   and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation", "triple_list": [["Mn", "ACTIVATOR", "MAPK"]]}, {"text": " Mn  exposure (20\u00a0mg/kg) increased p38(MAPK) and  Akt  phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation", "triple_list": [["Mn", "ACTIVATOR", "Akt"]]}, {"text": " Mn  (10 and 20\u00a0mg/kg) increased  caspase  activity and F(2)-isoprostane production (a biological marker of lipid peroxidation)", "triple_list": [["Mn", "ACTIVATOR", "caspase"]]}, {"text": "Notably, the antioxidant Trolox\u2122 reversed the  Mn  (20\u00a0mg/kg)-dependent augmentation in  p38  MAPK) phosphorylation and reduced the  Mn  (20\u00a0mg/kg)-induced caspase activity and F(2)-isoprostane production", "triple_list": [["Mn", "ACTIVATOR", "p38"]]}, {"text": "Notably, the antioxidant Trolox\u2122 reversed the  Mn  (20\u00a0mg/kg)-dependent augmentation in p38( MAPK   phosphorylation and reduced the  Mn  (20\u00a0mg/kg)-induced caspase activity and F(2)-isoprostane production", "triple_list": [["Mn", "ACTIVATOR", "MAPK"]]}, {"text": "Notably, the antioxidant Trolox\u2122 reversed the  Mn  (20\u00a0mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the  Mn  (20\u00a0mg/kg)-induced  caspase  activity and F(2)-isoprostane production", "triple_list": [["Mn", "ACTIVATOR", "caspase"]]}, {"text": " Mn  exposure (20\u00a0mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased  DARPP-32  Thr-34 phosphorylation", "triple_list": [["Mn", "DOWNREGULATOR", "DARPP-32"]]}, {"text": "Notably, the antioxidant  Trolox   reversed the Mn (20\u00a0mg/kg)-dependent augmentation in  p38  MAPK) phosphorylation and reduced the Mn (20\u00a0mg/kg)-induced caspase activity and F(2)-isoprostane production", "triple_list": [["Trolox", "DOWNREGULATOR", "p38"]]}, {"text": "Notably, the antioxidant  Trolox   reversed the Mn (20\u00a0mg/kg)-dependent augmentation in p38( MAPK   phosphorylation and reduced the Mn (20\u00a0mg/kg)-induced caspase activity and F(2)-isoprostane production", "triple_list": [["Trolox", "DOWNREGULATOR", "MAPK"]]}, {"text": "Notably, the antioxidant  Trolox   reversed the Mn (20\u00a0mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20\u00a0mg/kg)-induced  caspase  activity and F(2)-isoprostane production", "triple_list": [["Trolox", "DOWNREGULATOR", "caspase"]]}, {"text": " Nocapyrone H  (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and  interleukin-1\u03b2  (IL-1\u03b2)", "triple_list": [["Nocapyrone H", "DOWNREGULATOR", "interleukin-1\u03b2"]]}, {"text": " Nocapyrone H  (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1\u03b2 ( IL-1\u03b2  ", "triple_list": [["Nocapyrone H", "DOWNREGULATOR", "IL-1\u03b2"]]}, {"text": "Investigating the enteroenteric recirculation of  apixaban   a  factor Xa  inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats", "triple_list": [["apixaban", "DOWNREGULATOR", "factor Xa"]]}, {"text": "The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with  GF-120918   a dual  BCRP  and P-gp inhibitor)", "triple_list": [["GF-120918", "DOWNREGULATOR", "BCRP"]]}, {"text": "The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with  GF-120918   a dual BCRP and  P-gp  inhibitor)", "triple_list": [["GF-120918", "DOWNREGULATOR", "P-gp"]]}, {"text": " BCRP  appeared to play a more important role for absorption and intestinal and renal elimination of  apixaban  than P-gp in transporter-KO rats after oral and i.v", "triple_list": [["apixaban", "PRODUCT-OF", "BCRP"]]}, {"text": "BCRP appeared to play a more important role for absorption and intestinal and renal elimination of  apixaban  than  P-gp  in transporter-KO rats after oral and i.v", "triple_list": [["apixaban", "PRODUCT-OF", "P-gp"]]}, {"text": "A large number of  aromatic/heterocyclic sulfonamides  and some 5-mercapto-1,3,4-thiadiazoles were investigated as  TcCA  inhibitors", "triple_list": [["aromatic/heterocyclic sulfonamides", "DOWNREGULATOR", "TcCA"]]}, {"text": "A large number of aromatic/heterocyclic sulfonamides and some  5-mercapto-1,3,4-thiadiazoles  were investigated as  TcCA  inhibitors", "triple_list": [["5-mercapto-1,3,4-thiadiazoles", "DOWNREGULATOR", "TcCA"]]}, {"text": "Cloning, Characterization, and  Sulfonamide  and Thiol Inhibition Studies of an  \u03b1-Carbonic Anhydrase  from Trypanosoma cruzi, the Causative Agent of Chagas Disease", "triple_list": [["Sulfonamide", "DOWNREGULATOR", "\u03b1-Carbonic Anhydrase"]]}, {"text": "Cloning, Characterization, and Sulfonamide and  Thiol  Inhibition Studies of an  \u03b1-Carbonic Anhydrase  from Trypanosoma cruzi, the Causative Agent of Chagas Disease", "triple_list": [["Thiol", "DOWNREGULATOR", "\u03b1-Carbonic Anhydrase"]]}, {"text": "The enzyme (TcCA) has a very high catalytic activity for the  CO(2)  hydration reaction, being similar kinetically to the human (h) isoform  hCA II   although it is devoid of the His64 proton shuttle", "triple_list": [["CO(2)", "PRODUCT-OF", "hCA II"]]}, {"text": "The enzyme ( TcCA   has a very high catalytic activity for the  CO(2)  hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle", "triple_list": [["CO(2)", "PRODUCT-OF", "TcCA"]]}, {"text": "The mRNA level for  nestin  (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post- EDS   but not in the DEHP treated testes, suggesting that these  nestin  positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes", "triple_list": [["EDS", "ACTIVATOR", "nestin"]]}, {"text": "The mRNA level for nestin ( Nes   biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post- EDS   but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes", "triple_list": [["EDS", "ACTIVATOR", "Nes"]]}, {"text": "A dominant negative PKA (DNPKA) reduced  GnRH  stimulated  pCREB  and markedly decreased  GnRH  stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["GnRH", "ACTIVATOR", "pCREB"]]}, {"text": "A dominant negative PKA (DNPKA) reduced  GnRH -stimulated pCREB and markedly decreased  GnRH  stimulation of  FSH\u03b2  mRNA and  FSH\u03b2  UC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "In perifusion studies,  FSH\u03b2  mRNA levels and  FSH\u03b2  UC activities were increased by pulsatile  GnRH   with significantly greater increases at low compared with high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": " GnRH  pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of PKA and  CREB   Expression of pituitary FSH and LH, under the control of pulsatile  GnRH , is essential for fertility", "triple_list": [["GnRH", "ACTIVATOR", "CREB"]]}, {"text": " GnRH  pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of  PKA  and CREB", "triple_list": [["GnRH", "ACTIVATOR", "PKA"]]}, {"text": "Correlating with  FSH\u03b2  activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high  GnRH  pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "Correlating with FSH\u03b2 activation, both  PKA  activity and levels of pCREB were increased to a greater extent by low compared with high  GnRH  pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DN PKA  at both low and high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "PKA"]]}, {"text": "Correlating with FSH\u03b2 activation, both PKA activity and levels of  pCREB  were increased to a greater extent by low compared with high  GnRH  pulse frequencies, and the induction of  pCREB  was also attenuated by overexpression of DNPKA at both low and high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "pCREB"]]}, {"text": "Taken together, these data indicate that a PKA-mediated signaling pathway mediates  GnRH  activation of  CREB  at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic  GnRH  signal to result in frequency-dependent FSH\u03b2 activation.", "triple_list": [["GnRH", "ACTIVATOR", "CREB"]]}, {"text": "Taken together, these data indicate that a PKA-mediated signaling pathway mediates  GnRH  activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic  GnRH  signal to result in frequency-dependent  FSH\u03b2  activation.", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "cAMP response element-binding protein ( CREB ) has been implicated in the regulation of FSH\u03b2 gene expression, but the molecular mechanisms by which pulsatile  GnRH  regulates  CREB  activation remain poorly understood", "triple_list": [["GnRH", "ACTIVATOR", "CREB"]]}, {"text": "We hypothesized that  CREB  is activated by a distinct signaling pathway in response to pulsatile  GnRH  in a frequency-dependent manner to dictate the FSH\u03b2 transcriptional response", "triple_list": [["GnRH", "ACTIVATOR", "CREB"]]}, {"text": " GnRH  stimulation of  CREB  phosphorylation (p CREB ) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89", "triple_list": [["GnRH", "ACTIVATOR", "CREB"]]}, {"text": " GnRH  stimulation of CREB phosphorylation ( pCREB   in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89", "triple_list": [["GnRH", "ACTIVATOR", "pCREB"]]}, {"text": "A dominant negative PKA (DNPKA) reduced  GnRH -stimulated pCREB and markedly decreased  GnRH  stimulation of  FSH\u03b2  mRNA and  FSH\u03b2 LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "In perifusion studies,  FSH\u03b2  mRNA levels and  FSH\u03b2 LUC activities were increased by pulsatile  GnRH   with significantly greater increases at low compared with high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": " GnRH  pulse frequency-dependent stimulation of  FSH\u03b2  transcription is mediated via activation of PKA and CREB", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "DNPKA markedly reduced these  GnRH  stimulated  FSH\u03b2  responses at both low and high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "FSH\u03b2"]]}, {"text": "Correlating with FSH\u03b2 activation, both PKA activity and levels of  pCREB  were increased to a greater extent by low compared with high  GnRH  pulse frequencies, and the induction of  pCREB  was also attenuated by overexpression of DNPKA at both low and high pulse frequencies", "triple_list": [["GnRH", "ACTIVATOR", "pCREB"]]}, {"text": "GnRH stimulation of  CREB  phosphorylation (p CREB ) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor,  H89   A dominant negative PKA (DNPKA) reduced GnRH-stimulated p CREB  and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["H89", "DOWNREGULATOR", "CREB"]]}, {"text": "GnRH stimulation of CREB phosphorylation ( pCREB   in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor,  H89   A dominant negative PKA (DNPKA) reduced GnRH-stimulated  pCREB  and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["H89", "DOWNREGULATOR", "pCREB"]]}, {"text": "GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a  protein kinase A  (PKA) inhibitor,  H89   A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["H89", "DOWNREGULATOR", "protein kinase A"]]}, {"text": "GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A ( PKA   inhibitor,  H89   A dominant negative  PKA  (DN PKA ) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway", "triple_list": [["H89", "DOWNREGULATOR", "PKA"]]}, {"text": "We concluded that  sophocarpine  could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of  AMPK  ", "triple_list": [["sophocarpine", "ACTIVATOR", "AMPK"]]}, {"text": " Sophocarpine  alleviates hepatocyte steatosis through activating  AMPK  signaling pathway", "triple_list": [["Sophocarpine", "ACTIVATOR", "AMPK"]]}, {"text": "Moreover, compared with the model group,  sophocarpine  could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and  ACC  (>3.27-fold) protein expressions, and reduce P- ACC  (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression", "triple_list": [["sophocarpine", "ACTIVATOR", "ACC"]]}, {"text": "Moreover, compared with the model group,  sophocarpine  could significantly increase  P-AMPK\u03b1  (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression", "triple_list": [["sophocarpine", "ACTIVATOR", "P-AMPK\u03b1"]]}, {"text": "Moreover, compared with the model group,  sophocarpine  could significantly increase P- AMPK\u03b1  (>5.82-fold),  AMPK\u03b1  (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression", "triple_list": [["sophocarpine", "ACTIVATOR", "AMPK\u03b1"]]}, {"text": "While  sophocarpine  treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of  adiponectin  expression (>1.48-fold)", "triple_list": [["sophocarpine", "ACTIVATOR", "adiponectin"]]}, {"text": "Moreover, compared with the model group,  sophocarpine  could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce  P-ACC  (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression", "triple_list": [["sophocarpine", "DOWNREGULATOR", "P-ACC"]]}, {"text": "Moreover, compared with the model group,  sophocarpine  could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and  HNF-4\u03b1  (<0.20-fold) protein expression", "triple_list": [["sophocarpine", "DOWNREGULATOR", "HNF-4\u03b1"]]}, {"text": "While  sophocarpine  treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of  leptin  expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)", "triple_list": [["sophocarpine", "DOWNREGULATOR", "leptin"]]}, {"text": "The involvement of  P-gp  in the absorption of darunavir was clearly shown by coperfusion of darunavir with the  P-gp  inhibitor  zosuquidar   In presence of  zosuquidar , a 2.2-, 4.2- and 5.7-fold increase in Papp values were measured for duodenum, proximal jejunum and ileum, respectively", "triple_list": [["zosuquidar", "DOWNREGULATOR", "P-gp"]]}, {"text": "Upon studying the drug-drug interaction of darunavir with  ketoconazole , data were indicative for an inhibitory effect of  ketoconazole  on  P-gp  as the main mechanism for the increased transport of darunavir across the small intestine.", "triple_list": [["ketoconazole", "DOWNREGULATOR", "P-gp"]]}, {"text": "The involvement of  P-gp  in the absorption of  darunavir  was clearly shown by coperfusion of  darunavir  with the  P-gp  inhibitor zosuquidar", "triple_list": [["darunavir", "PRODUCT-OF", "P-gp"]]}, {"text": "Involvement of  P450  mediated metabolism in the absorption of  darunavir  could not be demonstrated in this rat model", "triple_list": [["darunavir", "PRODUCT-OF", "P450"]]}, {"text": "Upon studying the drug-drug interaction of  darunavir  with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on  P-gp  as the main mechanism for the increased transport of  darunavir  across the small intestine.", "triple_list": [["darunavir", "PRODUCT-OF", "P-gp"]]}, {"text": "To evaluate to what extent the regional differences in expression of  P-gp  and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of  darunavir  across different small intestinal segments (duodenum, proximal jejunum and ileum)", "triple_list": [["darunavir", "PRODUCT-OF", "P-gp"]]}, {"text": "To evaluate to what extent the regional differences in expression of P-gp and  P450 enzymes  affect the absorption of a dual substrate, we investigated the transport of  darunavir  across different small intestinal segments (duodenum, proximal jejunum and ileum)", "triple_list": [["darunavir", "PRODUCT-OF", "P450 enzymes"]]}, {"text": "In another experiment, topical application of CFB, CFE or  CLS  prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of  COX-2   iNOS, and TNF-\u03b1", "triple_list": [["CLS", "DOWNREGULATOR", "COX-2"]]}, {"text": "In another experiment, topical application of CFB, CFE or  CLS  prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2,  iNOS   and TNF-\u03b1", "triple_list": [["CLS", "DOWNREGULATOR", "iNOS"]]}, {"text": "In another experiment, topical application of CFB, CFE or  CLS  prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and  TNF-\u03b1   Furthermore, CFB, CFE and  CLS  suppressed oxidative damages caused by UVB irradiation for example lipid peroxidation and/or protein carbonylation, which seemed to be mediated by up-regulation of antioxidant defense enzymes", "triple_list": [["CLS", "DOWNREGULATOR", "TNF-\u03b1"]]}, {"text": "fragile extract (CFB or CFE) and a single compound,  clerosterol  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  cyclooxygenase-2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["clerosterol", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "fragile extract (CFB or CFE) and a single compound,  clerosterol  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( COX-2  , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["clerosterol", "DOWNREGULATOR", "COX-2"]]}, {"text": "fragile extract (CFB or CFE) and a single compound,  clerosterol  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  inducible nitric oxide synthase  (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["clerosterol", "DOWNREGULATOR", "inducible nitric oxide synthase"]]}, {"text": "fragile extract (CFB or CFE) and a single compound,  clerosterol  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( iNOS  , and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["clerosterol", "DOWNREGULATOR", "iNOS"]]}, {"text": "fragile extract (CFB or CFE) and a single compound,  clerosterol  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  tumor necrosis factor-\u03b1  (TNF- \u03b1)", "triple_list": [["clerosterol", "DOWNREGULATOR", "tumor necrosis factor-\u03b1"]]}, {"text": "fragile extract (CFB or CFE) and a single compound,  clerosterol  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 ( TNF- \u03b1  ", "triple_list": [["clerosterol", "DOWNREGULATOR", "TNF- \u03b1"]]}, {"text": "fragile extract (CFB or CFE) and a single compound, clerosterol ( CLS   isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  cyclooxygenase-2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["CLS", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "fragile extract (CFB or CFE) and a single compound, clerosterol ( CLS   isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( COX-2  , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["CLS", "DOWNREGULATOR", "COX-2"]]}, {"text": "fragile extract (CFB or CFE) and a single compound, clerosterol ( CLS   isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  inducible nitric oxide synthase  (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["CLS", "DOWNREGULATOR", "inducible nitric oxide synthase"]]}, {"text": "fragile extract (CFB or CFE) and a single compound, clerosterol ( CLS   isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( iNOS  , and tumor necrosis factor-\u03b1 (TNF- \u03b1)", "triple_list": [["CLS", "DOWNREGULATOR", "iNOS"]]}, {"text": "fragile extract (CFB or CFE) and a single compound, clerosterol ( CLS   isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  tumor necrosis factor-\u03b1  (TNF- \u03b1)", "triple_list": [["CLS", "DOWNREGULATOR", "tumor necrosis factor-\u03b1"]]}, {"text": "fragile extract (CFB or CFE) and a single compound, clerosterol ( CLS   isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 ( TNF- \u03b1  ", "triple_list": [["CLS", "DOWNREGULATOR", "TNF- \u03b1"]]}, {"text": "In overexpressing cell lines,  OATP1B1   and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin  flavonolignans  investigated", "triple_list": [["flavonolignans", "DOWNREGULATOR", "OATP1B1"]]}, {"text": "In overexpressing cell lines, OATP1B1- and  OATP1B3  mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin  flavonolignans  investigated", "triple_list": [["flavonolignans", "DOWNREGULATOR", "OATP1B3"]]}, {"text": "In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and  OATP2B1  mediated estrone-3-sulfate uptake were inhibited by most of the silymarin  flavonolignans  investigated", "triple_list": [["flavonolignans", "DOWNREGULATOR", "OATP2B1"]]}, {"text": " OATP1B1  , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively),  silybin A  (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silybin A", "DOWNREGULATOR", "OATP1B1"]]}, {"text": "OATP1B1-,  OATP1B3  , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively),  silybin A  (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silybin A", "DOWNREGULATOR", "OATP1B3"]]}, {"text": "OATP1B1-, OATP1B3-, and  OATP2B1  mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively),  silybin A  (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silybin A", "DOWNREGULATOR", "OATP2B1"]]}, {"text": " OATP1B1  , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively),  silybin B  (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silybin B", "DOWNREGULATOR", "OATP1B1"]]}, {"text": "OATP1B1-,  OATP1B3  , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively),  silybin B  (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silybin B", "DOWNREGULATOR", "OATP1B3"]]}, {"text": "OATP1B1-, OATP1B3-, and  OATP2B1  mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively),  silybin B  (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silybin B", "DOWNREGULATOR", "OATP2B1"]]}, {"text": " OATP1B1  , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and  silychristin  (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silychristin", "DOWNREGULATOR", "OATP1B1"]]}, {"text": "OATP1B1-,  OATP1B3  , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and  silychristin  (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silychristin", "DOWNREGULATOR", "OATP1B3"]]}, {"text": "OATP1B1-, OATP1B3-, and  OATP2B1  mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and  silychristin  (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)", "triple_list": [["silychristin", "DOWNREGULATOR", "OATP2B1"]]}, {"text": "Furthermore, silymarin,  silybin A   and silybin B (100 \u00b5M) significantly inhibited  OATP  mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes", "triple_list": [["silybin A", "DOWNREGULATOR", "OATP"]]}, {"text": "Furthermore, silymarin, silybin A, and  silybin B  (100 \u00b5M) significantly inhibited  OATP  mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes", "triple_list": [["silybin B", "DOWNREGULATOR", "OATP"]]}, {"text": "In overexpressing cell lines,  OATP1B1   and OATP1B3-mediated  estradiol-17\u03b2-glucuronide  uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated", "triple_list": [["estradiol-17\u03b2-glucuronide", "PRODUCT-OF", "OATP1B1"]]}, {"text": "In overexpressing cell lines, OATP1B1- and  OATP1B3  mediated  estradiol-17\u03b2-glucuronide  uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated", "triple_list": [["estradiol-17\u03b2-glucuronide", "PRODUCT-OF", "OATP1B3"]]}, {"text": "In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and  OATP2B1  mediated  estrone-3-sulfate  uptake were inhibited by most of the silymarin flavonolignans investigated", "triple_list": [["estrone-3-sulfate", "PRODUCT-OF", "OATP2B1"]]}, {"text": "Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited  OATP  mediated  estradiol-17\u03b2-glucuronide  and rosuvastatin uptake into human hepatocytes", "triple_list": [["estradiol-17\u03b2-glucuronide", "PRODUCT-OF", "OATP"]]}, {"text": "Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited  OATP  mediated estradiol-17\u03b2-glucuronide and  rosuvastatin  uptake into human hepatocytes", "triple_list": [["rosuvastatin", "PRODUCT-OF", "OATP"]]}, {"text": "Further investigation demonstrated that 8k reduced  H2O2  induced activation of mitochondrial apoptosis by inhibiting the expression of  Bax  and elevating the expression of Bcl-2", "triple_list": [["H2O2", "ACTIVATOR", "Bax"]]}, {"text": "Further investigation demonstrated that 8k reduced  H2O2  induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of  Bcl-2   Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways", "triple_list": [["H2O2", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  insulin  (achieved by administering  insulin  plus  glucose    glucose  only,  glucose  and GLP-1, and  glucose  and GLP-1 combined with arginine)", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  insulin  (achieved by administering  insulin  plus  glucose ,  glucose  only,  glucose  and GLP-1, and  glucose  and GLP-1 combined with arginine)", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  insulin  (achieved by administering  insulin  plus  glucose ,  glucose  only,  glucose  and GLP-1, and  glucose  and GLP-1 combined with arginine)", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  insulin  (achieved by administering  insulin  plus  glucose ,  glucose  only,  glucose  and GLP-1, and  glucose  and GLP-1 combined with arginine)", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  insulin  (achieved by administering  insulin  plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with  arginine  ", "triple_list": [["arginine", "ACTIVATOR", "insulin"]]}, {"text": "Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10\u00a0mg/kg/day), and the partial  N-methyl-D-aspartate (NMDA) receptor  agonist,  D-cycloserine  (10\u00a0mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD", "triple_list": [["D-cycloserine", "AGONIST", "N-methyl-D-aspartate (NMDA) receptor"]]}, {"text": "RATIONALE: The selective  CRF(1) (corticotropin releasing factor type 1) receptor  antagonist  SSR125543  has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure", "triple_list": [["SSR125543", "ANTAGONIST", "CRF(1) (corticotropin releasing factor type 1) receptor"]]}, {"text": "The  CRF(1) receptor  antagonist  SSR125543  prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine", "triple_list": [["SSR125543", "ANTAGONIST", "CRF(1) receptor"]]}, {"text": "CONCLUSIONS: These findings confirm that the  CRF(1) receptor  antagonist  SSR125543  is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.", "triple_list": [["SSR125543", "ANTAGONIST", "CRF(1) receptor"]]}, {"text": "A series of  indazole arylsulfonamides  were synthesized and examined as  human CCR4  antagonists", "triple_list": [["indazole arylsulfonamides", "ANTAGONIST", "human CCR4"]]}, {"text": "Mice given daily injections of high dose  JZL184  (\u226516 mg/kg) for six days displayed decreased  CB(1)  receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTP\u03b3S binding assays, respectively", "triple_list": [["JZL184", "DOWNREGULATOR", "CB(1)"]]}, {"text": "The monoacylglycerol lipase ( MAGL   inhibitor  JZL184  produces antinociceptive and anti-inflammatory effects", "triple_list": [["JZL184", "DOWNREGULATOR", "MAGL"]]}, {"text": "The  monoacylglycerol lipase  (MAGL) inhibitor  JZL184  produces antinociceptive and anti-inflammatory effects", "triple_list": [["JZL184", "DOWNREGULATOR", "monoacylglycerol lipase"]]}, {"text": "Repeated Low Dose Administration of the  Monoacylglycerol Lipase  Inhibitor  JZL184  Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects", "triple_list": [["JZL184", "DOWNREGULATOR", "Monoacylglycerol Lipase"]]}, {"text": " Bicyclic pyrazinone and pyrimidinone amides  were designed and synthesized as potent TF- FVIIa  inhibitors", "triple_list": [["Bicyclic pyrazinone and pyrimidinone amides", "DOWNREGULATOR", "FVIIa"]]}, {"text": " Bicyclic pyrazinone and pyrimidinone amides  were designed and synthesized as potent  TF  FVIIa inhibitors", "triple_list": [["Bicyclic pyrazinone and pyrimidinone amides", "DOWNREGULATOR", "TF"]]}, {"text": "Design and synthesis of  bicyclic pyrazinone and pyrimidinone amides  as potent  TF  FVIIa inhibitors", "triple_list": [["bicyclic pyrazinone and pyrimidinone amides", "DOWNREGULATOR", "TF"]]}, {"text": "Design and synthesis of  bicyclic pyrazinone and pyrimidinone amides  as potent TF- FVIIa  inhibitors", "triple_list": [["bicyclic pyrazinone and pyrimidinone amides", "DOWNREGULATOR", "FVIIa"]]}, {"text": "The most potent compound 5 ( HJC0123   has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved  caspase-3   inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values", "triple_list": [["HJC0123", "ACTIVATOR", "caspase-3"]]}, {"text": "The most potent compound 5 ( HJC0123   has demonstrated to inhibit  STAT3 promoter  activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values", "triple_list": [["HJC0123", "DOWNREGULATOR", "STAT3 promoter"]]}, {"text": "The most potent compound 5 ( HJC0123   has demonstrated to inhibit  STAT3  promoter activity, downregulate phosphorylation of  STAT3   increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values", "triple_list": [["HJC0123", "DOWNREGULATOR", "STAT3"]]}, {"text": "Fragment-based drug design and identification of  HJC0123   a novel orally bioavailable  STAT3  inhibitor for cancer therapy", "triple_list": [["HJC0123", "DOWNREGULATOR", "STAT3"]]}, {"text": "Therefore, we examined whether the  PDE5  I  vardenafil  improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults", "triple_list": [["vardenafil", "DOWNREGULATOR", "PDE5"]]}, {"text": "The effects of the  phosphodiesterase type 5  inhibitor  vardenafil  on cognitive performance in healthy adults: a behavioral- electroencephalography study", "triple_list": [["vardenafil", "DOWNREGULATOR", "phosphodiesterase type 5"]]}, {"text": "We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased  NADPH oxidase  activity and immunoreactivity for the protein nitration marker  3-nitrotyrosine  in the cerebral cortex", "triple_list": [["3-nitrotyrosine", "ACTIVATOR", "NADPH oxidase"]]}, {"text": "Statins are inhibitors of the enzyme  3-hydroxy-3-methylglutaryl coenzyme A reductase   the rate-limiting step in  cholesterol  biosynthesis", "triple_list": [["cholesterol", "PRODUCT-OF", "3-hydroxy-3-methylglutaryl coenzyme A reductase"]]}, {"text": "Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg/100\u200ag body weight (BW), i.p.) for 15 days or along with a  peroxisome proliferator-activated receptor alpha  agonist  bezafibrate  (Bzf; 30\u200a\u03bcg/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition", "triple_list": [["bezafibrate", "AGONIST", "peroxisome proliferator-activated receptor alpha"]]}, {"text": "Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg/100\u200ag body weight (BW), i.p.) for 15 days or along with a  peroxisome proliferator-activated receptor alpha  agonist bezafibrate ( Bzf   30\u200a\u03bcg/100\u200ag BW, oral) and were found to improve in the  Bzf  co-treated condition", "triple_list": [["Bzf", "AGONIST", "peroxisome proliferator-activated receptor alpha"]]}, {"text": "Moreover, the effects of the  DRD3  agonist  7-hydroxy-N,N-dipropyl-2-aminotetralin  (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when  DRD3  proteins were abundant", "triple_list": [["7-hydroxy-N,N-dipropyl-2-aminotetralin", "AGONIST", "DRD3"]]}, {"text": "Moreover, the effects of the  DRD3  agonist  7-hydroxy-N,N-dipropyl-2-aminotetralin  (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when  DRD3  proteins were abundant", "triple_list": [["7-hydroxy-N,N-dipropyl-2-aminotetralin", "AGONIST", "DRD3"]]}, {"text": "Moreover, the effects of the  DRD3  agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ( 7-OH-DPAT  -induced locomotor hypoactivity were significantly increased when  DRD3  proteins were abundant", "triple_list": [["7-OH-DPAT", "AGONIST", "DRD3"]]}, {"text": "Moreover, the effects of the  DRD3  agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ( 7-OH-DPAT  -induced locomotor hypoactivity were significantly increased when  DRD3  proteins were abundant", "triple_list": [["7-OH-DPAT", "AGONIST", "DRD3"]]}, {"text": " (2R)-IKM-159  locks the  GluA2  in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.", "triple_list": [["(2R)-IKM-159", "DOWNREGULATOR", "GluA2"]]}, {"text": " (2R)-IKM-159  locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of  AMPA receptors  ", "triple_list": [["(2R)-IKM-159", "ANTAGONIST", "AMPA receptors"]]}, {"text": "Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid  (AMPA) receptor  antagonist  IKM-159   asymmetric synthesis, neuroactivity, and structural characterization", "triple_list": [["IKM-159", "ANTAGONIST", "(AMPA) receptor"]]}, {"text": " IKM-159  was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as  AMPA receptor  selective antagonists", "triple_list": [["IKM-159", "ANTAGONIST", "AMPA receptor"]]}, {"text": "IKM-159 was developed and identified as a member of a new class of heterotricyclic  glutamate  analogues that act as  AMPA receptor  selective antagonists", "triple_list": [["glutamate", "ANTAGONIST", "AMPA receptor"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene,  flavanone   chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["flavanone", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by  2'-methoxy-5,7-dihydroxyflavone   2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["2'-methoxy-5,7-dihydroxyflavone", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone,  2-ethynylnaphthalene   2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["2-ethynylnaphthalene", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene,  2'-methoxyflavone   2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["2'-methoxyflavone", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone,  2-naphththalene propargyl ether   acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["2-naphththalene propargyl ether", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether,  acenaphthene   acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["acenaphthene", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone,  chrysin   3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["chrysin", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene,  acenaphthylene   naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["acenaphthylene", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynyl naphthalene , 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene,  naphthalene   1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["naphthalene", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene,  1-acetylpyrene   flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["1-acetylpyrene", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin,  3-ethynylphenanthrene   flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["3-ethynylphenanthrene", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxy flavone , 2-ethynylnaphthalene, 2'-methoxy flavone , 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene,  flavone   and 7-hydroxy flavone ; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["flavone", "DOWNREGULATOR", "P450 2A13"]]}, {"text": "Coumarin 7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and  7-hydroxyflavone   these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["7-hydroxyflavone", "DOWNREGULATOR", "P450 2A13"]]}, {"text": " Coumarin  7-hydroxylation, catalyzed by  P450 2A13   was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values", "triple_list": [["Coumarin", "PRODUCT-OF", "P450 2A13"]]}, {"text": "Full agonists to the  peroxisome proliferator-activated receptor (PPAR)\u03b3   such as  Rosiglitazone   have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity", "triple_list": [["Rosiglitazone", "AGONIST", "peroxisome proliferator-activated receptor (PPAR)\u03b3"]]}, {"text": "PURPOSE:  Omeprazole  has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with  cytochrome P450 (CYP) 2C19  genotype groups", "triple_list": [["Omeprazole", "PRODUCT-OF", "cytochrome P450 (CYP) 2C19"]]}, {"text": "The  (R)-omeprazole  hydroxylation index reflects  CYP2C19  activity in healthy Japanese volunteers", "triple_list": [["(R)-omeprazole", "PRODUCT-OF", "CYP2C19"]]}, {"text": "Additionally, there was a significant difference in plasma concentrations of  (R)-5-hydroxyomeprazole  among  CYP2C19  genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole", "triple_list": [["(R)-5-hydroxyomeprazole", "PRODUCT-OF", "CYP2C19"]]}, {"text": "Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among  CYP2C19  genotype groups, whereas no significant differences were observed in that of  (S)-5-hydroxyomeprazole   Similarly, (R)-omeprazole HI in hmEMs, htEMs, and PMs were 5.6, 3.1, and 0.3, respectively, which were significantly different, but no significant difference was present in the (S)-omeprazole HI", "triple_list": [["(S)-5-hydroxyomeprazole", "PRODUCT-OF", "CYP2C19"]]}, {"text": "CONCLUSION: Our findings demonstrate that  (R)-omeprazole  HI correlated better with  CYP2C19  genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in  CYP2C19  genotype groups prior to omeprazole treatment.", "triple_list": [["(R)-omeprazole", "PRODUCT-OF", "CYP2C19"]]}, {"text": "CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with  CYP2C19  genotype groups than  racemic-omeprazole  HI, and these results may be useful for classification among patients in  CYP2C19  genotype groups prior to omeprazole treatment.", "triple_list": [["racemic-omeprazole", "PRODUCT-OF", "CYP2C19"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  all-trans retinoic acid  (atRA), which regulates the expression of a battery of target genes through several families of  nuclear receptors  (RARs, RXRs and PPAR\u03b2/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators", "triple_list": [["all-trans retinoic acid", "ACTIVATOR", "nuclear receptors"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  all-trans retinoic acid  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors ( RARs   RXRs and PPAR\u03b2/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators", "triple_list": [["all-trans retinoic acid", "ACTIVATOR", "RARs"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  all-trans retinoic acid  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs,  RXRs  and PPAR\u03b2/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators", "triple_list": [["all-trans retinoic acid", "ACTIVATOR", "RXRs"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  all-trans retinoic acid  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2/\u03b4),  polymorphic retinoic acid (RA) response elements  and multiple coregulators", "triple_list": [["all-trans retinoic acid", "ACTIVATOR", "polymorphic retinoic acid (RA) response elements"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( atRA  , which regulates the expression of a battery of target genes through several families of  nuclear receptors  (RARs, RXRs and PPAR\u03b2/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators", "triple_list": [["atRA", "ACTIVATOR", "nuclear receptors"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( atRA  , which regulates the expression of a battery of target genes through several families of nuclear receptors ( RARs   RXRs and PPAR\u03b2/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators", "triple_list": [["atRA", "ACTIVATOR", "RARs"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( atRA  , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs,  RXRs  and PPAR\u03b2/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators", "triple_list": [["atRA", "ACTIVATOR", "RXRs"]]}, {"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( atRA  , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2/\u03b4),  polymorphic retinoic acid (RA) response elements  and multiple coregulators", "triple_list": [["atRA", "ACTIVATOR", "polymorphic retinoic acid (RA) response elements"]]}, {"text": "Interestingly,  miR-21  expression positively correlated with urine albumin  creatine  ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  creatine  clearance ratio (Ccr) and MMP-9 protein", "triple_list": [["creatine", "ACTIVATOR", "miR-21"]]}, {"text": "Interestingly,  miR-21  expression positively correlated with urine albumin  creatine  ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  creatine  clearance ratio (Ccr) and MMP-9 protein", "triple_list": [["creatine", "DOWNREGULATOR", "miR-21"]]}, {"text": "Studies on the kinetics of the  hSULT2A1  catalyzed sulfation of  dehydroepiandrosterone  (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme", "triple_list": [["dehydroepiandrosterone", "PRODUCT-OF", "hSULT2A1"]]}, {"text": "Studies on the kinetics of the  hSULT2A1  catalyzed sulfation of dehydroepiandrosterone ( DHEA   showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme", "triple_list": [["DHEA", "PRODUCT-OF", "hSULT2A1"]]}, {"text": "The  human cytosolic sulfotransferase hSULT2A1  catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous  hydroxysteroids  and bile acids", "triple_list": [["hydroxysteroids", "PRODUCT-OF", "human cytosolic sulfotransferase hSULT2A1"]]}, {"text": "The  human cytosolic sulfotransferase hSULT2A1  catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and  bile acids   Reversible modulation of the catalytic activity of this enzyme could play important roles in its physiologic functions", "triple_list": [["bile acids", "PRODUCT-OF", "human cytosolic sulfotransferase hSULT2A1"]]}, {"text": "Computational docking analysis was conducted to model the interaction of these antagonists with the human  ER \u03b1 and showed that they could tightly bind to the  ER \u03b1 in a manner similar to that of  ICI-182,780   a pure  ER  antagonist", "triple_list": [["ICI-182,780", "ANTAGONIST", "ER"]]}, {"text": "These results provide an example that attachment of a bulky side chain to the C-7\u03b1 position of E2 can produce  ER  antagonists with  ER  affinity comparable to that of  ICI-182,780  ", "triple_list": [["ICI-182,780", "ANTAGONIST", "ER"]]}, {"text": " 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole  11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as  activin receptor-like kinase 5  or ALK5) inhibitor", "triple_list": [["7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "DOWNREGULATOR", "activin receptor-like kinase 5"]]}, {"text": " 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole  11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or  ALK5   inhibitor", "triple_list": [["7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "DOWNREGULATOR", "ALK5"]]}, {"text": " 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole  11 (TASP0382088) was synthesized and evaluated as  transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor  (also known as activin receptor-like kinase 5 or ALK5) inhibitor", "triple_list": [["7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "DOWNREGULATOR", "transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor"]]}, {"text": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( TASP0382088   was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as  activin receptor-like kinase 5  or ALK5) inhibitor", "triple_list": [["TASP0382088", "DOWNREGULATOR", "activin receptor-like kinase 5"]]}, {"text": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( TASP0382088   was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or  ALK5   inhibitor", "triple_list": [["TASP0382088", "DOWNREGULATOR", "ALK5"]]}, {"text": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( TASP0382088   was synthesized and evaluated as  transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor  (also known as activin receptor-like kinase 5 or ALK5) inhibitor", "triple_list": [["TASP0382088", "DOWNREGULATOR", "transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor"]]}, {"text": "Discovery of  7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole  (TASP0382088): a potent and selective  transforming growth factor-\u03b2 type I receptor  inhibitor as a topical drug for alopecia", "triple_list": [["7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "DOWNREGULATOR", "transforming growth factor-\u03b2 type I receptor"]]}, {"text": "Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole ( TASP0382088  : a potent and selective  transforming growth factor-\u03b2 type I receptor  inhibitor as a topical drug for alopecia", "triple_list": [["TASP0382088", "DOWNREGULATOR", "transforming growth factor-\u03b2 type I receptor"]]}, {"text": "In non-pre-treated cells,  HMG-CoA  was up-regulated by both  7-ketosterols   However, exposure to inhibitors down-regulated the expression levels, mainly in 7-ketocholesterol-incubated cells", "triple_list": [["7-ketosterols", "ACTIVATOR", "HMG-CoA"]]}, {"text": "In non-pre-treated cells, only  efflux transporters  were down-regulated by  7-ketosterols   showing a greater influence upon ABCG5 expression", "triple_list": [["7-ketosterols", "DOWNREGULATOR", "efflux transporters"]]}, {"text": "Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced  NPC1L1  expression only in  7-ketocholesterol  incubated cells", "triple_list": [["7-ketocholesterol", "DOWNREGULATOR", "NPC1L1"]]}, {"text": "In lymphocytes, the NTPDase and  ADA  activities were increased in all groups treated with  caffeic acid  when compared to control (P<0.05)", "triple_list": [["caffeic acid", "ACTIVATOR", "ADA"]]}, {"text": "In lymphocytes, the  NTPDase  and ADA activities were increased in all groups treated with  caffeic acid  when compared to control (P<0.05)", "triple_list": [["caffeic acid", "ACTIVATOR", "NTPDase"]]}, {"text": "The procedure was to reduce liver  AOX  activity by providing  tungsten  or hydralazine in the drinking water or to use the  AOX -deficient DBA/2 mouse strain", "triple_list": [["tungsten", "DOWNREGULATOR", "AOX"]]}, {"text": "The procedure was to reduce liver  AOX  activity by providing tungsten or  hydralazine  in the drinking water or to use the  AOX -deficient DBA/2 mouse strain", "triple_list": [["hydralazine", "DOWNREGULATOR", "AOX"]]}, {"text": "Liver  AOX  activity was reduced by 45% with  tungsten  and 61% with hydralazine and 81% in  AOX -deficient mice relative to controls", "triple_list": [["tungsten", "DOWNREGULATOR", "AOX"]]}, {"text": "Liver  AOX  activity was reduced by 45% with tungsten and 61% with  hydralazine  and 81% in  AOX -deficient mice relative to controls", "triple_list": [["hydralazine", "DOWNREGULATOR", "AOX"]]}, {"text": "When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  AOX  generated nitrosoguanidine metabolite was decreased by 30% with  tungsten  and 56% with hydralazine and 86% in the  AOX -deficient mice", "triple_list": [["tungsten", "DOWNREGULATOR", "AOX"]]}, {"text": "When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  AOX  generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with  hydralazine  and 86% in the  AOX -deficient mice", "triple_list": [["hydralazine", "DOWNREGULATOR", "AOX"]]}, {"text": "When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  AOX  generated  nitrosoguanidine  metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the  AOX -deficient mice", "triple_list": [["nitrosoguanidine", "PRODUCT-OF", "AOX"]]}, {"text": "Possible  AOX  involvement in  IMI  metabolism in insects was evaluated using  AOX -expressing and  AOX -deficient Drosophila, but no differences were found in  IMI  nitroreduction or sensitivity between the two strains", "triple_list": [["IMI", "PRODUCT-OF", "AOX"]]}, {"text": "Possible  AOX  involvement in  IMI  metabolism in insects was evaluated using  AOX  expressing and  AOX -deficient Drosophila, but no differences were found in  IMI  nitroreduction or sensitivity between the two strains", "triple_list": [["IMI", "PRODUCT-OF", "AOX"]]}, {"text": "This is the first study to establish the in vivo relevance of  AOX  in  neonicotinoid  metabolism in mammals and one of the first for xenobiotics in general.", "triple_list": [["neonicotinoid", "PRODUCT-OF", "AOX"]]}, {"text": "Currently, the most important insecticides are  neonicotinoids   which are metabolized in vitro by  AOX  on reduction of the nitroimino group and by CYPs via oxidation reactions", "triple_list": [["neonicotinoids", "PRODUCT-OF", "AOX"]]}, {"text": "Currently, the most important insecticides are  neonicotinoids   which are metabolized in vitro by AOX on reduction of the nitroimino group and by  CYPs  via oxidation reactions", "triple_list": [["neonicotinoids", "PRODUCT-OF", "CYPs"]]}, {"text": "Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by  AOX  on reduction of the  nitroimino  group and by CYPs via oxidation reactions", "triple_list": [["nitroimino", "PRODUCT-OF", "AOX"]]}, {"text": "Thus, decreasing liver  AOX  activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of  IMI  treated mice", "triple_list": [["IMI", "PRODUCT-OF", "AOX"]]}, {"text": "Of the compounds active in the present assay system, the most potent compound 7,  platyphyllonol-5-O-\u03b2-d-xylopyranoside   significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and  CCAAT/enhancer binding protein \u03b1  (C/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist", "triple_list": [["platyphyllonol-5-O-\u03b2-d-xylopyranoside", "DOWNREGULATOR", "CCAAT/enhancer binding protein \u03b1"]]}, {"text": "Of the compounds active in the present assay system, the most potent compound 7,  platyphyllonol-5-O-\u03b2-d-xylopyranoside   significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT/enhancer binding protein \u03b1 ( C/EBP\u03b1   protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist", "triple_list": [["platyphyllonol-5-O-\u03b2-d-xylopyranoside", "DOWNREGULATOR", "C/EBP\u03b1"]]}, {"text": "Of the compounds active in the present assay system, the most potent compound 7,  platyphyllonol-5-O-\u03b2-d-xylopyranoside   significantly suppressed the induction of  peroxisome proliferator activated receptor \u03b3  (PPAR\u03b3 and CCAAT/enhancer binding protein \u03b1 (C/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist", "triple_list": [["platyphyllonol-5-O-\u03b2-d-xylopyranoside", "DOWNREGULATOR", "peroxisome proliferator activated receptor \u03b3"]]}, {"text": "Of the compounds active in the present assay system, the most potent compound 7,  platyphyllonol-5-O-\u03b2-d-xylopyranoside   significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 ( PPAR\u03b3  and CCAAT/enhancer binding protein \u03b1 (C/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a  PPAR\u03b3  agonist", "triple_list": [["platyphyllonol-5-O-\u03b2-d-xylopyranoside", "DOWNREGULATOR", "PPAR\u03b3"]]}, {"text": "Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 ( PPAR\u03b3  and CCAAT/enhancer binding protein \u03b1 (C/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by  troglitazone   a  PPAR\u03b3  agonist", "triple_list": [["troglitazone", "AGONIST", "PPAR\u03b3"]]}, {"text": "Based on our previously published work on  CXCR4  antagonists, we have synthesized a series of  aryl sulfonamides  that inhibit the  CXCR4  CXCL12 interaction", "triple_list": [["aryl sulfonamides", "DOWNREGULATOR", "CXCR4"]]}, {"text": "Based on our previously published work on CXCR4 antagonists, we have synthesized a series of  aryl sulfonamides  that inhibit the CXCR4/ CXCL12  interaction", "triple_list": [["aryl sulfonamides", "DOWNREGULATOR", "CXCL12"]]}, {"text": "These data demonstrate that  benzenesulfonamides  are a unique class of  CXCR4  inhibitors with high potency.", "triple_list": [["benzenesulfonamides", "DOWNREGULATOR", "CXCR4"]]}, {"text": " Benzenesulfonamides   a unique class of  chemokine receptor type 4  inhibitors", "triple_list": [["Benzenesulfonamides", "DOWNREGULATOR", "chemokine receptor type 4"]]}, {"text": "Measurement of Transport Activities of  3\u03b2-Hydroxy-\u0394(5)-bile Acids  in  Bile Salt Export Pump  and Multidrug Resistance-Associated Proteins Using LC-MS/MS", "triple_list": [["3\u03b2-Hydroxy-\u0394(5)-bile Acids", "PRODUCT-OF", "Bile Salt Export Pump"]]}, {"text": "Measurement of Transport Activities of  3\u03b2-Hydroxy-\u0394(5)-bile Acids  in Bile Salt Export Pump and  Multidrug Resistance-Associated Proteins  Using LC-MS/MS", "triple_list": [["3\u03b2-Hydroxy-\u0394(5)-bile Acids", "PRODUCT-OF", "Multidrug Resistance-Associated Proteins"]]}, {"text": "The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and  human bile salt export pump  expressing Sf9 cells for conjugated  3\u03b2-hydroxy-\u0394(5)-bile acids   The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated  3\u03b2-hydroxy-\u0394(5)-bile acids  along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.", "triple_list": [["3\u03b2-hydroxy-\u0394(5)-bile acids", "PRODUCT-OF", "human bile salt export pump"]]}, {"text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated  3\u03b2-hydroxy-\u0394(5)-bile acids  along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.", "triple_list": [["3\u03b2-hydroxy-\u0394(5)-bile acids", "PRODUCT-OF", "human multidrug resistance-associated protein 3"]]}, {"text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)- bile acids  along with common  bile acids  such as glycocholic acid and taurolithocholic acid 3-sulfate.", "triple_list": [["bile acids", "PRODUCT-OF", "human multidrug resistance-associated protein 3"]]}, {"text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as  glycocholic acid  and taurolithocholic acid 3-sulfate.", "triple_list": [["glycocholic acid", "PRODUCT-OF", "human multidrug resistance-associated protein 3"]]}, {"text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and  taurolithocholic acid 3-sulfate  ", "triple_list": [["taurolithocholic acid 3-sulfate", "PRODUCT-OF", "human multidrug resistance-associated protein 3"]]}, {"text": "A series of substituted  3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines  has been synthesised and tested in vitro as potential pro-apoptotic  Bcl-2  inhibitory anticancer agents", "triple_list": [["3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Active compounds, such as the  nitrobenzyl  analogue 6c, were found to exhibit sub-micromolar IC50 values in  Bcl-2  expressing human cancer cell lines", "triple_list": [["nitrobenzyl", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Synthesis and evaluation of  3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines  as  Bcl-2  inhibitory anticancer agents", "triple_list": [["3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Upon  nicotine  pre-exposure, brain  acetylcholinesterase  increased, while monoamine oxidase (MAO) decreased", "triple_list": [["nicotine", "ACTIVATOR", "acetylcholinesterase"]]}, {"text": "Upon  nicotine  pre-exposure, brain acetylcholinesterase increased, while  monoamine oxidase  (MAO) decreased", "triple_list": [["nicotine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Upon  nicotine  pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase ( MAO   decreased", "triple_list": [["nicotine", "DOWNREGULATOR", "MAO"]]}, {"text": "The toxic effects of  MAO  significantly attenuated with  nicotine  pre-exposure", "triple_list": [["nicotine", "DOWNREGULATOR", "MAO"]]}, {"text": " Glutathione-S-transferase   a phase II enzyme, was inhibited by both  arsenic  and nicotine but no such inhibition was noted in  arsenic -treated animals pre-exposed to nicotine", "triple_list": [["arsenic", "DOWNREGULATOR", "Glutathione-S-transferase"]]}, {"text": " Glutathione-S-transferase   a phase II enzyme, was inhibited by both arsenic and  nicotine  but no such inhibition was noted in arsenic-treated animals pre-exposed to  nicotine ", "triple_list": [["nicotine", "DOWNREGULATOR", "Glutathione-S-transferase"]]}, {"text": "We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the  aromatase  inhibitor,  fadrozole  (FAD)", "triple_list": [["fadrozole", "DOWNREGULATOR", "aromatase"]]}, {"text": "We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the  aromatase  inhibitor, fadrozole ( FAD  ", "triple_list": [["FAD", "DOWNREGULATOR", "aromatase"]]}, {"text": "We found that  pBQN  activates  TRPA1  starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline", "triple_list": [["pBQN", "ACTIVATOR", "TRPA1"]]}, {"text": "Interestingly, following pBQN desensitization, wild-type  TRPA1  had dramatically reduced response to the nonelectrophile agonist  carvacrol   whereas the triple cysteine mutant  TRPA1  retained its full response", "triple_list": [["carvacrol", "AGONIST", "TRPA1"]]}, {"text": "Although naturally occurring electrophilic plant compounds, such as mustard oil and  cinnamaldehyde   are  TRPA1  agonists, it is unknown whether arthropod-produced electrophiles activate mammalian  TRPA1 ", "triple_list": [["cinnamaldehyde", "AGONIST", "TRPA1"]]}, {"text": "Interestingly, following pBQN desensitization, wild-type  TRPA1  had dramatically reduced response to the nonelectrophile agonist  carvacrol   whereas the triple cysteine mutant  TRPA1  retained its full response", "triple_list": [["carvacrol", "AGONIST", "TRPA1"]]}, {"text": "Synthesis and in-silico studies of some  diaryltriazole  derivatives as potential  cyclooxygenase  inhibitors", "triple_list": [["diaryltriazole", "DOWNREGULATOR", "cyclooxygenase"]]}, {"text": "A highly potent inhibition of the  peroxidase  catalytic reaction by  NO  S NO  was seen in assays employing the coupled Prx-Trx system", "triple_list": [["NO", "DOWNREGULATOR", "peroxidase"]]}, {"text": "A highly potent inhibition of the  peroxidase  catalytic reaction by NO/ SNO  was seen in assays employing the coupled Prx-Trx system", "triple_list": [["SNO", "DOWNREGULATOR", "peroxidase"]]}, {"text": "In this setting,  S-nitrosocysteine  (10 \u03bcm) effectively blocked the  Trx  mediated regeneration of oxidized Prx1", "triple_list": [["S-nitrosocysteine", "DOWNREGULATOR", "Trx"]]}, {"text": "In this setting,  S-nitrosocysteine  (10 \u03bcm) effectively blocked the Trx-mediated regeneration of  oxidized Prx1   This effect appeared to be due to both competition between  S-nitrosocysteine  and Prx1 for the Trx system and direct modulation by  S-nitrosocysteine  of Trx reductase activity", "triple_list": [["S-nitrosocysteine", "DOWNREGULATOR", "oxidized Prx1"]]}, {"text": "CK significantly inhibited  DMN  induced increases in serum  alanine aminotransferase  (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content", "triple_list": [["DMN", "ACTIVATOR", "alanine aminotransferase"]]}, {"text": "CK significantly inhibited  DMN  induced increases in serum alanine aminotransferase ( ALT   and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content", "triple_list": [["DMN", "ACTIVATOR", "ALT"]]}, {"text": "CK significantly inhibited  DMN  induced increases in serum alanine aminotransferase (ALT) and  aspartate aminotransferase  (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content", "triple_list": [["DMN", "ACTIVATOR", "aspartate aminotransferase"]]}, {"text": "CK significantly inhibited  DMN  induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase ( AST   activities, fibrosis score, and hepatic malondialdehyde and collagen content", "triple_list": [["DMN", "ACTIVATOR", "AST"]]}, {"text": " DMN  induced cyclooxygenase-2 (COX-2) expression and  nuclear factor-kappa B  (NF-\u03baB) activation was reduced by CK treatment", "triple_list": [["DMN", "ACTIVATOR", "nuclear factor-kappa B"]]}, {"text": " DMN  induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B ( NF-\u03baB   activation was reduced by CK treatment", "triple_list": [["DMN", "ACTIVATOR", "NF-\u03baB"]]}, {"text": "CK significantly inhibited  DMN  induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and  collagen  content", "triple_list": [["DMN", "ACTIVATOR", "collagen"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in  matrix metalloproteinase-13  (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "matrix metalloproteinase-13"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 ( MMP-13  , tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "MMP-13"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 (MMP-13),  tissue inhibitor of metalloproteinase-1  (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "tissue inhibitor of metalloproteinase-1"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 ( TIMP-1  , and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "TIMP-1"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and  tumor necrosis factor-\u03b1  (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "tumor necrosis factor-\u03b1"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 ( TNF-\u03b1   mRNA, and collagen type I and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "TNF-\u03b1"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and  collagen type I  and \u03b1-smooth muscle actin protein", "triple_list": [["DMN", "ACTIVATOR", "collagen type I"]]}, {"text": "Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  DMN  induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and  \u03b1-smooth muscle actin  protein", "triple_list": [["DMN", "ACTIVATOR", "\u03b1-smooth muscle actin"]]}, {"text": " DMN  induced  cyclooxygenase-2  (COX-2) expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment", "triple_list": [["DMN", "ACTIVATOR", "cyclooxygenase-2"]]}, {"text": " DMN  induced cyclooxygenase-2 ( COX-2   expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment", "triple_list": [["DMN", "ACTIVATOR", "COX-2"]]}, {"text": "Extrinsic apoptotic pathway markers such as Fas levels and  caspase-8  activity increased as a result of  CdTe  QD exposure", "triple_list": [["CdTe", "ACTIVATOR", "caspase-8"]]}, {"text": "Our findings reveal that  CdTe  QDs cause oxidative stress, interfere with antioxidant defenses and activate protein  kinases   leading to apoptosis via both extrinsic and intrinsic pathways", "triple_list": [["CdTe", "ACTIVATOR", "kinases"]]}, {"text": "Extrinsic apoptotic pathway markers such as  Fas  levels and caspase-8 activity increased as a result of  CdTe  QD exposure", "triple_list": [["CdTe", "ACTIVATOR", "Fas"]]}, {"text": " Puerarin  administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and  PI3K  Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice", "triple_list": [["Puerarin", "ACTIVATOR", "PI3K"]]}, {"text": " Puerarin  administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/ Akt  pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice", "triple_list": [["Puerarin", "ACTIVATOR", "Akt"]]}, {"text": " Puerarin  administration enhanced glutathione (GSH) activity,  glial cell line-derived neurotrophic factor  (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice", "triple_list": [["Puerarin", "ACTIVATOR", "glial cell line-derived neurotrophic factor"]]}, {"text": " Puerarin  administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor ( GDNF   expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice", "triple_list": [["Puerarin", "ACTIVATOR", "GDNF"]]}, {"text": "In addition to the effect on ROS,  puerarin  ameliorated MPTP-reduced lysosome-associated membrane protein type 2A ( Lamp 2A   expression", "triple_list": [["puerarin", "DOWNREGULATOR", "Lamp 2A"]]}, {"text": "In addition to the effect on ROS, puerarin ameliorated  MPTP  reduced  lysosome-associated membrane protein type 2A  (Lamp 2A) expression", "triple_list": [["MPTP", "DOWNREGULATOR", "lysosome-associated membrane protein type 2A"]]}, {"text": "In addition to the effect on ROS, puerarin ameliorated  MPTP  reduced lysosome-associated membrane protein type 2A ( Lamp 2A   expression", "triple_list": [["MPTP", "DOWNREGULATOR", "Lamp 2A"]]}, {"text": "Taken together, our data demonstrate that  puerarin  attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of  Lamp 2A  expression", "triple_list": [["puerarin", "DOWNREGULATOR", "Lamp 2A"]]}, {"text": "Taken together, our data demonstrate that puerarin attenuates  MPTP -induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate  MPTP  induced ROS formation and decrease of  Lamp 2A  expression", "triple_list": [["MPTP", "DOWNREGULATOR", "Lamp 2A"]]}, {"text": "Instead, radiolabeled  nucleosides  resulting from  nuclease  hydrolysis were observed", "triple_list": [["nucleosides", "PRODUCT-OF", "nuclease"]]}, {"text": "A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the  vesicular monoamine transporter  and for their inhibition of vesicular  [(3)H]dopamine  uptake", "triple_list": [["[(3)H]dopamine", "PRODUCT-OF", "vesicular monoamine transporter"]]}, {"text": " IPI-926  is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of  P-glycoprotein   6", "triple_list": [["IPI-926", "DOWNREGULATOR", "P-glycoprotein"]]}, {"text": " IPI-926  is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of  P-glycoprotein   6", "triple_list": [["IPI-926", "PRODUCT-OF", "P-glycoprotein"]]}, {"text": "Oral  lorcaserin  (BELVIQ(\u00ae)), a selective serotonin  5-HT2C  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g", "triple_list": [["lorcaserin", "AGONIST", "5-HT2C"]]}, {"text": "Oral lorcaserin ( BELVIQ  \u00ae)), a selective serotonin  5-HT2C  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g", "triple_list": [["BELVIQ", "AGONIST", "5-HT2C"]]}, {"text": "Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 ( DPP-4 ) inhibitors, among them, the  cyclopropyl-substituted phenylalanine  derivative 11h displayed the most potent  DPP-4  inhibitory activity with an IC50 value of 0.247 \u03bcM", "triple_list": [["cyclopropyl-substituted phenylalanine", "DOWNREGULATOR", "DPP-4"]]}, {"text": "Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a  2-Cyanopyrrolidine  Moiety as Potent  Dipeptidyl Peptidase 4  Inhibitors", "triple_list": [["2-Cyanopyrrolidine", "DOWNREGULATOR", "Dipeptidyl Peptidase 4"]]}, {"text": "Design, Synthesis, Biological Evaluation, and Docking Studies of  (S)-Phenylalanine  Derivatives with a 2-Cyanopyrrolidine Moiety as Potent  Dipeptidyl Peptidase 4  Inhibitors", "triple_list": [["(S)-Phenylalanine", "DOWNREGULATOR", "Dipeptidyl Peptidase 4"]]}, {"text": " TCPOBOP   a CAR ligand, modestly induced  mdr1a  fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in  mdr1a  regulation", "triple_list": [["TCPOBOP", "ACTIVATOR", "mdr1a"]]}, {"text": "Furthermore,  galangin  attenuated  IgE  mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue", "triple_list": [["galangin", "DOWNREGULATOR", "IgE"]]}, {"text": " Galangin  decreased expression of pro-inflammatory  cytokines   such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and IL-8", "triple_list": [["Galangin", "DOWNREGULATOR", "cytokines"]]}, {"text": " Galangin  decreased expression of pro-inflammatory cytokines, such as  tumor necrosis factor (TNF)-\u03b1   interleukin (IL)-6, IL-1\u03b2, and IL-8", "triple_list": [["Galangin", "DOWNREGULATOR", "tumor necrosis factor (TNF)-\u03b1"]]}, {"text": " Galangin  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1,  interleukin  (IL)-6, IL-1\u03b2, and IL-8", "triple_list": [["Galangin", "DOWNREGULATOR", "interleukin"]]}, {"text": " Galangin  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin  (IL)-6   IL-1\u03b2, and IL-8", "triple_list": [["Galangin", "DOWNREGULATOR", "(IL)-6"]]}, {"text": " Galangin  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6,  IL-1\u03b2   and IL-8", "triple_list": [["Galangin", "DOWNREGULATOR", "IL-1\u03b2"]]}, {"text": " Galangin  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and  IL-8   The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1", "triple_list": [["Galangin", "DOWNREGULATOR", "IL-8"]]}, {"text": "The inhibitory effect of  galangin  on theses pro-inflammatory  cytokines  was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1", "triple_list": [["galangin", "DOWNREGULATOR", "cytokines"]]}, {"text": "Furthermore,  galangin  attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of  histamine receptor 1  at the inflamed tissue", "triple_list": [["galangin", "DOWNREGULATOR", "histamine receptor 1"]]}, {"text": "Our results showed that  galangin  down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory  cytokines   In light of in vitro and in vivo anti-allergic inflammatory effects,  galangin  could be a beneficial anti-allergic inflammatory agent.", "triple_list": [["galangin", "DOWNREGULATOR", "cytokines"]]}, {"text": "Next,  nobiletin  significantly decreased the levels of  phospho-ERK2  and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration", "triple_list": [["nobiletin", "DOWNREGULATOR", "phospho-ERK2"]]}, {"text": "Next,  nobiletin  significantly decreased the levels of phospho-ERK2 and  phospho-Akt  in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration", "triple_list": [["nobiletin", "DOWNREGULATOR", "phospho-Akt"]]}, {"text": "Next,  nobiletin  significantly decreased the levels of phospho- ERK2  and phospho-Akt in  ERK2  or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration", "triple_list": [["nobiletin", "DOWNREGULATOR", "ERK2"]]}, {"text": "Next,  nobiletin  significantly decreased the levels of phospho-ERK2 and phospho- Akt  in ERK2 or  Akt  siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration", "triple_list": [["nobiletin", "DOWNREGULATOR", "Akt"]]}, {"text": " Nobiletin  attenuates metastasis via both  ERK  and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells", "triple_list": [["Nobiletin", "DOWNREGULATOR", "ERK"]]}, {"text": " Nobiletin  attenuates metastasis via both ERK and  PI3K  Akt pathways in HGF-treated liver cancer HepG2 cells", "triple_list": [["Nobiletin", "DOWNREGULATOR", "PI3K"]]}, {"text": " Nobiletin  attenuates metastasis via both ERK and PI3K/ Akt  pathways in HGF-treated liver cancer HepG2 cells", "triple_list": [["Nobiletin", "DOWNREGULATOR", "Akt"]]}, {"text": "In conclusion,  nobiletin  attenuates  HGF  induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.", "triple_list": [["nobiletin", "DOWNREGULATOR", "HGF"]]}, {"text": "In conclusion,  nobiletin  attenuates HGF-induced HepG2 cells metastasis involving both  ERK  and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.", "triple_list": [["nobiletin", "DOWNREGULATOR", "ERK"]]}, {"text": "In conclusion,  nobiletin  attenuates HGF-induced HepG2 cells metastasis involving both ERK and  PI3K  Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.", "triple_list": [["nobiletin", "DOWNREGULATOR", "PI3K"]]}, {"text": "In conclusion,  nobiletin  attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/ Akt  pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.", "triple_list": [["nobiletin", "DOWNREGULATOR", "Akt"]]}, {"text": "Among them,  nobiletin  markedly inhibited  HGF  induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations", "triple_list": [["nobiletin", "DOWNREGULATOR", "HGF"]]}, {"text": "Data also showed  nobiletin  inhibited  HGF  induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia", "triple_list": [["nobiletin", "DOWNREGULATOR", "HGF"]]}, {"text": "Furthermore,  nobiletin  could inhibit  HGF  induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38", "triple_list": [["nobiletin", "DOWNREGULATOR", "HGF"]]}, {"text": "Furthermore,  nobiletin  could inhibit HGF-induced the membrane localization of phosphorylated  c-Met   ERK2, and Akt, but not phosphorylated JNK1/2 and p38", "triple_list": [["nobiletin", "DOWNREGULATOR", "c-Met"]]}, {"text": "Furthermore,  nobiletin  could inhibit HGF-induced the membrane localization of phosphorylated c-Met,  ERK2   and Akt, but not phosphorylated JNK1/2 and p38", "triple_list": [["nobiletin", "DOWNREGULATOR", "ERK2"]]}, {"text": "Furthermore,  nobiletin  could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and  Akt   but not phosphorylated JNK1/2 and p38", "triple_list": [["nobiletin", "DOWNREGULATOR", "Akt"]]}, {"text": "Excess of  cholesterol  converted into 24OHC may up-regulate  ApoE  synthesis which is a scavenger for A\u03b2 and Tau", "triple_list": [["cholesterol", "ACTIVATOR", "ApoE"]]}, {"text": "Excess of cholesterol converted into  24OHC  may up-regulate  ApoE  synthesis which is a scavenger for A\u03b2 and Tau", "triple_list": [["24OHC", "ACTIVATOR", "ApoE"]]}, {"text": " Cholesterol  also increases  Amyloid \u03b2  (A\u03b2) deposition and tau pathology", "triple_list": [["Cholesterol", "DOWNREGULATOR", "Amyloid \u03b2"]]}, {"text": " Cholesterol  also increases Amyloid \u03b2 ( A\u03b2   deposition and tau pathology", "triple_list": [["Cholesterol", "DOWNREGULATOR", "A\u03b2"]]}, {"text": " Cholesterol  also increases Amyloid \u03b2 (A\u03b2) deposition and  tau  pathology", "triple_list": [["Cholesterol", "DOWNREGULATOR", "tau"]]}, {"text": "In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular  glutamate  is reduced when  CaMKII  is inhibited", "triple_list": [["glutamate", "PRODUCT-OF", "CaMKII"]]}, {"text": "We have identified  3-hydroxypyridin-2-thione  (3-HPT) as a novel ZBG that is compatible with  HDAC  inhibition", "triple_list": [["3-hydroxypyridin-2-thione", "DOWNREGULATOR", "HDAC"]]}, {"text": "We have identified 3-hydroxypyridin-2-thione ( 3-HPT   as a novel ZBG that is compatible with  HDAC  inhibition", "triple_list": [["3-HPT", "DOWNREGULATOR", "HDAC"]]}, {"text": " 3-HPT  inhibits  HDAC 6  and HDAC 8 with an IC50 of 681 and 3675 nM, respectively", "triple_list": [["3-HPT", "DOWNREGULATOR", "HDAC 6"]]}, {"text": " 3-HPT  inhibits HDAC 6 and  HDAC 8  with an IC50 of 681 and 3675 nM, respectively", "triple_list": [["3-HPT", "DOWNREGULATOR", "HDAC 8"]]}, {"text": "Small molecules bearing hydroxamic acid as the  zinc  binding group (ZBG) have been the most effective  histone deacetylase  inhibitors (HDACi) to date", "triple_list": [["zinc", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Small molecules bearing hydroxamic acid as the  zinc  binding group (ZBG) have been the most effective histone deacetylase inhibitors ( HDAC  ) to date", "triple_list": [["zinc", "DOWNREGULATOR", "HDAC"]]}, {"text": "Subsequent optimization led to several novel  3HPT  based  HDAC   that are selective for  HDAC  6 and  HDAC  8", "triple_list": [["3HPT", "DOWNREGULATOR", "HDAC"]]}, {"text": "Subsequent optimization led to several novel  3HPT  based HDACi that are selective for  HDAC 6  and HDAC 8", "triple_list": [["3HPT", "DOWNREGULATOR", "HDAC 6"]]}, {"text": "Subsequent optimization led to several novel  3HPT  based HDACi that are selective for HDAC 6 and  HDAC 8   Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.", "triple_list": [["3HPT", "DOWNREGULATOR", "HDAC 8"]]}, {"text": " 3-Hydroxypyridin-2-thione  as Novel Zinc Binding Group for Selective  Histone Deacetylase  Inhibition", "triple_list": [["3-Hydroxypyridin-2-thione", "DOWNREGULATOR", "Histone Deacetylase"]]}, {"text": "3-Hydroxypyridin-2-thione as Novel  Zinc  Binding Group for Selective  Histone Deacetylase  Inhibition", "triple_list": [["Zinc", "DOWNREGULATOR", "Histone Deacetylase"]]}, {"text": "Maqui berry (Aristotelia chilensis) and the constituent  delphinidin glycoside  inhibit  photoreceptor  cell death induced by visible light", "triple_list": [["delphinidin glycoside", "ACTIVATOR", "photoreceptor"]]}, {"text": "These findings indicate that MBE and its  anthocyanidins  suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of  phosphorylated-p38  may be involved in the underlying mechanism.", "triple_list": [["anthocyanidins", "DOWNREGULATOR", "phosphorylated-p38"]]}, {"text": "Moreover,  curcumin  could also down-regulate the expression and activity of  matrix metalloproteinase-9  (MMP-9)", "triple_list": [["curcumin", "DOWNREGULATOR", "matrix metalloproteinase-9"]]}, {"text": "Moreover,  curcumin  could also down-regulate the expression and activity of matrix metalloproteinase-9 ( MMP-9  ", "triple_list": [["curcumin", "DOWNREGULATOR", "MMP-9"]]}, {"text": "Moreover,  curcumin  could also down-regulate the expression and activity of  matrix metalloproteinase-9  (MMP-9)", "triple_list": [["curcumin", "DOWNREGULATOR", "matrix metalloproteinase-9"]]}, {"text": "Moreover,  curcumin  could also down-regulate the expression and activity of matrix metalloproteinase-9 ( MMP-9  ", "triple_list": [["curcumin", "DOWNREGULATOR", "MMP-9"]]}, {"text": "Treatment with  EVn-50  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of  Histone 3  at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c", "triple_list": [["EVn-50", "ACTIVATOR", "Histone 3"]]}, {"text": "Treatment with  EVn-50  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of  Cdk1  at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c", "triple_list": [["EVn-50", "ACTIVATOR", "Cdk1"]]}, {"text": "Treatment with EVn-50 or  VB1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of  Histone 3  at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c", "triple_list": [["VB1", "ACTIVATOR", "Histone 3"]]}, {"text": "Treatment with EVn-50 or  VB1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of  Cdk1  at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c", "triple_list": [["VB1", "ACTIVATOR", "Cdk1"]]}, {"text": "Treatment with  EVn-50  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of  cyclin B1   and decreased expression of Cdc25c", "triple_list": [["EVn-50", "ACTIVATOR", "cyclin B1"]]}, {"text": "Treatment with EVn-50 or  VB1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of  cyclin B1   and decreased expression of Cdc25c", "triple_list": [["VB1", "ACTIVATOR", "cyclin B1"]]}, {"text": "Treatment with  EVn-50  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of  Cdc25c   Moreover, we found that exposure of MDA-MB-435 cells to  EVn-50  or VB1 caused obvious apoptosis of MDA-MB-435 cells", "triple_list": [["EVn-50", "DOWNREGULATOR", "Cdc25c"]]}, {"text": "Treatment with EVn-50 or  VB1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of  Cdc25c   Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or  VB1  caused obvious apoptosis of MDA-MB-435 cells", "triple_list": [["VB1", "DOWNREGULATOR", "Cdc25c"]]}, {"text": " Xanthohumol  and 2-hydroxychalcone induced apoptosis by  Bcl-2  downregulation", "triple_list": [["Xanthohumol", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Xanthohumol and  2-hydroxychalcone  induced apoptosis by  Bcl-2  downregulation", "triple_list": [["2-hydroxychalcone", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Importantly,  2-hydroxychalcone  and xanthohumol exerted more potent inhibitory effects on the proliferation,  MMP-9  expression and invasive phenotype of MDA-MB-231 than chalcone", "triple_list": [["2-hydroxychalcone", "DOWNREGULATOR", "MMP-9"]]}, {"text": "Importantly, 2-hydroxychalcone and  xanthohumol  exerted more potent inhibitory effects on the proliferation,  MMP-9  expression and invasive phenotype of MDA-MB-231 than chalcone", "triple_list": [["xanthohumol", "DOWNREGULATOR", "MMP-9"]]}, {"text": " 3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one  exhibited the predicted binding mode and demonstrated high inhibitory activity for  human DAAO  in enzyme- and cell-based assays", "triple_list": [["3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one", "DOWNREGULATOR", "human DAAO"]]}, {"text": " 4-Hydroxypyridazin-3(2H)-one  Derivatives as Novel  d-Amino Acid Oxidase  Inhibitors", "triple_list": [["4-Hydroxypyridazin-3(2H)-one", "DOWNREGULATOR", "d-Amino Acid Oxidase"]]}, {"text": "We identified a series of  4-hydroxypyridazin-3(2H)-one  derivatives as novel  DAAO  inhibitors with high potency and substantial cell permeability using fragment-based drug design", "triple_list": [["4-hydroxypyridazin-3(2H)-one", "DOWNREGULATOR", "DAAO"]]}, {"text": "d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including  d-serine   a coagonist of the  N-methyl-d-aspartate receptor   We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design", "triple_list": [["d-serine", "AGONIST", "N-methyl-d-aspartate receptor"]]}, {"text": " d-Amino acid oxidase  (DAAO) catalyzes the oxidation of d-amino acids including  d-serine   a coagonist of the N-methyl-d-aspartate receptor", "triple_list": [["d-serine", "PRODUCT-OF", "d-Amino acid oxidase"]]}, {"text": "d-Amino acid oxidase ( DAAO   catalyzes the oxidation of d-amino acids including  d-serine   a coagonist of the N-methyl-d-aspartate receptor", "triple_list": [["d-serine", "PRODUCT-OF", "DAAO"]]}, {"text": " d-Amino acid oxidase  (DAAO) catalyzes the oxidation of  d-amino acids  including d-serine, a coagonist of the N-methyl-d-aspartate receptor", "triple_list": [["d-amino acids", "PRODUCT-OF", "d-Amino acid oxidase"]]}, {"text": "d-Amino acid oxidase ( DAAO   catalyzes the oxidation of  d-amino acids  including d-serine, a coagonist of the N-methyl-d-aspartate receptor", "triple_list": [["d-amino acids", "PRODUCT-OF", "DAAO"]]}, {"text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12,  heptylparaben  (C7) and pentylparaben (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12", "triple_list": [["heptylparaben", "AGONIST", "ER\u03b1"]]}, {"text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12,  heptylparaben  (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12", "triple_list": [["heptylparaben", "AGONIST", "ER\u03b2"]]}, {"text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and  pentylparaben  (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12", "triple_list": [["pentylparaben", "AGONIST", "ER\u03b1"]]}, {"text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and  pentylparaben  (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12", "triple_list": [["pentylparaben", "AGONIST", "ER\u03b2"]]}, {"text": "Most  parabens  showing estrogenic activity exhibited  ER\u03b2  agonistic activity at lower concentrations than those inducing ER\u03b1-agonistic activity", "triple_list": [["parabens", "AGONIST", "ER\u03b2"]]}, {"text": "Most  parabens  showing estrogenic activity exhibited ER\u03b2-agonistic activity at lower concentrations than those inducing  ER\u03b1  agonistic activity", "triple_list": [["parabens", "AGONIST", "ER\u03b1"]]}, {"text": "These results indicate that  parabens  are selective agonists for  ER\u03b2  over ER\u03b1; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.", "triple_list": [["parabens", "AGONIST", "ER\u03b2"]]}, {"text": "These results indicate that  parabens  are selective agonists for ER\u03b2 over  ER\u03b1   their interactions with  ER\u03b1 /\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.", "triple_list": [["parabens", "AGONIST", "ER\u03b1"]]}, {"text": "Fourteen of 17  parabens  exhibited  hER\u03b1  and/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17  parabens  showed AR agonistic or antagonistic activity", "triple_list": [["parabens", "AGONIST", "hER\u03b1"]]}, {"text": "Fourteen of 17  parabens  exhibited hER\u03b1 and/or  hER\u03b2  agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17  parabens  showed AR agonistic or antagonistic activity", "triple_list": [["parabens", "AGONIST", "hER\u03b2"]]}, {"text": "Among 12  parabens  with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12", "triple_list": [["parabens", "AGONIST", "ER\u03b1"]]}, {"text": "Among 12  parabens  with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12", "triple_list": [["parabens", "AGONIST", "ER\u03b2"]]}, {"text": "Among 12 parabens with linear  alkyl  chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the  alkyl  chain was shortened to C1 or lengthened to C12", "triple_list": [["alkyl", "AGONIST", "ER\u03b1"]]}, {"text": "Among 12 parabens with linear  alkyl  chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the  alkyl  chain was shortened to C1 or lengthened to C12", "triple_list": [["alkyl", "AGONIST", "ER\u03b2"]]}, {"text": "These results indicate that  parabens  are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by  carboxylesterases   leading to attenuation of their estrogenic activity.", "triple_list": [["parabens", "PRODUCT-OF", "carboxylesterases"]]}, {"text": "Wattakaka volubilis  steroidal glycoside  mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the  COX-2  and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells", "triple_list": [["steroidal glycoside", "DOWNREGULATOR", "COX-2"]]}, {"text": "Wattakaka volubilis  steroidal glycoside  mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and  iNOS  enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells", "triple_list": [["steroidal glycoside", "DOWNREGULATOR", "iNOS"]]}, {"text": "Wattakaka volubilis steroidal glycoside mixture (WVSM) and  PPG  (1-50\u03bcM) significantly inhibited the  COX-2  and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells", "triple_list": [["PPG", "DOWNREGULATOR", "COX-2"]]}, {"text": "Wattakaka volubilis steroidal glycoside mixture (WVSM) and  PPG  (1-50\u03bcM) significantly inhibited the COX-2 and  iNOS  enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells", "triple_list": [["PPG", "DOWNREGULATOR", "iNOS"]]}, {"text": "Our data showed that chronic  ethanol  over-activated  CYP2E1  but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)", "triple_list": [["ethanol", "ACTIVATOR", "CYP2E1"]]}, {"text": " Quercetin  (100\u03bcM) induced  HO-1  and depleted heme pool when incubated to human hepatocytes", "triple_list": [["Quercetin", "ACTIVATOR", "HO-1"]]}, {"text": " Ethanol  stimulated (100mM)  CYP2E1  upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation", "triple_list": [["Ethanol", "ACTIVATOR", "CYP2E1"]]}, {"text": "CO donor dose-dependently inactivated  CYP2E1  of  ethanol  incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger", "triple_list": [["ethanol", "ACTIVATOR", "CYP2E1"]]}, {"text": "Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by  quercetin  through  HO-1  induction", "triple_list": [["quercetin", "ACTIVATOR", "HO-1"]]}, {"text": "Our data showed that chronic  ethanol  over-activated CYP2E1 but suppressed  HO-1  with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)", "triple_list": [["ethanol", "DOWNREGULATOR", "HO-1"]]}, {"text": "Ethanol-stimulated (100mM)  CYP2E1  upregulation was suppressed by  quercetin  but further enhanced by HO-1 inhibition with resultant heme accumulation", "triple_list": [["quercetin", "DOWNREGULATOR", "CYP2E1"]]}, {"text": " CO  scavenging blocked the suppression of quercetin only on  CYP2E1  activity", "triple_list": [["CO", "DOWNREGULATOR", "CYP2E1"]]}, {"text": " CO  donor dose-dependently inactivated  CYP2E1  of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by  CO  scavenger", "triple_list": [["CO", "DOWNREGULATOR", "CYP2E1"]]}, {"text": " Quercetin  suppressed  CYP2E1  dependent ethanol hepatotoxicity via depleting heme pool and releasing CO", "triple_list": [["Quercetin", "DOWNREGULATOR", "CYP2E1"]]}, {"text": " CO  donor dose-dependently inactivated  CYP2E1  of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by  CO  scavenger", "triple_list": [["CO", "DOWNREGULATOR", "CYP2E1"]]}, {"text": "However, the precise mechanism by which  quercetin  counteracts  CYP2E1  mediated ethanol hepatotoxicity through HO-1 system is still remained unclear", "triple_list": [["quercetin", "DOWNREGULATOR", "CYP2E1"]]}, {"text": " Ethanol  stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by  HO-1  inhibition with resultant heme accumulation", "triple_list": [["Ethanol", "DOWNREGULATOR", "HO-1"]]}, {"text": "Depleted heme pool and  CO  releasing limited protein synthesis and inhibited enzymatic activity of  CYP2E1   respectively.", "triple_list": [["CO", "DOWNREGULATOR", "CYP2E1"]]}, {"text": "Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by  HO-1  inhibition with resultant  heme  accumulation", "triple_list": [["heme", "PRODUCT-OF", "HO-1"]]}, {"text": "Novel racemic  tetrahydrocurcuminoid dihydropyrimidinone  analogues as potent  acetylcholinesterase  inhibitors", "triple_list": [["tetrahydrocurcuminoid dihydropyrimidinone", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "Furthermore, we detected that  ICI  treatment induced  glycogen synthase kinase  (Gsk3-\u03b2) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization", "triple_list": [["ICI", "ACTIVATOR", "glycogen synthase kinase"]]}, {"text": "Furthermore, we detected that  ICI  treatment induced glycogen synthase kinase ( Gsk3-\u03b2   Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization", "triple_list": [["ICI", "ACTIVATOR", "Gsk3-\u03b2"]]}, {"text": "Agonistic activity of  ICI 182 780  on activation of GSK 3\u03b2/ AKT  pathway in the rat uterus during the estrous cycle", "triple_list": [["ICI 182 780", "ACTIVATOR", "AKT"]]}, {"text": "The overall results indicate that  ICI  may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the  Akt  pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.", "triple_list": [["ICI", "ACTIVATOR", "Akt"]]}, {"text": "Both  ICI  treatments, induced a significant decrease (p<0.01) in uterine  estrogen receptor alpha  (ER\u03b1) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals", "triple_list": [["ICI", "DOWNREGULATOR", "estrogen receptor alpha"]]}, {"text": "Both  ICI  treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha ( ER\u03b1   content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals", "triple_list": [["ICI", "DOWNREGULATOR", "ER\u03b1"]]}, {"text": "We observed that the administration of  ICI  at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of  Akt  phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas  ICI  treatment at 00:00h on estrus day had no effect on these parameters", "triple_list": [["ICI", "DOWNREGULATOR", "Akt"]]}, {"text": "Agonistic activity of  ICI 182 780  on activation of  GSK 3\u03b2  AKT pathway in the rat uterus during the estrous cycle", "triple_list": [["ICI 182 780", "AGONIST", "GSK 3\u03b2"]]}, {"text": "A  N,N-dimethylaminopropyl  derivative showed promising inhibition of  Trypanosoma cruzi OSC  in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.", "triple_list": [["N,N-dimethylaminopropyl", "DOWNREGULATOR", "Trypanosoma cruzi OSC"]]}, {"text": " Aminopropylindenes  derived from Grundmann's ketone as a novel chemotype of  oxidosqualene cyclase  inhibitors", "triple_list": [["Aminopropylindenes", "DOWNREGULATOR", "oxidosqualene cyclase"]]}, {"text": "Aminopropylindenes derived from  Grundmann's ketone  as a novel chemotype of  oxidosqualene cyclase  inhibitors", "triple_list": [["Grundmann's ketone", "DOWNREGULATOR", "oxidosqualene cyclase"]]}, {"text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ( OSC  -mediated cyclization of 2,3-oxidosqualen to  lanosterol  was prepared from Grundmann's ketone", "triple_list": [["lanosterol", "PRODUCT-OF", "OSC"]]}, {"text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  oxidosqualene cyclase(1)  (OSC)-mediated cyclization of 2,3-oxidosqualen to  lanosterol  was prepared from Grundmann's ketone", "triple_list": [["lanosterol", "PRODUCT-OF", "oxidosqualene cyclase(1)"]]}, {"text": "A N,N-dimethylaminopropyl derivative showed promising inhibition of  Trypanosoma cruzi OSC  in combination with low cytotoxicity, and showed significant reduction of  cholesterol  biosynthesis in a human cell line.", "triple_list": [["cholesterol", "PRODUCT-OF", "Trypanosoma cruzi OSC"]]}, {"text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ( OSC  -mediated cyclization of  2,3-oxidosqualen  to lanosterol was prepared from Grundmann's ketone", "triple_list": [["2,3-oxidosqualen", "PRODUCT-OF", "OSC"]]}, {"text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  oxidosqualene cyclase(1)  (OSC)-mediated cyclization of  2,3-oxidosqualen  to lanosterol was prepared from Grundmann's ketone", "triple_list": [["2,3-oxidosqualen", "PRODUCT-OF", "oxidosqualene cyclase(1)"]]}, {"text": "During repetitive stimulation of skeletal muscle, extracellular  ATP  levels raise, activating  purinergic receptors   increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation", "triple_list": [["ATP", "ACTIVATOR", "purinergic receptors"]]}, {"text": "MRS2179, a  P2Y1 R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles  ATP  activates  P2Y1  but not P2X receptors", "triple_list": [["ATP", "ACTIVATOR", "P2Y1"]]}, {"text": "Consistent with two  glucose  uptake pathways, induced uptake of 2-NBDG, a fluorescent  glucose  derivative, was decreased by inhibition of HCs or  glucose  transporter (GLUT4), and blocked by dual blockade", "triple_list": [["glucose", "PRODUCT-OF", "glucose transporter"]]}, {"text": "Consistent with two  glucose  uptake pathways, induced uptake of 2-NBDG, a fluorescent  glucose  derivative, was decreased by inhibition of HCs or  glucose  transporter ( GLUT4  , and blocked by dual blockade", "triple_list": [["glucose", "PRODUCT-OF", "GLUT4"]]}, {"text": "Consistent with two glucose uptake pathways, induced uptake of  2-NBDG   a fluorescent glucose derivative, was decreased by inhibition of HCs or  glucose transporter  (GLUT4), and blocked by dual blockade", "triple_list": [["2-NBDG", "PRODUCT-OF", "glucose transporter"]]}, {"text": "Consistent with two glucose uptake pathways, induced uptake of  2-NBDG   a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter ( GLUT4  , and blocked by dual blockade", "triple_list": [["2-NBDG", "PRODUCT-OF", "GLUT4"]]}, {"text": "The  ATP  required for potentiation of skeletal muscle contraction is released via  pannexin  hemichannels", "triple_list": [["ATP", "PRODUCT-OF", "pannexin"]]}, {"text": "Opening of  Panx1  HCs during repetitive activation allows efflux of  ATP   influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction", "triple_list": [["ATP", "PRODUCT-OF", "Panx1"]]}, {"text": "Opening of  Panx1  HCs during repetitive activation allows efflux of ATP, influx of  glucose  and possibly Ca(2+) too, which are required for potentiation of contraction", "triple_list": [["glucose", "PRODUCT-OF", "Panx1"]]}, {"text": "Opening of  Panx1  HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly  Ca(2+)  too, which are required for potentiation of contraction", "triple_list": [["Ca(2+)", "PRODUCT-OF", "Panx1"]]}, {"text": "The rate limiting enzyme of beta-oxidation ( ACOX1   was significantly over-expressed in the liver with  tBHQ  treatment", "triple_list": [["tBHQ", "ACTIVATOR", "ACOX1"]]}, {"text": "These results indicate that  tBHQ  suppresses body weight gain in mice, possibly at least related to the up-regulation of  ACOX1  gene expression.", "triple_list": [["tBHQ", "ACTIVATOR", "ACOX1"]]}, {"text": "When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF ( VEGF ), are encapsulated separately in the core and shell domains, respectively, the  VEGF  release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  PLGA  and more than 45% with HMW core  PLGA ", "triple_list": [["PLGA", "ACTIVATOR", "VEGF"]]}, {"text": "When dual angiogenic growth factors (GFs), such as platelet-derived GF ( PDGF ) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of  PDGF   and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  PLGA  and more than 45% with HMW core  PLGA ", "triple_list": [["PLGA", "ACTIVATOR", "PDGF"]]}, {"text": "When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF ( VEGF ), are encapsulated separately in the core and shell domains, respectively, the  VEGF  release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  PLGA  and more than 45% with HMW core  PLGA   As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area", "triple_list": [["PLGA", "ACTIVATOR", "VEGF"]]}, {"text": "When dual angiogenic growth factors (GFs), such as platelet-derived GF ( PDGF ) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of  PDGF   and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  PLGA  and more than 45% with HMW core  PLGA   As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area", "triple_list": [["PLGA", "ACTIVATOR", "PDGF"]]}, {"text": "Potency switch between CHK1 and  MK2   Discovery of  imidazo[1,2-a]pyrazine   and imidazo[1,2-c]pyrimidine-based kinase inhibitors", "triple_list": [["imidazo[1,2-a]pyrazine", "DOWNREGULATOR", "MK2"]]}, {"text": "Potency switch between CHK1 and MK2: Discovery of  imidazo[1,2-a]pyrazine   and imidazo[1,2-c]pyrimidine-based  kinase  inhibitors", "triple_list": [["imidazo[1,2-a]pyrazine", "DOWNREGULATOR", "kinase"]]}, {"text": "Potency switch between  CHK1  and MK2: Discovery of  imidazo[1,2-a]pyrazine   and imidazo[1,2-c]pyrimidine-based kinase inhibitors", "triple_list": [["imidazo[1,2-a]pyrazine", "DOWNREGULATOR", "CHK1"]]}, {"text": "Potency switch between CHK1 and  MK2   Discovery of imidazo[1,2-a]pyrazine- and  imidazo[1,2-c]pyrimidine  based kinase inhibitors", "triple_list": [["imidazo[1,2-c]pyrimidine", "DOWNREGULATOR", "MK2"]]}, {"text": "Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and  imidazo[1,2-c]pyrimidine  based  kinase  inhibitors", "triple_list": [["imidazo[1,2-c]pyrimidine", "DOWNREGULATOR", "kinase"]]}, {"text": "Potency switch between  CHK1  and MK2: Discovery of imidazo[1,2-a]pyrazine- and  imidazo[1,2-c]pyrimidine  based kinase inhibitors", "triple_list": [["imidazo[1,2-c]pyrimidine", "DOWNREGULATOR", "CHK1"]]}, {"text": "A series of structurally novel  aryl ureas  was derived from optimization of the HTS lead as selective  histamine H3 receptor  (H3R) antagonists", "triple_list": [["aryl ureas", "ANTAGONIST", "histamine H3 receptor"]]}, {"text": "A series of structurally novel  aryl ureas  was derived from optimization of the HTS lead as selective histamine H3 receptor ( H3R   antagonists", "triple_list": [["aryl ureas", "ANTAGONIST", "H3R"]]}, {"text": "Discovery of  aryl ureas  and aryl amides as potent and selective  histamine H3 receptor  antagonists for the treatment of obesity (Part I)", "triple_list": [["aryl ureas", "ANTAGONIST", "histamine H3 receptor"]]}, {"text": "Discovery of aryl ureas and  aryl amides  as potent and selective  histamine H3 receptor  antagonists for the treatment of obesity (Part I)", "triple_list": [["aryl amides", "ANTAGONIST", "histamine H3 receptor"]]}, {"text": "In terms of the mechanisms, we found that fatty acid amide hydrolase ( FAAH   which degrades  anandamide   was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences", "triple_list": [["anandamide", "PRODUCT-OF", "FAAH"]]}, {"text": "In terms of the mechanisms, we found that  fatty acid amide hydrolase  (FAAH) which degrades  anandamide   was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences", "triple_list": [["anandamide", "PRODUCT-OF", "fatty acid amide hydrolase"]]}, {"text": "However, enzymes contributing to oxidative metabolism of  anandamide   namely  cyclooxygenase-1  and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  anandamide ", "triple_list": [["anandamide", "PRODUCT-OF", "cyclooxygenase-1"]]}, {"text": "However, enzymes contributing to oxidative metabolism of  anandamide   namely cyclooxygenase-1 and  Cyp2D6   were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  anandamide ", "triple_list": [["anandamide", "PRODUCT-OF", "Cyp2D6"]]}, {"text": "However, enzymes contributing to oxidative metabolism of  anandamide , namely  cyclooxygenase-1  and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  anandamide   This may overwhelm the capacity of R-flurbiprofen to restore  anandamide  homeostasis and may contribute to the heightened risk for neuropathic pain at old age.", "triple_list": [["anandamide", "PRODUCT-OF", "cyclooxygenase-1"]]}, {"text": "However, enzymes contributing to oxidative metabolism of  anandamide , namely cyclooxygenase-1 and  Cyp2D6   were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  anandamide   This may overwhelm the capacity of R-flurbiprofen to restore  anandamide  homeostasis and may contribute to the heightened risk for neuropathic pain at old age.", "triple_list": [["anandamide", "PRODUCT-OF", "Cyp2D6"]]}, {"text": "The expression of  ABCA1  and ABCG1 was induced by 24-OHC, as well as TO901317 and  retinoic acid   which are ligands of the nuclear receptors LXR/RXR", "triple_list": [["retinoic acid", "ACTIVATOR", "ABCA1"]]}, {"text": "The expression of ABCA1 and  ABCG1  was induced by 24-OHC, as well as TO901317 and  retinoic acid   which are ligands of the nuclear receptors LXR/RXR", "triple_list": [["retinoic acid", "ACTIVATOR", "ABCG1"]]}, {"text": "The expression of  ABCA1  and ABCG1 was induced by  24-OHC   as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR", "triple_list": [["24-OHC", "ACTIVATOR", "ABCA1"]]}, {"text": "The expression of ABCA1 and  ABCG1  was induced by  24-OHC   as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR", "triple_list": [["24-OHC", "ACTIVATOR", "ABCG1"]]}, {"text": "The expression of  ABCA1  and ABCG1 was induced by 24-OHC, as well as  TO901317  and retinoic acid, which are ligands of the nuclear receptors LXR/RXR", "triple_list": [["TO901317", "ACTIVATOR", "ABCA1"]]}, {"text": "The expression of ABCA1 and  ABCG1  was induced by 24-OHC, as well as  TO901317  and retinoic acid, which are ligands of the nuclear receptors LXR/RXR", "triple_list": [["TO901317", "ACTIVATOR", "ABCG1"]]}, {"text": "Because  24(S)-hydroxycholesterol  (24-OHC), produced by  24-hydroxylase   induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells", "triple_list": [["24(S)-hydroxycholesterol", "PRODUCT-OF", "24-hydroxylase"]]}, {"text": "Because 24(S)-hydroxycholesterol ( 24-OHC  , produced by  24-hydroxylase   induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells", "triple_list": [["24-OHC", "PRODUCT-OF", "24-hydroxylase"]]}, {"text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing  human ABCA1  or ABCG1; we clearly observed  24-OHC  efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal", "triple_list": [["24-OHC", "PRODUCT-OF", "human ABCA1"]]}, {"text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or  ABCG1   we clearly observed  24-OHC  efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal", "triple_list": [["24-OHC", "PRODUCT-OF", "ABCG1"]]}, {"text": " 24(S)-hydroxycholesterol  is actively eliminated from neuronal cells by  ABCA1   High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning", "triple_list": [["24(S)-hydroxycholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "These results suggest that  ABCA1  actively eliminates  24-OHC  in the presence of HDL as a lipid acceptor and protects neuronal cells", "triple_list": [["24-OHC", "PRODUCT-OF", "ABCA1"]]}, {"text": "High  cholesterol  turnover catalyzed by  cholesterol  24-hydroxylase is essential for neural functions, especially learning", "triple_list": [["cholesterol", "PRODUCT-OF", "cholesterol 24-hydroxylase"]]}, {"text": "The selective  CaMKII\u03b1  inhibitor  KN-62  reversed the blockade produced by ionomycin and K(+)-depolarization", "triple_list": [["KN-62", "DOWNREGULATOR", "CaMKII\u03b1"]]}, {"text": "The selective  CaMKII\u03b1  inhibitor KN-62 reversed the blockade produced by  ionomycin  and K(+)-depolarization", "triple_list": [["ionomycin", "DOWNREGULATOR", "CaMKII\u03b1"]]}, {"text": "In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when  CaMKII\u03b1  was blocked with  KN-62   In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM", "triple_list": [["KN-62", "DOWNREGULATOR", "CaMKII\u03b1"]]}, {"text": "In the presence of this inhibitor, the selective  D3  agonist  PD 128,907  reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM", "triple_list": [["PD 128,907", "AGONIST", "D3"]]}, {"text": "In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the  D1  agonist  SKF 38393  from 56 to 4\u00a0nM", "triple_list": [["SKF 38393", "AGONIST", "D1"]]}, {"text": "Additionally, treatment with  glucose  iron showed a higher  HO  activity", "triple_list": [["glucose", "ACTIVATOR", "HO"]]}, {"text": "Additionally, treatment with glucose/ iron  showed a higher  HO  activity", "triple_list": [["iron", "ACTIVATOR", "HO"]]}, {"text": "The  Bcl2  Bax ratio increased and Mfn2 expression decreased in MIN6 cells after  glucose  stimulation", "triple_list": [["glucose", "ACTIVATOR", "Bcl2"]]}, {"text": "The Bcl2/ Bax  ratio increased and Mfn2 expression decreased in MIN6 cells after  glucose  stimulation", "triple_list": [["glucose", "ACTIVATOR", "Bax"]]}, {"text": "Our study revealed that high  glucose  Fe concentrations in MIN6 cells induced an increase of the  Bcl2  Bax ratio, an indicator of increased cell apoptosis.", "triple_list": [["glucose", "ACTIVATOR", "Bcl2"]]}, {"text": "Our study revealed that high  glucose  Fe concentrations in MIN6 cells induced an increase of the Bcl2/ Bax  ratio, an indicator of increased cell apoptosis.", "triple_list": [["glucose", "ACTIVATOR", "Bax"]]}, {"text": "Our study revealed that high glucose/ Fe  concentrations in MIN6 cells induced an increase of the  Bcl2  Bax ratio, an indicator of increased cell apoptosis.", "triple_list": [["Fe", "ACTIVATOR", "Bcl2"]]}, {"text": "Our study revealed that high glucose/ Fe  concentrations in MIN6 cells induced an increase of the Bcl2/ Bax  ratio, an indicator of increased cell apoptosis.", "triple_list": [["Fe", "ACTIVATOR", "Bax"]]}, {"text": "The Bcl2/Bax ratio increased and  Mfn2  expression decreased in MIN6 cells after  glucose  stimulation", "triple_list": [["glucose", "DOWNREGULATOR", "Mfn2"]]}, {"text": "Targeted disruption of the gene encoding the  N-glycosyltransferase   prlH, abolished  pyralomicin  production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.", "triple_list": [["pyralomicin", "PRODUCT-OF", "N-glycosyltransferase"]]}, {"text": "Targeted disruption of the gene encoding the N-glycosyltransferase,  prlH   abolished  pyralomicin  production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.", "triple_list": [["pyralomicin", "PRODUCT-OF", "prlH"]]}, {"text": "Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of  PrlA  confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the  C7  cyclitol moiety.", "triple_list": [["C7", "PRODUCT-OF", "PrlA"]]}, {"text": "Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a  sugar phosphate cyclase  involved in the formation of the  C7  cyclitol moiety.", "triple_list": [["C7", "PRODUCT-OF", "sugar phosphate cyclase"]]}, {"text": "Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of  PrlA  confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7- cyclitol  moiety.", "triple_list": [["cyclitol", "PRODUCT-OF", "PrlA"]]}, {"text": "Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a  sugar phosphate cyclase  involved in the formation of the C7- cyclitol  moiety.", "triple_list": [["cyclitol", "PRODUCT-OF", "sugar phosphate cyclase"]]}, {"text": "This includes  nonribosomal peptide synthetases  (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "nonribosomal peptide synthetases"]]}, {"text": "This includes nonribosomal peptide synthetases ( NRPS   and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "NRPS"]]}, {"text": "This includes nonribosomal peptide synthetases (NRPS) and  polyketide synthases  (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "polyketide synthases"]]}, {"text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases ( PKS   required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "PKS"]]}, {"text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four  halogenases   an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "halogenases"]]}, {"text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  O-methyltransferase   and an N-glycosyltransferase) necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "O-methyltransferase"]]}, {"text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  N-glycosyltransferase   necessary for further modifications of the core structure", "triple_list": [["benzopyranopyrrole", "PRODUCT-OF", "N-glycosyltransferase"]]}, {"text": "To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the  ER\u03b1  selective agonist  PPT  or the ER\u03b2-selective agonist DPN were compared to Sham mice, and mice lacking either  ER\u03b1  (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates", "triple_list": [["PPT", "AGONIST", "ER\u03b1"]]}, {"text": "To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1-selective agonist PPT or the  ER\u03b2  selective agonist  DPN  were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or  ER\u03b2  (\u03b2ERKO) were compared to WT littermates", "triple_list": [["DPN", "AGONIST", "ER\u03b2"]]}, {"text": "The Intermediate-conductance  Calcium -activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling  Calcium  dependent Signaling", "triple_list": [["Calcium", "PRODUCT-OF", "Intermediate-conductance Calcium-activated Potassium Channel KCa3.1"]]}, {"text": "The current study examined the bioactivation potential of  ghrelin receptor  inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and  1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone  (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure", "triple_list": [["1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone", "AGONIST", "ghrelin receptor"]]}, {"text": "The current study examined the bioactivation potential of  ghrelin receptor  inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused  imidazo[2,1-b]thiazole  motif in the core structure", "triple_list": [["imidazo[2,1-b]thiazole", "AGONIST", "ghrelin receptor"]]}, {"text": "The current study examined the bioactivation potential of  ghrelin receptor  inverse agonists,  1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone  (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure", "triple_list": [["1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone", "AGONIST", "ghrelin receptor"]]}, {"text": "Reactive Metabolite Trapping Studies on  Imidazo- and 2-Methylimidazo[2,1-b]thiazole  based Inverse Agonists of the  Ghrelin Receptor   The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure", "triple_list": [["Imidazo- and 2-Methylimidazo[2,1-b]thiazole", "AGONIST", "Ghrelin Receptor"]]}, {"text": "Processing of polysialylated NCAM was reproduced in a mouse model by  bleomycin  administration leading to an activation of the inflammasome and secretion of  interleukin (IL)-1\u03b2   As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1\u03b2 or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM", "triple_list": [["bleomycin", "ACTIVATOR", "interleukin (IL)-1\u03b2"]]}, {"text": " 4-Hydroxytamoxifen  stimulated processing of  cyclin E  is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells", "triple_list": [["4-Hydroxytamoxifen", "ACTIVATOR", "cyclin E"]]}, {"text": " 17\u03b2-Estradiol  (E2) has been recently shown to induce  cyclin E  processing in breast cancer cells", "triple_list": [["17\u03b2-Estradiol", "ACTIVATOR", "cyclin E"]]}, {"text": "Collectively, our data indicate that  OHT  contributes to the production of proteolyzed  cyclin E  via GPR30 with augmented migration in MCF-7 cells.", "triple_list": [["OHT", "ACTIVATOR", "cyclin E"]]}, {"text": "In the current study, we show that systematic modification of an  aminoalkylindole  scaffold identifies two new compounds with dual CB1R antagonist/ CB2R  agonist activity", "triple_list": [["aminoalkylindole", "AGONIST", "CB2R"]]}, {"text": "Collectively, these initial findings suggest that design and systematic modification of  aminoalkylindoles  such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/ CB2R  agonist activity with potential for use as treatments of alcohol abuse.", "triple_list": [["aminoalkylindoles", "AGONIST", "CB2R"]]}, {"text": "We have recently reported that a mono-hydroxylated metabolite of the synthetic  aminoalkylindole  cannabinoid JHW-073 (3) exhibits neutral antagonist activity at  CB1Rs  and thus may serve as a promising lead for the development of novel alcohol abuse therapies", "triple_list": [["aminoalkylindole", "ANTAGONIST", "CB1Rs"]]}, {"text": "We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid  JHW-073  (3) exhibits neutral antagonist activity at  CB1Rs  and thus may serve as a promising lead for the development of novel alcohol abuse therapies", "triple_list": [["JHW-073", "ANTAGONIST", "CB1Rs"]]}, {"text": "In the current study, we show that systematic modification of an  aminoalkylindole  scaffold identifies two new compounds with dual  CB1R  antagonist/CB2R agonist activity", "triple_list": [["aminoalkylindole", "ANTAGONIST", "CB1R"]]}, {"text": "Collectively, these initial findings suggest that design and systematic modification of  aminoalkylindoles  such as 3 may lead to development of novel cannabinoid ligands with dual  CB1R  antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.", "triple_list": [["aminoalkylindoles", "ANTAGONIST", "CB1R"]]}, {"text": "The improved survival rates for obese mice chronically treated with  vildagliptin  suggest that chronic  DPP4  inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.", "triple_list": [["vildagliptin", "DOWNREGULATOR", "DPP4"]]}, {"text": "METHODS: After 1\u00a0month of HFD alone, the mice were given the  DPP4  inhibitor  vildagliptin  for a further 11\u00a0months", "triple_list": [["vildagliptin", "DOWNREGULATOR", "DPP4"]]}, {"text": "Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the  dipeptidyl peptidase-4  inhibitor  vildagliptin  in an advanced-aged diet-induced obesity mouse model", "triple_list": [["vildagliptin", "DOWNREGULATOR", "dipeptidyl peptidase-4"]]}, {"text": "Protein levels of the  glucose  transporter (GLUT4) involved in  glucose  transport via these two pathways were also increased", "triple_list": [["glucose", "PRODUCT-OF", "glucose transporter"]]}, {"text": "Protein levels of the  glucose  transporter ( GLUT4   involved in  glucose  transport via these two pathways were also increased", "triple_list": [["glucose", "PRODUCT-OF", "GLUT4"]]}, {"text": " Puerarin  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent  MEK  ERK and PI3K/Akt activation", "triple_list": [["Puerarin", "ACTIVATOR", "MEK"]]}, {"text": " Puerarin  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ ERK  and PI3K/Akt activation", "triple_list": [["Puerarin", "ACTIVATOR", "ERK"]]}, {"text": " Puerarin  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and  PI3K  Akt activation", "triple_list": [["Puerarin", "ACTIVATOR", "PI3K"]]}, {"text": " Puerarin  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/ Akt  activation", "triple_list": [["Puerarin", "ACTIVATOR", "Akt"]]}, {"text": "Moreover, we also demonstrate that  puerarin  functions at least partially through activation of  MEK  ERK and PI3K/Akt signaling", "triple_list": [["puerarin", "ACTIVATOR", "MEK"]]}, {"text": "Moreover, we also demonstrate that  puerarin  functions at least partially through activation of MEK/ ERK  and PI3K/Akt signaling", "triple_list": [["puerarin", "ACTIVATOR", "ERK"]]}, {"text": "Puerarin promotes proliferation by altering cell cycle distribution whereas  puerarin  mediated survival may be associated with up-regulation of  Bcl-xL  expression", "triple_list": [["puerarin", "ACTIVATOR", "Bcl-xL"]]}, {"text": "Moreover, we also demonstrate that  puerarin  functions at least partially through activation of MEK/ERK and  PI3K  Akt signaling", "triple_list": [["puerarin", "ACTIVATOR", "PI3K"]]}, {"text": "Moreover, we also demonstrate that  puerarin  functions at least partially through activation of MEK/ERK and PI3K/ Akt  signaling", "triple_list": [["puerarin", "ACTIVATOR", "Akt"]]}, {"text": "Treatment with the  ER  antagonist  ICI 182,780  abolishes the above actions of puerarin on osteoblast-derived cells", "triple_list": [["ICI 182,780", "ANTAGONIST", "ER"]]}, {"text": "RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the  phosphatidylinositol 3-kinase  (PI3-kinase) inhibitor,  wortmannin   Treatment of ucOC (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner", "triple_list": [["wortmannin", "DOWNREGULATOR", "phosphatidylinositol 3-kinase"]]}, {"text": "RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase ( PI3-kinase   inhibitor,  wortmannin   Treatment of ucOC (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a  PI3-kinase  dependent manner", "triple_list": [["wortmannin", "DOWNREGULATOR", "PI3-kinase"]]}, {"text": "In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150\u03bcgL(-1)  oxyfluorfen  showed a higher  CAT  activity than controls", "triple_list": [["oxyfluorfen", "ACTIVATOR", "CAT"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using  D1  D5 ( SCH23390  , D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice", "triple_list": [["SCH23390", "ANTAGONIST", "D1"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/ D5  ( SCH23390  , D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice", "triple_list": [["SCH23390", "ANTAGONIST", "D5"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390),  D2  D3 ( raclopride   amisulpride) and D3 (S33084) receptor antagonists, and by using  D2  receptor knockout mice", "triple_list": [["raclopride", "ANTAGONIST", "D2"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ D3  ( raclopride   amisulpride) and  D3  (S33084) receptor antagonists, and by using D2 receptor knockout mice", "triple_list": [["raclopride", "ANTAGONIST", "D3"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390),  D2  D3 (raclopride,  amisulpride   and D3 (S33084) receptor antagonists, and by using  D2  receptor knockout mice", "triple_list": [["amisulpride", "ANTAGONIST", "D2"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ D3  (raclopride,  amisulpride   and  D3  (S33084) receptor antagonists, and by using D2 receptor knockout mice", "triple_list": [["amisulpride", "ANTAGONIST", "D3"]]}, {"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ D3  (raclopride, amisulpride) and  D3  ( S33084   receptor antagonists, and by using D2 receptor knockout mice", "triple_list": [["S33084", "ANTAGONIST", "D3"]]}, {"text": " Haloperidol  promotes mTORC1-dependent phosphorylation of  ribosomal protein S6  via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1", "triple_list": [["Haloperidol", "ACTIVATOR", "ribosomal protein S6"]]}, {"text": "These results show that  haloperidol  promotes mTORC1- and S6K1-dependent phosphorylation of  rpS6  at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs", "triple_list": [["haloperidol", "ACTIVATOR", "rpS6"]]}, {"text": "This effect was prevented by  rapamycin   an inhibitor of the mammalian target of  rapamycin  complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)", "triple_list": [["rapamycin", "DOWNREGULATOR", "mammalian target of rapamycin complex 1"]]}, {"text": "This effect was prevented by  rapamycin   an inhibitor of the mammalian target of  rapamycin  complex 1 ( mTORC1  , or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)", "triple_list": [["rapamycin", "DOWNREGULATOR", "mTORC1"]]}, {"text": "This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by  PF470867   a selective inhibitor of the  p70 ribosomal S6 kinase 1  (S6K1)", "triple_list": [["PF470867", "DOWNREGULATOR", "p70 ribosomal S6 kinase 1"]]}, {"text": "This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by  PF470867   a selective inhibitor of the p70 ribosomal S6 kinase 1 ( S6K1  ", "triple_list": [["PF470867", "DOWNREGULATOR", "S6K1"]]}, {"text": "In line with this observation, incubation of striatal slices with  okadaic acid  and calyculin A, two inhibitors of  PP-1   increased Ser240/244 phosphorylation", "triple_list": [["okadaic acid", "DOWNREGULATOR", "PP-1"]]}, {"text": " Haloperidol  promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of  protein phosphatase-1   The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions", "triple_list": [["Haloperidol", "DOWNREGULATOR", "protein phosphatase-1"]]}, {"text": "In line with this observation, incubation of striatal slices with okadaic acid and  calyculin A   two inhibitors of  PP-1   increased Ser240/244 phosphorylation", "triple_list": [["calyculin A", "DOWNREGULATOR", "PP-1"]]}, {"text": "These compounds resulted from our efforts to merge the pharmacophores of selective  factor Xa  inhibitor  rivaroxaban  with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity", "triple_list": [["rivaroxaban", "DOWNREGULATOR", "factor Xa"]]}, {"text": "Resulting from this study, a structurally novel class of submicromolar fibrinogen  GPIIb/IIIa  binding inhibitor bearing  1,2,4-oxadiazol-5(4H)-one  moiety is also described.", "triple_list": [["1,2,4-oxadiazol-5(4H)-one", "DOWNREGULATOR", "GPIIb/IIIa"]]}, {"text": "The  caspase-3  immunopositivity was increased in degenerating neurons of the  Cd  group", "triple_list": [["Cd", "ACTIVATOR", "caspase-3"]]}, {"text": "Rats intoxicated with  Cd  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants  superoxide dismutase   glutathione peroxidase and catalase in the frontal cortex tissue", "triple_list": [["Cd", "DOWNREGULATOR", "superoxide dismutase"]]}, {"text": "Rats intoxicated with  Cd  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  glutathione peroxidase  and catalase in the frontal cortex tissue", "triple_list": [["Cd", "DOWNREGULATOR", "glutathione peroxidase"]]}, {"text": "Rats intoxicated with  Cd  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and  catalase  in the frontal cortex tissue", "triple_list": [["Cd", "DOWNREGULATOR", "catalase"]]}, {"text": "In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the  sodium iodide symporter   was significantly inhibited by  17beta-oestradiol  In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells", "triple_list": [["17beta-oestradiol", "DOWNREGULATOR", "sodium iodide symporter"]]}, {"text": "Simvastatin and lovastatin metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent  CYP3A  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or  boceprevir   and therefore their coadministration is contraindicated", "triple_list": [["boceprevir", "DOWNREGULATOR", "CYP3A"]]}, {"text": "All HIV PIs except nelfinavir are coadministered with a low dose of  ritonavir   a potent  CYP3A  inhibitor to improve their pharmacokinetic properties", "triple_list": [["ritonavir", "DOWNREGULATOR", "CYP3A"]]}, {"text": "The HCV-PIs  boceprevir  and telaprevir are both, to different extents, inhibitors of  CYP3A   This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions", "triple_list": [["boceprevir", "DOWNREGULATOR", "CYP3A"]]}, {"text": "The HCV-PIs boceprevir and  telaprevir  are both, to different extents, inhibitors of  CYP3A   This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions", "triple_list": [["telaprevir", "DOWNREGULATOR", "CYP3A"]]}, {"text": "Simvastatin and lovastatin metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent  CYP3A  inhibitors such as  ritonavir   or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated", "triple_list": [["ritonavir", "DOWNREGULATOR", "CYP3A"]]}, {"text": "Simvastatin and lovastatin metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent  CYP3A  inhibitors such as ritonavir- or  cobicistat  boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated", "triple_list": [["cobicistat", "DOWNREGULATOR", "CYP3A"]]}, {"text": "Simvastatin and lovastatin metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent  CYP3A  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI,  telaprevir  or boceprevir, and therefore their coadministration is contraindicated", "triple_list": [["telaprevir", "DOWNREGULATOR", "CYP3A"]]}, {"text": " Atorvastatin  is also a  CYP3A  substrate, but less potent drug-drug interactions have been reported with  CYP3A  inhibitors", "triple_list": [["Atorvastatin", "PRODUCT-OF", "CYP3A"]]}, {"text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile:  simvastatin   lovastatin and atorvastatin are metabolized through  cytochrome P450 (CYP) 3A   while the metabolism of the other statins is independent of this CYP", "triple_list": [["simvastatin", "PRODUCT-OF", "cytochrome P450 (CYP) 3A"]]}, {"text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin,  lovastatin  and atorvastatin are metabolized through  cytochrome P450 (CYP) 3A   while the metabolism of the other statins is independent of this CYP", "triple_list": [["lovastatin", "PRODUCT-OF", "cytochrome P450 (CYP) 3A"]]}, {"text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and  atorvastatin  are metabolized through  cytochrome P450 (CYP) 3A   while the metabolism of the other statins is independent of this CYP", "triple_list": [["atorvastatin", "PRODUCT-OF", "cytochrome P450 (CYP) 3A"]]}, {"text": " Simvastatin  and lovastatin metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent  CYP3A  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated", "triple_list": [["Simvastatin", "PRODUCT-OF", "CYP3A"]]}, {"text": "Simvastatin and  lovastatin  metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent  CYP3A  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated", "triple_list": [["lovastatin", "PRODUCT-OF", "CYP3A"]]}, {"text": "The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective  anaplastic lymphoma kinase  inhibitor 15b ( LDK378   are described", "triple_list": [["LDK378", "DOWNREGULATOR", "anaplastic lymphoma kinase"]]}, {"text": "In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation  ALK  inhibitor 4 ( TAE684  ", "triple_list": [["TAE684", "DOWNREGULATOR", "ALK"]]}, {"text": "These findings suggest that limitation of SRF was produced by binding of  BDZs , but not beta CCs, to voltage-dependent  sodium channels  and not to high affinity central BDZ receptors, and that  BDZs  limit SRF by slowing recovery of  sodium channels  from inactivation", "triple_list": [["BDZs", "ACTIVATOR", "sodium channels"]]}, {"text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  BDZ receptor s (Ro 5-4864) at high nanomolar concentrations and by a  BDZ receptor  weak partial agonist ( Ro 15-1788   at micromolar concentrations", "triple_list": [["Ro 15-1788", "AGONIST", "BDZ receptor"]]}, {"text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  BDZ receptor   including  Ro 15-1788  and the beta CCs", "triple_list": [["Ro 15-1788", "AGONIST", "BDZ receptor"]]}, {"text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  BDZ receptor   including Ro 15-1788 and the  beta CCs   These findings suggest that limitation of SRF was produced by binding of BDZs, but not  beta CCs , to voltage-dependent sodium channels and not to high affinity central  BDZ receptor s, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation", "triple_list": [["beta CCs", "AGONIST", "BDZ receptor"]]}, {"text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  BDZ receptor   including  Ro 15-1788  and the beta CCs", "triple_list": [["Ro 15-1788", "AGONIST", "BDZ receptor"]]}, {"text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  BDZ receptor   including Ro 15-1788 and the  beta CCs   These findings suggest that limitation of SRF was produced by binding of BDZs, but not  beta CCs , to voltage-dependent sodium channels and not to high affinity central  BDZ receptor s, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation", "triple_list": [["beta CCs", "AGONIST", "BDZ receptor"]]}, {"text": "In addition to effects on cell proliferation,  DHT  increased the percentage of  alkaline phosphatase  (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens", "triple_list": [["DHT", "ACTIVATOR", "alkaline phosphatase"]]}, {"text": "In addition to effects on cell proliferation,  DHT  increased the percentage of alkaline phosphatase ( ALP   positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens", "triple_list": [["DHT", "ACTIVATOR", "ALP"]]}, {"text": "We conclude that  androgens  can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the  osteoblast-line differentiation marker  ALP, presumably by an androgen receptor mediated mechanism.", "triple_list": [["androgens", "ACTIVATOR", "osteoblast-line differentiation marker"]]}, {"text": "We conclude that  androgens  can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker  ALP   presumably by an androgen receptor mediated mechanism.", "triple_list": [["androgens", "ACTIVATOR", "ALP"]]}, {"text": "The effect of  histamine-H1 receptor  antagonism with  terfenadine  on concentration-related AMP-induced bronchoconstriction in asthma", "triple_list": [["terfenadine", "ANTAGONIST", "histamine-H1 receptor"]]}, {"text": " Ibrutinib  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits  B-cell antigen receptor  signalling downstream of BTK", "triple_list": [["Ibrutinib", "DOWNREGULATOR", "B-cell antigen receptor"]]}, {"text": "Ibrutinib ( Imbruvica(R)   is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits  B-cell antigen receptor  signalling downstream of BTK", "triple_list": [["Imbruvica(R)", "DOWNREGULATOR", "B-cell antigen receptor"]]}, {"text": " Ibrutinib  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase ( BTK   that inhibits B-cell antigen receptor signalling downstream of  BTK ", "triple_list": [["Ibrutinib", "DOWNREGULATOR", "BTK"]]}, {"text": " Ibrutinib  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase ( BTK ) that inhibits B-cell antigen receptor signalling downstream of  BTK   Oral ibrutinib is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation", "triple_list": [["Ibrutinib", "DOWNREGULATOR", "BTK"]]}, {"text": " Ibrutinib  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of  Bruton's tyrosine kinase  (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK", "triple_list": [["Ibrutinib", "DOWNREGULATOR", "Bruton's tyrosine kinase"]]}, {"text": "Ibrutinib ( Imbruvica(R)   is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase ( BTK   that inhibits B-cell antigen receptor signalling downstream of  BTK ", "triple_list": [["Imbruvica(R)", "DOWNREGULATOR", "BTK"]]}, {"text": "Ibrutinib ( Imbruvica(R)   is a first-in-class, potent, orally administered, covalent inhibitor of  Bruton's tyrosine kinase  (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK", "triple_list": [["Imbruvica(R)", "DOWNREGULATOR", "Bruton's tyrosine kinase"]]}, {"text": " Propranolol  treatment (4 X 40 mg/day) increased the density of  beta 2-adrenoceptors  by 25% after 2 days; concomitantly PRA and heart rate were reduced", "triple_list": [["Propranolol", "ACTIVATOR", "beta 2-adrenoceptors"]]}, {"text": " Mepindolol  treatment (2 X 5 mg/day) caused a 30% decrease of  beta 2-adrenoceptor  density and PRA after 2 days; both parameters remained reduced during treatment", "triple_list": [["Mepindolol", "DOWNREGULATOR", "beta 2-adrenoceptor"]]}, {"text": "To study the mechanism underlying this phenomenon, the effects of the nonselective  beta-adrenoceptor  antagonists  propranolol  [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years", "triple_list": [["propranolol", "ANTAGONIST", "beta-adrenoceptor"]]}, {"text": "To study the mechanism underlying this phenomenon, the effects of the nonselective  beta-adrenoceptor  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)],  alprenolol  (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years", "triple_list": [["alprenolol", "ANTAGONIST", "beta-adrenoceptor"]]}, {"text": "To study the mechanism underlying this phenomenon, the effects of the nonselective  beta-adrenoceptor  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and  mepindolol  (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years", "triple_list": [["mepindolol", "ANTAGONIST", "beta-adrenoceptor"]]}, {"text": "Inhibition of  5-lipoxygenase  pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and  5-aminosalicylic acid   The possible effect of sulfasalazine,  5-aminosalicylic acid , and acetyl- 5-aminosalicylic acid  on endogenous arachidonic acid release and metabolism was studied in human polymorphonuclear leukocytes (PMNs)", "triple_list": [["5-aminosalicylic acid", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "Inhibition of  5-lipoxygenase  pathway of arachidonic acid metabolism in human neutrophils by  sulfasalazine  and 5-aminosalicylic acid", "triple_list": [["sulfasalazine", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "Interference with  lipoxygenase  enzymes, rather than a  steroid  like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.", "triple_list": [["steroid", "DOWNREGULATOR", "lipoxygenase"]]}, {"text": "Inhibition of  5-lipoxygenase  pathway of  arachidonic acid  metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid", "triple_list": [["arachidonic acid", "PRODUCT-OF", "5-lipoxygenase"]]}, {"text": "Interference with  lipoxygenase  enzymes, rather than a steroid-like inhibition of  arachidonic acid  release from intracellular phospholipids, seems to be the mode of action.", "triple_list": [["arachidonic acid", "PRODUCT-OF", "lipoxygenase"]]}, {"text": "It is suggested that all the additional actions of  bevantolol  can be attributed to a partial agonist action on  alpha-adrenoceptors  ", "triple_list": [["bevantolol", "AGONIST", "alpha-adrenoceptors"]]}, {"text": "UNLABELLED:  Bevantolol  is a  beta-1 adrenoceptor  antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension", "triple_list": [["Bevantolol", "ANTAGONIST", "beta-1 adrenoceptor"]]}, {"text": " Bevantolol   a  beta-1 adrenoceptor  antagonist with unique additional actions", "triple_list": [["Bevantolol", "ANTAGONIST", "beta-1 adrenoceptor"]]}, {"text": "The apparent affinity of  benzodiazepine receptors  for clonazepam in mice receiving  alprazolam  (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of  alprazolam  increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)", "triple_list": [["alprazolam", "ACTIVATOR", "benzodiazepine receptors"]]}, {"text": "In contrast, serum  alkaline phosphatase  was elevated in animals dosed with  13cisRA  or 4HPR but not in those dose with ROAc", "triple_list": [["13cisRA", "ACTIVATOR", "alkaline phosphatase"]]}, {"text": "In contrast, serum  alkaline phosphatase  was elevated in animals dosed with 13cisRA or  4HPR  but not in those dose with ROAc", "triple_list": [["4HPR", "ACTIVATOR", "alkaline phosphatase"]]}, {"text": "When menadione was omitted from the diet, however,  4HPR  dosed animals had elevated  prothrombin  times", "triple_list": [["4HPR", "ACTIVATOR", "prothrombin"]]}, {"text": "In the high-dose  ROAc  group, there was a twofold increase in  prothrombin  times but only after prolonged dosing", "triple_list": [["ROAc", "ACTIVATOR", "prothrombin"]]}, {"text": "The order of effect was  4HPR  greater than ROAc greater than 13cisRA, with increases in  prothrombin  times correlating with increases in hemorrhagic deaths", "triple_list": [["4HPR", "ACTIVATOR", "prothrombin"]]}, {"text": "The order of effect was 4HPR greater than  ROAc  greater than 13cisRA, with increases in  prothrombin  times correlating with increases in hemorrhagic deaths", "triple_list": [["ROAc", "ACTIVATOR", "prothrombin"]]}, {"text": "The order of effect was 4HPR greater than ROAc greater than  13cisRA   with increases in  prothrombin  times correlating with increases in hemorrhagic deaths", "triple_list": [["13cisRA", "ACTIVATOR", "prothrombin"]]}, {"text": " 13cisRA  and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma  osteocalcin   an effect that correlated with retinoid-induced bone effects", "triple_list": [["13cisRA", "DOWNREGULATOR", "osteocalcin"]]}, {"text": "13cisRA and  ROAc   but not 4HPR, caused a dose-dependent reduction in plasma  osteocalcin   an effect that correlated with retinoid-induced bone effects", "triple_list": [["ROAc", "DOWNREGULATOR", "osteocalcin"]]}, {"text": "13cisRA and ROAc, but not  4HPR   caused a dose-dependent reduction in plasma  osteocalcin   an effect that correlated with retinoid-induced bone effects", "triple_list": [["4HPR", "DOWNREGULATOR", "osteocalcin"]]}, {"text": "However, in the presence of 100 mM  Na+   which is required for opiate inhibition of  adenylate cyclase  activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM", "triple_list": [["Na+", "DOWNREGULATOR", "adenylate cyclase"]]}, {"text": "Kinetic analysis revealed that the inhibition of the  leukotriene C synthetase  reaction by  diethylcarbamazine  was competitive with respect to LTA4", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "leukotriene C synthetase"]]}, {"text": "In contrast to  diethylcarbamazine   piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  5-lipoxygenase  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "In contrast to  diethylcarbamazine   piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  leukotriene synthetase  of these cells", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "leukotriene synthetase"]]}, {"text": "In contrast to diethylcarbamazine,  piriprost  (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  5-lipoxygenase  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells", "triple_list": [["piriprost", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "In contrast to diethylcarbamazine, piriprost ( U-60,257   6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  5-lipoxygenase  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells", "triple_list": [["U-60,257", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "In contrast to diethylcarbamazine, piriprost (U-60,257;  6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1  , which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  5-lipoxygenase  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells", "triple_list": [["6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "Inhibition of the leukotriene synthetase of rat basophil leukemia cells by  diethylcarbamazine , and synergism between  diethylcarbamazine  and piriprost, a  5-lipoxygenase  inhibitor", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and  piriprost   a  5-lipoxygenase  inhibitor", "triple_list": [["piriprost", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "Inhibition of the  leukotriene synthetase  of rat basophil leukemia cells by  diethylcarbamazine   and synergism between  diethylcarbamazine  and piriprost, a 5-lipoxygenase inhibitor", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "leukotriene synthetase"]]}, {"text": "Similar concentrations also inhibited the formation of  leukotriene C4  (LTC4) by  LTC synthetase   a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione", "triple_list": [["leukotriene C4", "PRODUCT-OF", "LTC synthetase"]]}, {"text": "Similar concentrations also inhibited the formation of leukotriene C4 ( LTC4   by  LTC synthetase   a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione", "triple_list": [["LTC4", "PRODUCT-OF", "LTC synthetase"]]}, {"text": "In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of  sulfidopeptide leuktrienes  in RBL cells at the  5-lipoxygenase  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells", "triple_list": [["sulfidopeptide leuktrienes", "PRODUCT-OF", "5-lipoxygenase"]]}, {"text": "These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of  LTA4  in the  leukotriene C synthetase  reaction.", "triple_list": [["LTA4", "PRODUCT-OF", "leukotriene C synthetase"]]}, {"text": "Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by  LTC synthetase   a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling  LTA4  to glutathione", "triple_list": [["LTA4", "PRODUCT-OF", "LTC synthetase"]]}, {"text": "The EC50 for inhibition of the  leukotriene C synthetase  of RBL cells was directly proportional to the  LTA4  concentration in the incubations, ranging from 1.5 mM at 10 microM  LTA4  to over 40 mM at 500 microM  LTA4 ", "triple_list": [["LTA4", "PRODUCT-OF", "leukotriene C synthetase"]]}, {"text": "The test procedure was verified with respect to intestinal  lactose  hydrolysis by demonstrating a linear relationship between  lactose /lactulose excretion and log jejunal mucosal  lactase  activity by in vitro assay (R2 = 0.95) in a further group of subjects", "triple_list": [["lactose", "PRODUCT-OF", "lactase"]]}, {"text": "The test procedure was verified with respect to intestinal  lactose  hydrolysis by demonstrating a linear relationship between  lactose  lactulose excretion and log jejunal mucosal  lactase  activity by in vitro assay (R2 = 0.95) in a further group of subjects", "triple_list": [["lactose", "PRODUCT-OF", "lactase"]]}, {"text": "The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/ lactulose  excretion and log jejunal mucosal  lactase  activity by in vitro assay (R2 = 0.95) in a further group of subjects", "triple_list": [["lactulose", "PRODUCT-OF", "lactase"]]}, {"text": "Differential  lactose  lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  lactase  deficiency.", "triple_list": [["lactose", "PRODUCT-OF", "lactase"]]}, {"text": "Differential lactose/ lactulose  L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  lactase  deficiency.", "triple_list": [["lactulose", "PRODUCT-OF", "lactase"]]}, {"text": "Differential lactose/lactulose/ L-rhamnose  absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  lactase  deficiency.", "triple_list": [["L-rhamnose", "PRODUCT-OF", "lactase"]]}, {"text": "The irreversible complex between  phenoxybenzamine  and  calmodulin  may be useful for inhibiting certain  calmodulin  dependent reactions and for studying the various biological functions of  calmodulin .", "triple_list": [["phenoxybenzamine", "DOWNREGULATOR", "calmodulin"]]}, {"text": " Xanthines  are classical antagonists for  adenosine receptors  for many of their pharmacological actions may be due to blockade of  adenosine receptors   Caffeine and theophylline are virtually non-selective for A2 and A2 receptors", "triple_list": [["Xanthines", "DOWNREGULATOR", "adenosine receptors"]]}, {"text": " Xanthines  are classical antagonists for  adenosine receptors  for many of their pharmacological actions may be due to blockade of  adenosine receptors ", "triple_list": [["Xanthines", "ANTAGONIST", "adenosine receptors"]]}, {"text": "Inhibition of testicular  LDH-X  from laboratory animals and man by  gossypol  and its isomers", "triple_list": [["gossypol", "DOWNREGULATOR", "LDH-X"]]}, {"text": " Gossypol acetic acid  (0-100 mumol/l) inhibited  LDH-X  prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster", "triple_list": [["Gossypol acetic acid", "DOWNREGULATOR", "LDH-X"]]}, {"text": "The inhibitory effect of  (+)-, (-)-, (+/-)-gossypol  and (+/-)-gossypol acetic acid upon testicular cytosolic  LDH-X  was measured in vitro", "triple_list": [["(+)-, (-)-, (+/-)-gossypol", "DOWNREGULATOR", "LDH-X"]]}, {"text": " Gossypol  and its isomers were non-competitive inhibitors of  human and hamster LDH-X  with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate", "triple_list": [["Gossypol", "DOWNREGULATOR", "human and hamster LDH-X"]]}, {"text": "The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and  (+/-)-gossypol acetic acid  upon testicular cytosolic  LDH-X  was measured in vitro", "triple_list": [["(+/-)-gossypol acetic acid", "DOWNREGULATOR", "LDH-X"]]}, {"text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme  NADH   competitive inhibitors of  human LDH-X  and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate", "triple_list": [["NADH", "DOWNREGULATOR", "human LDH-X"]]}, {"text": "Gossypol and its isomers were non-competitive inhibitors of human and  hamster LDH-X  with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of  hamster LDH-X  with respect to the substrate  alpha-ketobutyrate   Co-incubation with human serum albumin or poly-L-lysine but not lysine protected human and  hamster LDH-X  from gossypol.", "triple_list": [["alpha-ketobutyrate", "PRODUCT-OF", "hamster LDH-X"]]}, {"text": "Most reducing cofactors for the peroxidase protect  PHS  and prostacyclin synthase from inactivation by  hydroperoxides   PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation", "triple_list": [["hydroperoxides", "DOWNREGULATOR", "PHS"]]}, {"text": "Most reducing cofactors for the peroxidase protect PHS and  prostacyclin synthase  from inactivation by  hydroperoxides   PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation", "triple_list": [["hydroperoxides", "DOWNREGULATOR", "prostacyclin synthase"]]}, {"text": "Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of  PHS  is markedly increased in the presence of 100 microM  H2O2   This inactivation is a linear function of PB concentration between 10 and 250 microM, with a half-maximal effect in this range at about 100 microM PB", "triple_list": [["H2O2", "DOWNREGULATOR", "PHS"]]}, {"text": "Inactivation of  prostaglandin H synthase  and prostacyclin synthase by  phenylbutazone   Requirement for peroxidative metabolism", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "prostaglandin H synthase"]]}, {"text": "Inactivation of prostaglandin H synthase and  prostacyclin synthase  by  phenylbutazone   Requirement for peroxidative metabolism", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "prostacyclin synthase"]]}, {"text": "Chromatographic analysis of the metabolism of  14C-labeled arachidonic acid  in this system revealed that PB-dependent inactivation of  PHS  is markedly increased in the presence of 100 microM H2O2", "triple_list": [["14C-labeled arachidonic acid", "PRODUCT-OF", "PHS"]]}, {"text": "In plasma membranes prepared from these isolated brown fat cells by  borate  extraction there was a similar enrichment of activity of  SSAO  and of the plasma membrane marker enzyme, phosphodiesterase I", "triple_list": [["borate", "ACTIVATOR", "SSAO"]]}, {"text": "Staining was largely absent when substrate was omitted or after pretreatment with the irreversible  SSAO  inhibitor,  hydralazine  and the slowly reversible inhibitor, semicarbazide", "triple_list": [["hydralazine", "DOWNREGULATOR", "SSAO"]]}, {"text": "Staining was largely absent when substrate was omitted or after pretreatment with the irreversible  SSAO  inhibitor, hydralazine and the slowly reversible inhibitor,  semicarbazide   It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that  SSAO  in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)", "triple_list": [["semicarbazide", "DOWNREGULATOR", "SSAO"]]}, {"text": "Positive staining of mitochondria was achieved in the presence of the  MAO  substrate,  tryptamine   Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine", "triple_list": [["tryptamine", "PRODUCT-OF", "MAO"]]}, {"text": "Staining around the edges of the brown fat cells was observed with the  SSAO  substrates,  tyramine  and benzylamine", "triple_list": [["tyramine", "PRODUCT-OF", "SSAO"]]}, {"text": "Staining around the edges of the brown fat cells was observed with the  SSAO  substrates, tyramine and  benzylamine   Staining was largely absent when substrate was omitted or after pretreatment with the irreversible  SSAO  inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide", "triple_list": [["benzylamine", "PRODUCT-OF", "SSAO"]]}, {"text": "This agent acts synergistically with many  penicillins   such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["penicillins", "ACTIVATOR", "peptidoglycan"]]}, {"text": "This agent acts synergistically with many penicillins, such as  ampicillin   carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["ampicillin", "ACTIVATOR", "peptidoglycan"]]}, {"text": "This agent acts synergistically with many penicillins, such as ampicillin,  carbenicillin   and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["carbenicillin", "ACTIVATOR", "peptidoglycan"]]}, {"text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with  cephalosporins   cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["cephalosporins", "ACTIVATOR", "peptidoglycan"]]}, {"text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins,  cefazolin   cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["cefazolin", "ACTIVATOR", "peptidoglycan"]]}, {"text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin,  cefamandole   or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["cefamandole", "ACTIVATOR", "peptidoglycan"]]}, {"text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or  cefoxitin  to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  peptidoglycan  of the bacterial cell wall", "triple_list": [["cefoxitin", "ACTIVATOR", "peptidoglycan"]]}, {"text": "Since both  TFP  and W-7 are potent inhibitors of  calmodulin   we investigated the possibility that inhibition of  calmodulin  was responsible for the loss of receptors", "triple_list": [["TFP", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Since both TFP and  W-7  are potent inhibitors of  calmodulin   we investigated the possibility that inhibition of  calmodulin  was responsible for the loss of receptors", "triple_list": [["W-7", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Three lines of evidence suggest that  calmodulin  inhibition is not responsible for the inhibition of binding and endocytosis: 1)  Promethazine   a phenothiazine that is a poor inhibitor of  calmodulin , is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several  calmodulin  functions, did not cause a loss of binding; 2) the microinjection of  calmodulin  into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of  calmodulin  over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a  calmodulin -binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin", "triple_list": [["Promethazine", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Three lines of evidence suggest that  calmodulin  inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a  phenothiazine  that is a poor inhibitor of  calmodulin , is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several  calmodulin  functions, did not cause a loss of binding; 2) the microinjection of  calmodulin  into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of  calmodulin  over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a  calmodulin -binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin", "triple_list": [["phenothiazine", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Three lines of evidence suggest that  calmodulin  inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of  calmodulin , is nearly as effective as  TFP  at inhibiting endocytosis; calmidazolium, a potent inhibitor of several  calmodulin  functions, did not cause a loss of binding; 2) the microinjection of  calmodulin  into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of  calmodulin  over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a  calmodulin -binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin", "triple_list": [["TFP", "DOWNREGULATOR", "calmodulin"]]}, {"text": "From these results, it is proposed that  tyrosine hydroxylase  activity determines p-HPAA concentrations by regulating  p-tyrosine  availability", "triple_list": [["p-tyrosine", "PRODUCT-OF", "tyrosine hydroxylase"]]}, {"text": "The binding of  FHA  HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists  diphenhydramine  and clemastine", "triple_list": [["diphenhydramine", "DOWNREGULATOR", "FHA"]]}, {"text": "The binding of  FHA  HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and  clemastine   The histamine H2 receptor antagonist cimetidine blocked the  FHA -HIS binding on 14-37% of the platelets", "triple_list": [["clemastine", "DOWNREGULATOR", "FHA"]]}, {"text": "The histamine H2 receptor antagonist  cimetidine  blocked the  FHA  HIS binding on 14-37% of the platelets", "triple_list": [["cimetidine", "DOWNREGULATOR", "FHA"]]}, {"text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  histamine H1 receptor  antagonists  diphenhydramine  and clemastine", "triple_list": [["diphenhydramine", "ANTAGONIST", "histamine H1 receptor"]]}, {"text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  histamine H1 receptor  antagonists diphenhydramine and  clemastine   The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets", "triple_list": [["clemastine", "ANTAGONIST", "histamine H1 receptor"]]}, {"text": "The  histamine H2 receptor  antagonist  cimetidine  blocked the FHA-HIS binding on 14-37% of the platelets", "triple_list": [["cimetidine", "ANTAGONIST", "histamine H2 receptor"]]}, {"text": "Alanine: glyoxylate  aminotransferase (AGT) in the liver catalyzes most of the  glyoxylate  transamination in mammalian tissues (E", "triple_list": [["glyoxylate", "PRODUCT-OF", "Alanine:glyoxylate aminotransferase"]]}, {"text": "Alanine: glyoxylate  aminotransferase ( AGT   in the liver catalyzes most of the  glyoxylate  transamination in mammalian tissues (E", "triple_list": [["glyoxylate", "PRODUCT-OF", "AGT"]]}, {"text": "The holo activity of combined peroxisomal and mitochondrial  AGT 1  with a low Km for  L-alanine  rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)", "triple_list": [["L-alanine", "PRODUCT-OF", "AGT 1"]]}, {"text": "The holo activity of AGT 2 with a high Km for  L-alanine  decreased more slowly than  AGT 1  (by 33% in 14 days, by 60% in 28 days)", "triple_list": [["L-alanine", "PRODUCT-OF", "AGT 1"]]}, {"text": "The holo activity of  AGT 2  with a high Km for  L-alanine  decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)", "triple_list": [["L-alanine", "PRODUCT-OF", "AGT 2"]]}, {"text": " Triclosan  inhibited both  cyclooxygenase 1  and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively", "triple_list": [["Triclosan", "DOWNREGULATOR", "cyclooxygenase 1"]]}, {"text": " Triclosan  inhibited both cyclooxygenase 1 and  cyclo-oxygenase 2  with IC-50 values of 43 microM and 227 microM, respectively", "triple_list": [["Triclosan", "DOWNREGULATOR", "cyclo-oxygenase 2"]]}, {"text": " Triclosan  also inhibited  5-lipoxygenase  with an IC-50 of 43 microM", "triple_list": [["Triclosan", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "The  15-lipoxygenase  was similarly inhibited by  triclosan  with an IC-50 of 61 microM", "triple_list": [["triclosan", "DOWNREGULATOR", "15-lipoxygenase"]]}, {"text": "Hence,  triclosan  has the ability to inhibit both the  cyclo-oxygenase  and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy", "triple_list": [["triclosan", "DOWNREGULATOR", "cyclo-oxygenase"]]}, {"text": "Hence,  triclosan  has the ability to inhibit both the cyclo-oxygenase and  lipoxygenase  pathways of arachidonic acid metabolism with similar efficacy", "triple_list": [["triclosan", "DOWNREGULATOR", "lipoxygenase"]]}, {"text": "In cell culture experiments, it was found that  triclosan  inhibited  IL-1 beta  induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations", "triple_list": [["triclosan", "DOWNREGULATOR", "IL-1 beta"]]}, {"text": "In cell culture experiments, it was found that triclosan inhibited  IL-1 beta  induced  prostaglandin E2  production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "IL-1 beta"]]}, {"text": "Hence, triclosan has the ability to inhibit both the  cyclo-oxygenase  and lipoxygenase pathways of  arachidonic acid  metabolism with similar efficacy", "triple_list": [["arachidonic acid", "PRODUCT-OF", "cyclo-oxygenase"]]}, {"text": "Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and  lipoxygenase  pathways of  arachidonic acid  metabolism with similar efficacy", "triple_list": [["arachidonic acid", "PRODUCT-OF", "lipoxygenase"]]}, {"text": "Cells propagated in medium containing  N5-methyltetrahydrofolate  and homocysteine showed a substantial increase in  MS  activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.", "triple_list": [["N5-methyltetrahydrofolate", "ACTIVATOR", "MS"]]}, {"text": "Cells propagated in medium containing N5-methyltetrahydrofolate and  homocysteine  showed a substantial increase in  MS  activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.", "triple_list": [["homocysteine", "ACTIVATOR", "MS"]]}, {"text": " Ergovaline  binding and activation of  D2 dopamine receptors  in GH4ZR7 cells", "triple_list": [["Ergovaline", "ACTIVATOR", "D2 dopamine receptors"]]}, {"text": "These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several  ergot alkaloids  including ergovaline, may be due to  D2 dopamine receptor  activation.", "triple_list": [["ergot alkaloids", "ACTIVATOR", "D2 dopamine receptor"]]}, {"text": "These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including  ergovaline   may be due to  D2 dopamine receptor  activation.", "triple_list": [["ergovaline", "ACTIVATOR", "D2 dopamine receptor"]]}, {"text": " Ergot alkaloids  were also effective in inhibiting  VIP  stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["Ergot alkaloids", "DOWNREGULATOR", "VIP"]]}, {"text": "Ergot alkaloids were also effective in inhibiting  VIP  stimulated cyclic AMP production, with EC50 values for  ergovaline   ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["ergovaline", "DOWNREGULATOR", "VIP"]]}, {"text": "Ergot alkaloids were also effective in inhibiting  VIP  stimulated cyclic AMP production, with EC50 values for ergovaline,  ergonovine   alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["ergonovine", "DOWNREGULATOR", "VIP"]]}, {"text": "Ergot alkaloids were also effective in inhibiting  VIP  stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine,  alpha-ergocryptine   ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["alpha-ergocryptine", "DOWNREGULATOR", "VIP"]]}, {"text": "Ergot alkaloids were also effective in inhibiting  VIP  stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine,  ergotamine   and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["ergotamine", "DOWNREGULATOR", "VIP"]]}, {"text": "Ergot alkaloids were also effective in inhibiting  VIP  stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and  dopamine  of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["dopamine", "DOWNREGULATOR", "VIP"]]}, {"text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and  ergot alkaloid  inhibition of  vasoactive intestinal peptide  (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated", "triple_list": [["ergot alkaloid", "DOWNREGULATOR", "vasoactive intestinal peptide"]]}, {"text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and  ergot alkaloid  inhibition of vasoactive intestinal peptide ( VIP  -stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated", "triple_list": [["ergot alkaloid", "DOWNREGULATOR", "VIP"]]}, {"text": "Inhibition of cyclic AMP production by ergovaline was blocked by the  dopamine receptor  antagonist,  (-)-sulpiride  (IC50, 300 +/- 150 nM)", "triple_list": [["(-)-sulpiride", "ANTAGONIST", "dopamine receptor"]]}, {"text": "Ergot alkaloids were also effective in inhibiting  VIP  stimulated  cyclic AMP  production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively", "triple_list": [["cyclic AMP", "PRODUCT-OF", "VIP"]]}, {"text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of  vasoactive intestinal peptide  (VIP)-stimulated  cyclic AMP  production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated", "triple_list": [["cyclic AMP", "PRODUCT-OF", "vasoactive intestinal peptide"]]}, {"text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide ( VIP  -stimulated  cyclic AMP  production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated", "triple_list": [["cyclic AMP", "PRODUCT-OF", "VIP"]]}, {"text": "Incubation of rat aortic membranes with the irreversible  alpha 1B-adrenoceptor  antagonist,  chloroethylclonidine  (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)", "triple_list": [["chloroethylclonidine", "ANTAGONIST", "alpha 1B-adrenoceptor"]]}, {"text": "Incubation of rat aortic membranes with the irreversible  alpha 1B-adrenoceptor  antagonist, chloroethylclonidine ( CEC   10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)", "triple_list": [["CEC", "ANTAGONIST", "alpha 1B-adrenoceptor"]]}, {"text": "Moreover,  clenbuterol HCl  (0.1-0.5 mg/kg, IP), a lipophilic  beta 2-adrenoceptor  agonist, significantly increased the duration of basal aggressive behavior", "triple_list": [["clenbuterol HCl", "AGONIST", "beta 2-adrenoceptor"]]}, {"text": "Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by  yohimbine   an  alpha 2-adrenoceptor  antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.", "triple_list": [["yohimbine", "ANTAGONIST", "alpha 2-adrenoceptor"]]}, {"text": "Intraperitoneal administration of  (+/- )propranolol HCl  (2.5-10 mg/kg), a nonselective  beta-adrenoceptor  antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses", "triple_list": [["(+/- )propranolol HCl", "ANTAGONIST", "beta-adrenoceptor"]]}, {"text": " ICI118,551 HCl  (1.25-5 mg/kg, IP), a selective  beta 2-adrenoceptor  antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it", "triple_list": [["ICI118,551 HCl", "ANTAGONIST", "beta 2-adrenoceptor"]]}, {"text": "ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas  metoprolol tartrate  (5-20 mg/kg, IP), a selective  beta 1-adrenoceptor  antagonist, did not affect it", "triple_list": [["metoprolol tartrate", "ANTAGONIST", "beta 1-adrenoceptor"]]}, {"text": "Furthermore, the phosphorylation of  myosin light chain  produced by  norepinephrine  was greater than that produced by clonidine", "triple_list": [["norepinephrine", "ACTIVATOR", "myosin light chain"]]}, {"text": "Furthermore, the phosphorylation of  myosin light chain  produced by norepinephrine was greater than that produced by  clonidine   These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.", "triple_list": [["clonidine", "ACTIVATOR", "myosin light chain"]]}, {"text": "In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective  alpha 1A-adrenoceptor  antagonist  WB 4101  (100 nM)", "triple_list": [["WB 4101", "ANTAGONIST", "alpha 1A-adrenoceptor"]]}, {"text": "The drug had a potent cytotoxic effect on RIN cells expressing  GLUT2   but had no effect on cells lacking  GLUT2  expression, as indicated by histological analysis and measurement of the blood  glucose  levels of treated animals", "triple_list": [["glucose", "PRODUCT-OF", "GLUT2"]]}, {"text": "Consistent with these data, only  GLUT2  expressing RIN or AtT-20ins cells transported  STZ  efficiently", "triple_list": [["STZ", "PRODUCT-OF", "GLUT2"]]}, {"text": "We conclude that expression of  GLUT2  is required for efficient killing of neuroendocrine cells by  STZ   and this effect is related to specific recognition of the drug as a transported substrate by  GLUT2  but not GLUT1.", "triple_list": [["STZ", "PRODUCT-OF", "GLUT2"]]}, {"text": "We conclude that expression of  GLUT2  is required for efficient killing of neuroendocrine cells by  STZ   and this effect is related to specific recognition of the drug as a transported substrate by  GLUT2  but not GLUT1.", "triple_list": [["STZ", "PRODUCT-OF", "GLUT2"]]}, {"text": "The data suggest that  lysine  analogues, even at low concentrations, reduce the rate of  t-PA  induced whole blood clot lysis by several mechanisms.", "triple_list": [["lysine", "DOWNREGULATOR", "t-PA"]]}, {"text": " AMCA  (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous  t-PA  or if (2) whole blood clots were formed in the presence of exogenous  t-PA  and a lysine analogue", "triple_list": [["AMCA", "DOWNREGULATOR", "t-PA"]]}, {"text": " AMCA  (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous  t-PA  or if (2) whole blood clots were formed in the presence of exogenous  t-PA  and a lysine analogue", "triple_list": [["AMCA", "DOWNREGULATOR", "t-PA"]]}, {"text": "AMCA (0.06 mM) and  EACA  (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous  t-PA  or if (2) whole blood clots were formed in the presence of exogenous  t-PA  and a lysine analogue", "triple_list": [["EACA", "DOWNREGULATOR", "t-PA"]]}, {"text": "AMCA (0.06 mM) and  EACA  (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous  t-PA  or if (2) whole blood clots were formed in the presence of exogenous  t-PA  and a lysine analogue", "triple_list": [["EACA", "DOWNREGULATOR", "t-PA"]]}, {"text": "Inhibitory effects of  lysine  analogues on  t-PA  induced whole blood clot lysis", "triple_list": [["lysine", "DOWNREGULATOR", "t-PA"]]}, {"text": "However, their inhibitory effect was markedly reduced if clots were formed in the presence of  t-PA  and then exposed to either of the  lysine  analogues", "triple_list": [["lysine", "DOWNREGULATOR", "t-PA"]]}, {"text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of  lysine  analogues required for inhibition of clot lysis induced by exogenous  t-PA   AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a  lysine  analogue and exogenous  t-PA  or if (2) whole blood clots were formed in the presence of exogenous  t-PA  and a  lysine  analogue", "triple_list": [["lysine", "DOWNREGULATOR", "t-PA"]]}, {"text": " Histamine  enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via  H1-receptor  activation", "triple_list": [["Histamine", "ACTIVATOR", "H1-receptor"]]}, {"text": "In summary, these results show that the excitatory effect of  histamine  on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the  H1-receptor  mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.", "triple_list": [["histamine", "ACTIVATOR", "H1-receptor"]]}, {"text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the  histamine H1-receptor  agonist  2-thiazolylethylamine  and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine", "triple_list": [["2-thiazolylethylamine", "AGONIST", "histamine H1-receptor"]]}, {"text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine  H1-receptor  agonist 2-thiazolylethylamine and was reduced or blocked by the  H1-receptor  antagonist  promethazine   but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine", "triple_list": [["promethazine", "ANTAGONIST", "H1-receptor"]]}, {"text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the  histamine H2-receptor  antagonist,  cimetidine   In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.", "triple_list": [["cimetidine", "ANTAGONIST", "histamine H2-receptor"]]}, {"text": "Finally, the three drugs were compared with the  angiotensin converting enzyme  inhibitor  cilazapril   The effects of the three drugs on the plasma components of the renin-angiotensin system (plasma renin activity, immunoreactive renin, and immunoreactive angiotensin II concentrations) were also measured", "triple_list": [["cilazapril", "DOWNREGULATOR", "angiotensin converting enzyme"]]}, {"text": "The goal of the present study was to compare the effects of three potent reference  renin  inhibitors ( remikiren   CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys", "triple_list": [["remikiren", "DOWNREGULATOR", "renin"]]}, {"text": "The goal of the present study was to compare the effects of three potent reference  renin  inhibitors (remikiren,  CGP 38560A   and enalkiren) in sodium-depleted normotensive squirrel monkeys", "triple_list": [["CGP 38560A", "DOWNREGULATOR", "renin"]]}, {"text": "The goal of the present study was to compare the effects of three potent reference  renin  inhibitors (remikiren, CGP 38560A, and  enalkiren   in sodium-depleted normotensive squirrel monkeys", "triple_list": [["enalkiren", "DOWNREGULATOR", "renin"]]}, {"text": "One possible explanation is that, in our model,  remikiren  in contrast to CGP 38560A and enalkiren is able to inhibit  renin  in a functionally important extraplasmatic compartment.", "triple_list": [["remikiren", "DOWNREGULATOR", "renin"]]}, {"text": "One possible explanation is that, in our model, remikiren in contrast to  CGP 38560A  and enalkiren is able to inhibit  renin  in a functionally important extraplasmatic compartment.", "triple_list": [["CGP 38560A", "DOWNREGULATOR", "renin"]]}, {"text": "One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and  enalkiren  is able to inhibit  renin  in a functionally important extraplasmatic compartment.", "triple_list": [["enalkiren", "DOWNREGULATOR", "renin"]]}, {"text": "RESULTS:  Nedocromil sodium  inhibited the chemotactic response toward FMLP and NAF/IL-8 of  GM-CSF  primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)", "triple_list": [["Nedocromil sodium", "DOWNREGULATOR", "GM-CSF"]]}, {"text": "Inhibition of  cytokine  primed eosinophil chemotaxis by  nedocromil sodium   BACKGROUND: Eosinophil influx into the lung tissue is considered to be relevant for the pathogenesis of asthma", "triple_list": [["nedocromil sodium", "DOWNREGULATOR", "cytokine"]]}, {"text": "CONCLUSIONS: The chemotactic responses toward  C5a  were inhibited by  nedocromil sodium  at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L)", "triple_list": [["nedocromil sodium", "DOWNREGULATOR", "C5a"]]}, {"text": "RESULTS:  Nedocromil sodium  inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of  IL-3  primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)", "triple_list": [["Nedocromil sodium", "DOWNREGULATOR", "IL-3"]]}, {"text": "RESULTS:  Nedocromil sodium  inhibited the chemotactic response toward FMLP and  NAF  IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)", "triple_list": [["Nedocromil sodium", "DOWNREGULATOR", "NAF"]]}, {"text": "RESULTS:  Nedocromil sodium  inhibited the chemotactic response toward FMLP and NAF/ IL-8  of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)", "triple_list": [["Nedocromil sodium", "DOWNREGULATOR", "IL-8"]]}, {"text": "Glutathione-independent prostaglandin D synthase [ prostaglandin-H2 D-isomerase   (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of  prostaglandin D2  in the central nervous system", "triple_list": [["prostaglandin D2", "PRODUCT-OF", "prostaglandin-H2 D-isomerase"]]}, {"text": "Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase   EC 5.3.99.2] is an enzyme responsible for biosynthesis of  prostaglandin D2  in the central nervous system", "triple_list": [["prostaglandin D2", "PRODUCT-OF", "(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase"]]}, {"text": "Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase,  EC 5.3.99.2   is an enzyme responsible for biosynthesis of  prostaglandin D2  in the central nervous system", "triple_list": [["prostaglandin D2", "PRODUCT-OF", "EC 5.3.99.2"]]}, {"text": "Glutathione-independent  prostaglandin D synthase  [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of  prostaglandin D2  in the central nervous system", "triple_list": [["prostaglandin D2", "PRODUCT-OF", "prostaglandin D synthase"]]}, {"text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- N-methyl-D-aspartate (NMDA) receptor  antagonist  CNQX  (6-cyano-7-nitro-quinoxalinedione)", "triple_list": [["CNQX", "ANTAGONIST", "N-methyl-D-aspartate (NMDA) receptor"]]}, {"text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- N-methyl-D-aspartate (NMDA) receptor  antagonist CNQX ( 6-cyano-7-nitro-quinoxalinedione  ", "triple_list": [["6-cyano-7-nitro-quinoxalinedione", "ANTAGONIST", "N-methyl-D-aspartate (NMDA) receptor"]]}, {"text": "Although  DEC  exerts local antioxidant activity with beneficial effects on lung tissue, this  5-LO  inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.", "triple_list": [["DEC", "DOWNREGULATOR", "5-LO"]]}, {"text": "One group of experimental animals was treated with  5-lipoxygenase  (5-LO) inhibitor,  diethylcarbamazine  (DEC, Sigma, St", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "One group of experimental animals was treated with 5-lipoxygenase ( 5-LO   inhibitor,  diethylcarbamazine  (DEC, Sigma, St", "triple_list": [["diethylcarbamazine", "DOWNREGULATOR", "5-LO"]]}, {"text": "One group of experimental animals was treated with  5-lipoxygenase  (5-LO) inhibitor, diethylcarbamazine ( DEC   Sigma, St", "triple_list": [["DEC", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "One group of experimental animals was treated with 5-lipoxygenase ( 5-LO   inhibitor, diethylcarbamazine ( DEC   Sigma, St", "triple_list": [["DEC", "DOWNREGULATOR", "5-LO"]]}, {"text": " Tamsulosin   the first prostate-selective  alpha 1A-adrenoceptor  antagonist", "triple_list": [["Tamsulosin", "ANTAGONIST", "alpha 1A-adrenoceptor"]]}, {"text": "Expressions of  insulin  and PC3, but not PC2, are coordinately regulated by  glucose   consistent with the important role of PC3 in regulating pro insulin  processing", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "Expressions of insulin and  PC3   but not PC2, are coordinately regulated by  glucose   consistent with the important role of  PC3  in regulating proinsulin processing", "triple_list": [["glucose", "ACTIVATOR", "PC3"]]}, {"text": "The present results suggest that the action of  DMI  in this animal model is unlikely to be directly related to a reduction in  beta-adrenoceptors  but may be related to a reduction in frontal cortical 5-HT2A receptors.", "triple_list": [["DMI", "DOWNREGULATOR", "beta-adrenoceptors"]]}, {"text": "After 7 days of  DMI  administration the number of  beta-adrenoceptors  was lower in frontal and occipital cortex and hippocampus", "triple_list": [["DMI", "DOWNREGULATOR", "beta-adrenoceptors"]]}, {"text": "The  DMI  induced reduction in  beta-adrenoceptors  did not differ in OB and sham-operated control rats", "triple_list": [["DMI", "DOWNREGULATOR", "beta-adrenoceptors"]]}, {"text": " DMI  administration for up to 21 days produced a progressive reduction in the number of  5-HT2A  receptors in frontal cortex, without significant alterations in occipital cortex", "triple_list": [["DMI", "DOWNREGULATOR", "5-HT2A"]]}, {"text": "The time course of the reduction in the number of  5-HT2A  receptors was similar to that of the  DMI  induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different", "triple_list": [["DMI", "DOWNREGULATOR", "5-HT2A"]]}, {"text": "The time course of the reduction in the number of 5-HT2A receptors was similar to that of the  DMI  induced behavioural changes whereas that for the reduction in  beta-adrenoceptors  was clearly different", "triple_list": [["DMI", "DOWNREGULATOR", "beta-adrenoceptors"]]}, {"text": "The present results suggest that the action of  DMI  in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical  5-HT2A  receptors.", "triple_list": [["DMI", "DOWNREGULATOR", "5-HT2A"]]}, {"text": "We show that the binding of  thalidomide  photoaffinity label to authentic human AGP is competed with both  thalidomide  and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of  tumor necrosis factor alpha  from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of  thalidomide .", "triple_list": [["thalidomide", "DOWNREGULATOR", "tumor necrosis factor alpha"]]}, {"text": "Binding of  thalidomide  to alpha1-acid glycoprotein may be involved in its inhibition of  tumor necrosis factor alpha  production", "triple_list": [["thalidomide", "DOWNREGULATOR", "tumor necrosis factor alpha"]]}, {"text": "The immunomodulatory activity of  thalidomide  has been ascribed to the selective inhibition of  tumor necrosis factor alpha  from monocytes", "triple_list": [["thalidomide", "DOWNREGULATOR", "tumor necrosis factor alpha"]]}, {"text": "In conclusion, our data suggest that chronic  cocaine  use is associated with modestly reduced levels of striatal DA and the  DA transporter  in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.", "triple_list": [["cocaine", "DOWNREGULATOR", "DA transporter"]]}, {"text": "It appears likely that the  histamine H2 receptor  blocked by  cimetidine  obviated the pulmonary vasodilator effect of tolazoline therapy.", "triple_list": [["cimetidine", "DOWNREGULATOR", "histamine H2 receptor"]]}, {"text": " GYKI 52466  decreased the peak amplitude of hippocampal area CA1  AMPA receptor  mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics", "triple_list": [["GYKI 52466", "DOWNREGULATOR", "AMPA receptor"]]}, {"text": " Cyclothiazide  prolonged the decay time constant of  AMPA receptor  mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c", "triple_list": [["Cyclothiazide", "DOWNREGULATOR", "AMPA receptor"]]}, {"text": "Activation of cytoprotective  prostaglandin synthase-1  by  minoxidil  as a possible explanation for its hair growth-stimulating effect", "triple_list": [["minoxidil", "ACTIVATOR", "prostaglandin synthase-1"]]}, {"text": "We thus speculated that activation of  PGHS-1  might be a mechanism by which  minoxidil  (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo", "triple_list": [["minoxidil", "ACTIVATOR", "PGHS-1"]]}, {"text": "We thus speculated that activation of  PGHS-1  might be a mechanism by which minoxidil ( 2,4-diamino-6-piperidinopyrimidine-3-oxyde   stimulates hair growth in vivo", "triple_list": [["2,4-diamino-6-piperidinopyrimidine-3-oxyde", "ACTIVATOR", "PGHS-1"]]}, {"text": "We demonstrate here that  minoxidil  is a potent activator of purified  PGHS-1  (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production", "triple_list": [["minoxidil", "ACTIVATOR", "PGHS-1"]]}, {"text": "This study was designed to determine the gastroprotective properties of  cinitapride  (CNT), a novel prokinetic benzamide derivative agonist of  5-HT4  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["cinitapride", "AGONIST", "5-HT4"]]}, {"text": "This study was designed to determine the gastroprotective properties of  cinitapride  (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and  5-HT1  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["cinitapride", "AGONIST", "5-HT1"]]}, {"text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  benzamide  derivative agonist of  5-HT4  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["benzamide", "AGONIST", "5-HT4"]]}, {"text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  benzamide  derivative agonist of 5-HT4 and  5-HT1  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["benzamide", "AGONIST", "5-HT1"]]}, {"text": "This study was designed to determine the gastroprotective properties of cinitapride ( CNT  , a novel prokinetic benzamide derivative agonist of  5-HT4  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["CNT", "AGONIST", "5-HT4"]]}, {"text": "This study was designed to determine the gastroprotective properties of cinitapride ( CNT  , a novel prokinetic benzamide derivative agonist of 5-HT4 and  5-HT1  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["CNT", "AGONIST", "5-HT1"]]}, {"text": "This study was designed to determine the gastroprotective properties of  cinitapride  (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and  5-HT2  antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["cinitapride", "ANTAGONIST", "5-HT2"]]}, {"text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  benzamide  derivative agonist of 5-HT4 and 5-HT1 receptors and  5-HT2  antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["benzamide", "ANTAGONIST", "5-HT2"]]}, {"text": "This study was designed to determine the gastroprotective properties of cinitapride ( CNT  , a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and  5-HT2  antagonist, on mucosal injury produced by 50% (v/v) ethanol", "triple_list": [["CNT", "ANTAGONIST", "5-HT2"]]}, {"text": "We have identified  adenosine deaminase   an enzyme involved in  purine  metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2", "triple_list": [["purine", "PRODUCT-OF", "adenosine deaminase"]]}, {"text": "Here we report that  alendronate  is a potent inhibitor of the  protein-tyrosine-phosphatase-meg1  (PTPmeg1)", "triple_list": [["alendronate", "DOWNREGULATOR", "protein-tyrosine-phosphatase-meg1"]]}, {"text": "Here we report that  alendronate  is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 ( PTPmeg1  ", "triple_list": [["alendronate", "DOWNREGULATOR", "PTPmeg1"]]}, {"text": "With either substrate,  alendronate  was a slow binding inhibitor of  PTPmeg1   Among the other bisphosphonates studied,  alendronate  was more potent and selective for  PTPmeg1 ", "triple_list": [["alendronate", "DOWNREGULATOR", "PTPmeg1"]]}, {"text": "Among the other  bisphosphonates  studied, alendronate was more potent and selective for  PTPmeg1   The hydrolysis of fluorescein diphosphate by PTP epsilon and  PTPmeg1  was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate", "triple_list": [["bisphosphonates", "DOWNREGULATOR", "PTPmeg1"]]}, {"text": "Among the other bisphosphonates studied,  alendronate  was more potent and selective for  PTPmeg1   The hydrolysis of fluorescein diphosphate by PTP epsilon and  PTPmeg1  was sensitive to  alendronate , with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM  alendronate ", "triple_list": [["alendronate", "DOWNREGULATOR", "PTPmeg1"]]}, {"text": "The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to  alendronate , with IC50 values of less than 1 microM;  PTPsigma   however, under the same conditions, was inhibited by only 50% with 141 microM  alendronate   Similarly, with the src-pY527 substrate,  alendronate  inhibition was also PTP dependent", "triple_list": [["alendronate", "DOWNREGULATOR", "PTPsigma"]]}, {"text": " Alendronate  inhibited  PTPmeg1  with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM", "triple_list": [["Alendronate", "DOWNREGULATOR", "PTPmeg1"]]}, {"text": " Alendronate  inhibited PTPmeg1 with an IC50 value of 23 microM,  PTPsigma  with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM", "triple_list": [["Alendronate", "DOWNREGULATOR", "PTPsigma"]]}, {"text": " Alendronate  inhibition of  protein-tyrosine-phosphatase-meg1    Alendronate  (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent bisphosphonate that inhibits osteoclastic bone resorption and has proven effective for the treatment of osteoporosis", "triple_list": [["Alendronate", "DOWNREGULATOR", "protein-tyrosine-phosphatase-meg1"]]}, {"text": "The  alendronate  inhibition of these three  PTPs  and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor", "triple_list": [["alendronate", "DOWNREGULATOR", "PTPs"]]}, {"text": " PTP  inhibition by  hisphosphonates  or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition", "triple_list": [["hisphosphonates", "DOWNREGULATOR", "PTP"]]}, {"text": " PTP  inhibition by hisphosphonates or  vanadate  was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition", "triple_list": [["vanadate", "DOWNREGULATOR", "PTP"]]}, {"text": "These observations show substrate- and enzyme-specific  PTP  inhibition by  alendronate  and support the possibility that a certain  PTP (s) may be the molecular target for  alendronate  action.", "triple_list": [["alendronate", "DOWNREGULATOR", "PTP"]]}, {"text": "The hydrolysis of fluorescein  diphosphate  by  PTP epsilon  and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate", "triple_list": [["diphosphate", "PRODUCT-OF", "PTP epsilon"]]}, {"text": "The hydrolysis of fluorescein  diphosphate  by PTP epsilon and  PTPmeg1  was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate", "triple_list": [["diphosphate", "PRODUCT-OF", "PTPmeg1"]]}, {"text": " M&B-28767   a putative  EP3  agonist, and misoprostol, a putative EP2/ EP3  agonist, also bound to this receptor with Ki values of 120 nM", "triple_list": [["M&B-28767", "AGONIST", "EP3"]]}, {"text": "M&B-28767, a putative EP3 agonist, and  misoprostol   a putative  EP2  EP3 agonist, also bound to this receptor with Ki values of 120 nM", "triple_list": [["misoprostol", "AGONIST", "EP2"]]}, {"text": "M&B-28767, a putative  EP3  agonist, and  misoprostol   a putative EP2/ EP3  agonist, also bound to this receptor with Ki values of 120 nM", "triple_list": [["misoprostol", "AGONIST", "EP3"]]}, {"text": "16,16-dimethyl-PGE2 and two putative  EP1  antagonists,  AH6809  and SC-19220, did not show any significant binding to this receptor", "triple_list": [["AH6809", "ANTAGONIST", "EP1"]]}, {"text": "16,16-dimethyl-PGE2 and two putative  EP1  antagonists, AH6809 and  SC-19220   did not show any significant binding to this receptor", "triple_list": [["SC-19220", "ANTAGONIST", "EP1"]]}, {"text": "At -20 mV, 10 nM  cisapride  reduced  HERG  tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "Block of  HERG  with  cisapride  after channel activation was voltage dependent", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "Blockage of the  HERG human cardiac K+ channel  by the gastrointestinal prokinetic agent  cisapride   Cisapride, a gastrointestinal prokinetic agent, is known to cause long Q-T syndrome and ventricular arrhythmias", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG human cardiac K+ channel"]]}, {"text": "We conclude that  cisapride  is a potent blocker of  HERG  channels expressed in HEK293 cells", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "We tested the hypothesis that  cisapride  blocks  HERG   The whole cell patch-clamp recording technique was used to study  HERG  channels stably expressed heterologously in HEK293 cells", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "Under voltage-clamp conditions,  cisapride  block of  HERG  is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells)", "triple_list": [["cisapride", "DOWNREGULATOR", "HERG"]]}, {"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  monoamine transporter  selectivities ( BTCP   indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["BTCP", "DOWNREGULATOR", "monoamine transporter"]]}, {"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  monoamine transporter  selectivities (BTCP,  indatraline   GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["indatraline", "DOWNREGULATOR", "monoamine transporter"]]}, {"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  monoamine transporter  selectivities (BTCP, indatraline,  GBR 12935   mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["GBR 12935", "DOWNREGULATOR", "monoamine transporter"]]}, {"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  monoamine transporter  selectivities (BTCP, indatraline, GBR 12935,  mazindol   nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["mazindol", "DOWNREGULATOR", "monoamine transporter"]]}, {"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  monoamine transporter  selectivities (BTCP, indatraline, GBR 12935, mazindol,  nomifensine   and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["nomifensine", "DOWNREGULATOR", "monoamine transporter"]]}, {"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  monoamine transporter  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and  zimeldine   either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["zimeldine", "DOWNREGULATOR", "monoamine transporter"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers  acetylprocainamide   dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP", "triple_list": [["acetylprocainamide", "DOWNREGULATOR", "sodium channel"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers acetylprocainamide,  dibucaine   dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP", "triple_list": [["dibucaine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers acetylprocainamide, dibucaine,  dyclonine   prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP", "triple_list": [["dyclonine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers acetylprocainamide, dibucaine, dyclonine,  prilocaine   proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP", "triple_list": [["prilocaine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine,  proparacaine   quinidine, and tetracaine produced a small pressor response or no increase in BP", "triple_list": [["proparacaine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine,  quinidine   and tetracaine produced a small pressor response or no increase in BP", "triple_list": [["quinidine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "At nonconvulsant doses, the  sodium channel  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and  tetracaine  produced a small pressor response or no increase in BP", "triple_list": [["tetracaine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "The  sodium channel  blocking action of  cocaine  per se does not appear to be involved in the rapid pressor response to  cocaine ", "triple_list": [["cocaine", "DOWNREGULATOR", "sodium channel"]]}, {"text": "Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the  dopamine receptor  antagonist,  SCH 23390   Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response", "triple_list": [["SCH 23390", "ANTAGONIST", "dopamine receptor"]]}, {"text": "In conclusion, these findings indicate that  [3H]SR 142948A  is a new potent antagonist radioligand which recognizes with high affinity both  neurotensin NT1  and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.", "triple_list": [["[3H]SR 142948A", "ANTAGONIST", "neurotensin NT1"]]}, {"text": "In conclusion, these findings indicate that  [3H]SR 142948A  is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and  NT2 receptors  and represents thus an excellent tool to study neurotensin receptors in the rat brain.", "triple_list": [["[3H]SR 142948A", "ANTAGONIST", "NT2 receptors"]]}, {"text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  neurotensin receptors    [3H]SR 142948A  (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain", "triple_list": [["[3H]SR 142948A", "ANTAGONIST", "neurotensin receptors"]]}, {"text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  neurotensin receptors   [3H]SR 142948A ( 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride  , in the rat brain", "triple_list": [["2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride", "ANTAGONIST", "neurotensin receptors"]]}, {"text": "Characterization of binding sites of a new  neurotensin receptor  antagonist,  [3H]SR 142948A   in the rat brain", "triple_list": [["[3H]SR 142948A", "ANTAGONIST", "neurotensin receptor"]]}, {"text": "Saturation and competition studies in the presence or absence of the  histamine H1 receptor  antagonist,  levocabastine   revealed that [3H]SR 142948A bound with similar affinities to both the  levocabastine -insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned  levocabastine -sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)", "triple_list": [["levocabastine", "ANTAGONIST", "histamine H1 receptor"]]}, {"text": "Isoform-specific inhibition of  L-type calcium channels  by  dihydropyridines  is independent of isoform-specific gating properties", "triple_list": [["dihydropyridines", "DOWNREGULATOR", "L-type calcium channels"]]}, {"text": " Dihydropyridines  (DHPs) block  L-type Ca2+ channels  more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state", "triple_list": [["Dihydropyridines", "DOWNREGULATOR", "L-type Ca2+ channels"]]}, {"text": "We thus conclude that the more potent  nisoldipine  inhibition of smooth muscle versus  cardiac L-type Ca2+ channels  is not attributable to differences in channel inactivation or activation", "triple_list": [["nisoldipine", "DOWNREGULATOR", "cardiac L-type Ca2+ channels"]]}, {"text": " Nisoldipine  (a DHP antagonist) blocks the  smooth muscle channel  more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels", "triple_list": [["Nisoldipine", "DOWNREGULATOR", "smooth muscle channel"]]}, {"text": "Nisoldipine (a  DHP  antagonist) blocks the  smooth muscle channel  more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels", "triple_list": [["DHP", "DOWNREGULATOR", "smooth muscle channel"]]}, {"text": "Dihydropyridines ( DHPs   block  L-type Ca2+ channels  more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state", "triple_list": [["DHPs", "DOWNREGULATOR", "L-type Ca2+ channels"]]}, {"text": " Methylenetetrahydrofolate reductase  deficiency impairs  methyltetrahydrofolate  synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis", "triple_list": [["methyltetrahydrofolate", "PRODUCT-OF", "Methylenetetrahydrofolate reductase"]]}, {"text": "Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  methionine synthase  (CblE/G) are associated with defective  methyl cobalamin  synthesis", "triple_list": [["methyl cobalamin", "PRODUCT-OF", "methionine synthase"]]}, {"text": "These results suggest that  Cat3  compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity  arginine  transport.", "triple_list": [["arginine", "PRODUCT-OF", "Cat3"]]}, {"text": "The majority of  L-Arg  transport is mediated by  System y+   although several other carriers have been kinetically defined", "triple_list": [["L-Arg", "PRODUCT-OF", "System y+"]]}, {"text": " System y+  cationic  amino acid  transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3", "triple_list": [["amino acid", "PRODUCT-OF", "System y+"]]}, {"text": "System y+ cationic  amino acid  transport is mediated by proteins encoded by a family of genes,  Cat1   Cat2, and Cat3", "triple_list": [["amino acid", "PRODUCT-OF", "Cat1"]]}, {"text": "System y+ cationic  amino acid  transport is mediated by proteins encoded by a family of genes, Cat1,  Cat2   and Cat3", "triple_list": [["amino acid", "PRODUCT-OF", "Cat2"]]}, {"text": "System y+ cationic  amino acid  transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and  Cat3   High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1", "triple_list": [["amino acid", "PRODUCT-OF", "Cat3"]]}, {"text": "However, the apparent affinity for  lysine  transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of  Cat3  mediated transport", "triple_list": [["lysine", "PRODUCT-OF", "Cat3"]]}, {"text": "Increased  Cat3  mediated cationic  amino acid  transport functionally compensates in Cat1 knockout cell lines", "triple_list": [["amino acid", "PRODUCT-OF", "Cat3"]]}, {"text": " Lintitript  markedly increased postprandial plasma  CCK  release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo", "triple_list": [["Lintitript", "ACTIVATOR", "CCK"]]}, {"text": " Lintitript  markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial  PP  levels (P<0.01) as compared to placebo", "triple_list": [["Lintitript", "DOWNREGULATOR", "PP"]]}, {"text": "The study demonstrates for the first time the marked gastrokinetic properties of the new  CCK-A receptor  antagonist  lintitript  in humans.", "triple_list": [["lintitript", "ANTAGONIST", "CCK-A receptor"]]}, {"text": "We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent  CCK-A receptor  antagonist  lintitript   Gastric emptying was assessed in nine healthy male volunteers using a randomized, double blind, two-period crossover design with oral  lintitript  (15 mg 1 h prior to meal intake) or placebo on two different days", "triple_list": [["lintitript", "ANTAGONIST", "CCK-A receptor"]]}, {"text": "Effect of  lintitript   a new  CCK-A receptor  antagonist, on gastric emptying of a solid-liquid meal in humans", "triple_list": [["lintitript", "ANTAGONIST", "CCK-A receptor"]]}, {"text": "The observed inhibition on  IFN-gamma   GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist  ICI 118,551  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist", "triple_list": [["ICI 118,551", "ACTIVATOR", "IFN-gamma"]]}, {"text": "The observed inhibition on IFN-gamma,  GM-CSF   and IL-3 mRNA was blocked by the selective beta2AR antagonist  ICI 118,551  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist", "triple_list": [["ICI 118,551", "ACTIVATOR", "GM-CSF"]]}, {"text": "The observed inhibition on IFN-gamma, GM-CSF, and  IL-3  mRNA was blocked by the selective beta2AR antagonist  ICI 118,551  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist", "triple_list": [["ICI 118,551", "ACTIVATOR", "IL-3"]]}, {"text": "The observed inhibition on  IFN-gamma   GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by  timolol  (10(-6) M), a nonselective antagonist", "triple_list": [["timolol", "ACTIVATOR", "IFN-gamma"]]}, {"text": "The observed inhibition on IFN-gamma,  GM-CSF   and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by  timolol  (10(-6) M), a nonselective antagonist", "triple_list": [["timolol", "ACTIVATOR", "GM-CSF"]]}, {"text": "The observed inhibition on IFN-gamma, GM-CSF, and  IL-3  mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by  timolol  (10(-6) M), a nonselective antagonist", "triple_list": [["timolol", "ACTIVATOR", "IL-3"]]}, {"text": "Secretion of  GM-CSF  protein in the presence of increasing concentrations of  isoproterenol  followed a similar pattern as observed for  GM-CSF  mRNA", "triple_list": [["isoproterenol", "ACTIVATOR", "GM-CSF"]]}, {"text": "Secretion of  GM-CSF  protein in the presence of increasing concentrations of  isoproterenol  followed a similar pattern as observed for  GM-CSF  mRNA", "triple_list": [["isoproterenol", "ACTIVATOR", "GM-CSF"]]}, {"text": "Concanavalin A (Con A)-induced  IFN-gamma   GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  isoproterenol  and by the selective beta2AR agonist fenoterol", "triple_list": [["isoproterenol", "DOWNREGULATOR", "IFN-gamma"]]}, {"text": "Concanavalin A (Con A)-induced IFN-gamma,  GM-CSF   and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  isoproterenol  and by the selective beta2AR agonist fenoterol", "triple_list": [["isoproterenol", "DOWNREGULATOR", "GM-CSF"]]}, {"text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and  IL-3  mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  isoproterenol  and by the selective beta2AR agonist fenoterol", "triple_list": [["isoproterenol", "DOWNREGULATOR", "IL-3"]]}, {"text": "Concanavalin A (Con A)-induced  IFN-gamma   GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  fenoterol   IL-4 mRNA accumulation was not susceptible to betaAR stimulation", "triple_list": [["fenoterol", "DOWNREGULATOR", "IFN-gamma"]]}, {"text": "Concanavalin A (Con A)-induced IFN-gamma,  GM-CSF   and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  fenoterol   IL-4 mRNA accumulation was not susceptible to betaAR stimulation", "triple_list": [["fenoterol", "DOWNREGULATOR", "GM-CSF"]]}, {"text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and  IL-3  mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  fenoterol   IL-4 mRNA accumulation was not susceptible to betaAR stimulation", "triple_list": [["fenoterol", "DOWNREGULATOR", "IL-3"]]}, {"text": "Although  beta3AR  mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the  beta3AR  agonist  BRL 37344  had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels", "triple_list": [["BRL 37344", "AGONIST", "beta3AR"]]}, {"text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective  betaAR  agonist  isoproterenol  and by the selective beta2AR agonist fenoterol", "triple_list": [["isoproterenol", "AGONIST", "betaAR"]]}, {"text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective  beta2AR  agonist  fenoterol   IL-4 mRNA accumulation was not susceptible to betaAR stimulation", "triple_list": [["fenoterol", "AGONIST", "beta2AR"]]}, {"text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective  beta2AR  antagonist  ICI 118,551  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist", "triple_list": [["ICI 118,551", "ANTAGONIST", "beta2AR"]]}, {"text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective  beta2AR  antagonist ICI 118,551 (10(-6) M) and by  timolol  (10(-6) M), a nonselective antagonist", "triple_list": [["timolol", "ANTAGONIST", "beta2AR"]]}, {"text": "The selective  beta1AR  antagonist  atenolol  (0.3 x 10(-6) M) did not have any effect", "triple_list": [["atenolol", "ANTAGONIST", "beta1AR"]]}, {"text": "All three compounds displayed antagonistic properties against  oxytocin  in vitro, with  carbetocin  being the strongest inhibitor (pA2 = 8.21) and  carbetocin  metabolite II (pA2 = 8.01) being stronger than  carbetocin  metabolite I (pA2 = 7.81)", "triple_list": [["carbetocin", "DOWNREGULATOR", "oxytocin"]]}, {"text": "All three compounds displayed antagonistic properties against  oxytocin  in vitro, with  carbetocin  being the strongest inhibitor (pA2 = 8.21) and  carbetocin  metabolite II (pA2 = 8.01) being stronger than  carbetocin  metabolite I (pA2 = 7.81)", "triple_list": [["carbetocin", "DOWNREGULATOR", "oxytocin"]]}, {"text": "All three compounds displayed antagonistic properties against  oxytocin  in vitro, with  carbetocin  being the strongest inhibitor (pA2 = 8.21) and  carbetocin  metabolite II (pA2 = 8.01) being stronger than  carbetocin  metabolite I (pA2 = 7.81)", "triple_list": [["carbetocin", "DOWNREGULATOR", "oxytocin"]]}, {"text": "These results indicate that  carbetocin  is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites  carbetocin  metabolite I and  carbetocin  metabolite II are pure antagonists", "triple_list": [["carbetocin", "AGONIST", "oxytocin receptor"]]}, {"text": "These results indicate that  carbetocin  is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites  carbetocin  metabolite I and  carbetocin  metabolite II are pure antagonists", "triple_list": [["carbetocin", "ANTAGONIST", "oxytocin receptor"]]}, {"text": "These results indicate that  carbetocin  is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites  carbetocin  metabolite I and  carbetocin  metabolite II are pure antagonists", "triple_list": [["carbetocin", "ANTAGONIST", "oxytocin receptor"]]}, {"text": "These results indicate that  carbetocin  is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites  carbetocin  metabolite I and  carbetocin  metabolite II are pure antagonists", "triple_list": [["carbetocin", "ANTAGONIST", "oxytocin receptor"]]}, {"text": "Crystallographic analysis of the  human phenylalanine hydroxylase catalytic domain  with bound  catechol  inhibitors at 2.0 A resolution", "triple_list": [["catechol", "DOWNREGULATOR", "human phenylalanine hydroxylase catalytic domain"]]}, {"text": "The  aromatic amino acid hydroxylases  represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by  catechol  derivatives", "triple_list": [["catechol", "DOWNREGULATOR", "aromatic amino acid hydroxylases"]]}, {"text": "Crystallographic comparison with the structurally related  rat tyrosine hydroxylase  binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the  catechols  and the cofactor, compatible with a competitive type of inhibition of the  catechols  versus BH4", "triple_list": [["catechols", "DOWNREGULATOR", "rat tyrosine hydroxylase"]]}, {"text": "Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of  human phenylalanine hydroxylase  (hPheOH), cocrystallized with various potent and well-known  catechol  inhibitors and refined at a resolution of 2.0 A", "triple_list": [["catechol", "DOWNREGULATOR", "human phenylalanine hydroxylase"]]}, {"text": "Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase ( hPheOH  , cocrystallized with various potent and well-known  catechol  inhibitors and refined at a resolution of 2.0 A", "triple_list": [["catechol", "DOWNREGULATOR", "hPheOH"]]}, {"text": "All GCs including the antagonistic compound  RU486  efficiently reduced  NF-kappaB  mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression", "triple_list": [["RU486", "DOWNREGULATOR", "NF-kappaB"]]}, {"text": "The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of  glucose  induced  insulin  secretion", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to  NBF2  or by hydrolysis of bound  MgATP  at  NBF2   stabilizes prebound 8-azido-ATP binding at NBF1", "triple_list": [["MgATP", "PRODUCT-OF", "NBF2"]]}]